Introduction

The National Institutes of Health Grants Policy Statement (NIHGPS) is intended to make available to NIH grantees, in a single document, the policy requirements that serve as the terms and conditions of NIH grant awards. This document also is designed to be useful to those interested in NIH grants by providing information about NIH—its organization, its staff, and its grants process. The NIHGPS is available online from the NIH home page at http://grants.nih.gov/grants/policy/policy.htm#gps.

NIHGPS ORGANIZATION

The NIHGPS has three parts, which allows general information, application information, and other types of reference material to be separated from legally binding terms and conditions:

◆ Part I: NIH Grants—General Information. Part I contains a glossary defining commonly used terms and abbreviations used throughout the document; describes NIH and its relationship to other organizations within the Department of Health and Human Services (HHS); specifies grantee, NIH, and other HHS staff responsibilities; outlines the grant application and review processes; and explains the various resources available to those interested in the NIH grants process.

◆ Part II: Terms and Conditions of NIH Grant Awards. Part II includes generally applicable terms and conditions. This part also specifies the terms and conditions that apply to particular types of grants, grantees, and activities that differ from, supplement, or elaborate on the standard terms and conditions. These requirements, in separate sections, pertain to construction grants, research training grants and fellowships, modular applications and awards, conference grants, consortium agreements, grants to foreign and international organizations (and grants with substantial foreign components awarded to domestic organizations), grants to Federal institutions and payments to (or on behalf of) Federal employees, grants to for-profit organizations, and research patient care activities.

◆ Part III: Points of Contact. Part III lists pertinent offices and officials with their addresses and telephone numbers.

CONVENTIONS

Certain conventions are followed throughout this document. The term “grant” is used to mean both grants and cooperative agreements; however, for clarity, certain sections mention both grants and cooperative agreements. The term “grantee” generally is used to refer to recipients of grants and awardees of cooperative agreements; however the terms “recipient” or “awardee” also are used. “NIH” may be used in this document to refer to the entire organization or to its component organizations, or else to contrast an action by NIH, including actions by its ICs, with an action by a grantee or other organization. A reference to “Part II” or “Part III” without further elaboration means the corresponding part of the NIHGPS.
SUPERSESSION

The NIHGPS was originally published with an effective date of October 1, 1998. It was subsequently revised with an effective date of March 1, 2001. This revision of the NIHGPS, which is an update of the 2001 publication, has an effective date of December 1, 2003. It applies to all NIH grants and cooperative agreements for budget periods beginning on or after December 1, 2003. It remains largely unchanged; however, it incorporates several new and modified requirements, clarifies certain policies, and emphasizes policies that require increased attention by grantees on the basis of recent developments. A number of the changes are ones that have been published since March 2001 as notices in the NIH Guide for Grants and Contracts; others implement recent changes in statutes, regulations, and policies. An explanation of the major changes from the March 2001 NIHGPS is included in the NIH Guide for Grants and Contracts notice announcing the reissuance of the NIHGPS.

ADDITIONAL INFORMATION

OPERA develops and maintains this document. Changes in statutes, regulations, or policies that take effect before the next revision of the NIHGPS will be published separately in the NIH Guide for Grants and Contracts. Grantees are responsible for reviewing the NIH Guide for Grants and Contracts, which is published on the NIH home page at http://grants.nih.gov/grants/guide/index.html, for changes and for implementing them, as appropriate.
Table of Contents

PART I: NIH GRANTS—GENERAL INFORMATION .............................................................. 1

GLOSSARY ................................................................................................................................... 1
Abbreviations .............................................................................................................................. 1
Definitions of Terms ................................................................................................................... 6

THE NATIONAL INSTITUTES OF HEALTH AS A GRANT-MAKING ORGANIZATION ................................................... 16
Roles and Responsibilities ........................................................................................................ 16
NIH and HHS Staff ................................................................................................................. 17
Grantee Staff .............................................................................................................................. 18
Application and Review Processes ........................................................................................... 19
Support Mechanisms ............................................................................................................... 19
Eligibility .................................................................................................................................. 19
Types of Award Instruments .................................................................................................. 19
Types of Applications ............................................................................................................. 20
Types of Funding Opportunities ............................................................................................. 20
Application Submission ........................................................................................................... 22
The Peer Review Process ......................................................................................................... 26
Sources of Information about NIH’s Grants Process and Programs ........................................ 30

PART II: TERMS AND CONDITIONS OF NIH GRANT AWARDS ......................................................... 32

SUBPART A: GENERAL ............................................................................................................ 32

COMPLETING THE PRE-AWARD PROCESS ........................................................................... 32
Just-in-Time Procedures ........................................................................................................... 32
Funding Principles .................................................................................................................... 33
Eligibility .................................................................................................................................. 33
Cost Analysis and Assessment of Management Systems ......................................................... 35

OVERVIEW OF TERMS AND CONDITIONS ........................................................................... 35

PUBLIC POLICY REQUIREMENTS AND OBJECTIVES ........................................................................... 36
Ethical and Safe Conduct in Science and Organizational Operations ....................................... 43
Standards of Conduct ............................................................................................................... 44
Financial Conflict of Interest ................................................................................................... 44
Debarment and Suspension ...................................................................................................... 46
Drug-Free Workplace ............................................................................................................... 47
Health and Safety Regulations and Guidelines ........................................................................ 48
Limitation on Use of Funds for Promotion or Legalization of Controlled Substances ............... 49
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAYMENT</td>
<td>76</td>
</tr>
<tr>
<td>SMARTLINK II/ACH</td>
<td>77</td>
</tr>
<tr>
<td>CASHLINE/ACH</td>
<td>77</td>
</tr>
<tr>
<td>Cash Request</td>
<td>77</td>
</tr>
<tr>
<td>Interest Earned on Advances of Grant Funds</td>
<td>78</td>
</tr>
<tr>
<td>COST CONSIDERATIONS</td>
<td>78</td>
</tr>
<tr>
<td>General</td>
<td>78</td>
</tr>
<tr>
<td>The Cost Principles</td>
<td>79</td>
</tr>
<tr>
<td>Direct Costs and Facilities and Administrative Costs</td>
<td>81</td>
</tr>
<tr>
<td>Reimbursement of Facilities and Administrative Costs</td>
<td>81</td>
</tr>
<tr>
<td>Cost Transfers, Overruns, and Accelerated and Delayed Expenditures</td>
<td>83</td>
</tr>
<tr>
<td>Allocation of Costs and Closely Related Work</td>
<td>84</td>
</tr>
<tr>
<td>Applicable Credits</td>
<td>85</td>
</tr>
<tr>
<td>Services Provided by Affiliated Organizations</td>
<td>85</td>
</tr>
<tr>
<td>Allowability of Costs/Activities</td>
<td>86</td>
</tr>
<tr>
<td>Selected Items of Cost</td>
<td>87</td>
</tr>
<tr>
<td>ADMINISTRATIVE REQUIREMENTS</td>
<td>102</td>
</tr>
<tr>
<td>Changes in Project and Budget</td>
<td>102</td>
</tr>
<tr>
<td>Expanded Authorities</td>
<td>102</td>
</tr>
<tr>
<td>Prior-Approval Requirements</td>
<td>105</td>
</tr>
<tr>
<td>Requests for Prior Approval</td>
<td>112</td>
</tr>
<tr>
<td>Availability of Research Results: Publications, Intellectual Property Rights, and Sharing</td>
<td>113</td>
</tr>
<tr>
<td>Research Resources</td>
<td>113</td>
</tr>
<tr>
<td>Rights in Data (Publication and Copyrighting)</td>
<td>114</td>
</tr>
<tr>
<td>Sharing of Research Data</td>
<td>115</td>
</tr>
<tr>
<td>Sharing of Unique Research Resources</td>
<td>115</td>
</tr>
<tr>
<td>Inventions and Patents</td>
<td>116</td>
</tr>
<tr>
<td>Management Systems and Procedures</td>
<td>120</td>
</tr>
<tr>
<td>Financial Management System Standards</td>
<td>121</td>
</tr>
<tr>
<td>Program Income</td>
<td>121</td>
</tr>
<tr>
<td>Property Management System Standards</td>
<td>123</td>
</tr>
<tr>
<td>Procurement System Standards and Requirements</td>
<td>126</td>
</tr>
<tr>
<td>Monitoring</td>
<td>128</td>
</tr>
<tr>
<td>Reporting</td>
<td>129</td>
</tr>
<tr>
<td>Record Retention and Access</td>
<td>133</td>
</tr>
<tr>
<td>Audit</td>
<td>134</td>
</tr>
<tr>
<td>Enforcement Actions</td>
<td>136</td>
</tr>
<tr>
<td>Modification of the Terms of Award</td>
<td>136</td>
</tr>
<tr>
<td>Suspension, Termination, and Withholding of Support</td>
<td>137</td>
</tr>
<tr>
<td>Other Enforcement Actions</td>
<td>138</td>
</tr>
<tr>
<td>Recovery of Funds</td>
<td>138</td>
</tr>
<tr>
<td>Debt Collection</td>
<td>138</td>
</tr>
<tr>
<td>Closeout</td>
<td>139</td>
</tr>
<tr>
<td>Final Reports</td>
<td>139</td>
</tr>
<tr>
<td>Grant Appeals Procedures</td>
<td>141</td>
</tr>
</tbody>
</table>
GRANTS TO FOR-PROFIT ORGANIZATIONS................................................................. 237
General..................................................................................................................... 237
Eligibility ................................................................................................................... 238
Allowable and Unallowable Costs......................................................................... 238
  Cost Principles ...................................................................................................... 238
  Independent Research and Development Costs .............................................. 238
  Facilities and Administrative Costs (Indirect Costs) ........................................ 238
Profit or Fee ............................................................................................................. 238
Administrative Requirements .............................................................................. 238
  Intellectual Property .......................................................................................... 238
  Program Income ................................................................................................ 239
  Operating Authorities ......................................................................................... 239
  Audit ..................................................................................................................... 239
Small Business Innovation Research and Small Business Technology Transfer Programs 240
  Eligibility ........................................................................................................... 241
  Public Policy Requirements and Objectives .................................................. 243
  Allowable Costs and Fee .................................................................................. 243
  Administrative Requirements ........................................................................... 244

RESEARCH PATIENT CARE COSTS........................................................................... 246
General..................................................................................................................... 246
Definitions............................................................................................................... 246
Policy....................................................................................................................... 247
Allowable Costs ..................................................................................................... 247
  Computing Research Patient Care Costs ......................................................... 248
  Facilities and Administrative Costs ............................................................... 248
  Special Procedures for Certain Hospitals ....................................................... 249
  Financial Responsibilities ............................................................................... 249
Program Requirements........................................................................................ 250

PART III: POINTS OF CONTACT .............................................................................. 251

INDEX ..................................................................................................................... 261
Part I: NIH Grants—General Information

This part contains a glossary defining terms and abbreviations commonly used throughout the NIHGPS; describes NIH and its relationship to other organizations within HHS; specifies grantee, NIH, and other HHS staff responsibilities; outlines the grant application and review processes; and explains the various resources available to those interested in the NIH grants process.

GLOSSARY

The glossary lists commonly used acronyms and other abbreviations used in the NIHGPS. The glossary also defines terms commonly used throughout the NIHGPS. The definitions may be amplified and additional definitions may be found in other sections of this document and in source documents, such as applicable statutes, grants administration regulations, and OMB circulars.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>A&amp;R</td>
<td>Alteration and Renovation</td>
</tr>
<tr>
<td>ACF</td>
<td>Administration for Children and Families</td>
</tr>
<tr>
<td>ACH</td>
<td>Automated Clearinghouse</td>
</tr>
<tr>
<td>AHRQ</td>
<td>Agency for Healthcare Research and Quality</td>
</tr>
<tr>
<td>AIA</td>
<td>American Institute of Architects</td>
</tr>
<tr>
<td>AoA</td>
<td>Administration on Aging</td>
</tr>
<tr>
<td>AOO</td>
<td>Authorized Organizational Official</td>
</tr>
<tr>
<td>APAC</td>
<td>Annual Payback Activities Certification</td>
</tr>
<tr>
<td>AREA</td>
<td>Academic Research and Enhancement Award</td>
</tr>
<tr>
<td>ASHRAE</td>
<td>American Society of Heating, Refrigeration and Air Conditioning Engineers</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>CGMO</td>
<td>Chief Grants Management Officer</td>
</tr>
<tr>
<td>CMS</td>
<td>Centers for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>CoC</td>
<td>Certificate of Confidentiality</td>
</tr>
</tbody>
</table>

1 This is the only location in the NIHGPS where these terms are defined. If an abbreviation used in the NIHGPS is unfamiliar, the reader should consult this list for its meaning.
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
<td>Career Opportunities in Research Education and Training Program</td>
</tr>
<tr>
<td>CRISP</td>
<td>Computer Retrieval of Information on Scientific Projects</td>
</tr>
<tr>
<td>CSR</td>
<td>Center for Scientific Review</td>
</tr>
<tr>
<td>DAB</td>
<td>Departmental Appeals Board</td>
</tr>
<tr>
<td>DCA</td>
<td>Division of Cost Allocation, HHS</td>
</tr>
<tr>
<td>DEA</td>
<td>Drug Enforcement Administration</td>
</tr>
<tr>
<td>DEOIR</td>
<td>Division of Extramural Outreach and Information Resources, NIH</td>
</tr>
<tr>
<td>DES</td>
<td>Department of Engineering Services, NIH</td>
</tr>
<tr>
<td>DFAS</td>
<td>Division of Financial Advisory Services, NIH</td>
</tr>
<tr>
<td>DoC</td>
<td>Department of Commerce</td>
</tr>
<tr>
<td>DoD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DoL</td>
<td>Department of Labor</td>
</tr>
<tr>
<td>DPM</td>
<td>Division of Payment Management, HHS</td>
</tr>
<tr>
<td>DSMB</td>
<td>Data and Safety Monitoring Board</td>
</tr>
<tr>
<td>EA</td>
<td>Expanded Authorities</td>
</tr>
<tr>
<td>EO</td>
<td>Executive Order</td>
</tr>
<tr>
<td>eRA</td>
<td>Electronic Research Administration</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>Facilities and Administrative (costs)</td>
</tr>
<tr>
<td>FAC</td>
<td>Federal Audit Clearinghouse</td>
</tr>
<tr>
<td>FAR</td>
<td>Federal Acquisition Regulation</td>
</tr>
<tr>
<td>FCTR</td>
<td>Federal Cash Transactions Report (SF 272)</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FDP</td>
<td>Federal Demonstration Partnership</td>
</tr>
<tr>
<td>FEMA</td>
<td>Federal Emergency Management Agency</td>
</tr>
<tr>
<td>FIC</td>
<td>Fogarty International Center</td>
</tr>
<tr>
<td>FICA</td>
<td>Federal Insurance Contributions Act</td>
</tr>
<tr>
<td>FOI</td>
<td>Freedom of Information</td>
</tr>
<tr>
<td>FOIA</td>
<td>Freedom of Information Act</td>
</tr>
<tr>
<td>FSR</td>
<td>Financial Status Report (SF 269 or 269A)</td>
</tr>
<tr>
<td>FTR</td>
<td>Federal Travel Regulation</td>
</tr>
<tr>
<td>FWA</td>
<td>Federal-Wide Assurance</td>
</tr>
<tr>
<td>GCRC</td>
<td>General Clinical Research Centers</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>GMO</td>
<td>Grants Management Officer</td>
</tr>
<tr>
<td>GMS</td>
<td>Grants Management Specialist</td>
</tr>
<tr>
<td>GMP</td>
<td>Guaranteed Maximum Price</td>
</tr>
<tr>
<td>GPO</td>
<td>Government Printing Office</td>
</tr>
<tr>
<td>GSA</td>
<td>General Services Administration</td>
</tr>
<tr>
<td>hESC</td>
<td>Human Embryonic Stem Cells</td>
</tr>
<tr>
<td>HHS</td>
<td>Department of Health and Human Services</td>
</tr>
<tr>
<td>HRSA</td>
<td>Health Resources and Services Administration</td>
</tr>
<tr>
<td>HVAC</td>
<td>Heating, Ventilating, and Air Conditioning</td>
</tr>
<tr>
<td>IACUC</td>
<td>Institutional Animal Care and Use Committee</td>
</tr>
<tr>
<td>IBC</td>
<td>Institutional Biosafety Committee</td>
</tr>
<tr>
<td>IC</td>
<td>Institute or Center</td>
</tr>
<tr>
<td>IDE</td>
<td>Investigational Device Exception</td>
</tr>
<tr>
<td>IHS</td>
<td>Indian Health Service</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>IPA</td>
<td>Intergovernmental Personnel Act</td>
</tr>
<tr>
<td>IR&amp;D</td>
<td>Independent Research and Development</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IRG</td>
<td>Initial Review Group</td>
</tr>
<tr>
<td>IRS</td>
<td>Internal Revenue Service</td>
</tr>
<tr>
<td>K award</td>
<td>Career award</td>
</tr>
<tr>
<td>Kirschstein-NRSA</td>
<td>Ruth L. Kirschstein National Research Service Award</td>
</tr>
<tr>
<td>LWOP</td>
<td>Leave Without Pay</td>
</tr>
<tr>
<td>MARC-U*STAR</td>
<td>Minority Access to Research Careers Undergraduate Student Training in Academic Research Program</td>
</tr>
<tr>
<td>MOU</td>
<td>Memorandum Of Understanding</td>
</tr>
<tr>
<td>MPA</td>
<td>Multiple Project Assurance</td>
</tr>
<tr>
<td>NCRR</td>
<td>National Center for Research Resources</td>
</tr>
<tr>
<td>NEARC</td>
<td>National External Audit Review Center, OIG</td>
</tr>
<tr>
<td>NEI</td>
<td>National Eye Institute</td>
</tr>
<tr>
<td>NEPA</td>
<td>National Environmental Policy Act</td>
</tr>
<tr>
<td>NFI</td>
<td>Notice of Federal Interest</td>
</tr>
<tr>
<td>NFPA</td>
<td>National Fire Protection Association</td>
</tr>
</tbody>
</table>
PSC Payback Service Center, NIH
R&D Research and Development
RFA Request For Applications
RFP Request For Proposals
S&W Salaries and Wages
SAMHSA Substance Abuse and Mental Health Services Administration
SBA Small Business Administration
SBC Small Business Concern
SBIR Small Business Innovation Research Program
SEP Special Emphasis Panel
SF Standard Form
SII Successor-In-Interest
SNAP Streamlined Non-competing Award Process
SO Signing Official
SPOC State Single Point of Contact
SRA Scientific Review Administrator
SRG Scientific Review Group
STTR Small Business Technology Transfer Program
USDA United States Department of Agriculture
USPS United States Postal Service
VA Department of Veterans Affairs
VAMC VA Medical Center
VANPC VA-Affiliated Non-Profit research Corporation
**Definitions of Terms**

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>alteration and renovation</td>
<td>Work that changes the interior arrangements or other physical characteristics of an existing facility or of installed equipment so that it can be used more effectively for its currently designated purpose or adapted to an alternative use to meet a programmatic requirement. Major A&amp;R (including modernization, remodeling, or improvement) of an existing building is permitted under an NIH grant only when the authorizing statute for the program specifically allows that activity. (See “Allowability of Costs/Activities—Selected Items of Cost—Alteration and Renovation” and “Allowability of Costs/Activities—Selected Items of Cost—Construction.”)</td>
<td></td>
</tr>
<tr>
<td>application</td>
<td>A request for financial support of a project or activity submitted to NIH on specified forms and in accordance with NIH instructions. (See “Application and Review Processes” for detailed information about the application process, including an explanation of the types of applications.)</td>
<td></td>
</tr>
<tr>
<td>approved budget</td>
<td>The financial expenditure plan for the grant-supported project or activity, including revisions approved by NIH and permissible revisions made by the grantee. The approved budget consists of Federal (grant) funds and, if required by the terms and conditions of the award, non-Federal participation in the form of matching or cost sharing. The approved budget specified in the NGA may be shown in detailed budget categories or as total costs without a categorical breakout. Expenditures charged to an approved budget that consists of both Federal and non-Federal shares are deemed to be borne by the grantee in the same proportion as the percentage of Federal/non-Federal participation in the overall budget.</td>
<td></td>
</tr>
<tr>
<td>authorized organizational official</td>
<td>The individual, named by the applicant organization, who is authorized to act for the applicant and to assume the obligations imposed by the Federal laws, regulations, requirements, and conditions that apply to grant applications or grant awards. This official is equivalent to the SO in NIH’s eRA Commons.</td>
<td></td>
</tr>
<tr>
<td>award</td>
<td>The provision of funds by NIH, based on an approved application and budget or progress report, to an organizational entity or an individual to carry out a project or activity.</td>
<td></td>
</tr>
<tr>
<td>awarding office</td>
<td>The NIH IC responsible for the award, administration, and monitoring of particular grants.</td>
<td></td>
</tr>
<tr>
<td>budget period</td>
<td>The intervals of time (usually 12 months each) into which a project period is divided for budgetary and funding purposes.</td>
<td></td>
</tr>
</tbody>
</table>
capital expenditure  The cost of an asset (land, building, equipment), including the cost to put it in place. A capital expenditure for equipment includes the net invoice price and the cost of any modifications, attachments, accessories, or auxiliary apparatus to make it usable for the purpose for which it was acquired. Other charges, such as taxes, in-transit insurance, freight, and installation, may be included in capital expenditure costs in accordance with the recipient’s regular accounting practices consistently applied regardless of the source of funds. (See “Administrative Requirements—Changes in Project and Budget—Prior-Approval Requirements—Capital Expenditures.”)

clinical research  Patient-oriented research, including epidemiologic and behavioral studies, outcomes research, and health services research. Patient-oriented research is research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) in which a researcher directly interacts with human subjects. It includes research on mechanisms of human disease, therapeutic interventions, clinical trials, and development of new technologies, but does not include in vitro studies that use human tissues that cannot be linked to a living individual. Studies falling under 45 CFR 46.101(a) (4) are not considered clinical research for purposes of this definition.

clinical trial  A biomedical or behavioral research study of human subjects that is designed to answer specific questions about biomedical or behavioral interventions (drugs, treatments, devices, or new ways of using known drugs, treatments, or devices). Clinical trials are used to determine whether new biomedical or behavioral interventions are safe, efficacious, and effective. Clinical trials of an experimental drug, treatment, device, or intervention may proceed through four phases:

Phase I. Testing in a small group of people (e.g. 20-80) to determine efficacy and evaluate safety (e.g., determine a safe dosage range and identify side effects).

Phase II. Study in a larger group of people (several hundred) to determine efficacy and further evaluate safety.

Phase III. Study to determine efficacy in large groups of people (from several hundred to several thousand) by comparing the intervention to other standard or experimental interventions, to monitor adverse effects, and to collect information to allow safe use.

Phase IV. Studies done after the intervention has been marketed. These studies are designed to monitor the effectiveness of the approved intervention in the general population and to collect information about any adverse effects associated with widespread use.
<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>competitive segment</td>
<td>The initial project period recommended for support (up to 5 years) or each extension of a project period resulting from a competing continuation award.</td>
</tr>
<tr>
<td>consortium agreement</td>
<td>A formalized agreement whereby a research project is carried out by the grantee and one or more other organizations that are separate legal entities. Under the agreement, the grantee must perform a substantive role in the conduct of the planned research and not merely serve as a conduit of funds to another party or parties. (See “Consortium Agreements” in Part II, Subpart B.)</td>
</tr>
<tr>
<td>contract under a grant</td>
<td>A written agreement between a grantee and a third party to acquire routine goods or services.</td>
</tr>
<tr>
<td>consultant</td>
<td>An individual who provides professional advice or services for a fee, but normally not as an employee of the engaging party. In unusual situations, an individual may be both a consultant and an employee of the same party, receiving compensation for some services as a consultant and for other work as a salaried employee. Consultants also include firms that provide professional advice or services. (See “Allowability of Costs/Activities—Selected Items of Cost—Consultant Services.”)</td>
</tr>
<tr>
<td>cooperative agreement</td>
<td>A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, scientific or program staff will assist, guide, coordinate, or participate in project activities.</td>
</tr>
<tr>
<td>co-investigator</td>
<td>An individual involved with the PI in the scientific development or execution of a project. The co-investigator (collaborator) may be employed by, or be affiliated with, the applicant/grantee organization or another organization participating in the project under a consortium agreement. A co-investigator typically devotes a specified percentage of time to the project and is considered “key personnel.” The designation of a co-investigator, if applicable, does not affect the PI’s roles and responsibilities as specified in the NIHGPS.</td>
</tr>
<tr>
<td>cost overrun</td>
<td>Any amount charged in excess of the Federal share of costs for the project period (competitive segment).</td>
</tr>
<tr>
<td>cost sharing</td>
<td>See “matching or cost sharing” in this section.</td>
</tr>
<tr>
<td>direct costs</td>
<td>Costs that can be specifically identified with a particular project or activity.</td>
</tr>
<tr>
<td>domestic organization</td>
<td>A public (including a State or other governmental agency) or private non-profit or for-profit organization that is located in the United States or its territories, is subject to U.S. laws, and assumes legal and financial accountability for awarded funds and for the performance of the grant-supported activities.</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>equipment</td>
<td>An article of tangible nonexpendable personal property that has a useful life of more than 1 year and an acquisition cost per unit that equals or exceeds $5,000 or the capitalization threshold established by the organization, whichever is less.</td>
</tr>
<tr>
<td>expanded authorities</td>
<td>Operating authorities provided to grantees that waive the requirement for NIH prior approval for specified actions (see “Administrative Requirements—Changes in Project and Budget—Expanded Authorities”).</td>
</tr>
<tr>
<td>facilities and administrative costs</td>
<td>Costs that are incurred by a grantee for common or joint objectives and cannot be identified specifically with a particular project or program. These costs also are known as “indirect costs.”</td>
</tr>
<tr>
<td>Federal Demonstration Partnership</td>
<td>A cooperative initiative among some Federal agencies, including NIH, selected organizations receiving Federal funding for research, and certain professional associations. Its efforts include demonstration projects intended to simplify and standardize Federal requirements in order to increase research productivity and reduce administrative costs.</td>
</tr>
<tr>
<td>Federal institution</td>
<td>A Cabinet-level department or independent agency of the executive branch of the Federal government or any component organization of such a department or agency.</td>
</tr>
<tr>
<td>fee</td>
<td>An amount, in addition to actual, allowable costs, paid to an organization providing goods or services consistent with normal commercial practice. This payment also is referred to as “profit.” (See “Grants to For-Profit Organizations—Small Business Innovation Research and Small Business Technology Transfer Programs—Allowable Costs and Fee—Profit or Fee.”)</td>
</tr>
<tr>
<td>financial assistance</td>
<td>Transfer by NIH of money or property to an eligible entity to support or stimulate a public purpose authorized by statute.</td>
</tr>
<tr>
<td>foreign component</td>
<td>The performance of any significant scientific element or segment of a project outside of the United States, either by the grantee or by a researcher employed by a foreign organization, whether or not grant funds are expended. Activities that would meet this definition include, but are not limited to, (1) the involvement of human subjects or animals, (2) extensive foreign travel by grantee project staff for the purpose of data collection, surveying, sampling, and similar activities, or (3) any activity of the grantee that may have an impact on U.S. foreign policy through involvement in the affairs or environment of a foreign country. Foreign travel for consultation is not considered a foreign component. (See “Grants to Foreign Institutions, International Organizations, and Domestic Grants with Foreign Components.”)</td>
</tr>
</tbody>
</table>
foreign institution

An organization located in a country other than the United States and its territories that is subject to the laws of that country, regardless of the citizenship of the proposed PI.

for-profit organization

An organization, institution, corporation, or other legal entity that is organized or operated for the profit or financial benefit of its shareholders or other owners. Such organizations also are referred to as “commercial organizations.”

full-time appointment

The number of days per week and/or months per year representing full-time effort at the applicant/grantee organization, as specified in organizational policy. The organization’s policy must be applied consistently regardless of the source of support.

grant

A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity. A grant is used whenever the NIH IC anticipates no substantial programmatic involvement with the recipient during performance of the financially assisted activities.

grant-supported project or activity

Those activities specified or described in a grant application or in a subsequent submission that are approved by an NIH IC for funding, regardless of whether Federal funding constitutes all or only a portion of the financial support necessary to carry them out.

grantee

The organization or individual awarded a grant or cooperative agreement by NIH that is responsible and accountable for the use of the funds provided and for the performance of the grant-supported project or activity. The grantee is the entire legal entity even if a particular component is designated in NGA. The grantee is legally responsible and accountable to NIH for the performance and financial aspects of the grant-supported project or activity.

Grants Management Officer

An NIH official responsible for the business management aspects of grants and cooperative agreements, including review, negotiation, award, and administration, and for the interpretation of grants administration policies and provisions. Only GMOs are authorized to obligate NIH to the expenditure of funds and permit changes to approved projects on behalf of NIH. Each NIH IC that awards grants has one or more GMOs with responsibility for particular programs or awards.

Grants Management Specialist

An NIH staff member who oversees the business and other non-programmatic aspects of one or more grants and/or cooperative agreements. These activities include, but are not limited to, evaluating grant applications for administrative content and compliance with statutes, regulations, and guidelines; negotiating grants; providing consultation and technical assistance to grantees; and administering grants after award.
hospital  A non-profit or for-profit hospital or a medical care provider component of a non-profit organization (for example, a foundation). The term includes all types of medical, psychiatric, and dental facilities, such as clinics, infirmaries, and sanatoria.

human subject  A living individual about whom an investigator (whether professional or student) conducting research obtains data through intervention or interaction with the individual or obtains identifiable private information. Regulations governing the use of human subjects in research extend to use of human organs, tissues, and body fluids from identifiable individuals as human subjects and to graphic, written, or recorded information derived from such individuals. (See “Requirements Affecting the Rights and Welfare of Individuals as Research Subjects, Patients, or Recipients of Services—Human Subjects.”)

indirect costs  See “facilities and administrative costs.”

Institute or Center  The NIH organizational component responsible for a particular grant program or set of activities. The terms “NIH IC” or “awarding office” are used throughout this document to designate a point of contact for advice and interpretation of grant requirements and to establish the focal point for requesting necessary prior approvals or changes in the terms and conditions of award. In the latter case, the terms refer specifically to the designated GMO.

institutional base salary  The annual compensation paid by an organization for an employee’s appointment, whether that individual’s time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual is permitted to earn outside of duties for the applicant/grantee organization. Base salary may not be increased as a result of replacing organizational salary funds with NIH grant funds. (See “Allowability of Costs/Activities—Selected Items of Cost—Salaries and Wages.”)

international organization  An organization that identifies itself as international or intergovernmental and has membership from, and represents the interests of, more than one country, without regard to whether the headquarters of the organization and location of the activity are inside or outside of the United States.

key personnel  The PI and other individuals who contribute to the scientific development or execution of a project in a substantive, measurable way, whether or not they receive salaries or compensation under the grant. Typically these individuals have doctoral or other professional degrees, although individuals at the masters or baccalaureate level may be considered key personnel if their involvement meets this definition. Consultants also may be considered key personnel if they meet this definition. “Zero percent” effort or “as needed” is not an acceptable level of involvement for key personnel.
matching or cost sharing  The value of third-party in-kind contributions and the portion of the costs of a federally assisted project or program not borne by the Federal government. Matching or cost sharing may be required by law, regulation, or administrative decision of an NIH IC. Costs used to satisfy matching or cost-sharing requirements are subject to the same policies governing allowability as other costs under the approved budget.

modular application  A type of grant application in which support is requested in specified increments without the need for detailed supporting information related to separate budget categories. When modular procedures apply, they affect not only application preparation but also review of the application, award, and post-award administration.

monitoring  A process whereby the programmatic and business management performance aspects of a grant are assessed by reviewing information gathered from various required reports, audits, site visits, and other sources.

new investigator  An individual who has not previously served as a PI on any PHS-supported research project other than a small grant (R03), an Academic Research Enhancement Award (R15), an exploratory development grant (R21), or certain research career awards directed principally to physicians, dentists, or veterinarians at the beginning of their research careers ((K01, K08, and K12). Current or past recipients of Independent Scientist and other non-mentored career awards (K02 and K04) are not considered “new investigators.”

Notice of Grant Award  The legally binding document that notifies the grantee and others that an award has been made, contains or references all terms and conditions of the award, and documents the obligation of Federal funds. The award notice may be in letter format and may be issued electronically.

organization  A generic term used to refer to an educational institution or other entity, including an individual, which applies for or receives an NIH grant or cooperative agreement.

other support  Includes all financial resources, whether Federal, non-Federal, commercial or organizational, available in direct support of an individual’s research endeavors, including, but not limited to, research grants, cooperative agreements, contracts, or organizational awards. Other support does not include training awards, prizes, or gifts.
<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase III clinical trial</td>
<td>As defined by NIH, a broadly based prospective Phase III clinical investigation (usually involving several hundred or more human subjects) to evaluate an experimental intervention in comparison with a standard or control intervention or to compare two or more existing treatments. The definition includes pharmacologic, non-pharmacologic, and behavioral interventions given for disease prevention, prophylaxis, diagnosis, or therapy. Community trials and other population-based intervention trials also are included. (See “clinical trial.”)</td>
</tr>
<tr>
<td>Principal Investigator/Program Director/Project Director</td>
<td>An individual designated by the grantee to direct the project or activity being supported by the grant. He or she is responsible and accountable to the grantee and NIH for the proper conduct of the project or activity.</td>
</tr>
<tr>
<td>Prior approval</td>
<td>Written approval from the designated GMO required for specified post-award changes in the approved project or budget. Such approval must be obtained before undertaking the proposed activity or spending NIH funds (see “Administrative Requirements—Changes in Project and Budget—Prior-Approval Requirements”).</td>
</tr>
<tr>
<td>Priority score</td>
<td>A numerical rating of an application that reflects the scientific merit of the proposed research relative to stated evaluation criteria.</td>
</tr>
<tr>
<td>Profit</td>
<td>See “fee.”</td>
</tr>
<tr>
<td>Program</td>
<td>A coherent assembly of plans, project activities, and supporting resources contained within an administrative framework, the purpose of which is to implement an organization’s mission or some specific program-related aspect of that mission. For the NIHGPS, “program” refers to those NIH programs that carry out their missions through the award of grants or cooperative agreements to other organizations.</td>
</tr>
<tr>
<td>Program Income</td>
<td>Gross income earned by a grantee that is directly generated by the grant-supported project or activity or earned as a result of the award (see “Administrative Requirements—Management Systems and Procedures—Program Income”).</td>
</tr>
<tr>
<td>Program Official</td>
<td>The NIH official responsible for the programmatic, scientific, and/or technical aspects of a grant.</td>
</tr>
<tr>
<td>Progress report</td>
<td>Periodic, usually annual, report submitted by the grantee and used by NIH to assess progress and, except for the final progress report of a project period, to determine whether to provide funding for the budget period subsequent to that covered by the report.</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>project period</td>
<td>The total time for which support of a project has been programmatically approved. The total project period comprises the initial competitive segment, any subsequent competitive segments resulting from a competing continuation award, and non-competing extensions.</td>
</tr>
<tr>
<td>real property</td>
<td>Land, including land improvements, structures, and appurtenances, but not movable machinery and equipment.</td>
</tr>
<tr>
<td>recipient</td>
<td>The organizational entity or individual receiving a grant or cooperative agreement. See “grantee.”</td>
</tr>
<tr>
<td>research</td>
<td>A systematic, intensive study intended to increase knowledge or understanding of the subject studied, a systematic study specifically directed toward applying new knowledge to meet a recognized need, or a systematic application of knowledge to the production of useful materials, devices, and systems or methods, including design, development, and improvement of prototypes and new processes to meet specific requirements. Also termed “research and development.”</td>
</tr>
<tr>
<td>research misconduct</td>
<td>Fabrication, falsification, or plagiarism in proposing, performing, or reporting research, or in reporting research results. Fabrication is making up data or results and recording or reporting them. Falsification is manipulating research materials, equipment, or processes, or changing or omitting data or results such that research is not accurately represented in the research record. Plagiarism is the appropriation of another person’s ideas, processes, results, or words without giving appropriate credit. The term does not include honest error or honest differences of opinion.</td>
</tr>
<tr>
<td>significant rebudgeting</td>
<td>A threshold that is reached when expenditures in a single direct cost budget category deviate (increase or decrease) from the categorical commitment level established for the budget period by more than 25 percent of the total costs awarded. Significant rebudgeting is one indicator of change in scope.</td>
</tr>
<tr>
<td>small business concern</td>
<td>A business that is independently owned and operated and not dominant in its field of operation; has its principal place of business in the United States and is organized for profit; is at least 51 percent owned, or in the case of a publicly owned business, at least 51 percent of its voting stock is owned by U.S. citizens or lawfully admitted permanent resident aliens; has, including its affiliates, not more than 500 employees; and meets other regulatory requirements established by the SBA at 13 CFR 121.</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>State government</td>
<td>The government of any State of the United States, the District of Columbia, the Commonwealth of Puerto Rico, any U.S. territory or possession, or any agency or instrumentality of a State exclusive of local governments. For purposes of NIH grants, federally recognized Indian tribal governments generally are considered State governments. State institutions of higher education and State hospitals are not considered State governments for HHS’s general administrative requirements for grants and the NIHGPS.</td>
</tr>
<tr>
<td>stipend</td>
<td>A payment made to an individual under a fellowship or training grant in accordance with preestablished levels to provide for the individual’s living expenses during the period of training. A stipend is not considered compensation for the services expected of an employee.</td>
</tr>
<tr>
<td>suspension</td>
<td>Temporary withdrawal of a grantees authority to obligate grant funds, pending either corrective action by the grantees, as specified by NIH, or a decision by NIH to terminate the award. This meaning of the term “suspension” differs from that used in conjunction with the debarment and suspension process (see “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—Debarment and Suspension” and “Administrative Requirements—Enforcement Actions.”)</td>
</tr>
<tr>
<td>termination</td>
<td>Permanent withdrawal by NIH of a grantees authority to obligate previously awarded grant funds before that authority would otherwise expire, including the voluntary relinquishment of that authority by the grantee.</td>
</tr>
<tr>
<td>terms and conditions of award</td>
<td>All legal requirements imposed on a grant by NIH, whether based on statute, regulation, policy, or other document referenced in the grant award, or specified by the grant award document itself. The NGA may include both standard and special conditions that are considered necessary to attain the grant’s objectives, facilitate post-award administration of the grant, conserve grant funds, or otherwise protect the Federal government’s interests.</td>
</tr>
<tr>
<td>total project costs</td>
<td>The total allowable costs (both direct costs and F&amp;A costs) incurred by the grantee to carry out a grant-supported project or activity. Total project costs include costs charged to the NIH grant and costs borne by the grantee to satisfy a matching or cost-sharing requirement.</td>
</tr>
<tr>
<td>United States</td>
<td>The 50 States, territories, and possessions of the United States, the Commonwealth of Puerto Rico, the Trust Territory of the Pacific Islands, and the District of Columbia.</td>
</tr>
<tr>
<td>withholding of support</td>
<td>A decision by NIH not to make a non-competing continuation award within the current competitive segment.</td>
</tr>
</tbody>
</table>
THE NATIONAL INSTITUTES OF HEALTH
AS A GRANT-MAKING ORGANIZATION

This section provides information about how NIH is organized to award and administer grants and describes its relationship to other organizations within HHS (or the Department) and external to HHS.

NIH, whose mission is to improve human health by increasing scientific knowledge related to disease and health, is an organizational component of HHS. NIH operates under the general policy guidance of the Department in carrying out its mission, which is accomplished through the conduct and support of biomedical and behavioral research, research training, research infrastructure, and communications. These efforts take place intramurally (primarily at NIH) and extramurally (through grants, cooperative agreements, and contracts awarded to institutions of higher education, governmental organizations, non-profit research organizations, for-profit organizations, and individuals). NIH also works closely with other HHS components and other Federal departments and agencies.2

HHS develops, issues, and maintains regulations that govern the Department’s grants process. Among these are the regulations that implement the OMB Circular A-102 common rule (applicable to grants to State, local, and Indian tribal governments) and OMB Circular A-110 (applicable to grants to institutions of higher education, hospitals, and other non-profit organizations). These regulations are codified at 45 CFR Part 74 (Uniform Administrative Requirements for Awards and Subawards to Institutions of Higher Education, Hospitals, Other Non-Profit Organizations, and Commercial Organizations; and Certain Grants and Agreements with States, Local Governments, and Indian Tribal Governments) and 45 CFR Part 92 (Uniform Administrative Requirements for Grants and Cooperative Agreements to State and Local Governments).3 They provide the framework for the terms and conditions of NIH awards as specified in Part II of the NIHGPS.

NIH is organized into ICs, each with its own mission and functions, separate appropriations, and statutory authorities. The ICs that award grants are listed in Part III. Although the ICs operate under the same general grant process and requirements, applicants and grantees need to be aware of differences that may exist. This information may be obtained from NIH staff. The policies and procedures generally applicable to NIH grants are set forth in the NIHGPS.

Roles and Responsibilities

NIH, as a Federal grantor agency, is responsible to Congress and the U.S. taxpayer for carrying out its mission in a manner that not only facilitates research but does so cost-effectively and in compliance with applicable rules and regulations. NIH seeks to ensure integrity and accountability in its grant award and administration processes by relying on a system of checks and balances and separation of responsibilities within its own staff and by establishing a similar

---

2 HHS components include SAMHSA, FDA, CDC, IHS, AHRQ, HRSA, ACF, AoA, OPHS, and CMS.
3 Although the government-wide requirements do not cover grants to for-profit organizations, HHS has included them in the coverage of 45 CFR Part 74.
set of expectations for grantee organizations. The grantee’s roles and responsibilities have assumed greater importance as NIH has shifted to increased reliance on systems compliance and provided greater decision-making authority to grantees.

The following subsections highlight the major functions and areas of responsibility of Federal and grantee staffs. NIH recognizes that additional staff members in a number of different organizations may be involved in grant-related activities; however, this section details only the major participants representing the Federal government and the grantee. The responsibilities of CSR staff members, who are involved only in the initial review phase of the peer review process, are described in the “Application and Review Processes” section in this Part. The responsibilities of other offices, such as OHRP, are described in Part II.

NIH and HHS Staff

The roles and responsibilities of NIH and HHS participants are as follows:

- **Grants Management Officer.** The GMO whose name appears on the NGA is the NIH official responsible for the business management and other non-programmatic aspects of the award. These activities include, but are not limited to, evaluating grant applications for administrative content and compliance with statutes, regulations, and guidelines; negotiating grants; providing consultation and technical assistance to applicants and grantees, including interpretation of grants administration policies and provisions; and administering and closing out grants. The GMO works closely with his or her counterparts in other NIH ICs and with the designated PO. The GMO is the focal point for receiving and acting on requests for NIH prior approval or for changes in the terms and conditions of award and is the only NIH official authorized to obligate NIH to the expenditure of Federal funds or to change the funding, duration, or other terms and conditions of award.

- **Grants Management Specialist.** The GMS is an agent of the GMO and is assigned responsibility for the day-to-day management of a portfolio of grants.

- **Program Official.** The PO is responsible for the programmatic, scientific, and/or technical aspects of assigned applications and grants. The PO’s responsibilities include, but are not limited to, development of research and research training programs to meet the IC’s mission; coordination with CSR/IC SRAs; and post-award administration, including review of progress reports, participation in site visits, and other activities complementary to those of the GMO. The PO and the GMO work as a team in many of these activities.

- **Scientific Review Administrator.** SRAs are health science administrators who manage the activities of SRGs, including CSR study sections. For the SRG for which he or she is responsible, the SRA reviews applications for completeness and conformity to requirements, ensures that adequate numbers of reviewers with appropriate expertise are available for application review, assigns applications to individual reviewers as discussion leaders and for preparation of written critiques, and serves as the overall point
of contact with applicants during the initial phase of the peer review process, i.e., until the conclusion of the SRG meeting.

◆ **Other NIH and HHS Staffs.** In addition to the GMO and PO, the grantee may be required to interact with other NIH or HHS staff members or offices with respect to its organization-wide systems and/or individual transactions. These include the office responsible for negotiating F&A costs and research patient care rates, typically the cognizant (based on geographical location) DCA office or DFAS; OIG; OHRP; OLAW; and ORI. Staff members in these offices generally coordinate with the GMO, but they are responsible for discrete areas of specialization and are not required to channel their communications with the grantee through the GMO. Part III includes a list of these organizations and their addresses and telephone numbers.

**Grantee Staff**

The roles and responsibilities of grantee participants are as follows:

◆ **Authorized Organizational Official.** The AOO is the designated representative of the grantee organization in matters related to the award and administration of its NIH grants, including those that require NIH approval. In signing a grant application, this individual certifies that the applicant organization will comply with all applicable assurances and certifications referenced in the application. This individual’s signature on the grant application further certifies that the applicant organization will be accountable both for the appropriate use of funds awarded and for the performance of the grant-supported project or activities resulting from the application. (Also see “Legal Implication of Application.”) This individual also is responsible to NIH for ensuring that the organization complies with applicable Federal laws and regulations, including required certifications and assurances, its application, and the terms and conditions of individual awards. Under NIH’s eRA Commons, this individual is the SO. Although NIH requires that the grantee organization designate such an official, NIH does not specify the organizational location or full set of responsibilities for this official.

◆ **Principal Investigator.** The PI (who also may be known as the PD) is the individual, designated by the grantee, responsible for the scientific or technical aspects of the grant and for day-to-day management of the project or program. The PI is not required to be an employee of the grantee. However, because the grant, if awarded, is made to the organization, the applicant organization must have a formal written agreement with the PI that specifies an official relationship between the parties even if the relationship does not involve a salary or other form of remuneration. If the PI is not an employee of the applicant organization, NIH will assess whether the arrangement will result in the organization being able to fulfill its responsibilities under the grant, if awarded.

The PI is a member of the grantee team responsible for ensuring compliance with the financial and administrative aspects of the award. This individual works closely with

---

4 Onr is the cognizant agency for negotiation of F&A costs for some NIH grantees.
designated officials within the grantee organization to create and maintain necessary
documentation, including both technical and administrative reports; prepare
justifications; appropriately acknowledge Federal support of research findings in
publications, announcements, news programs, and other media; and ensure compliance
with other Federal and organizational requirements. NIH encourages the PI to maintain
contact with the NIH PO with respect to the scientific aspects of the project and the GMO
concerning the business and administrative aspects of the award.

NOTE: NIH staff members conduct official business only with the designated PI and AOOs.

Application and Review Processes

This subsection provides an overview of NIH’s grant support mechanisms, types of entities
eligible to receive grants, types of applications, types of funding opportunities, application
submission (including application forms, application receipt points and deadlines, legal
implication, and proprietary information), and the peer review process. It includes publications
and NIH websites that can be accessed for additional information concerning the NIH grants
process and programs.

Support Mechanisms

NIH ICs award grants under multiple programs and subprogram initiatives and use a variety of
support mechanisms. NIH grants may be distinguished by purpose, type of recipient, amount, or
other characteristics. One method NIH uses to differentiate the various support mechanisms is
activity coding that indicates the category and specific form of support (e.g., R01, F32). The
applicability of requirements may vary for different activity codes. Therefore, applicants should
consult one or more of the information sources described in “Sources of Information about
NIH’s Grants Process and Programs” at the end of this section. Some of the distinctions also are
significant for purposes of applying Part II of the NIHGPS.

Eligibility

In general, NIH grants may be awarded to organizations that are domestic or foreign, public or
private, or non-profit or for-profit. Eligible organizations include governments, including Federal
institutions, institutions of higher education, hospitals, and, in this usage, also include
individuals. Any special criteria for applicant eligibility or requirements concerning the
qualifications of the PI or other staff or participants will be specified in the program solicitation,
program guidelines, or other publicly available documents. Part II includes information on fellow
and trainee eligibility.

Types of Award Instruments

NIH uses several different extramural award instruments in support of its mission. NIH grants
and cooperative agreements are financial assistance instruments. Under a cooperative agreement,
NIH expects to be substantially involved in carrying out the project. Grants are used both for
investigator-initiated research and for more targeted research. Cooperative agreements generally
do not result from investigator-initiated applications. The NIHGPS pertains to grants and
cooperative agreements; however, NIH may apply terms and conditions that differ from those in the NIHGPS consistent with the nature of its involvement under cooperative agreements.

Types of Applications

In the NIH grants process, five types of applications are used most frequently. Each of the first four application types is considered “competing” because, through the peer review process, the application must compete for available funding with other applications.

- **New Application (Type 1)**—a request for financial assistance for a project or activity that is not currently receiving NIH support and must compete for support.

- **Competing Continuation Application (Type 2)**—a request for funding to renew, by one or more additional budget periods, a project period that would otherwise expire.

- **Competing Supplemental Application (Type 3)**—a request for an increase in support in a current budget period for expansion of the project’s approved scope or research protocol. The request may specify budgetary changes required for the remainder of the project period as well as for the current budget period. (A Type 3 prefix also refers to a request/award for a non-competing administrative supplement [see “Administrative Requirements—Changes in Project and Budget—Prior-Approval Requirements—Need for Additional NIH Funding without Extension of Budget and Project Period.”].)

- **Revised (Amended) Application**—an unfunded application that the applicant has modified following initial review and resubmitted for consideration. NIH allows a maximum of two revised applications. An amended application may be submitted for any of the three preceding types of applications. However, NIH generally treats unfunded applications resubmitted under a different process or research grant mechanism than the original application (e.g., an application originally submitted as investigator-initiated and, subsequently, resubmitted in response to an RFA, or an application originally submitted as an R01 and, subsequently, resubmitted as an R21) as new applications rather than as amended applications.

- **Non-Competing Grant Progress Report (Type 5)**—a progress report and request for funding of a non-competing continuation award for the second or subsequent budget period within an approved competitive segment (see “Administrative Requirements—Monitoring—Reporting—Non-Competing Grant Progress Reports”).

NIH uses the numbers shown in parentheses as prefixes to distinguish the application types and any resulting awards.

Types of Funding Opportunities

The preponderance of applications submitted to NIH under the categories of research and research training (including fellowships) are for investigator-initiated research and are considered “unsolicited” applications. NIH reviews such applications in three review cycles per
year. The schedules for submission, review, and award of unsolicited applications are included in the application instructions and on the NIH home page.

All applicants are encouraged to contact the IC from which they plan to seek funding. See Part III for a list of the IC contact points. However, any applicant requesting $500,000 or more in direct costs in any year in an unsolicited application is required to contact the IC PO, in writing or by telephone, as early as possible during development of the application but no later than 6 weeks before submission. This requirement applies to a single application, whether a new, competing continuation, competing supplemental, or revised (amended) grant application, under any NIH support mechanism; it also applies to a group of applications, such as those for clinical trial networks, meeting that threshold in the aggregate even if no single application in the group requests that much. Applicants that are uncertain about which IC to contact should contact the Division of Receipt and Referral, CSR (see Part III). CSR will accept such applications for review only if an IC has agreed to accept the application for consideration and the applicant submits with its application a letter to that effect with the name of the authorizing program staff member and IC affiliation (see “The Peer Review Process”). An application subject to this policy that does not include the required information in the cover letter accompanying the application will be returned to the applicant without review. This policy does not apply to applications submitted in response to RFAs or other announcements that include specific budgetary limits. However, such applications must be responsive to any budgetary limits specified or NIH will return them to applicants without review.

NIH may develop areas of high priority or special research interest and use a special solicitation to stimulate submission of applications in those areas. These solicitations are published in the NIH Guide for Grants and Contracts, which is electronically linked to Grants.gov, a government-wide site for locating grant and cooperative agreement funding opportunities (http://www.fedgrants.gov).

NIH solicitations take one of two forms: PAs and RFAs. NIH uses PAs to describe new, continuing, or expanded program interests of an IC or to announce the availability of a new mechanism of support. PAs may be used for any support mechanism other than construction awards. Unless otherwise specified in the PA, new applications (and associated competing continuation and competing supplemental applications) submitted in response to PAs are treated as unsolicited, are subject to the common receipt dates, compete for funding with all other unsolicited applications, and are subject to the standard peer review process. PAs also are used to annually solicit applications for the SBIR and STTR programs. Those applications must be received by the dates specified in the PA.

An RFA is a more targeted solicitation; it may be used to solicit the following:

- Grant applications in a well-defined scientific area
- Research grant applications for a one-time competition

---

Some ICs review applications for Institutional National Research Service Awards (T32) only once a year. See the Appendix in Part II of the NIHGPS.
Construction grant applications

Applications for cooperative agreements.

RFAs are stand-alone solicitations, and each will provide sufficient information to allow prospective applicants to determine whether to apply. That information includes the amount of funding available, the number of awards anticipated, whether cost sharing is required, the deadline date for receipt of applications, and other information describing the nature of the effort desired and the obligations of recipients. For cooperative agreements, the RFA will describe the responsibilities and obligations of NIH and awardees as well as joint responsibilities and obligations.

Application Submission

To be considered for support, an applicant must be an eligible entity and must submit a complete application in accordance with established receipt (deadline) dates. Information to be submitted typically includes a project description, budget and budget justification, biographical sketches of key personnel, and other information specified in the application instructions, in the solicitation, and/or in program guidelines, if any. Applicants should consult the cost principles and general administrative requirements for grants pertaining to their organizational type in order to prepare the budget and complete other parts of the application. Applicants may be required to provide proof of organizational eligibility (such as proof of non-profit status), trainee or fellow eligibility and citizenship, or other eligibility information. Applications also must demonstrate compliance (or intent to comply), through certification or other means, with a number of public policy requirements. The more significant of the public policy requirements for the purpose of peer review are those concerning research involving human subjects; inclusion of both genders, members of minority groups, and children in clinical research; and research involving live vertebrate animals. Part II details public policy requirements and cost and administrative policies.

Application Forms

Exhibit 1 lists the required application forms, which vary by support mechanism. These forms and associated instructions are available electronically on the NIH home page (http://grants.nih.gov/grants/forms.htm). Questions about application forms and instructions may be directed to DEOIR, OER, NIH by telephone at 301-435-0714 or by e-mail at GrantsInfo@nih.gov (see Part III). Certain forms (rather than a complete application kit) are available electronically on the NIH home page (http://grants.nih.gov/grants/forms.htm).
Exhibit 1. Required Forms for Competing Applications

<table>
<thead>
<tr>
<th>Application title</th>
<th>Form number</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application for a Public Health Service Grant</td>
<td>PHS 398</td>
<td>Research project grants and cooperative agreements, program projects, centers, K awards, Kirschstein-NRSA institutional research training grants, conference grants, and SBIR and STTR grants (see Section VI of the instructions)</td>
</tr>
<tr>
<td>Application for Ruth L. Kirschstein National Research Service Award Individual Fellowship</td>
<td>PHS 416-1</td>
<td>Kirschstein-NRSA fellowships</td>
</tr>
<tr>
<td>Public Health Service Grant Application for Use by: State and Local Government Applicants and Nongovernmental Applicants for Health Services Projects</td>
<td>PHS 5161-1, with budget and assurances applicable to nonconstruction (424-A and 424-B) or construction (424-C and 424-D)</td>
<td>State, local, and Indian tribal governmental applicants for all types of grants, and nongovernmental applicants for construction grants</td>
</tr>
</tbody>
</table>

*Application Receipt Points and Deadlines*

All competing applications, whether solicited or unsolicited, are required to be sent or delivered via the USPS or a courier delivery service, in the number of copies specified in the application instructions or solicitation, to the central NIH receipt point:

Center for Scientific Review  
National Institutes of Health  
Suite 1040  
6701 Rockledge Drive, MSC-7710  
Bethesda, MD 20892-7710 (zip code for applications sent by USPS regular or Express mail)  
Bethesda, MD 20817 (zip code for applications sent using a courier service)

Preaddressed mailing labels are included with the application forms.

CSR will not accept applications delivered by individuals.

Applicants responding to RFAs should submit copies of their application concurrently to CSR and the soliciting IC.

An unsolicited application will be considered to be on time for a particular review cycle if it is received by or mailed on or before the published receipt date for that cycle and a proof of mailing is provided. If the receipt date falls on a weekend or a Federal holiday, the date for receipt/mailing is extended to the next business day.

An application submitted in response to an RFA or a PA but received after the deadline date (if one is specified in the RFA or PA) may be accepted only if it carries a legible proof-of-mailing date assigned by the carrier and that date is no later than 1 week prior to the deadline date. This
applies only to PAs with specific, published receipt dates, i.e., dates other than the standard ones used for unsolicited applications. For PAs using the standard receipt dates, the rules for unsolicited applications apply as described above.

The established receipt or deadline date will be waived only in extenuating circumstances. A request for a waiver must accompany the application and must explain the basis for requesting a waiver. A waiver will not be considered before the application is received. Only CSR has the authority to waive an established receipt date.

**Legal Implication of Application**

The signature of an AOO on the application certifies that the organization will comply with all applicable assurances and certifications referenced in the application. The applicant organization is responsible for verifying the accuracy, validity, and conformity with the most current organizational guidelines of all the administrative, fiscal, and scientific information in the application, including the F&A cost (indirect cost) rate. The AOO’s signature further certifies that the applicant organization will be accountable for the appropriate use of any funds awarded and for the performance of the grant-supported project or activities resulting from the application.

Applicants for and recipients of NIH grant funds, whether such funds are received directly from NIH, indirectly under a contract or consortium agreement, or as student assistance under a training grant, are responsible for and must adhere to all applicable Federal statutes, regulations, and policies, including income tax regulations. Questions concerning the applicability of income tax regulations to grant funds should be directed to the IRS. The applicant also is expected to be in compliance with applicable State and local laws and ordinances.

The HHS OIG maintains a post office box and a toll-free hot line for receiving information from individuals concerning fraud, waste, or abuse under HHS grants and cooperative agreements. The identity of the caller is kept confidential, and callers are not required to give their names. The address and telephone number of the OIG and the OIG hot line are included in Part III. Anyone who becomes aware of the existence (or apparent existence) of fraud, waste, or abuse related to NIH grants or grant funds is encouraged to report this information to the OIG in writing or to the OIG hot line. Examples of fraud, waste, and abuse that should be reported include, but are not limited to, embezzlement, misuse, or misappropriation of grant funds or property, and false statements, whether by organizations or individuals. This includes theft of grant funds for personal use; using funds for non-grant-related purposes; theft of federally owned property or property acquired or leased under a grant; charging the Federal government for the services of “ghost” individuals; charging inflated building rental fees for a building owned by the grantee; submitting false financial reports; and submitting false financial data in bids submitted to the grantee (for eventual payment under the grant).

Part II of the NIHGPS includes administrative and other remedies the Federal government may use if a grantee deliberately withholds information or submits fraudulent information or does not comply with applicable requirements. Even if a grant is not awarded, the applicant may be subject to penalties if the information contained in or submitted as part of an application, including its certifications and assurances, is found to be false, fictitious, or fraudulent. The
Federal government may pursue civil or criminal action under a variety of statutes and regulations.

The Program Fraud and Civil Remedies Act of 1986, 31 U.S.C. 3801 et seq., provides for the administrative imposition by HHS of civil penalties and assessments against persons who knowingly make false, fictitious, or misleading claims to the Federal government for money, including money representing grants, loans, or benefits. A civil penalty of not more than $5,000 may be assessed for each such claim. If a grant is awarded and payment is made on a false or fraudulent claim, an assessment of not more than twice the amount of the claim, up to $150,000, may be made in lieu of damages. Regulations at 45 CFR Part 79 specify the process for imposing civil penalties and assessments, including hearing and appeal rights.

The Criminal False Claims Act, 18 U.S.C. 287 and 1001, provides for criminal prosecution of a person who knowingly makes or presents any false, fictitious, or fraudulent statements or representations or claims against the United States. Violations carry a maximum sentence of 5 years imprisonment and a fine of $250,000.

The Civil False Claims Act, 31 U.S.C. 3729(a), provides for imposition of penalties and damages by the United States, through civil litigation, against any person who knowingly makes a false or fraudulent claim for payment, makes or uses a false record or false statement to get a false claim paid or approved, or conspires to defraud the Federal government to get a false claim paid. A “false claim” is any request or demand for money or property made to the United States or to a contractor, grantee, or other recipient, if the Federal government provides or will reimburse any portion of the funds claimed. Civil penalties of $5,500 to $11,000 may be imposed for each false claim, plus damages of up to three times the amount of the false claim.

NIH also may administratively recover misspent grant funds pursuant to the authorities contained in 45 CFR Parts 74 and 92.

Confidentiality of Information (Proprietary Information)

Applicants are discouraged from submitting information considered proprietary unless it is deemed essential for proper evaluation of the application. However, if the application contains information that the applicant organization considers to be trade secrets, information that is commercial or financial, or information that is privileged or confidential, the pages containing that information should be identified as specified in the PHS 398 instructions.

When such information is included in the application, it is furnished to the Federal government in confidence, with the understanding that the information will be used or disclosed only for evaluation of the application. The information contained in an application will be protected by NIH from unauthorized disclosure, consistent with the need for peer review of the application and the requirements of the FOI and Privacy Acts, which are discussed in “Public Policy Requirements and Objectives” in Part II. However, if a grant is awarded as a result of or in connection with an application, the Federal government shall have the right to use or disclose the information to the extent authorized by law. This restriction does not limit the Federal government’s right to use the information if it is obtained without restriction from another source.
The Peer Review Process

Competing applications for NIH grants and cooperative agreements, including those for competing continuations and competing supplements, are subject to peer review as required by sections 406 and 492 of the PHS Act or by NIH policy. The peer review system used by NIH, often referred to as the “dual review system,” is based on two sequential levels of review for each application—initial review and National Advisory Council/Board review. The NIH peer review process has evolved over the years to accommodate changes in workload, resource constraints, and recommendations of various groups that have studied it. However, the underlying basis for the system—to provide a fair and objective review process in the overall interest of science—has not changed. Information concerning NIH’s peer review process may be found at the following websites: http://www.csr.nih.gov and http://grants.nih.gov/grants/peer/peer.htm. Information also is available by e-mail at GrantsInfo@nih.gov, or by calling, writing, or faxing a request to CSR (see Part III).

Initial Review

Responsibilities

CSR is the receipt point for all competing grant applications submitted to NIH, whether the peer review will be conducted by CSR or by an IC. The primary determining factors in whether CSR or an IC will be responsible for the peer review are the solicitation type, the support mechanism, and/or the program. In general, CSR is responsible for the initial review of research project grant applications (including AREA applications), Kirschstein-NRSA individual fellowship applications, and SBIR/STTR applications, while the ICs handle the initial review of conference grant applications, applications resulting from RFAs, and program project grant applications.

CSR also may review other types of applications at IC request. When the IC is responsible for the initial review, CSR reviews the application for completeness, and the scientific review office of the soliciting IC reviews the application for responsiveness to the RFA, coordinates the initial technical review, and prepares the summary statements.

CSR Referral Officers, who are senior health science administrators with both research and scientific review experience, assign each application to one or more ICs for potential funding and to an SRG for initial review of the scientific merit of the application. These determinations are made on the basis of the application’s contents, the referral guidelines, and any written request by the applicant organization (accompanying the application) for a specific study section or IC assignment.

SRGs, including CSR study sections, are organized by scientific discipline or current research areas and are managed by health scientist administrators functioning as SRAs. Generally, study sections are chartered groups composed of formally appointed members serving multiyear terms, to which the SRA often adds temporary members or other additional reviewers. Ad hoc SEPs are formed to review applications that cannot be reviewed by a standing review group or study section because they require special expertise or involve other special circumstances.
SRGs, whether study sections or SEPs, are primarily composed of scientists actively engaged in research. NIH’s conflict-of-interest and confidentiality of information policies for reviewers are intended to ensure an unbiased review process by minimizing even the appearance of a conflict of interest and by restricting the use of privileged application information.

Within 6 to 8 weeks following the established application receipt date, applicants are notified that the application has been received and are advised of the SRA, SRG, and IC assignments. At this time, applicants may request reconsideration of the SRG and IC assignment. Once the assignment process is completed, the SRA is the contact for all communication with the applicant until the conclusion of the SRG meeting. An applicant may withdraw an application from consideration at any time during the review process. A request to withdraw an application must be signed by the PI and an AOO. If an application is withdrawn before it enters the review process, CSR will return the application to the applicant. Applications withdrawn by the applicant after the beginning of the formal review may be destroyed by NIH or returned to the applicant at NIH’s discretion.

In preparation for the initial review, SRAs review applications to determine whether they are complete, conform to administrative requirements, and contain the information necessary for a detailed review. For each reviewable application, they then assign (from among the standing and temporary members) reviewers to write a critique of the application and readers to be prepared to discuss the application in detail.

Following the initial review, the SRA prepares a summary statement for each application reviewed. The summary statement includes the reviewers’ written comments, and, for scored applications, a summary of strengths and weaknesses, other summary highlights of the discussion, and a priority score. Summary statements are then provided to the IC’s program staff and the PI.

**Review Criteria**

The goals of NIH-supported research are to advance the understanding of biological systems, improve the control of disease, and enhance health. Reviewers judge the likelihood that the proposed research will have a substantial impact on the pursuit of NIH’s research goals by addressing, in their written comments about the application, the following criteria:

- **Significance.** Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field?

- **Approach.** Are the conceptual framework, design, methods, and analyses adequately developed, well integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?

- **Innovation.** Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing models or develop new methodologies or technologies?
◆ *Investigator.* Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the PI and other researchers (if any)?

◆ *Environment.* Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of organizational support?

All of the criteria, weighted as appropriate for each application, will be considered when assigning the overall score. An application does not need to be strong in all categories to be judged likely to have a major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out work that, by its nature, is not innovative but is essential to move a field forward.

Although the review criteria are intended for use primarily with unsolicited research project grant applications (e.g., R01 and P01), including those in response to PAs, to the extent reasonable, the criteria also will form the basis of the review of solicited applications and non-research activities. However, for some activities (e.g., construction grants), the use of these criteria may not be feasible. Applications also may be reviewed against specific criteria as stated in RFAs or PAs.

In addition to the above criteria, in accordance with NIH policy, all applications will be reviewed with respect to the following:

◆ Adequacy of plans to include both genders, members of minority groups, children, and their subgroups, as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects also will be evaluated.

◆ Reasonableness of the proposed budget and duration in relation to the proposed research.

◆ Adequacy of the proposed protection for humans, animals, or the environment to the extent they may be adversely affected by the project proposed in the application.

*Appeals of Initial Scientific Review*

To preserve and underscore the fairness of the NIH peer review process, NIH has established a peer review appeal system to provide applicants the opportunity to seek reconsideration of the initial review results if, after review of the summary statement, they believe the review process was procedurally flawed. This appeal process is not intended to deal with differences of scientific opinion between or among PIs and reviewers.

The applicant should discuss concerns about the conduct of the review, whether the initial review was conducted by CSR or by the IC, with the PO responsible for the application; the PO who will attempt to resolve the applicant’s concerns. If, after discussion with the PO, the applicant still has concerns, the AOO may submit a formal letter of appeal to the PO, who will handle it in accordance with the appeal procedures outlined below.
The PO will consult with the SRA or staff of the IC scientific review office. This consultation may result in a decision to re-review the application. A re-review consists of a review of the same application, not a revised version, by the same or another review group without access to the summary statement of the disputed review. If the NIH staff and the PI cannot agree on a course of action, the appeal will be reviewed by the designated IC Appeals Officer. That official will make the appeal letter available to the Council along with the IC recommendation on the appeal and any written comments from the SRA or review group. The Council may reject the appeal and let the initial review results stand or recommend that the application be re-reviewed. The Council’s decision may not be further appealed.

**National Advisory Council or Board Review**

Summary statements for those applications recommended for further consideration are presented to the assigned IC National Advisory Council or Board (hereafter “Council”) for use in the second level of review. Council members include senior scientists with broad experience and members of the public with general knowledge of, and interest in, the IC’s mission. The Council reviews applications not only for scientific and technical merit but also for relevance to the IC’s programs and priorities. The Council may concur with the SRG’s recommendation, may decide not to recommend an application on the basis of program or policy considerations, or may recommend deferral of an application and refer it back to the SRG for re-review. With very limited exception, an application may not be considered for funding unless it has received a favorable recommendation by both the SRG and the Council.

**Disposition of Applications**

All incomplete applications, non-compliant modular applications, and applications determined to be nonresponsive to solicitation requirements will be returned to the applicant by CSR or by the IC referral office without further action. The applicant may resubmit a changed or complete version of an unsolicited application for consideration in the next review cycle.

Following the initial review, the PI will receive a copy of the summary statement and will be advised by letter from the responsible IC whether the application has been recommended for further consideration by the Council.

The IC Director or designee is the official that has the authority to make final award decisions from among those applications receiving a favorable initial review and Council recommendation. If an application has been recommended for further consideration but is not expected to be funded in the current cycle, the application may be held by NIH for one or more additional cycles and will compete with other applications submitted for that cycle. If an application is unsuccessful, the applicant may subsequently submit up to two revised versions of the application for review in a future cycle(s).

Successful applicants will be notified of additional information that may be required or other actions leading to an award. The process leading to an award, including the business management review performed by the GMO, is described in Part II. The decision not to award a grant, or to award a grant at a particular funding level, is discretionary and is not subject to appeal to any NIH or HHS official or board.
Sources of Information about NIH’s Grants Process and Programs

NIH maintains a number of information resources about its grant programs and activities that can be accessed through OER’s home page. Some are descriptive materials that enable interested parties to learn about NIH grant initiatives, funding opportunities, and proposed and actual policy changes. Others provide historical data. This information is updated annually or as needed. The NIH website address for these materials and other grant-related materials is http://grants.nih.gov/grants/oer.htm (a more specific address may be provided below). In addition, these materials may be requested by e-mail from GrantsInfo@nih.gov or by telephone at 301-435-0714 (see Part III).

The information resources include the following:

◆ **NIH Extramural Programs.** A compendium of the scientific programs of the NIH components that award grants, cooperative agreements, and contracts. It indicates current areas of research emphasis, highlights special interests of each IC, and identifies specific NIH offices to be contacted for further information about particular programs, policies, and procedures. The website address is [http://grants.nih.gov/grants/oer.htm](http://grants.nih.gov/grants/oer.htm).


◆ **NIH Electronic Research Administration Commons.** The NIH eRA Commons facilitates research administration between, NIH, grantee organizations, and the public by providing the capability for an electronic exchange of information. The eRA Commons is divided into both unrestricted and restricted portions that provide for public and confidential information, respectively. For additional information, see [https://commons.era.nih.gov/commons/](https://commons.era.nih.gov/commons/).

◆ **Grants.gov.** An Internet site that will provide a simple, unified “storefront” for all customers of Federal grants to electronically find opportunities, apply, and manage grants. It will facilitate the quality, coordination, effectiveness, and efficiency of operations for grant-makers and grantees. For additional information, see [http://www.fedgrants.gov](http://www.fedgrants.gov).

◆ **Research Grants.** A compendium of information that includes data on NIH research grant awards organized in a variety of ways. The website address is [http://grants.nih.gov/grants/award/award.htm](http://grants.nih.gov/grants/award/award.htm).

◆ **Computer Retrieval of Information on Scientific Projects.** CRISP is an online system ([http://www.crisp.cit.nih.gov](http://www.crisp.cit.nih.gov)) available to the public that is updated quarterly and provides a brief description of and administrative data on each NIH-funded research project.
Program Guidelines. Publications that include detailed policy and procedural information applicable to specific programs/activities. NIH-wide program guidelines are published initially in the NIH Guide for Grants and Contracts (see above) and also are accessible by title at http://grants.nih.gov/grants/documentindex.htm. The SBIR/STTR Phase I grant guidelines are available at NIH’s “Small Business Funding Opportunities” site (http://grants.nih.gov/grants/funding/sbir.htm). IC home pages also should be consulted for IC-specific guidelines (see Part III).

Each IC also maintains its own home page accessible through the NIH home page “Institutes and Offices” submenu (also see Part III for website addresses).
Part II: Terms and Conditions of NIH Grant Awards

Subpart A: General

COMPLETING THE PRE-AWARD PROCESS

Following the peer review process, applications that an IC may fund are reviewed for a number of other considerations. These include, as applicable, alignment with NIH’s funding principles, review of the project budget, assessment of the applicant’s management systems, determination of applicant eligibility, and compliance with public policy requirements. The applicant may be asked to submit additional information (such as other support or verification of IACUC review) or to undertake certain activities (such as negotiation of an F&A cost rate) in anticipation of an award. However, such requests by NIH do not guarantee that an award will be made. Following review of all applicable information, the IC will determine whether an award can be made, if special conditions are required, and what level of funding is appropriate.

Although these reviews and determinations occur before NIH makes a new award, grantees must continue to comply with eligibility and public policy requirements and maintain adequate management systems throughout the period of support. The pre-award process for non-competing continuation awards is a streamlined version of this process, including an assessment of progress (see “Administrative Requirements—Monitoring—Reporting—Non-Competing Grant Progress Reports”).

Just-in-Time Procedures

NIH uses just-in-time procedures for certain programs and award mechanisms. These procedures call for limited information (e.g., a budget justification and a biographical sketch) to be submitted with investigator-initiated applications and allow for a possible NIH request for additional information, including information concerning other support, when the application is under consideration for funding. Just-in-time procedures also allow an applicant to defer certification of IRB approval of the project’s proposed use of human subjects, verification of IACUC approval of the project’s proposed use of live vertebrate animals, and evidence of compliance with the education in the protection of human research participants requirement until after completion of the peer review and just prior to funding. (Applications in response to RFAs also may be subject to these procedures. The RFA will specify the timing and nature of required submissions.)

Information on other support will be requested as part of the just-in-time procedures. IC scientific program and grants management staff will review this information before award to ensure the following:

◆ Sufficient levels of effort are committed to the project.
◆ There is no scientific, budgetary, or commitment overlap.

➢ Scientific overlap occurs when (1) substantially the same research is proposed in more than one application or is submitted to two or more funding sources for review and funding consideration or (2) a specific research objective and the research design for accomplishing the objective are the same or closely related in two or more applications or awards, regardless of the funding source.

➢ Budgetary overlap occurs when duplicate or equivalent budgetary items (e.g., equipment, salaries) are requested in an application but already are provided by another source.

➢ Commitment overlap occurs when an individual’s time commitment exceeds 100 percent, whether or not salary support is requested in the application.

Overlap, whether scientific, budgetary, or commitment of an individual’s effort greater than 100 percent, is not permitted. Any overlap will be resolved by the IC with the applicant and the PI at the time of award.

◆ Only funds necessary to the approved project are included in the award.

For modular applications, the applicant is not required to submit detailed budget information in the application. In lieu of the standard budget forms, the applicant requests total direct costs for each year of support requested. The request must be accompanied by budget narrative for all personnel (by position, title, and level of effort), including consultants and “to be appointed” positions, and, when applicable, for consortium/contractual costs. NIH will request additional budget information in exceptional circumstances only. Other support information will be requested only for modular applications likely to result in an award. (See Subpart B of this part for more detailed coverage of modular applications and awards.)

Funding Principles

The amount of NIH funding is based on reasonable and allowable costs consistent with the principles of sound cost management, considering IC priorities (e.g., program relevance), constraints on the growth of average grant costs, and available funds. NIH also has adopted the following core funding principles specifically for research project grants:

◆ NIH generally will award non-competing continuation research project grants at committed levels.

◆ When determining commitments for future years, NIH will consider stability of support for investigators, optimum portfolio balance, and opportunities to address emerging problems.

Eligibility

NIH awards may be made only to eligible applicants. Continued funding is dependent on the grantee’s maintaining eligibility. In general, domestic or foreign, public or private, non-profit or
for-profit organizations are eligible to receive NIH grants. However, on the basis of statutory, regulatory, or published policy limitations, under certain programs or types of awards, NIH may limit eligibility to, or exclude from eligibility, classes or types of entities. Examples are limitations on the participation of foreign entities, and programs under which only small businesses are eligible applicants. The determination of eligibility includes verification of the applicant’s status. The applicant may be required to provide proof of its status by submitting documentation; otherwise the AOO’s signature on the application certifies that the applicant is eligible to apply for and receive an award (e.g., a small business applying under the SBIR or STTR programs).

In addition to reviewing organizational eligibility, NIH may consider other factors relating to the applicant’s ability to responsibly handle and account for Federal funds and to carry out the project. These factors include the applicant’s intended role in the project, the location where the project will be performed, the role of the PI in the project, and the PI’s employment and citizenship status. Although some of these same considerations are reviewed as part of the peer review, NIH’s concern at this stage in the process is making an award to a legal entity that will be accountable for both the performance of the approved project or activity and the appropriate expenditure of funds. NIH will not make an award to an applicant that does not have a substantive role in the project and would simply serve as a conduit for another entity.

The GMO also will verify whether the applicant, proposed PI, or other key personnel are debarred or suspended from participation in Federal assistance programs (see “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations” for certification requirements).

Generally, PIs and other personnel supported by NIH research grants are not required to be U.S. citizens. However, some NIH programs/mechanisms have a citizenship requirement. Any citizenship requirement will be stated in the PA or RFA. In these cases, individuals are required to have the appropriate citizenship status when the award is made rather than when the application is submitted. For example, under K awards or Kirschstein-NRSA individual fellowships, the individual to be trained must be a citizen or a non-citizen national of the United States or have been lawfully admitted for permanent residence at the time of award.

NIH requires the applicant to determine that individuals’ visas will allow them to remain in this country long enough for them to be productive on the research project, but NIH does not provide guidance on or assess the different types of visas. NIH expects grantee organizations to have policies, consistently applied regardless of the source of funds, to address this area. If a grant is awarded and an individual’s visa will not allow a long enough stay to be productive on the project, NIH may terminate the grant (see “Administrative Requirements—Changes in Project and Budget” and “Administrative Requirements—Enforcement Actions—Suspension, Termination, and Withholding of Support”).

The eligibility requirements for trainees and additional eligibility requirements for fellows are addressed in “Ruth L. Kirschstein National Research Service Awards” in Subpart B of this part of the NIHGPS.
In the post-award phase, NIH monitors changes in grantee and project status to ensure they meet legal and programmatic requirements and takes actions necessary to protect the Federal government’s interests.

**Cost Analysis and Assessment of Management Systems**

The GMO will ensure that a cost analysis is performed on any application that requires a detailed budget. Cost analysis involves obtaining cost breakdowns, validating cost data, evaluating specific elements of cost, and examining data to determine the necessity for, and the reasonableness and allowability of, the costs included in the application budget. The extent of cost analysis will depend on the type of funding instrument and award mechanism, the complexity of the project, prior experience with the applicant, and other factors. Information on the applicable cost principles and on allowable and unallowable costs under NIH grants is provided in “Cost Considerations.”

In addition to considering the specific information provided in the application, the GMO determines the adequacy of the applicant’s financial and business management systems that will support the expenditure of and accountability for NIH funds. When an applicant has had no prior Federal grants or cost-reimbursement contracts, the GMO may review the applicant’s financial management and other management systems before award, or within a reasonable time after award, to determine their adequacy and acceptability. For an applicant with prior NIH or other Federal cost-reimbursement awards, the GMO may review recent audit reports and other available information to determine whether the applicant’s management systems meet the standards established in 45 CFR Part 74 or 45 CFR Part 92, as appropriate. The GMO will advise the applicant if additional information is required. On the basis of the review results, the GMO will determine the need for any corrective action and may impose special conditions on the award.

**OVERVIEW OF TERMS AND CONDITIONS**

The remainder of Part II serves as the terms and conditions of NIH grants and cooperative agreements and is incorporated by reference in all NIH grant and cooperative agreement awards. Subpart A includes those terms and conditions that apply, in general, to NIH awards. Subpart B either expands on Subpart A coverage or specifies additional or alternate terms and conditions for particular types of awards, recipients, or activities.

These terms and conditions are not intended to be all-inclusive. In addition to the requirements in the NIHGPS, some of which repeat or highlight requirements found in the following, NIH grants are subject to all of the applicable requirements of the following:

- Authorizing program legislation
- Program regulations, including those in 42 CFR Part 52
- Other statutory requirements, such as those included in appropriations acts
Notice of requirements not specified in the NIHGPS generally will be provided in the NGA, but such notice is not required for the award to be subject to the requirements of pertinent statutes and regulations. An individual award also may contain award-specific terms and conditions. For example, the GMO may include terms or conditions necessary to address concerns about an applicant’s management systems.

Program and administrative policies and the terms and conditions of individual awards are intended to supplement, rather than substitute for, governing statutory and regulatory requirements. Thus, the requirements of the NIHGPS apply in addition to governing statutory and regulatory requirements not cited herein, and award-specific terms apply in addition to the requirements of the NIHGPS.

This NIHGPS is written in “plain language” and is meant to be an aid to the interpretation of statutory and regulatory requirements. These terms and conditions are intended to be compliant with governing statutes and the requirements of 45 CFR Parts 74 and 92, as modified by previously approved waivers and deviations. However, in the case of a conflict, the statutes and regulations govern.

If there is a perceived conflict between or among these three categories of requirements—statutory and regulatory requirements, the terms and conditions in the NIHGPS, and award-specific terms and conditions—or if the grantee has other questions concerning award terms and conditions, the grantee should request written clarification from the GMO. This may be done at any time; however, if the inclusion of the term or condition would cause the grantee not to accept the award or to be unable to comply, the question should be raised before funds are requested from the HHS payment system. By drawing funds from the HHS payment system, the grantee agrees to the terms and conditions of the award.

PUBLIC POLICY REQUIREMENTS AND OBJECTIVES

This section addresses public policy requirements and objectives applicable to NIH awards. The term “public policy” indicates that the requirement is based on social, economic, or other objectives or considerations that may be attached to the expenditure of Federal funds by grantees, consortium participants, and contractors, in general, or may relate to the expenditure of Federal funds for research or other specified activities. In addition to cross-cutting requirements that some or all Federal agencies must apply to their grant programs, NIH grantees are subject to requirements contained in HHS’s annual appropriations acts that apply to the use of NIH grant funds, applicable provisions in other Federal agencies’ appropriations acts, including Treasury, and other Federal statutes. Some of those requirements are included here since they have been included in the appropriations acts for several years without change, but those requirements may be changed or other requirements may be added in the future.

NIH intends to uphold high ethical, health, and safety standards in both the conduct of the research it funds and the expenditure of public funds by its grantees. The public policy requirements specified in this section set many of those standards. The signature of the AOO on
the application certifies that the organization complies, or intends to comply, with all applicable certifications and assurances referenced (and, in some cases, included) in the application instructions.

Instructions for applications submitted on the PHS 398 include the following topics, which also are discussed in this section of the NIHGPS:

- Debarment and Suspension (specific certification language included in application instructions)
- Drug-Free Workplace
- Lobbying (specific certification language included in application instructions)
- Financial Conflict of Interest
- Research Misconduct
- Nondelinquency on Federal Debt
- Human Embryonic Stem Cell Research
- Human Subjects
- Research on Transplantation of Fetal Tissue
- Recombinant DNA Molecules and Human Gene Transfer Research
- Vertebrate Animals
- Women and Minority Inclusion Policy
- Inclusion of Children Policy
- Age Discrimination
- Civil Rights
- Sex Discrimination
- Handicapped Individuals.

Public policy requirements under Kirschstein-NRSA individual fellowships are specified in the application instructions for the PHS 416-1 and are discussed in “Ruth L. Kirschstein National Research Service Awards—Individual Fellowships” in Subpart B of this part.

As noted in this section, some certifications and assurances may require submission of a separate document (e.g., human subjects assurance, IRB certification, civil rights assurance). Applicants and grantees should take particular note of these requirements (for example, see “Human
Subjects” and “Civil Rights”), the absence or inadequacy of which may delay an award or make an applicant ineligible for award.

The grantee is responsible for establishing and maintaining the necessary processes to monitor its compliance and that of its employees, consortium participants, and contractors with these requirements; taking appropriate action to meet the stated objectives; and informing NIH of any problems or concerns.

If a grant is awarded on the basis of false or misrepresented information, or if a grantee does not comply with these public policy requirements, NIH may take any necessary and appropriate action, including using any of the remedies described in “Administrative Requirements—Enforcement Actions” or other available legal remedies.

Exhibit 2 contains information to help the grantee determine what public policy requirements and objectives apply to its activities and whether a requirement should be included in a consortium agreement or a contract for routine goods or services under the grant (see “Glossary” for definitions). The exhibit distinguishes between these types of transactions under a grant and indicates (by “Y” for Yes or “NA” for Not Applicable) whether a given public policy requirement normally would apply. However, even if the exhibit indicates that a requirement is not applicable that public policy requirement potentially could be applicable in a specific situation, e.g., if a contract under a grant involves research activity. Therefore, this exhibit should be used as general guidance only. The grantee should consult the terms and conditions of its award and should contact the GMO if it has any question concerning the applicability of a particular public policy requirement or objective.

Exhibit 2 also indicates where, in the NIHGPS, the individual public policy requirements and objectives are covered in more detail. The grantee should consult the governing statute, regulations, or other cited policies or documents for complete information.
<table>
<thead>
<tr>
<th>Requirement or objective</th>
<th>Grantee</th>
<th>Consortium participant</th>
<th>Contractor under grant (routine goods/services)*</th>
<th>NIHGPS section for additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acknowledgment of Federal Funding</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>Availability of Information, Ruth L. Kirschstein National Research Service Awards</td>
</tr>
<tr>
<td>Age Discrimination Act of 1975</td>
<td>Y</td>
<td>Y</td>
<td>Y (NA to foreign and international organizations)</td>
<td>Civil Rights, Grants to Foreign Institutions, International Organizations and Domestic Grants with Foreign Components (hereafter, Grants to Foreign Institutions)</td>
</tr>
<tr>
<td>Animal Welfare</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Animal Welfare, Ruth L. Kirschstein National Research Service Awards, Grants to Foreign Institutions</td>
</tr>
<tr>
<td>Ban on Human Embryo Research and Cloning</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals as Research Subjects, Patients or Recipients of Services (hereafter, Requirements Affecting the Rights and Welfare of Individuals)</td>
</tr>
<tr>
<td>Certificates of Confidentiality</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals</td>
</tr>
<tr>
<td>Civil Rights Act of 1964 (Title VI)</td>
<td>Y</td>
<td>Y</td>
<td>Y (NA* to foreign and international organizations)</td>
<td>Civil Rights, Grants to Foreign Institutions</td>
</tr>
<tr>
<td>Confidentiality of Patient Records</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals</td>
</tr>
<tr>
<td>Controlled Substances</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals</td>
</tr>
<tr>
<td>Data and Safety Monitoring</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals, Ruth L. Kirschstein National Research Service Awards</td>
</tr>
<tr>
<td>Debarment and Suspension</td>
<td>Y</td>
<td>Y</td>
<td>If contract equals or exceeds $100,000 (NA to certain foreign organizations)</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations, Grants to Foreign Institutions</td>
</tr>
</tbody>
</table>
### Exhibit 2. Public Policy Requirements and Objectives

<table>
<thead>
<tr>
<th>Requirement or objective</th>
<th>Grantee</th>
<th>Consortium participant</th>
<th>Contractor under grant (routine goods/services)*</th>
<th>NIHGPS section for additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug-Free Workplace</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations Grants to Foreign Institutions</td>
</tr>
<tr>
<td>Education Amendments of 1972 (Title IX)</td>
<td>Y (NA to foreign and international organizations)</td>
<td>Y (NA to foreign and international organizations)</td>
<td>Y (NA to foreign and international organizations)</td>
<td>Civil Rights Grants to Foreign Institutions</td>
</tr>
<tr>
<td>Elimination of Architectural Barriers to the Handicapped</td>
<td>Y</td>
<td>NA</td>
<td>Y</td>
<td>Construction Grants</td>
</tr>
<tr>
<td>Financial Conflict of Interest</td>
<td>Y (NA to Phase I of the SBIR/STTR programs and to Federal institutions)</td>
<td>Y</td>
<td>NA</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations Grants to Federal Institutions and Payments to (or on behalf of) Federal Employees under Grants</td>
</tr>
<tr>
<td>Flood Insurance</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>Construction Grants</td>
</tr>
<tr>
<td>Freedom of Information Act</td>
<td>Y (Applies to certain research data produced by specified types of grantees; NA to commercial organizations)</td>
<td>Y (Applies to certain research data produced by specified types of grantees; NA to commercial organizations)</td>
<td>Y Applies to certain research data produced by specified types of entities; NA to commercial organizations)</td>
<td>Availability of Information</td>
</tr>
<tr>
<td>Additional Health and Safety Regulations and Guidelines</td>
<td>Y</td>
<td>Y</td>
<td>Apply as required by Federal, State or local regulations</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
<tr>
<td>Health Insurance Portability and Accountability Act (HIPAA)</td>
<td>Y (if a covered entity)</td>
<td>Y (if a covered entity)</td>
<td>Y (if a covered entity)</td>
<td>Requirements Affecting the Rights and Welfare of Individuals</td>
</tr>
<tr>
<td>Historic Properties/ Archeological Sites</td>
<td>Y</td>
<td>NA</td>
<td>Y</td>
<td>Construction Grants</td>
</tr>
<tr>
<td>Human Embryonic Stem Cell Research</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations Ruth L. Kirschstein National Research Service Awards</td>
</tr>
</tbody>
</table>
### Exhibit 2. Public Policy Requirements and Objectives

<table>
<thead>
<tr>
<th>Requirement or objective</th>
<th>Grantee</th>
<th>Consortium participant</th>
<th>Contractor under grant (routine goods/services)*</th>
<th>NIHGPS section for additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Subjects</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ruth L. Kirschstein National Research Service Awards</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grants to Foreign Institutions</td>
</tr>
<tr>
<td>Inclusion of Children as Subjects in Clinical Research</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>Requirements for Inclusiveness in Research Design</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ruth L. Kirschstein National Research Service Awards</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grants to Foreign Institutions</td>
</tr>
<tr>
<td>Inclusion of Women/Minorities as Subjects in Clinical Research</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>Requirements for Inclusiveness in Research Design</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ruth L. Kirschstein National Research Service Awards</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grants to Foreign Institutions</td>
</tr>
<tr>
<td>Intergovernmental Review under EO 12372</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>Construction Grants</td>
</tr>
<tr>
<td>Investigational New Drug Applications/ Investigational Device Exceptions</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals</td>
</tr>
<tr>
<td>Labor Standards under Federally Assisted Construction</td>
<td>Y</td>
<td>NA</td>
<td>Y</td>
<td>Construction Grants</td>
</tr>
<tr>
<td>Limited English Proficiency</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>Civil Rights</td>
</tr>
<tr>
<td>Limitation on Use of Funds for Promotion or Legalization of Controlled Substances</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
<tr>
<td>Lobbying</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
<tr>
<td>Metric System</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Other Public Policy Requirements and Objectives</td>
</tr>
<tr>
<td>Military Recruiting and ROTC Program Access to Institutions of Higher Education</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Other Public Policy Requirements and Objectives</td>
</tr>
<tr>
<td>Requirement or objective</td>
<td>Grantee</td>
<td>Consortium participant</td>
<td>Contractor under grant (routine goods/services)*</td>
<td>NIHGPS section for additional information</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>------------------------</td>
<td>---------------------------------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>National Environmental Policy Act of 1969</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>Construction Grants</td>
</tr>
<tr>
<td>Nondelinquency on Federal Debt</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations Grants to Foreign Institutions</td>
</tr>
<tr>
<td>Preservation of Open Competition and Government Neutrality Toward Government Contractors’ Labor Relations on Federal and Federally Funded Construction Projects</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>Construction Grants</td>
</tr>
<tr>
<td>Privacy Act</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Availability of Information</td>
</tr>
<tr>
<td>Pro-Children Act of 1994</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals</td>
</tr>
<tr>
<td>Program Fraud and Civil Remedies and False Claims Acts</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>Application and Review Processes—Legal Implication of Application</td>
</tr>
<tr>
<td>Protection of Research Subjects’ Identity</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals</td>
</tr>
<tr>
<td>Public Disclosure</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>Construction Grants</td>
</tr>
<tr>
<td>Public Health Security and Bioterrorism Preparedness and Response Act</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
<tr>
<td>Recombinant DNA Molecules and Human Gene Transfer Research</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations Ruth L. Kirschstein National Research Service Awards</td>
</tr>
<tr>
<td>Rehabilitation Act of 1973 (section 504)</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Civil Rights Grants to Foreign Institutions</td>
</tr>
</tbody>
</table>
### Exhibit 2. Public Policy Requirements and Objectives

<table>
<thead>
<tr>
<th>Requirement or objective</th>
<th>Grantee</th>
<th>Consortium participant</th>
<th>Contractor under grant (routine goods/services)*</th>
<th>NIHGPS section for additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Misconduct</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
<tr>
<td>Research on Human Fetal Tissue</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals</td>
</tr>
<tr>
<td>Research on Transplantation of Fetal Tissue</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Requirements Affecting the Rights and Welfare of Individuals</td>
</tr>
<tr>
<td>Restriction on Abortions</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
<tr>
<td>Restriction on Distribution of Sterile Needles</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
<tr>
<td>Seat Belt Use</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
<tr>
<td>Smoke-Free Workplace</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
<tr>
<td>Standards of Conduct</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
<tr>
<td>Uniform Relocation Assistance and Real Property Acquisition</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>Construction Grants</td>
</tr>
<tr>
<td>USA PATRIOT Act</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Ethical and Safe Conduct in Science and Organizational Operations</td>
</tr>
</tbody>
</table>

*A designation of NA in this table indicates that a particular requirement does not apply to an otherwise eligible grantee, consortium participant, or contractor or may not apply because the type of activity covered is one not normally performed by such an entity.

### Ethical and Safe Conduct in Science and Organizational Operations

NIH grants are subject to requirements intended to ensure that recipient organizations handle their Federal awards responsibly. Grantees are required to adopt and enforce policies that minimize the opportunity for improper financial gain on the part of the organization, its employees, and organizations and individuals with whom they may collaborate, and that limit the potential for research results to be tainted by possible personal financial or other gain.

In addition, NIH grantees are expected to provide safe and healthful working conditions for their employees and foster work environments conducive to high-quality research.
Standards of Conduct

NIH requires grantees to establish safeguards to prevent employees, consultants, members of governing bodies, and others who may be involved in grant-supported activities from using their positions for purposes that are, or give the appearance of being, motivated by a desire for private financial gain for themselves or others, such as those with whom they have family, business, or other ties. These safeguards must be reflected in written standards of conduct. Except as provided below, NIH does not require a grantee to establish separate standards of conduct if it maintains such standards for its non-grant-supported activities, as long as those standards are consistent with State and local laws and cover, at a minimum, expected conduct in regard to financial interests, gifts, gratuities and favors, nepotism, and such other areas as political participation and bribery. The standards also must do the following:

- Address the conditions under which outside activities, relationships, or financial interests are proper or improper.
- Provide for advance notification of outside activities, relationships, or financial interests to a responsible organizational official.
- Include a process for notification and review by the responsible official of potential or actual violations of the standards.
- Specify the nature of penalties that the grantee may impose. These penalties would be in addition to any penalties that NIH or a cognizant Federal agency may impose for infractions that also violate the terms or conditions of award.

The grantee is not required to submit its general standards of conduct to NIH for review or approval. However, a copy must be made available to each of its officers, each employee and consultant working on the grant-supported project or activity, each member of the governing board, if applicable, and, upon request, to NIH. The grantee is responsible for enforcing its standards of conduct, taking appropriate action on individual infractions, and, in the case of financial conflict of interest, informing the IC CGMO if the infraction is related to an NIH award. (A listing of the NIH CGMOs is available at http://grants.nih.gov/grants/stafflist_gmos.htm.) If a suspension or separation action is taken by a grantee against a PI or other key personnel under an NIH grant, the grantee must request prior approval of the proposed replacement as specified in “Administrative Requirements—Changes in Project and Budget—Prior-Approval Requirements.”

Financial Conflict of Interest

NIH requires grantees and investigators to comply with the requirements of 42 CFR Part 50, Subpart F, “Responsibility of Applicants for Promoting Objectivity in Research for Which PHS Funding is Sought.” That subpart promotes objectivity in research by establishing standards to ensure that the design, conduct, and reporting of research funded under PHS grants or cooperative agreements will not be biased by any conflicting financial interest of an investigator. These requirements do not apply to Phase I of the SBIR/STTR programs.
The signature of the AOO on the face page of the application serves as certification of compliance with the requirements of 42 CFR Part 50, Subpart F. Under those requirements the organization must do the following:

- Have a written and enforced administrative process to identify and manage, reduce, or eliminate conflicting financial interests with respect to research projects for which NIH funding is sought
- Before spending any NIH funds awarded under a new award, inform the CGMO of the existence of any conflicting financial interests it identified of the type covered by 42 CFR 50.605
- When informing the CGMO that a financial conflict of interest has been identified, ensure that the interest has been addressed in accordance with the regulations by indicating whether the conflict has either been managed, reduced, or eliminated
- Continue to make similar reports on subsequently identified conflicts within 60 days of identifying them
- Make additional information available to NIH, upon request, as to how it handled conflicting interests in accordance with the regulations.

As described in the regulations, examples of how financial conflicts of interest might be addressed include the following:

- Public disclosure of significant financial interests
- Monitoring of research by independent reviewers
- Modification of the research plan
- Disqualification from participation in all or a portion of the research funded by PHS
- Divestiture of significant financial interests
- Severance of relationships that create actual or potential conflicts.

Grantees also must ensure that consortium agreements address whether the consortium participant’s employees will be subject to the financial conflict of interest requirements of the consortium participant or to those of the grantee (see “Consortium Agreements” in Subpart B of this part).

Some IRBs also consider investigator financial conflict of interest in their deliberations, although they are not required to do so (see “Public Policy Requirements and Objectives—Requirements Affecting the Rights and Welfare of Individuals as Research Subjects, Patients, or Recipients of Services—Human Subjects”).

45
Following are some strategies used by IRBs:

◆ Make IRB members aware of the organization’s conflict of interest policies and procedures.

◆ Include a statement in the informed consent form that all clinical investigators comply with the organizational guidelines.

◆ Ask investigators to complete a short questionnaire about whether they—or any person responsible for the design, conduct, or reporting of research—have an economic interest in or act as an officer or a director of any outside entity whose financial interest could reasonably appear to be affected by the research.

◆ Instruct IRB members during their orientation on how to identify and respond to a perceived financial, academic, or other conflict of interest.


**Debarment and Suspension**

HHS regulations published in 45 CFR Part 76 implement the government-wide debarment and suspension system for HHS’ non-procurement transactions. “Non-procurement transactions” include grants, cooperative agreements, scholarships, fellowships, and loans. Accordingly, applicants for NIH grants (“primary covered transactions”), including applicants for Kirschstein-NRSA individual fellowships, are required to certify that, to the best of their knowledge and belief, they and their principals (including PIs and other key personnel)

◆ are not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from covered transactions by any Federal department or agency;

◆ have not, within the 3-year period preceding the application, been convicted of, or had a civil judgment rendered against them for
  
  ➢ committing fraud or a criminal offense in connection with obtaining, attempting to obtain, or performing a public (Federal, State, or local) transaction or contract under a public transaction;
  
  ➢ violating a Federal or State antitrust statute;
  
  ➢ embezzlement, theft, forgery, bribery, falsification or destruction of records; or

6 This certification is accomplished by the signature of the AOO on the application. States need only certify as to their principals.
making false statements or receiving stolen property;

are not presently indicted or otherwise criminally or civilly charged by a governmental entity (Federal, State, or local) with commission of any of the offenses enumerated above; and

have not, within a 3-year period preceding the application, had any public transaction (Federal, State, or local) terminated for cause or default.

If the applicant is unable to certify to these statements, it must, nonetheless, submit the certification and attach an explanation. The inability to certify does not automatically disqualify an organization from receiving an NIH award; however, failure to submit the required certification or the necessary explanation will cause NIH not to make an award. Appendix A of 45 CFR Part 76 contains the full text of the instructions and the certification.

A variety of “lower-tier” transactions also are subject to the certification requirement. Contractors under grants (where the contract requires the provision of goods or services that will equal or exceed $100,000) and all consortium participants must certify that they are not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from participation in this transaction by any Federal agency. Grantees also are required to obtain a certification from each trainee under a Kirschstein-NRSA institutional research training grant before their appointment. If an entity or individual is unable to certify to this effect, an explanation should be attached to its proposal or to the document that defines the legal relationship between the parties (for example, the consortium agreement).

Regardless of whether a certification is required or made, organizations or individuals that are suspended, debarred, or voluntarily excluded from eligibility cannot receive NIH grants or be paid from NIH grant funds, whether under a primary or lower-tier transaction, during the period of suspension, debarment, or exclusion. Because individuals who have been debarred, suspended, declared ineligible, or voluntarily excluded from covered transactions may not receive Federal funds for a specified period of time, charges made to the NIH grants for such individuals (e.g., salary) are unallowable.

Drug-Free Workplace

The Drug-Free Workplace Act of 1988 (Public Law 100-690, Title V, Subtitle D, as amended) requires that all organizations receiving grants from any Federal agency agree to maintain a drug-free workplace. By signing the application, the AOO agrees that the grantee will provide a drug-free workplace and will comply with the requirement to notify NIH if an employee is convicted of violating a criminal drug statute. Failure to comply with these requirements may be cause for debarment. HHS implementing regulations are set forth in 45 CFR Part 76, “Governmentwide Debarment and Suspension (Nonprocurement) and Governmentwide Requirements for Drug-Free Workplace (Grants).”
Health and Safety Regulations and Guidelines

Public Health Security and Bioterrorism Preparedness and Response Act

The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (P.L. 107-188) is designed to provide protection against misuse of select agents and toxins whether inadvertent or the result of terrorist acts against the United States homeland or other criminal acts. The Act was implemented, in part, through regulations published by CDC at 42 CFR 73, Select Agents and Toxins. Those regulations supersede the requirements at 42 CFR 76.2 (Interstate Shipment of Etiological Agents), which established certain shipping and handling requirements on laboratory facilities that send or receive select agents. Copies of these regulations are available from the Import Permit Program and Select Agent Program, respectively, CDC, 1600 Clifton Road, MS E-79, Atlanta, GA 30333; telephone: 404-498-2255. These regulations also are available at http://www.cdc.gov/od/ohs/biosfty/shipregs.htm.

Research involving select agents and recombinant DNA molecules also is subject to the NIH Guidelines for Research Involving DNA Molecules (NIH Guidelines) (see “NIH Guidelines for Research Involving DNA Molecules and Human Gene Transfer Research” in this subsection for applicability of these guidelines). The NIH Guidelines apply to (1) research projects involving recombinant DNA that are conducted at or sponsored by an organization that receives NIH support for recombinant DNA research (for research performed abroad, the NIH Guidelines apply if the research is supported by NIH funds) and (2) research projects involving testing in humans of materials containing recombinant DNA developed with NIH funds, if the organization that developed the materials sponsors or participates in those projects. The NIH Guidelines are available at http://oba.od.nih.gov/oba/rac/guidelines_02/NIH_Guidelines_Apr_02.htm.

USA PATRIOT Act

The Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act (USA PATRIOT Act) (P.L. 107-56) amends 18 U.S.C. 10 and provides criminal penalties for possession of any biological agent, toxin, or delivery system of a type or in a quantity that is not reasonably justified by a prophylactic, protective, bona fide research, or other peaceful purpose. The Act also establishes restrictions on access to specified materials. “Restricted persons,” as defined by the Act, may not possess, ship, transport, or receive any biological agent or toxin that is listed as a select agent (see “Public Health Security and Bioterrorism Preparedness and Response Act” in this subsection).

Additional Health and Safety Regulations and Guidelines

Grantees are responsible for meeting Federal, State, and local health and safety standards and for establishing and implementing necessary measures to minimize their employees’ risk of injury or illness in activities related to NIH grants. In addition to applicable Federal, State, and local laws and regulations, the following regulations must be followed when developing and implementing health and safety operating procedures and practices for both personnel and facilities:

- 29 CFR 1910.1030, Bloodborne pathogens; 29 CFR 1910.1450, Occupational exposure to hazardous chemicals in laboratories; and other applicable occupational health and


The following guidelines are recommended for use in developing and implementing health and safety operating procedures and practices for both personnel and facilities:

♦ Biosafety in Microbiological and Biomedical Laboratories, CDC and NIH, HHS. This publication is available at http://bmbl.od.nih.gov/index.htm.


Grantee organizations are not required to submit documented assurance of their compliance with or implementation of these regulations and guidelines. However, if requested by the awarding office, grantees should be able to provide evidence that applicable Federal, State, and local health and safety standards have been considered and have been put into practice.

**Limitation on Use of Funds for Promotion or Legalization of Controlled Substances**

Grantees are prohibited from knowingly using appropriated funds to support activities that promote the legalization of any drug or other substance included in Schedule I of the schedule of controlled substances established by section 202 of the Controlled Substances Act, 21 U.S.C. 812. This limitation does not apply if the grantee notifies the GMO that there is significant medical evidence of a therapeutic advantage to the use of such drug or other substance or that federally sponsored clinical trials are being conducted to determine therapeutic advantage (see “Requirements Affecting the Rights and Welfare of Individuals as Research Subjects, Patients, or Recipients of Services—Controlled Substances”).

**Lobbying**

Recipients of Federal grants, cooperative agreements, contracts, and loans are prohibited by 31 U.S.C. 1352, “Limitation on use of appropriated funds to influence certain Federal contracting and financial transactions,” from using appropriated Federal funds to pay any person for influencing or attempting to influence any officer or employee of an agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress with respect to the award, continuation, renewal, amendment, or modification of any of these instruments. These requirements are implemented for HHS in 45 CFR Part 93, which also describes types of activities, such as legislative liaison activities and professional and technical services, which are not subject to this prohibition.
Applicants for NIH awards with total costs expected to exceed $100,000 are required to certify that they

- have not made, and will not make, such a prohibited payment;
- will be responsible for reporting the use of nonappropriated funds for such purposes; and
- will include these requirements in consortium agreements and contracts under grants that will exceed $100,000 and obtain necessary certifications from those consortium participants and contractors.

The signature of the AOO on the application serves as the required certification of compliance for the applicant organization.Disclosure reporting is addressed in “Administrative Requirements—Monitoring—Reporting.”

NIH appropriated funds may not be used to pay the salary or expenses of an employee of a grantee, consortium participant, or contractor or those of an agent related to any activity designed to influence legislation or appropriations pending before Congress or any State legislature. This prohibition extends to the use of funds for publicity or propaganda purposes, including the preparation, distribution, or use of any kit, pamphlet, booklet, publication, radio, television, or video presentation designed to support or defeat legislation pending before Congress or a State legislature except in presentation to the Congress or State legislature itself or as part of normal, recognized legislative-executive relationships. Also see Cost Considerations—Allowability of Costs and Activities—Selected Items of Cost.”

Research Misconduct

The grantee will inquire into and, if necessary, investigate and resolve promptly and fairly all instances of alleged or apparent research misconduct. Title 42 CFR Part 50, Subpart A, “Responsibilities for PHS Awardee and Applicant Institutions for Dealing With and Reporting Possible Misconduct in Science,” specifies grantee responsibilities in dealing with and reporting possible research misconduct. By signing the application, the AOO certifies that the organization has established administrative policies as required by 42 CFR 50, Subpart A, and will comply with those policies and the requirements of the regulations. The regulations are available from the ORI on its home page (http://www.ori.dhhs.gov) and, in hard copy, at the address shown in Part III.

As stated throughout the NIHGPS, the grantee has primary responsibility for ensuring that it is conducting its NIH-funded project in accordance with the approved application and budget and the terms and conditions of the award. The grantee must carry out its responsibilities with extra care where research misconduct has been found or where a research misconduct investigation has been initiated, as specified in 42 CFR 50.103 and 50.104. The grantee must report promptly to ORI any incident of alleged or apparent research misconduct that it judges as warranting investigation and must advise ORI of any decision to initiate an investigation. The regulations also require that the grantee submit an annual report (see “Administrative Requirements—Monitoring—Reporting”).
If a misconduct investigation has been initiated, the grantee must take any necessary steps, in addition to its normal and ongoing responsibilities under the grant, to protect the scientific integrity of the project, protect human subjects and animals, provide reports to ORI, and ensure the proper expenditure of funds and continuation of the project during the investigation, if appropriate. ORI staff members are available to help grantees with investigating and reporting on research misconduct, and IC staff members are available to provide technical assistance and to work with grantees to protect funded projects from the adverse effects of research misconduct.

The grantee is responsible for the actions of its employees and other research collaborators, including third parties, involved in the project. When the grantee finds research misconduct by anyone working on an NIH grant-supported project, whether at the grantee organization or at a third-party organization, the grantee must assess the effect of that finding on the ability to continue that project, as originally approved by NIH, and must promptly obtain NIH approval of any intended change of PI or other key personnel. Examples of possible sanctions by NIH are withdrawal of approval of the PI or other key personnel, debarment, disallowance of costs associated with the invalid or unreliable research, withholding of a continuation award, or suspension or termination, in whole or in part, of the current award. These actions are described in “Administrative Requirements—Enforcement Actions.”

Where research misconduct has affected data validity or reliability, ORI or NIH may require the grantee and its employee/collaborator authors to submit a correction or retraction of the data to a journal, publish the corrected data, or both. If the grantee does not comply with this requirement, NIH may invoke its rights, under 45 CFR Part 74 or 92, to access the data (including copyrightable material developed under the award), have the data reviewed, and submit the correction.

The grantee must promptly report issues involving potential criminal violations, such as misappropriation of Federal funds, to the HHS OIG (see Part III).

NIH Guidelines for Research Involving Recombinant DNA Molecules and Human Gene Transfer Research

Scope and Applicability

The NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) (April 2002 or latest revision) apply to all research projects that involve recombinant DNA and are conducted at or sponsored by an organization that receives NIH support for recombinant DNA research. A copy of the NIH Guidelines is available at http://oba.od.nih.gov/oba/rac/guidelines_02/NIH_Guidelines_Apr_02.htm. As defined by the NIH Guidelines, recombinant DNA molecules are either (1) molecules that are constructed outside of living cells by joining natural or synthetic DNA segments to DNA molecules that can replicate in a living cell or (2) molecules that result from the replication of those described in (1). The NIH Guidelines apply to both basic and clinical research studies. Recombinant DNA research involving select agents also is subject to pertinent CDC and USDA regulations.7 Specific

7 42 CFR Part 73, Select Agents and Toxins; and 7 CFR Part 331 and 9 CFR Part 121, Possession, Use, and Transfer of Biological Agents and Toxins.
guidance for the conduct of human gene transfer studies appears in Appendix M of the NIH Guidelines. Failure to comply with these requirements may result in suspension or termination of an award for recombinant DNA research at the organization, or a requirement for NIH prior approval of any or all recombinant DNA projects at the organization. Two specific requirements of the NIH Guidelines are discussed below, but the grantee should carefully review the NIH Guidelines in their entirety to ensure compliance with all of the requirements for projects involving recombinant DNA techniques.

**Institutional Biosafety Committee**

Each organization that conducts research involving recombinant DNA, including contractors under grants, must have policies and procedures to ensure compliance with the NIH Guidelines and must establish a standing IBC. The IBC is required to review each proposed project for recombinant DNA experiments and certify that the procedures, project, personnel, and facilities are adequate and in compliance with the NIH Guidelines. Section IV of the NIH Guidelines specifies the composition of IBCs. A roster of the IBC members must be submitted to NIH’s OBA (see Part III for address). At a minimum, the roster should include the names, addresses, occupations, and qualifications of the chairperson and members of the committee. The roster also should indicate which IBC members are serving as the chairperson, contact person, and, as applicable, experts in biosafety or plant, animal, or human experimentation. Section IV of the NIH Guidelines also specifies the roles and responsibilities of PIs and grantees in relation to IBCs and in other areas.

**Safety and Annual Reporting**

Appendix M-I-C-4 of the NIH Guidelines requires serious adverse events that are unexpected and are possibly associated with human gene transfer intervention to be reported to OBA and the IBC within 15 calendar days of investigator notification of the sponsor, or within 7 days if life-threatening or fatal. In addition, annually, investigators must submit to OBA certain information about protocols. Further information about the content of these reports can be found in Appendix M-I-C-3 of the NIH Guidelines.

**Nondelinquency on Federal Debt**

The Federal Debt Collection Procedures Act of 1990 (Act), 28 U.S.C. 3201(e), provides that an organization or individual that is indebted to the United States, and has a judgment lien filed against it, is ineligible to receive a Federal grant. NIH cannot award a grant unless the AOO of the applicant organization (or individual in the case of a Kirschstein-NRSA individual fellowship) certifies, by means of his/her signature on the application, that the organization (or individual) is not delinquent in repaying any Federal debt. If the applicant discloses delinquency on a debt owed to the Federal government, NIH may not award the grant until the debt is satisfied or satisfactory arrangements are made with the agency to which the debt is owed. In addition, once the debt is repaid or satisfactory arrangements made, NIH still will take that delinquency into account when determining whether the applicant would be responsible with respect to an NIH grant, if awarded.
Anyone who has been judged to be in default on a Federal debt and who has had a judgment lien filed against him or her should not be listed as a participant in an application for an NIH grant until the judgment is paid in full or is otherwise satisfied. No funds may be rebudgeted following an award to pay such an individual. NIH will disallow costs charged to awards that provide funds to individuals in violation of this Act.

These requirements apply to all types of organizations and awards, including foreign grants.

**NIH Guidelines for Research Using Human Embryonic Stem Cells**

NIH will fund research using human pluripotent stem cells derived from human embryos (technically known as human embryonic stem cells) or human fetal tissue (technically known as human embryonic germ cells). For purposes of these NIH Guidelines, human pluripotent stem cells are cells that are self-replicating, are derived from human embryos or human fetal tissue, and are known to develop into cells and tissues of the three primary germ layers. Although human pluripotent stem cells may be derived from embryos or fetal tissue, such stem cells are not in themselves embryos.

NIH research funded under these Guidelines will involve human pluripotent stem cells derived: (1) from human fetal tissue or (2) from human embryos that are the result of in vitro fertilization and meet the following Presidential criteria. On August 9, 2001 at 9:00 p.m. EDT, the President announced his decision to allow Federal funds to be used for research on existing human embryonic stem cell lines as long as prior to his announcement (1) the derivation process (which begins with removal of the inner cell mass from the blastocyst) had already been initiated and (2) the embryo from which the stem cell line was derived no longer had the possibility of development as a human being.

In addition, the President established the following criteria that must be met:

- The stem cells must have been derived from an embryo that was created for reproductive purposes.
- The embryo was no longer needed for those purposes.
- Informed consent must have been obtained for donation of the embryo.
- No financial inducements were provided for donation of the embryo.

The complete notice explaining the President’s policy can be found at [http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html](http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html).

In order to facilitate research using human embryonic stem cells, the NIH Human Embryonic Stem Cell Registry lists the human embryonic stem cells that meet the eligibility criteria. The laboratories or companies that provide the cells listed on the Registry must have submitted to NIH a signed assurance. Each provider must retain for submission to NIH, if necessary, written documentation to verify the statements in the signed assurance. The Registry is accessible to investigators on the NIH home page at [http://escr.nih.gov/](http://escr.nih.gov/). Requests for Federal funding must cite a human embryonic stem cell line that is listed on the NIH Registry.

53
Although NIH withdrew those sections of the NIH Guidelines for Research Involving Human Pluripotent Stem Cells (http://stemcells.nih.gov/policy/guidelines.asp) that pertain to research involving human pluripotent stem cells derived from human embryos, the NIH Guidelines contain important and current information regarding specific types of research that are eligible and ineligible for NIH funding.


Restriction on Distribution of Sterile Needles

NIH appropriated funds may not be used to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

Restriction on Abortion Funding

NIH funds may not be spent for an abortion.

Seat Belt Use

Pursuant to EO 13043 (April 16, 1997), Increasing the Use of Seat Belts in the United States, NIH encourages grantees to adopt and enforce on-the-job seat belt policies and programs for their employees when operating vehicles, whether organizationally owned or rented or personally owned.

Smoke-Free Workplace

NIH strongly encourages grantees to provide smoke-free workplaces and to promote the nonuse of tobacco products. NIH defines the term “workplace” to mean office space (including private offices and other workspace), conference or meeting rooms, corridors, stairways, lobbies, rest rooms, cafeterias, and other public spaces.

Requirements Affecting the Rights and Welfare of Individuals as Research Subjects, Patients, or Recipients of Services

Human Embryo Research, Cloning, and Transplantation

Ban on Human Embryo Research and Cloning

NIH funds may not be used to support human embryo research under any extramural award instrument. NIH funds may not be used for the creation of a human embryo for research purposes or for research in which a human embryo is destroyed, discarded, or knowingly subjected to risk of injury or death greater than that allowed for research on fetuses in utero under 45 CFR 46.204 and 46.207 and subsection 498(b) of the PHS Act. The term “human embryo” includes any organism not protected as a human subject under 45 CFR 46, as of the date of enactment of the governing appropriations act, that is derived by fertilization,
parthenogenesis, cloning, or any other means from one or more human gametes or human diploid cells.

In addition to the statutory restrictions on human fetal research under subsection 498((b) of the PHS Act, by Presidential memorandum of March 4, 1997, NIH is prohibited from using Federal funds for cloning of human beings.

**Research on Human Fetal Tissue**

Human fetal tissue is defined as tissue or cells obtained from a dead human embryo or fetus after a spontaneous or induced abortion or stillbirth. This definition does not include established human fetal cell lines. Research involving the transplantation of human fetal tissue must be conducted in accordance with applicable State and local laws as well as the following NIH guidance.


The scientific and ethical challenges associated with research utilizing human fetal tissue make it imperative that researchers and their organizations be fully aware of and in compliance with the Federal requirements, particularly section 498B. When an application involving human fetal tissue research is submitted to NIH, the AOO’s signature certifies that researchers using these tissues are in compliance with section 498B of the PHS Act. The statute specifically prohibits any person from knowingly acquiring, receiving, or transferring any human fetal tissue for valuable consideration. The term “valuable consideration” is a concept similar to profit and does not include reasonable payment for costs associated with the collection, processing, preservation, storage, quality control, or transportation of these tissues. Violation of this statute carries criminal penalties that apply to both those that supply and those that acquire human fetal tissue.

Sections 498A and 498B contain additional legal requirements for research on the transplantation of human fetal tissue for therapeutic purposes conducted or supported by NIH. Under section 498A, the official who signs the application is certifying that the research on transplantation of human fetal tissue will adhere to the following provisions:

- The woman who donates the fetal tissue must sign a statement declaring that the donation is being made
  - for therapeutic transplantation research,
  - without any restriction regarding the identity of individuals who may receive the transplantation, and
  - without the donor knowing the identity of the recipient.
◆ The attending physician must sign a statement that he/she has

- obtained the tissue in accordance with the donor’s signed statement and
- fully disclosed to the donor his or her intent, if any, to use the tissue in research and any known medical risks to the donor or risks to her privacy associated with the donation that are in addition to risks associated with the woman’s medical care.

In the case of tissue obtained pursuant to an induced abortion, the physician’s statement also must state that he/she

- obtained the woman’s consent for the abortion before requesting or obtaining consent for the tissue to be used;
- did not alter the timing, method, or procedures used to terminate the pregnancy solely for the purpose of obtaining the tissue for research; and
- performed the abortion in accordance with applicable State and local laws.

◆ The PI must sign a statement certifying that he/she is aware that the tissue is human fetal tissue obtained in a spontaneous or induced abortion, or pursuant to a stillbirth and that the tissue was donated for research purposes. The PI also must certify that this information has been shared with others who have responsibilities regarding the research and, before eliciting informed consent from the transplantation recipient, will obtain written acknowledgment that the patient is aware of the aforementioned information.

◆ The PI must certify in writing that he/she has had no part in any decisions as to the timing, method, or procedures used to terminate the pregnancy.

The AOO also is certifying that the physician’s statement, the PI’s statement, and the acknowledgment of the transplantation recipient will be available for audit by the HHS Secretary or designee.

**Research on Transplantation of Fetal Tissue**

In submitting an application to NIH, the AOO that signs the application is certifying that, if research on the transplantation of human fetal tissue is conducted under the grant-supported project, the organization will make available for audit by the HHS Secretary or designee, the physician statements and informed consents required by subsections 498A(b)(2) and (c) of the PHS Act or will ensure HHS access to those records, if maintained by an entity other than the grantee. This requirement is in addition to the requirements concerning human subjects in research.

In addition, FDA issued a letter on November 30, 2000, indicating that it has jurisdiction over fetal cells and tissues intended for use in humans. FDA is requesting that investigators contact them to determine whether any planned or ongoing clinical research would require submission of an IND application. Additional information and FDA contact information is available at http://www.fda.gov/cber/ltr/fetal113000.htm.
Confidentiality

NIH expects grantees and others involved in NIH grant-supported research to take appropriate actions to protect the confidentiality of information about and the privacy of individuals participating in the research. Investigators, DSMBs, IRBs, and other appropriate entities should ensure that policies and procedures are in place to protect identifying information and must oversee compliance with those policies and procedures.

Certificates of Confidentiality

Section 301(d) of the PHS Act provides that the Secretary may authorize people engaged in biomedical, behavioral, clinical, or other research activities to protect the privacy of research subjects by withholding the names and other identifying characteristics of those subjects from individuals not engaged in the research. Individuals that have authorization may not be compelled to disclose subjects’ identities in any Federal, State, or local civil, criminal, administrative, legislative or other proceeding. CoCs may be granted for studies collecting information that, if disclosed, could have adverse consequences for subjects or damage their financial standing, employability, insurability, or reputation. By protecting researchers from being compelled to disclose information that would identify research subjects, CoCs contribute to achieving research objectives and promote participation in studies by helping to ensure confidentiality and privacy to participants. Information on CoCs is available on the NIH website at the CoC Kiosk at http://grants.nih.gov/grants/policy/coc/index.htm. Requests for CoCs should be submitted to the GMO, and, subject to awarding office review and approval, a certificate may be issued pursuant to section 301(d).

Confidentiality of Patient Records

Section 543 of the PHS Act requires that records of substance abuse patients be kept confidential except under specified circumstances and purposes. The covered records are those that include the identity, diagnosis, prognosis, or treatment of any patient maintained in connection with any program or activity relating to substance abuse education, prevention, training, treatment, rehabilitation, or research that is conducted, regulated, or directly or indirectly assisted by any department or agency of the United States. This requirement is implemented in 42 CFR Part 2.

Standards for Privacy of Individually Identifiable Health Information

HHS issued the final version of the “Standards for Privacy of Individually Identifiable Health Information”—the Privacy Rule—on August 14, 2002. The Privacy Rule is a Federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information. It is administered and enforced by OCR, HHS. Those entities required to comply with the Privacy Rule (classified under the rule as “covered entities”) had until April 14, 2003 to do so (with the exception of small health plans which have an extra year to comply).

Decisions about applicability and implementation of the Privacy Rule reside with the researcher and the grantee organization. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including the complete text of the regulation and a set of decision tools for
determining whether a particular entity is subject to the rule. An educational booklet, Protecting Heath Information in Research: Understanding the HIPAA Privacy Rule, is available through OCR’s website and also at http://privacyruleandresearch.nih.gov/. That website also includes other educational materials sanctioned by OCR and the Office of the General Counsel, HHS. Additional information on the impact of the Privacy Rule on NIH processes involving the review, funding, and performance monitoring of grants can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.

Controlled Substances

If controlled substances are proposed to be administered as part of a research protocol or if research is to be conducted on the drugs themselves, applicants/grantees must ensure that the DEA requirements, including registration, inspection, and certification, as applicable, are met. Regional DEA offices can supply forms and information concerning the type of registration required for a particular substance for research use. The main registration office in Washington, DC may be reached at 800-882-9539. Information also is available from the National Institute on Drug Abuse at 301-443-6300.

Human Subjects

HHS regulations for the protection of human subjects, in 45 CFR Part 46, implement section 491(a) of the PHS Act and provide a systematic means, based on established, internationally recognized ethical principles, to safeguard the rights and welfare of individuals who participate as subjects in research activities supported or conducted by NIH or other HHS components.

The Federal regulations require that each institution, domestic or foreign, “engaged” in human subjects research provide OHRP with a satisfactory Assurance of compliance with the regulations, unless the research is exempt under 45 CFR 46.101(b). An institution becomes “engaged” in human subjects research when its employees or agents (1) intervene or interact with living individuals for research purposes, or (2) obtain individually identifiable private information for research purposes (45 CFR 46.102(d) and (f)).

The HHS regulations require that departments and agencies (e.g., NIH) will conduct or support research covered by this policy only if the institution has an assurance approved by OHRP, and only if the institution has certified to NIH that the research has been reviewed and approved by an IRB provided for in the assurance and will be subject to continuing review by the IRB. Under no condition shall research covered by the regulations be supported prior to receipt of the certification that the research has been reviewed and approved by the IRB (45 CFR 46.103(b) and (f)).

If, at the time of award, a grantee does not have an assurance approved by OHRP and certification of IRB review and approval, NIH will place a restriction on the award so that no human subjects research can be conducted or supported at that site until the assurance and certification of IRB review and approval have been obtained and accepted by NIH. The awardee institution bears ultimate responsibility for protecting human subjects under the award, including human subjects at all participating and consortium sites, and for ensuring that an Assurance
approved by OHRP and certification of IRB review and approval have been obtained before
human subjects research can be conducted at each collaborating site.

For this requirement, the definitions in 45 CFR 46.102 apply as follows:

- **Human subject.** A living individual about whom an investigator (whether professional or
  student) conducting research obtains (1) data through intervention or interaction with the
  individual or (2) identifiable private information.

- **Research.** A systematic investigation, including research, development, test, and
  evaluation, designed to develop or contribute to generalizable knowledge. Activities
  which meet this definition constitute research for purposes of this policy, whether or not
  they are conducted or supported under a program which is considered research for other
  purposes. For example, some demonstration and service programs include research
  activities.

The use of autopsy materials is governed by applicable State and local law and is not directly
regulated by 45 CFR 46.

**Assurance Requirements and Institutional Review Boards**

OHRP negotiates assurances covering all of an organization’s federally supported research
activities involving human subjects. Applicant organizations proposing to involve human
subjects in nonexempt research must file (or have previously filed) a written assurance (FWA)
with OHRP setting forth the commitment of the organization to establish appropriate policies
and procedures for the protection of human subjects. For organizations proposing nonexempt
research involving human subjects and not currently holding an approved assurance, OHRP will
negotiate an FWA.

Each legally separate entity must file its own FWA even if the organization does not operate its
own IRB and designates another IRB (registered with OHRP and agreeing to the designation) for
that purpose. Affiliated organizations or organizations that will serve as additional performance
sites for the grant-supported research also must file an FWA. No individual may receive NIH
grant funds for nonexempt research involving human subjects unless the individual is affiliated
with or sponsored by an organization that assumes responsibility for the research under an FWA
or the individual makes other arrangements with OHRP.

Detailed information concerning FWAs, including the OHRP Assurance Training Module, is
available on the OHRP website ([http://www.hhs.gov/ohrp/](http://www.hhs.gov/ohrp/)).

---

8 As of February 28, 2001, OHRP no longer accepted applications for Multiple Project Assurances (MPAs) or
Single Project Assurances (SPAs) limited to HHS-supported research, to special categories of research, or to
individual research projects. Current MPAs will remain in effect until the designated expiration date or December
31, 2003, whichever comes first; however, MPA organizations may file a new FWA at any time prior to that date.
OHRP will not accept changes to existing MPAs (except for IRB membership updates). If changes are necessary,
the organization should file an FWA. Current SPAs will remain in effect through the expiration of their respective
grant (or contract) award and any non-competing continuation award.
In addition to the requirement for an assurance, NIH will not award a grant for nonexempt research in which human subjects are involved unless the grantee provides a certification to NIH that the research has been approved by an appropriate IRB, consistent with 45 CFR Part 46, within 12 months before the budget period start date. IRB approval is not required before NIH peer review of an application. Rather, following peer review and notification of priority score/percentile, applicant organizations should proceed with IRB review for those applications that have not yet received IRB approval and that appear to be in a fundable range. Regardless of when the IRB review occurs, the IRB should ensure that the research described in the application is consistent with any corresponding protocols reviewed and approved by the IRB.

It is the grantee organization’s responsibility to ensure that all sites engaged in research involving human subjects have an appropriate OHRP-approved assurance and IRB approval of the research consistent with 45 CFR Part 46. It also is the grantee’s responsibility to comply with NIH prior-approval requirements related to the addition of sites not included in the approved application (see “Administrative Requirements—Changes in Project and Budget—Prior-Approval Requirements”). The list of organizations with approved assurances is available at the OHRP website (http://www.hhs.gov/ohrp/). Grantees may not draw funds from the payment system, request funds from the paying office, or make obligations against Federal funds for research involving human subjects at any site engaged in nonexempt research for any period not covered by both an OHRP-approved assurance and IRB approval consistent with 45 CFR Part 46. Costs associated with IRB review of human research protocols are not allowable as direct charges to NIH-funded research unless such costs are not covered by the organization’s F&A rate.

As specified in 45 CFR 46.111, the IRB review must include a determination that, for research covered by the regulations, the following conditions are met:

◆ The procedures to be used will minimize risks to subjects.

◆ Risks to subjects are reasonable in relation to expected benefits, if any, to subjects and the importance of the knowledge that may reasonably be expected to result.

◆ Selection of subjects is equitable.

◆ Informed consent is sought from each prospective subject or the subject’s legally authorized representative and is appropriately documented in accordance with, and to the extent required by, the regulation.

◆ When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects, the protection of privacy, and the confidentiality of data.

◆ When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as children, prisoners, pregnant women, people with acute or severe physical or mental illness, or people who are economically or educationally disadvantaged, appropriate additional safeguards are included in the study to protect the rights and welfare of these subjects.
If an IRB considers the impact of potential financial (or other) conflicts of interest on the research and the protection of human subjects, it should refer to the organization’s policies and procedures for identifying and monitoring conflicts of interest (see “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—Standards of Conduct—Financial Conflict of Interest”).

The regulations specify additional protections for research involving human fetuses, pregnant women, and neonates (Subpart B); prisoners (Subpart C); and children (Subpart D).

OHRP also has responsibility for oversight of grantee compliance with the HHS human subjects regulations. In carrying out this responsibility, OHRP evaluates all written allegations or indications of non-compliance with the HHS regulations it receives from any source. All compliance oversight evaluations are predicated on the HHS regulations and the organization’s assurance of compliance. Any corrective actions imposed as a result of compliance oversight evaluations are intended to remedy identified non-compliance and prevent reoccurrence. Because each case is different, OHRP tailors corrective actions to foster the best interest of human research subjects and, to the extent possible, of the organization, research community, and HHS. Most compliance oversight evaluations and resultant corrective actions are resolved at the OHRP level. However, OHRP may recommend actions to be taken by other HHS officials.

Information about FWA preparation and negotiation and about OHRP activities related to oversight and compliance, as well as copies of the human subjects regulations, may be obtained from OHRP at the address shown in Part III or from its home page at http://www.hhs.gov/ohrp/_. OHRP also has produced a publication, available through the GPO9, and an instructional videotape.

**Education in the Protection of Human Research Participants**

Before funds are awarded for competing applications involving human subjects, applicants must submit documentation that all key personnel have received training in the protection of human subjects. Key personnel include all individuals responsible for the design or conduct of the study, including key personnel of consortium participants or alternate performance sites if they are participating in research that involves human subjects. This documentation should be part of a cover letter signed by the AOO that accompanies the description of other support, IRB and IACUC approval, and other information submitted prior to funding in accordance with just-in-time procedures. For non-competing continuation awards, the description of education for new key personnel should be part of the progress report submitted as a prerequisite to award. Additional information about this education requirement is available on the NIH website at: http://grants.nih.gov/grants/policy/hsEduc_faq.htm.

---

Data and Safety Monitoring

For all federally funded research involving human subjects, the regulations for the protection of human subjects (45 CFR 46) specify criteria for IRB approval of research and require, at 45 CFR 46.111(a)(6), that “[W]hen appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.”

NIH provides the following more specific requirements for data and safety monitoring. NIH requires oversight and monitoring of all human intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. The NIH policies on data and safety monitoring specify that the level of monitoring should be commensurate with the risks and the size and complexity of the clinical trial, and are in addition to any monitoring requirements imposed by FDA or the *NIH Guidelines for Research Involving Recombinant DNA Molecules*. The frequency of monitoring will depend on potential risks, complexity, and the nature of the trial; therefore, a number of options for monitoring trials are available. These can include, but are not limited to, monitoring by a/an

- PI (required),
- independent individual/safety officer,
- designated medical monitor,
- internal committee or board with explicit guidelines,
- DSMB (required for multi-site trials), and
- IRB (required).

For competing research applications including clinical trials, the applicant must include a general description of the data and safety monitoring for review by the SRG. A general description of a monitoring plan establishes the overall framework for data and safety monitoring. It should describe the entity that will be responsible for monitoring and how adverse events will be reported to the IRB and, if appropriate, OBA, and FDA in accordance with IND or IDE regulations. In specific cases where the NIH awarding office is the sponsor of the test agent, i.e., the holder of the IND application, investigators must submit individual adverse event reports to the awarding office in accordance with FDA regulations.

A detailed monitoring plan must be included as part of the research protocol, be submitted to the local IRB, and be reviewed and approved by the NIH awarding office prior to the accrual of human subjects. The awarding office may specify the reporting requirements for adverse events, which are in addition to the annual report to the IRB. The clinical trial monitoring function is above and beyond that traditionally provided by IRBs; however, the IRB must be cognizant of the procedures used by clinical trial monitoring entities and the monitor must provide periodic reports to investigators for transmittal to the local IRB.

NIH specifically requires the establishment of DSMBs for multi-site clinical trials involving interventions that entail potential risk to the participants, and generally for Phase III clinical
trials. Although Phase I and Phase II clinical trials also may use DSMBs, smaller clinical trials may not require this oversight format, and alternative monitoring plans may be appropriate.

For multi-site Phase I and II trials, investigators should organize a central reporting entity that will be responsible for preparing timely summary reports of adverse events for distribution among sites and the IRBs of participating sites. The frequency of summary reports will depend on the nature of the trial. Organizations with a large number of clinical trials may develop standard monitoring plans for Phase I and II clinical trials. However, such plans should always be evaluated for appropriateness for the particular investigation.

For multi-site Phase I and II trials, investigators should organize a central reporting entity that will be responsible for preparing timely summary reports of adverse events for distribution among sites and the IRBs of participating sites. The frequency of summary reports will depend on the nature of the trial. Organizations with a large number of clinical trials may develop standard monitoring plans for Phase I and II clinical trials. However, such plans always should be evaluated for appropriateness for the particular investigation.

All multi-site trials with DSMBs are expected to forward summary reports of adverse events to individual IRBs so they can address reports related to the site for which they have responsibility. Grantees should address questions on this subject to the NIH PO.


Investigational New Drug Applications/Investigational Device Exceptions

To be eligible for NIH funding, all clinical research involving INDs, drugs approved for a different indication, or experimental combinations of drugs must meet FDA’s IND regulations, FDA’s human subjects’ protection requirements, and HHS’s human subjects’ requirements. As provided in the FDA regulations, an IND or IDE also may apply to biologics or devices. The FDA regulations are published in 21 CFR Parts 50 and 312.

The official sponsor of the IND/IDE, whether NIH, a grantee, or a third party, is legally responsible for meeting the FDA requirements. If the IND/IDE sponsor is a third party, such as a pharmaceutical company or research organization under contract to a grantee or to a pharmaceutical company, the legal responsibility for monitoring the clinical trial and reporting to FDA rests with the sponsor rather than the grantee. This generally will be the case for larger, multi-site clinical trials. If the grantee is the IND/IDE holder, commonly referred to as an “investigator-initiated IND/IDE,” the grantee or the investigator serves as the sponsor and assumes the legal responsibility. In any case, the grantee is ultimately responsible to NIH for ensuring compliance with the requirements for protection of human subjects, including compliance with FDA’s requirements.
Following the filing of an IND, FDA has a 30-day period in which to review it. FDA may allow the IND to proceed or may defer approval of the IND until changes it deems acceptable are made. FDA also may order a clinical trial to be suspended or terminated, at any time, based on information it receives about that clinical trial.

When NIH funds all, or part of, a clinical study involving an IND or an IDE, NIH must be knowledgeable about any significant communications with FDA concerning the study. The grantee organization must report certain types of FDA communications to the NIH awarding office within 72 hours of receiving a copy of or upon being informed of the FDA communication (through the PI or another person acting on behalf of the grantee), whichever occurs first. This notification requirement applies to any of the following communications from FDA with the sponsor of the IND or IDE:

- Warning letters (whether sent to the grantee or to the commercial sponsor)
- Notices of Initiation of Disqualification Proceedings and Opportunity to Explain
- Notice of Opportunity for Hearing
- Notice of Disqualification
- Consent Agreements
- Clinical hold letters that pertain to breaches of good manufacturing practices, good clinical practices, or other major issue requiring significant changes in the protocol.

The notification should be made in writing, but also may be done by telephone if a written notice would delay the notification. It should include a statement of the action taken or contemplated and the assistance needed to resolve the situation. These requirements apply to the grantee even if the grantee or the NIH-funded PI is the sponsor. Failure to comply with this requirement may result in NIH imposing a corrective and/or enforcement action (see “Administrative Requirements—Enforcement Actions”). FDA communications are considered grant-related records for purposes of retention and access (see “Administrative Requirements—Monitoring—Record Retention and Access”).

Pro-Children Act of 1994

Public Law 103-227, Title X, Part C, Environmental Tobacco Smoke, also known as the Pro-Children Act of 1994, imposes restrictions on smoking in facilities where federally funded children’s services are provided. NIH grants are subject to these requirements only if they meet the Act’s specified coverage. The Act specifies that smoking is prohibited in any indoor facility (owned, leased, or contracted for) used for the routine or regular provision of kindergarten, elementary, or secondary education or library services to children under the age of 18. In addition, smoking is prohibited in any indoor facility or portion of a facility (owned, leased, or contracted for) used for the routine or regular provision of federally funded health care, day care, or early childhood development (Head Start) services to children under the age of 18. The statutory prohibition also applies if such facilities are constructed, operated, or maintained with Federal funds. The statute does not apply to children’s services provided in private residences,
facilities funded solely by Medicare or Medicaid funds, portions of facilities used for inpatient
drug or alcohol treatment, or facilities where Women, Infants and Children (WIC) coupons are
redeemed. Failure to comply with the provisions of the law may result in the imposition of a civil
monetary penalty of up to $1,000 per violation and/or the imposition of an administrative
compliance order on the responsible entity.

Because of the nature of NIH programs and funding, individual transactions, rather than entire
programs, may be subject to these requirements. The signature of the AOO will indicate the
intent to comply. Any questions concerning the applicability of these provisions to an NIH grant
should be directed to the GMO.

**Animal Welfare**

The *PHS Policy on Humane Care and Use of Laboratory Animals* (the Policy) requires
applicants proposing to use vertebrate animals in NIH-supported activities to file a written
Animal Welfare Assurance with OLAW. The Policy defines “animal” as any live, vertebrate
animal used or intended for use in research, research training, experimentation, biological
testing, or related purposes. Under the Policy, the applicant/grantee is responsible for the humane
care and treatment of animals in NIH grant-supported activities. The Policy implements and
supplements the U.S. Government Principles for the Care and Utilization of Vertebrate Animals
used in Testing, Research, and Training. The Policy also requires the applicant to establish
appropriate policies and procedures for the humane care and use of animals, based on the Guide
for the Care and Use of Laboratory Animals, and to comply with the Animal Welfare Act and its
implementing regulations. This includes appointing an IACUC with specified responsibilities.

NIH will not make an award for research involving live vertebrate animals unless the applicant
organization and all performance sites are operating in accordance with an approved Animal
Welfare Assurance and provide verification that the IACUC has reviewed and approved those
sections of the application that involve use of vertebrate animals, in accordance with the
requirements of the Policy. NIH will not make an award for research involving live vertebrate
animals to an individual unless that individual is affiliated with an organization that accepts
responsibility for compliance with the Policy and has filed the necessary assurance with OLAW.

Applications from organizations with approved Animal Welfare Assurances will be considered
incomplete if they do not contain the information concerning the use of vertebrate animals
required as part of the application’s research plan (see instructions for completing the PHS 398
and PHS 416-1 for the specific points that need to be addressed). In the case of apparent or
potential violation of the Policy, NIH may refer an application back to the applicant for further
IACUC review.

Verification of the IACUC review may be filed at any time before award unless required earlier
by the IC. Therefore, following peer review and notification of priority score/percentile,
applicant organizations with approved Assurances should proceed with IACUC review for those
applications that have not yet received IACUC approval and that appear to be in a fundable
range. Regardless of when the review occurs, the IACUC should ensure that the research
described in the application is consistent with any corresponding protocols reviewed and
approved by the IACUC. If an application is selected for award and the verification of IACUC
review has not been submitted, the awarding office will contact the organization with instructions for negotiating an assurance or submitting the IACUC verification.

When organizations collaborate and multiple recognized IACUCs may be involved, only one of those IACUCs is required to review the research project or evaluate a program facility. In such cases, organizations must define their respective responsibilities to ensure compliance with the Policy. If both institutions have full Animal Welfare Assurances, they may exercise discretion in determining which IACUC will review the research protocol(s) and under which organization’s program the research will be performed.

OLAW may negotiate an inter-organizational Animal Welfare Assurance when an awardee organization without an animal care and use program or IACUC will rely on the program of an organization with an assurance. Assured institutions also have the option to amend their Animal Welfare Assurances to cover performance sites without such assurances.

Foreign organizations proposing activities involving vertebrate animals are required to comply with the Policy or provide evidence that acceptable standards for the humane care and use of animals will be met.

The Policy does not affect applicable State or local laws or regulations that impose more stringent standards for the care and use of laboratory animals. In addition, all organizations are required to comply, as applicable, with the Animal Welfare Act, as amended, 7 U.S.C. 2131 et seq., and other Federal statutes and regulations relating to animals.

Information about preparing and submitting Animal Welfare Assurances and copies of the Policy and other relevant materials are available from OLAW (see Part III for contact information).

**Requirements for Inclusiveness in Research Design**

NIH requires grant-supported research projects to be as inclusive in design as possible to extend the validity of research findings and allow for enhancement of the health status of all population groups.

**Inclusion of Women and Minorities as Subjects in Clinical Research**

Clinical research involving human subjects of any age must comply with the NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research (http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm), implementing section 492B of the PHS Act. These guidelines require that women and members of minority groups and their subpopulations (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-01-053.html) be included in any NIH-supported biomedical and behavioral clinical research project involving human subjects, unless a clear and compelling rationale and justification establishes, to the satisfaction of the IC Director, that inclusion is inappropriate with respect to the health of the subjects, the purpose of the research, or other circumstances. Cost is not an acceptable reason for exclusion, except when the research would duplicate data already available from other sources. Women of childbearing potential should not be routinely excluded from participation in clinical research. The guidelines should be reviewed for policy concerning
inclusion of these groups in all NIH-supported clinical trials. This policy applies to subjects of all ages.

One of the requirements of those guidelines is collecting information on racial/ethnic group in accordance with government-wide requirements to allow comparisons to other Federal databases, especially the census and national health databases. OMB Directive No. 15 (http://www.whitehouse.gov/omb/fedreg/race-ethnicity.html) defines minimum standards for maintaining, collecting, and presenting data on race and ethnicity for all Federal reporting. The categories in this classification are social-political constructs and should not be interpreted as being scientific or anthropological in nature. The standards include five racial categories: American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, and White. There are two categories for ethnicity: “Hispanic or Latino,” and “Not Hispanic or Latino.” Reports of data on race and ethnicity shall use these categories. These categories are defined in OMB Directive 15.

Peer reviewers will evaluate proposed plans for inclusion of members of minority groups and both genders, the design of clinical trials, and recruitment and outreach as part of the scientific assessment. Failure to comply with this policy may result in NIH not making an award. Grantees are required to report annually on the enrollment of individuals by gender and racial or ethnic minority group as part of the grant progress report, including SNAP reporting (see “Administrative Requirements—Monitoring—Reporting—Non-Competing Grant Progress Reports”).

Inclusion of Children as Subjects in Clinical Research

NIH has a separate policy on inclusion of children as subjects in clinical research that is similar to the policy regarding inclusion of women and minorities (http://grants.nih.gov/grants/funding/children/children.htm). All new research projects involving human subjects research must include children in the research design unless there are scientific or ethical reasons not to include them. If children will be excluded from the research, the application must present an acceptable justification for the exclusion. For the purpose of addressing the NIH policy requirement for inclusion, a child is defined as an individual under the age of 21 years.

The inclusion of children as subjects in research must comply with all applicable provisions of pertinent Federal laws and regulations, including 45 CFR Part 46. Regulatory requirements in 45 CFR 46 Subpart D address HHS protections for children who participate in research. These requirements must be addressed when “children” (persons who, under the applicable law of the jurisdiction in which the research will be conducted, have not attained the legal age for consent to treatments or procedures involved in the research) are involved as subjects in research.

This policy applies to both exempt and nonexempt research activities (see “Human Subjects” in this section); however, if the applicant claims that the proposed study meets the criteria for exemption 4 under 45 CFR Part 46, no justification for the exclusion of children is required.
Civil Rights

Before NIH may make an award to a domestic organization, the AOO must certify, by means of the signature on the application, that the organization has on file with OCR an Assurance of Compliance with the statutes described in this subsection. The Assurance, Form HHS 690, is filed for the organization and is not required for each application. If the application has been recommended for funding and the applicant organization does not have an Assurance of Compliance on file, it will receive, from the awarding office, the required form and instructions for completion and submission. The HHS 690 also is available from GrantsInfo@nih.gov or by telephone at 301-435-0714.

Domestic organizations that receive funding from grantees (including consortium participants and contractors under grants) rather than directly from NIH also are required to file an HHS 690. The applicant/grantee is responsible for determining whether those organizations have the required Assurance on file and, if not, ensuring that it is filed with OCR.

Age Discrimination Act of 1975

The Age Discrimination Act of 1975 prohibits discrimination on the basis of age in any program or activity receiving Federal financial assistance. The HHS implementing regulations are codified at 45 CFR Part 91.

Civil Rights Act of 1964

Title VI of the Civil Rights Act of 1964 provides that no person in the United States shall, on the grounds of race, color, or national origin, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any program or activity receiving Federal financial assistance. The HHS implementing regulations are codified at 45 CFR Part 80.

Education Amendments of 1972

Title IX of the Education Amendments of 1972 provides that no person in the United States shall, on the basis of sex, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any educational program or activity receiving Federal financial assistance. The HHS implementing regulations are codified at 45 CFR Part 86.

Rehabilitation Act of 1973

Section 504 of the Rehabilitation Act of 1973, as amended, provides that no otherwise qualified handicapped individual in the United States shall, solely by reason of the handicap, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any program or activity receiving Federal financial assistance. These requirements pertain to the provision of benefits or services as well as to employment. The HHS implementing regulations are codified at 45 CFR Parts 84 and 85.
Limited English Proficiency

EO 13166, August 11, 2000, requires grantees receiving Federal financial assistance to take steps to ensure that people with limited English proficiency can meaningfully access health and social services. A program of language assistance should provide for effective communication between the service provider and the person with limited English proficiency to facilitate participation in, and meaningful access to, services. The obligations of grantees are explained on the OCR website at http://www.hhs.gov/ocr/lep/revisedlep.html.

Environmental Impact and Other Requirements Related to Acquisition, Alteration and Renovation, and Construction of Facilities

Public policy requirements that apply to construction activities are described in “Construction Grants—Public Policy Requirements and Objectives.” Those requirements also may apply to A&R activities. A grantee undertaking an A&R project under a nonconstruction award should consult the GMO concerning potential applicability of these requirements.

Availability of Information

Except for certain types of information that may be considered proprietary or private information that cannot be released, most grant-related information submitted to NIH by the applicant or grantee in the application or in the post-award phase is considered public information and, once an award is made, is subject to possible release to individuals or organizations outside NIH. The statutes and policies that require this information to be made public are intended to foster an open system of government and accountability for governmental programs and expenditures and, in the case of research, to provide information about federally funded activities.

NIH routinely places information about awarded grants, including project title, the name of the PI, and the project description, in the CRISP system. For funded research grant applications, NIH also sends the project description provided by an applicant to the DoC’s NTIS. NTIS disseminates scientific information for classification and program analysis. The public may obtain the project descriptions from CRISP (available from the OER home page) or request them from NTIS. Other information may be released case by case as described in this subsection.

Several policies require acknowledgment of support and a disclaimer for publications, inventions, and other research products, as provided in “Administrative Requirements—Availability of Research Results: Publications, Intellectual Property Rights, and Sharing Research Resources” and elsewhere in the NIHGPS.

Acknowledgment of Federal Funding

As required by HHS appropriations acts, all HHS grantees must acknowledge Federal funding when issuing statements, press releases, requests for proposals, bid invitations, and other documents describing projects or programs funded in whole or in part with Federal money. Grantees are required to state (1) the percentage and dollar amounts of the total program or project costs financed with Federal money and (2) the percentage and dollar amount of the total costs financed by nongovernmental sources.
The Freedom of Information Act

The Freedom of Information Act, 5 U.S.C. 552, and implementing HHS regulations (45 CFR Part 5) require NIH to release certain grant documents and records requested by members of the public, regardless of the intended use of the information. These policies and regulations apply to information in the possession of NIH and generally do not require grantees or contractors under grants to permit public access to their records. An exception related to certain research data is described in this subsection.

NIH generally will release the following types of records pursuant to a FOIA request:

◆ Funded applications and funded progress reports, including award data
◆ Final reports that have been transmitted to the grantee organization of any audit, survey, review, or evaluation of grantee performance.

NIH generally will withhold the following types of records or information in response to a FOIA request:

◆ Pending competing grant applications
◆ Unfunded new and competing continuations and competing supplemental applications
◆ Financial information pertaining to project personnel, such as institutional base salary information
◆ Information pertaining to an individual, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy
◆ Predecisional opinions in interagency or intraagency memorandums or letters expressed by Federal government officers, employees, or consultants
◆ Evaluative portions of site visit reports and peer review summary statements, including priority scores
◆ Trade secrets and commercial, financial, and otherwise intrinsically valuable items of information that are obtained from a person or organization and are privileged or confidential
◆ Information which, if released, would adversely affect the competitive position of the person or organization
◆ Patent or other valuable commercial rights of the person or organization.

If, after receiving a FOIA request, NIH has substantial reason to believe that information in its records could reasonably be considered exempt from release, the appropriate NIH FOI office will notify the applicant or grantee, through the PI, before the information is released. The PI will be given an opportunity to identify potentially patentable or commercially valuable information that
the PI believes should not be disclosed. After NIH consideration of the response, the PI and grantee will be informed if NIH does not agree with the PI’s position. If a document contains both disclosable and nondisclosable information, the nondisclosable information will be deleted and the balance of the document will be disclosed.

The HHS regulations implementing FOIA provide that only the NIH FOI Officer may deny requests for information. Requests for information, the release of which is believed to be exempt under FOIA, are referred to the NIH FOI Officer along with written documentation of the rationale for nondisclosure. If the NIH FOI Officer determines that the requested information is exempt from release under FOIA, the requester may appeal that determination to the Deputy Assistant Secretary for Public Affairs (Media), HHS. Additional information on the FOIA process is available at the NIH FOI Office website (http://www.nih.gov/icd/od/foia).

Access to Research Data

NIH handles requests for the release of research data by certain types of recipients as FOIA requests. The term “research data” is defined as the recorded factual material commonly accepted in the scientific community as necessary to validate research findings. It does not include preliminary analyses; drafts of scientific papers; plans for future research; peer reviews; communications with colleagues; physical objects (e.g., laboratory samples, audio or video tapes); trade secrets; commercial information; materials necessary to be held confidential by a researcher until publication in a peer-reviewed journal; information that is protected under the law (e.g., intellectual property); personnel and medical files and similar files, the disclosure of which would constitute an unwarranted invasion of personal privacy; or information that could be used to identify a particular person in a research study.

As required by 45 CFR 74.36, grantees that are institutions of higher education, hospitals, or non-profit organizations must release research data first produced in a project supported in whole or in part with Federal funds that are cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., regulations and administrative orders). If the data are publicly available, NIH directs the requester to the public source. Otherwise, the IC FOI coordinator handles the request, consulting with the affected grantee and the PI. This requirement also provides for assessment of a reasonable fee to cover grantee costs and (separately) the NIH costs of responding.

This requirement to release research data does not apply to commercial organizations or to research data produced by State or local governments. However, if a State or local governmental grantee contracts with an educational institution, hospital, or non-profit organization, and the contract results in covered research data, those data are subject to the disclosure requirement.

The Privacy Act

The Privacy Act of 1974, 5 U.S.C. 552a, and its implementing regulations (45 CFR Part 5b) provide certain safeguards for information about individuals maintained in a system of records (i.e., information may be retrieved by the individual’s name or other identifying information). These safeguards include the rights of individuals to determine what information about them is maintained in Federal agencies’ files (hard copy or electronic) and how it is used, to have access to such records, and to correct, amend, or request deletion of information in their records that is inaccurate, irrelevant, or outdated.

Records maintained by NIH with respect to grant applications, grant awards, and the administration of grants are subject to the provisions of the Privacy Act. NIH has two Privacy Act systems of records that cover NIH grant records:

- **09-25-0036, Extramural Awards and Chartered Advisory Committees: IMPAC (Grant/Contract/Cooperative Agreement Information/Chartered Advisory Committee Information), HHS/NIH/OER and HHS/NIH/CMO**

- **09-25-0112, Grants and Cooperative Agreements: Research, Research Training, Fellowship and Construction Applications and Related Awards, HHS/NIH/OD.**

These two systems provide guidance on requirements for the management of applicable grant records in NIH’s possession and include appropriate routine uses of such information. They also include requirements for safeguarding the records and for record retention and disposal.

 Parties other than PIs may request the release of Privacy Act records. Such requests are processed in the same manner as FOIA requests. For example, information requested by co-investigators in grant applications is released to them only when required under FOIA because they have no right of access under the Privacy Act. When releasing information about an individual to a party other than that individual, NIH will balance the individual’s right to privacy with the public’s right to know as provided by the FOIA.

Records maintained by grantees ordinarily are not subject to the requirements of 45 CFR Part 5b.

**Other Public Policy Requirements and Objectives**

**Metric System**

Consistent with EO 12770 (July 25, 1991), Metric Usage in Federal Government Programs, measurement values in applications and grantee-prepared reports, publications, and other grant-related documents should be in metric. See “Construction Grants” in Subpart B of this part for requirements for metric usage in construction activities.

**Military Recruiting and Reserve Officer Training Corps Program Access to Institutions of Higher Education**

NIH is subject to section 588 of the National Defense Authorization Act of 1995, as implemented in 32 CFR Part 216, that precludes grant awards to institutions of higher education that DoD determines have an anti-Reserve Officer Training Corps (ROTC) policy or practice.
(regardless of when implemented) that either prohibits or, in effect, prevents the Secretary of Defense from gaining entry to campuses or access to students or information for military recruiting. DoD publishes each determination of ineligibility in the Federal Register as well as publishing, once every 6 months, a list of all currently ineligible schools. If DoD determines that an institution is ineligible during an ongoing project period, NIH may either continue the award or take an action to end the award as provided in “Administrative Requirements—Enforcement Actions—Suspension, Termination, and Withholding of Support.” Funding eligibility may be restored on the basis of new information provided to DoD.
THE NOTICE OF GRANT AWARD

The NGA is the legal document issued to notify the grantee that an award has been made and that funds may be requested from the designated HHS payment system or office. An NGA is issued for the initial budget period and each subsequent budget period in the approved project period. The NGA reflects any future-year commitments. A revised NGA may be issued during a budget period to effect an action resulting in a change in the period or amount of support or other change in the terms and conditions of award. NIH will not issue a revised NGA to reflect a grantee’s post-award rebudgeting. Until an IC has issued an NGA for the initial award, any costs incurred by the applicant for the project are incurred at its own risk (see “Allowability of Costs/Activities—Selected Items of Cost—Pre-Award (Pre-Agreement) Costs” for NIH policy on the allowability of pre-award costs).

The NGA sets forth pertinent information about the grant, including, but not limited to, the following:

◆ Application/grant identification number ("grant number")
◆ Name of grantee organization
◆ Name of the PI
◆ Approved project period and budget period start and end dates
◆ Amount of funds authorized for obligation by the grantee
◆ Amount of anticipated future-year commitments (if applicable)
◆ Names of the cognizant IC PO, GMO, and GMS
◆ Applicable terms and conditions of award, either by reference or inclusion.

A grantee indicates acceptance of an NIH award and its associated terms and conditions by drawing or requesting funds from the designated HHS payment system or office. If the grantee cannot accept the award, including the legal obligation to perform in accordance with its provisions, it should notify the GMO immediately upon receipt of the NGA. If resolution cannot be reached, the GMO will void the grant. NIH’s determination of applicable terms and conditions of award or a GMO’s denial of a request to change the terms and conditions is discretionary and not subject to appeal (post-award appeal rights are discussed in “Administrative Requirements—Grant Appeals Procedures”). Once the award is accepted by the grantee, the contents of the NGA are binding on the grantee unless and until modified by a revised NGA signed by the GMO.

Funding

For most grants, NIH uses the project period system of funding. Under this system, projects are programmatically approved for support in their entirety but are funded in annual increments
called budget periods. The length of an initial project period (competitive segment) or of any subsequent competitive segment is determined by the NIH awarding office on the basis of

- any statutory or regulatory requirements,
- the length of time requested by the applicant to complete the project,
- any limitation on the length of the project period recommended by the peer reviewers,
- the awarding office’s programmatic determination of the frequency of competitive review desirable for managing the project, and
- NIH’s funding principles.

The total project period consists of the initial competitive segment, any additional competitive segments authorized by approval of a competing continuation application, and any non-competing extensions. NIH policy limits each competitive segment to a maximum of 5 years (exclusive of non-competing extensions). A single award covering the entire period of support generally is used only if the project is solely for construction or A&R of real property, if the total planned period of support will be less than 18 months, or if the project is awarded under a special support mechanism.

The initial NGA provides funds for the project during the first budget period. Budget periods usually are 12 months long; however, shorter or longer budget periods may be established for compelling programmatic or administrative reasons. An NGA that documents approval of a project period that extends beyond the budget period for which funds are provided (including anticipated levels of future support) expresses NIH’s intention to provide continued financial support for the project. The amounts shown for subsequent years represent projections of future funding levels based on the information available at the time of the initial award. Such projected levels of future support are contingent on satisfactory progress, the availability of funds, and the continued best interests of the Federal government. They are not guarantees by NIH that the project will be funded or will be funded at those levels and create no legal obligation to provide funding beyond the ending date of the current budget period as shown in the NGA.

Grantees are required to submit an annual progress report as a prerequisite to NIH approval and funding of each subsequent budget period (non-competing continuation award) within an approved project period (see “Administrative Requirements—Monitoring—Reporting—Non-Competing Grant Progress Report”). A decision to fund the next budget period will be formalized by the issuance of an NGA indicating the new budget period and the amount of new funding. The NGA also will reflect any remaining future-year commitments. NIH may decide to withhold support for one or more of the reasons cited in “Administrative Requirements—Enforcement Actions—Suspension, Termination, and Withholding of Support.” A grantee may appeal this decision only if the withholding was for the grantee’s failure to comply with the terms and conditions of a previous award (see “Administrative Requirements—Grant Appeals Procedures”).

75
Budget

Each NGA sets forth the amount of funds awarded. The amount may be shown either as a categorical (line item) budget or as an amount for total direct costs (not broken down by category) and an amount for F&A costs, if applicable. Modular awards represent a type of award made without a categorical budget (see “Modular Applications and Awards”). The grantee has certain rebudgeting flexibility within the overall amount awarded (see “Administrative Requirements—Changes in Project and Budget”). The grantee may be required to provide matching funds under construction awards as specified in “Construction Grants—Matching” in Subpart B of this part as well as under other NIH programs or awards if specified in the funding opportunity announcement.

Additional Terms and Conditions

In addition to, or in lieu of, the standard terms and conditions of award specified in the NIHGPS, NIH may use terms and conditions for program-specific or award-specific reasons. For example, if, on the basis of a grantee’s application or other available information, the GMO finds—at the time of award or at any time subsequent to award—that the grantee’s management systems and practices are not adequate to ensure the appropriate stewardship of NIH funds or to achieve the objectives of the award, the GMO may impose special, more restrictive terms and conditions on the award in accordance with 42 CFR 52.9 and 45 CFR 74.14 or 92.12. For example, NIH could require a grantee to obtain prior approval for expenditures that ordinarily do not require such approval or to provide more frequent reports. In addition to closer monitoring, NIH may assist the grantee in taking any necessary corrective action.

PAYMENT

HHS grant payments may be made by one of several advance payment methods, including SMARTLINK II/ACH, CASHLINE/ACH, or cash request, or by cash request on a reimbursement basis, as specified in the NGA and as described in this section. Payments under NIH grants generally are made as advance payments. Except as indicated in this section, NIH grant payments are made by PMS, operated by DPM, in accordance with Department of the Treasury and OMB requirements, as implemented by 45 CFR 74.22 and 92.21. These requirements are intended to minimize the time elapsing between the transfer of funds from the Federal government and disbursement by a grantee. Therefore, although the grant may be financed by advance payments, the intent is that grantees draw funds on an as-needed basis—specifically, no more than 3 days before the funds are needed.

All Federal funds deposited by PMS in a grantee’s bank account as an unrestricted advance payment should be fully disbursed (checks written, signed, and issued to the payees) by the close of business the next workday after receipt of the funds. The potential for excessive Federal cash on hand exists each time a grantee does not disburse Federal funds in this manner. The grantee is responsible for determining when the Federal funds have been deposited into its bank account for each drawdown, ensuring that the funds are fully disbursed by the close of business the next workday after they are received, and immediately returning all undisbursed Federal funds to PMS.
The Treasury and OMB policies also establish accountability for interest earned on advances of grant funds and provide for use of the reimbursement method if cash management requirements are not met. Advances made by grantees to consortium participants and contractors under grants must conform to substantially the same standards of timing and amount that govern advances to the grantee.

Operational guidance for recipients is contained in the *DHHS Manual for Recipients Financed under the Payment Management System* (available through the HHS website at http://www.dpm.psc.gov/doc/hhsrecmanual.pdf). Inquiries regarding payments should be directed to DPM at the address shown in Part III of the NIHGPS.

OOF makes payments under grants to foreign or international organizations, awards to individuals, and awards to agencies of the Federal government.

**SMARTLINK II/ACH**

The SMARTLINK II/ACH method of advance payment makes direct deposit of funds to a grantee’s bank account and requires grantees to have Internet access to submit a request for funds to PMS. SMARTLINK II/ACH provides funds the day following the request with direct deposit using the Federal Reserve Bank’s (Richmond, Virginia) ACH process.

**CASHLINE/ACH**

The CASHLINE/ACH method of advance payment provides for direct deposit of funds to the recipient’s bank account using a touch-tone telephone to dial directly to a “voice-response” computer located at PMS. CASHLINE/ACH makes funds available the day following the request with direct deposit using the Federal Reserve Bank’s ACH process.

**Cash Request**

Grantees not eligible for an unrestricted advance of funds by SMARTLINK II/ACH or CASHLINE/ACH must submit a cash request, usually monthly. The cash request may be on either an advance or reimbursement basis, as specified by the NIH awarding office. Cash requests are used when a grantee’s cash management must be closely monitored (for example, grantees whose financial management systems do not meet the standards specified in 45 CFR 74.21 or 92.20) or under programs where reimbursement financing is appropriate. A grantee also may be converted from an unrestricted advance payment method to a cash request basis if, during post-award administration, the GMO determines that a grantee is not complying with the cash management requirements or other requirements of the award, including the submission of complete and timely reports (see “Administrative Requirements—Monitoring—Reporting” and “Administrative Requirements—Enforcement Actions—Modification of the Terms of Award”).

If the cash request is for an advance payment, the grantee may request grant funds from PMS monthly on the basis of expected disbursements during the succeeding month and the amount of Federal funds already on hand. A request for reimbursement may be submitted more often, if authorized. For timely receipt of cash, a grantee must submit the request through the awarding office early enough for it to be forwarded to PMS at least 2 weeks before the cash is needed.
PMS makes payment to the grantee electronically through the ACH process upon receipt of the approved payment request from the awarding office.

**Interest Earned on Advances of Grant Funds**

Except as provided in 45 CFR 74.22(k), any NIH grantee subject to the requirements of 45 CFR Part 74 that receives advance payments must maintain those advances in an interest-bearing account.

Interest earned on advances of Federal funds must be handled as follows:

- **Nongovernmental grantees.** Any interest on Federal advances of grant funds that exceeds $250 per year in the aggregate must be remitted annually to PMS (as the government-wide agent for collection). Recipients with electronic funds transfer (EFT) capability should use an electronic medium to remit interest.

- **Governmental grantees other than States.** Except as provided in 45 CFR 92.21(i), any interest in excess of $100 per year in the aggregate earned by local governments or Indian tribal governments on Federal advances of grant funds must be remitted promptly, and at least quarterly, to PMS.

- **State governments.** State governments operating under Treasury-State agreements are subject to the payment and receipt of interest as specified in their agreements. All other State grantees are expected to follow sound financial management practices that minimize the potential for excessive Federal cash on hand and to comply with the cash management requirements of 45 CFR 92.20 and 21.

**COST CONSIDERATIONS**

**General**

Cost considerations are critical throughout the life cycle of a grant. An applicant’s budget request is reviewed for compliance with the governing cost principles and other requirements and policies applicable to the type of recipient and the type of award. Any resulting award will include a budget that is consistent with these requirements.

NIH anticipates that, because of the nature of research, the grantee may need to modify its award budget during performance to accomplish the award’s programmatic objectives. Therefore, NIH provides some flexibility for grantees to deviate from the award budget, depending on the deviation’s significance to the project or activity. More significant post-award changes require NIH prior approval. Prior-approval requirements and authorities are discussed in “Administrative Requirements—Changes in Project and Budget.”

During post-award administration, the GMO monitors expenditures for conformance with cost policies. The GMO’s monitoring includes, among other things, responding to prior-approval requests and reviewing progress reports, audit reports, and other periodic reports. The GMO also may use audit findings as the basis for final cost adjustments (see “Administrative Requirements—Closeout”).
This section addresses the general principles underlying the allowability of costs, differentiates direct costs from F&A costs, and highlights a number of specific costs and categories of cost for NIH applicants and grantees. It is not intended to be all-inclusive and should be used as a supplement to the applicable cost principles.

**The Cost Principles**

In general, NIH grant awards provide for reimbursement of actual, allowable costs incurred and are subject to Federal cost principles. The cost principles establish standards for the allowability of costs, provide detailed guidance on the cost accounting treatment of costs as direct or F&A costs, and set forth allowability and allocability principles for selected items of cost. Applicability of a particular set of cost principles depends on the type of organization making the expenditure. For example, a for-profit organization collaborating with a university grantee would be subject to the cost principles for commercial organizations, while the university would be subject to the cost principles for educational institutions.

The cost principles are set forth in the following documents and are incorporated by reference in 45 CFR 74.27 and 92.22:

- **OMB Circular A-21**—Cost Principles for Educational Institutions
- **OMB Circular A-87**—Cost Principles for State and Local Governments and Indian Tribal Governments
- **OMB Circular A-122**—Cost Principles for Non-Profit Institutions
- **45 CFR Part 74, Appendix E**—Principles for Determining Costs Applicable to Research and Development under Grants and Contracts with Hospitals
- **48 CFR Subpart 31.2 (Federal Acquisition Regulation)**—Contracts with Commercial Organizations.

The cost principles apply to all NIH award instruments, award mechanisms, and special programs and authorities, including modular awards and awards under SNAP with one exception: they do not apply to Kirschstein-NRSA individual fellowship awards. The allowable use of funds under those awards is included in “Ruth L. Kirschstein National Research Service Awards” in Subpart B of this part.

Grantees can use their own accounting systems, policies, and procedures to implement the cost principle requirements as long as the standards prescribed in 45 CFR 74.21 or 92.20 for financial management systems are met.

---

10Larger non-profit organizations that are specifically listed in Attachment C to OMB Circular A-122 are subject to the Federal cost principles applicable to commercial organizations (48 CFR Subpart 31.2) rather than to the cost principles for non-profit organizations.
The cost principles address four tests that NIH follows in determining the allowability of costs. The tests are as follows:

◆ *Reasonableness (including necessity).* A cost may be considered reasonable if the nature of the goods or services acquired or applied and the associated dollar amount reflect the action that a prudent person would have taken under the circumstances prevailing when the decision to incur the cost was made. The cost principles elaborate on this concept and address considerations such as whether the cost is of a type generally necessary for the organization’s operations or the grant’s performance, whether the recipient complied with its established organizational policies in incurring the cost or charge, and whether the individuals responsible for the expenditure acted with due prudence in carrying out their responsibilities to the Federal government and the public at large as well as to the organization.

◆ *Allocability.* A cost is allocable to a specific grant, function, department, or other component, known as a cost objective, if the goods or services involved are chargeable or assignable to that cost objective in accordance with the relative benefits received or other equitable relationship. A cost is allocable to a grant if it is incurred solely in order to advance work under the grant; it benefits both the grant and other work of the institution, including other grant-supported projects; or it is necessary to the overall operation of the organization and is deemed to be assignable, at least in part, to the grant.

◆ *Consistency.* Grantees must be consistent in assigning costs to cost objectives. Therefore, under NIH grants, although costs may be charged as either direct costs or F&A costs, depending on their identifiable benefit to a particular project or program. They must be treated consistently for all work of the organization under similar circumstances, regardless of the source of funding, so as to avoid duplicate charges.

◆ *Conformance.* This test of allowability—conformance with limitations and exclusions as contained in the terms and conditions of award, including those in the cost principles—varies by the type of activity, the type of recipient, and other characteristics of individual awards. “Allowability of Costs/Activities” provides information common to most NIH grants and, where appropriate, specifies some of the distinctions if there is a different treatment based on the type of grant or grantee. Subpart B of this part contains additional information on allowability of costs for particular types of grants, grantees, and activities.

These four tests apply regardless of whether the particular category of costs is one specified in the cost principles or one governed by other terms and conditions of an award. These tests also apply regardless of treatment as a direct cost or an F&A cost. The fact that a proposed cost is awarded as requested by an applicant does not indicate a determination of allowability.
Direct Costs and Facilities and Administrative Costs

Project costs consist of the allowable direct costs directly related to the performance of the grant plus the allocable portion of the allowable F&A costs of the organization, less applicable credits (as described below and in the cost principles). A “direct cost” is any cost that can be specifically identified with a particular project, program, or activity or that can be directly assigned to such activities relatively easily and with a high degree of accuracy. Direct costs include, but are not limited to, salaries, travel, equipment, and supplies directly benefiting the grant-supported project or activity. Most organizations also incur costs for common or joint objectives that, therefore, cannot be readily identified with an individual project, program, or organizational activity. Facilities operation and maintenance costs, depreciation, and administrative expenses are examples of costs that usually are treated as F&A costs. The organization is responsible for presenting costs consistently and must not include costs associated with its F&A rate as direct costs.

The amount NIH awards for each budget period will reflect the total approved budget for the grant, including direct costs and, if applicable, F&A costs. (SBIR and STTR awards also may include a fee as specified in “Grants to For-Profit Organizations—Small Business Innovation Research and Small Business Technology Transfer Programs” in Subpart B of this part.) If a grantee waives reimbursement of full F&A costs, NIH will either not award F&A costs or will award only partial F&A costs, as appropriate. The NIH award amount shown in the NGA constitutes NIH’s maximum financial obligation to the grantee under that award.

Reimbursement of Facilities and Administrative Costs

NIH will not reimburse F&A costs unless the grantee has established an F&A cost rate covering the applicable activities and period of time, except for awards under which F&A costs are reimbursed at a fixed rate or for awards under which NIH does not reimburse F&A costs.

In addition, NIH will not require a recipient to establish an F&A rate if the organization’s total operations consist of a single grant-supported project or if the organization appropriately and consistently treats all costs as direct costs to projects and accounts for them as such. In the latter case, the GMO must be satisfied that the organization’s accounting system can adequately identify and support all costs as direct costs to the project. This includes being able to identify and segregate costs on the basis of a process that assigns costs commensurate with the benefits provided to individual projects (see “Administrative Requirements—Management Systems and Procedures—Financial Management System Standards”).

F&A rates are negotiated by DCA, DFAS in the Office of Acquisition Management and Policy, NIH (responsible for negotiating F&A cost rates for for-profit entities receiving awards from HHS), or other agency with cognizance for F&A cost rate (and other special rate) negotiation. If an applicant is advised by the GMO of the need to establish a rate, the GMO will indicate the responsible office to be contacted.

---

11 This term and the term “indirect costs” may be used interchangeably to determine applicable policies. For NIH purposes, including the NIHGPS, these costs will be referred to as F&A costs; however, other documents or non-NIH functions may refer to them as “indirect costs.”
F&A cost proposals must be prepared in accordance with the applicable cost principles and guidance provided by the cognizant office or agency, and must conform to cost policies in the NIHGPS. Further information concerning the establishment of F&A rates and the reimbursement of F&A costs may be obtained from DCA or DFAS (see Part III). DCA should be consulted to determine the need to submit a Disclosure Statement (DS-2) pursuant to the requirements of OMB Circular A-21.

In accordance with NIH’s cost management plan, regardless of the type of recipient, the negotiated rate(s) in effect at the beginning of the competitive segment will be used to determine the amount budgeted for F&A costs for each year of the competitive segment. If the rate agreement does not extend to the end of the project period, the last rate in effect will be used to establish the total cost commitment for any remaining future years. NIH generally will not award additional F&A costs beyond those calculated in the approved budget.

F&A costs awarded may be subject to upward or downward adjustment, depending on the type of rate negotiated, and grantees may rebudget between direct and F&A costs (in either direction) without NIH prior approval, provided there is no change in the scope of the approved project. F&A costs are subject to downward adjustment if the proposal that served as the basis for the negotiation included unallowable costs.

Some award mechanisms require negotiation of project costs annually, e.g., GCRCs, clinical trials, and Primate Research Center Grants (P51). For these awards, the policies pertain to each year of support rather than to a multiyear competitive segment.

Once NIH awards a grant, it is not obligated to make any supplemental or other award for additional F&A costs or for any other purpose. There are limited circumstances under which the GMO may award F&A costs where none were previously awarded or may increase the amount previously awarded. If an award does not include an amount for F&A costs because the applicant or grantee did not submit a timely F&A cost proposal and the grantee subsequently establishes a rate, the GMO may amend the award to provide an appropriate amount for F&A costs if the amendment can be made using funds from the same Federal fiscal year in which the award was made. However, the amount will be limited to the F&A costs applicable to the period after the date of the grantee’s F&A cost proposal submission. This provision does not affect local governmental agencies that are not required to submit their F&A (indirect) cost proposals to the Federal government. They may charge F&A costs to NIH grants based on the rate computations they prepare and keep on file for subsequent Federal review.

If funds are available, a GMO may amend an award to provide additional funds for F&A costs, but only under the following circumstances:

- NIH made an error in computing the award. This includes situations in which a higher rate than the rate used in the grant award is negotiated and the date of the rate agreement for the higher rate is on or before 1 calendar month prior to the beginning date of the grant budget period.

- NIH restores funds previously recaptured as part of a grantee’s unobligated balance.
The grantee is eligible for additional F&A costs associated with additional direct costs awarded for the supplementation or extension of a project.

NIH does not reimburse indirect costs under the following classes of awards:

- **Fellowships.** F&A costs will not be provided on Kirschstein-NRSA individual fellowships or similar awards for which NIH funding is in the form of fixed amounts or is determined by the normal published tuition rates of an institution and for which the recipient is not required to account on an actual cost basis.

- **Construction.** F&A costs will not be provided on construction grants.

- **Grants to individuals.** F&A costs will not be provided on awards to individuals.

- **Grants to Federal institutions.** F&A costs will not be provided on grants to Federal institutions.

- **Grants in support of scientific meetings (conference grants).** F&A costs will not be provided under grants in support of scientific meetings.

NIH provides F&A costs without the need for a negotiated rate under the following classes of awards:

- **Research training and education grants (e.g., R25), and K awards.** F&A costs under Kirschstein-NRSA institutional research training grants and K awards will be budgeted and reimbursed at a rate of 8 percent of modified total direct costs, exclusive of tuition and fees, expenditures for equipment, and subgrants and contracts in excess of $25,000. State and local governmental agencies, except State universities or hospitals, and Indian tribal governments may receive full F&A cost reimbursement under NIH Kirschstein-NRSA institutional research training grants and K awards.

- **Grants to foreign institutions and international organizations.** With the exception of the American University of Beirut and the World Health Organization, which are eligible for full F&A cost reimbursement, F&A costs under grants to foreign and international organizations will be funded at a rate of 8 percent of modified total direct costs, exclusive of expenditures for equipment. NIH provides F&A costs under these grants to support the costs of compliance with applicable public policy requirements including, but not limited to, the protection of human subjects, animal welfare, financial conflict of interest, and invention reporting. NIH will not support the acquisition of or provide for depreciation on any capital expenses (facilities) or the normal general operations of foreign and international organizations. Awards to domestic organizations with a foreign or international consortium participant may include 8 percent of modified total direct costs, less equipment, for the consortium.

### Cost Transfers, Overruns, and Accelerated and Delayed Expenditures

Cost transfers to NIH grants by grantees, consortium participants, or contractors under grants that represent corrections of clerical or bookkeeping errors should be accomplished within 90
days of when the error was discovered. The transfers must be supported by documentation that fully explains how the error occurred and a certification of the correctness of the new charge by a responsible organizational official of the grantee, consortium participant, or contractor. An explanation merely stating that the transfer was made “to correct error” or “to transfer to correct project” is not sufficient. Transfers of costs from one project to another or from one competitive segment to the next solely to cover cost overruns are not allowable.

Grantees must maintain documentation of cost transfers, pursuant to 45 CFR 74.53 or 92.42, and must make it available for audit or other review (see “Administrative Requirements—Monitoring—Record Retention and Access”). The grantee should have systems in place to detect such errors within a reasonable time frame; untimely discovery of errors could be an indication of poor internal controls. Frequent errors in recording costs may indicate the need for accounting system improvements, enhanced internal controls, or both. If such errors occur, grantees are encouraged to evaluate the need for improvements and to make whatever improvements are deemed necessary to prevent reoccurrence. NIH also may require a grantee to take corrective action by imposing additional terms and conditions on an award(s).

The GMO monitors grantee expenditure rates under individual grants within each budget period and within the overall project period. The funding that NIH provides for each budget period is based on an assessment of the effort to be performed during that period and the grantee’s associated budget, including the availability of unobligated balances. Although NIH allows its grantees certain flexibilities with respect to rebudgeting (see “Administrative Requirements—Changes in Project and Budget”), NIH expects the rate and types of expenditures to be consistent with the approved project and budget and may question or restrict expenditures that appear inconsistent with these expectations.

The GMO may review grantee cash drawdowns to determine whether they indicate any pattern of accelerated or delayed expenditures. Expenditure patterns are of particular concern because they may indicate a deficiency in the grantee’s financial management system or internal controls. Accelerated or delayed expenditures may result in a grantee’s inability to complete the approved project within the approved budget and period of performance. In these situations, the GMO may seek additional information from the grantee and may make any necessary and appropriate adjustments.

**Allocation of Costs and Closely Related Work**

When salaries or other activities are supported by two or more sources, issues arise as to how the direct costs should be allocated among the sources of support. In general, a cost that benefits two or more projects or activities in proportions that can be determined without undue effort or cost should be allocated to the projects on the basis of the proportional benefit. A cost that benefits two or more projects or activities in proportions that cannot be determined because of the interrelationship of the work involved may be allocated or transferred to the benefiting projects on any reasonable basis as long as the costs charged are allowable, allocable, and reasonable under the applicable cost principles and the grantee’s financial management system includes adequate internal controls (for example, no one person has complete control over all aspects of a financial transaction). As a result, a grantee may allocate costs normally assignable to multiple projects to one of those projects.
Applicable Credits

The term “applicable credits” refers to those receipt or negative expenditure types of transactions that operate to offset or reduce direct or F&A cost items. Typical examples are purchase discounts, rebates or allowances, recoveries or indemnities on losses, and adjustments for overpayments or erroneous charges. Additional information concerning applicable credits is included in the cost principles.

Applicable credits to direct charges made to NIH grants must be treated as an adjustment on the grantee’s FSR, whether those credits accrue during or after the period of grant support. (See “Administrative Requirements—Monitoring—Reporting” and “Administrative Requirements—Closeout—Final Reports.”) The NIH awarding office will notify the grantee of any additional actions that may be necessary.

Services Provided by Affiliated Organizations

A number of universities and other organizations have established closely affiliated, but separately incorporated, organizations to facilitate the administration of research and other programs supported by Federal funds. Such legally independent entities are often referred to as “foundations,” although this term does not necessarily appear in the name of the organization. Typically, the parent organization provides considerable support services, in the form of administration, facilities, equipment, accounting, and other services, to its foundation, and the latter, acting in its own right as an NIH grantee, includes the cost of these services in its F&A proposal.

Costs incurred by an affiliated, but separate, legal entity in support of a grantee foundation are allowable for reimbursement under NIH grants only if at least one of the following conditions is met:

◆ The grantee foundation is charged for, and is legally obligated to pay for, the services provided by the parent organization.

◆ The affiliated organizations are subject to State or local law that prescribes how Federal reimbursement for the costs of the parent organization’s services will be expended and requires that a State or local official acting in his or her official capacity approves such expenditures.

◆ There is a valid written agreement between the affiliated organizations whereby the parent organization agrees that the grantee foundation may retain Federal reimbursement of parent organization costs. The parent organization may either direct how the funds will be used or permit the grantee foundation that discretion.

If none of the above conditions is met, the costs of the services provided by the parent organization to the grantee foundation are not allowable for reimbursement under an NIH grant. However, the services may be acceptable for cost-sharing (matching) purposes.
Allowability of Costs/Activities

The governing cost principles address selected items of cost, some of which are mentioned in this subsection for emphasis. This subsection is not intended to be all-inclusive. The cost principles should be consulted for the complete explanation of the allowability or unallowability of these costs.

This subsection also includes NIH-specific requirements concerning costs and activities. The allowability of costs under individual NIH awards may be subject to other requirements specified in the program legislation, regulations, or the specific terms and conditions of an award, which will take precedence over the general discussion provided here. Applicants or grantees that have questions concerning the allowability of particular costs should contact the GMO.

If a cost is allowable, it is allocable as either a direct cost or an F&A cost, depending on the grantee’s accounting system. For some costs addressed in this subsection, the text specifies whether the cost is usually a direct cost or an F&A cost.

Unless otherwise indicated in the NGA, an award based on an application that includes specific information concerning any costs or activities that require NIH prior approval constitutes the prior approval for those costs or activities. The grantee is not required to obtain any additional approval for those costs/activities. Post-award requests to incur costs or undertake activities requiring prior approval that are not described in the approved application are subject to the requirements in “Administrative Requirements—Changes in Project and Budget.”

Consortium participants and contractors under grants are subject to the requirements of the cost principles otherwise applicable to their type of organization and to any requirements placed on them by the grantee to be able to comply with the terms and conditions of the NIH grant.

The cost principles do not address profit or fee. NIH policy allows the payment of fee on SBIR/STTR grants (see “Grants to For-Profit Organizations”) but NIH will not provide profit or fee to any other type of recipient under any other grant program or support mechanism. A fee may not be paid by a grantee to a consortium participant, including a for-profit organization. However, a fee (profit) may be paid to a contractor providing routine goods or services under a grant in accordance with normal commercial practice.
### Selected Items of Cost

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advertising</td>
<td>Allowable only for recruitment of staff or trainees, procurement of goods and services, disposal of scrap or surplus materials, and other specific purposes necessary to meet the requirements of the grant-supported project or activity.</td>
</tr>
<tr>
<td>Alcoholic Beverages</td>
<td>Unallowable as an entertainment expense, but allowable if within the scope of an approved research project.</td>
</tr>
<tr>
<td>Alteration and Renovation</td>
<td>Individual A&amp;R projects that are treated as direct costs and that will not exceed $500,000 will be subject to the A&amp;R policies specified in this subsection and in the “Construction Grants” section, as applicable. Individual A&amp;R projects exceeding $500,000 in direct costs will be subject to the requirements specified in the “Construction Grants” section. Routine maintenance and repair of the organization’s physical plant or its equipment, which is allowable and is ordinarily treated as an F&amp;A cost, is not considered A&amp;R for purposes of applying this policy. Certain allowable costs of installing equipment, such as the temporary removal and replacement of wall sections and door frames to place equipment in its permanent location, or the costs of connecting utility lines, replacing finishes and furnishings, and installing any accessory devices required for the equipment’s proper and safe utilization, may be considered either equipment costs or A&amp;R costs, depending on the grantee’s accounting system. A&amp;R costs are not allowable under grants to individuals, foreign grants, and grants in support of scientific meetings (conference grants). In all other cases, these costs are allowable unless the program legislation, implementing regulations, program guidelines, or other terms and conditions of the award specifically exclude such activity. The A&amp;R must be consistent with the following criteria and documentation requirements:◆ The building has a useful life consistent with program purposes and is architecturally and structurally suitable for conversion to the type of space required◆ The A&amp;R is essential to the purpose of the grant-supported project◆ The space involved will be occupied by the project◆ The space is suitable for human occupancy before A&amp;R work is started except where the purpose of the A&amp;R is to make the space suitable for some purpose other than human occupancy, such as storage◆ If the space is rented, evidence is provided that the terms of the lease are compatible with the A&amp;R proposed and cover the duration of the project period. Work necessary to obtain an initial occupancy permit for the intended use is not an allowable A&amp;R cost. A grantee may rebudget up to 25 percent of the total approved budget for a budget period into A&amp;R costs without NIH prior approval unless such rebudgeting would result in a change in scope. If the rebudgeting results in an A&amp;R project exceeding $300,000, NIH will consider the rebudgeting to be a change in scope, and the grantee must submit to the NIH awarding office the documentation specified in “Construction Grants” for approval of A&amp;R projects above that dollar level.</td>
</tr>
</tbody>
</table>

87
<table>
<thead>
<tr>
<th>Animals</th>
<th>Allowable for the acquisition, care, and use of experimental animals, contingent upon compliance with the applicable requirements of the PHS Policy on Humane Care and Use of Laboratory Animals (see “Public Policy Requirements and Objectives—Animal Welfare”). If the grantee operates an animal resource facility, charges for use of the facility should be determined in accordance with the Cost Analysis and Rate Setting Manual for Animal Resource Facilities (May 2000), available from NCRR at its website: (<a href="http://www.ncrr.nih.gov/newspub/CARS.pdf">http://www.ncrr.nih.gov/newspub/CARS.pdf</a>) or from NCRR’s Office of Science Policy and Public Liaison (telephone: 301-435-0888; e-mail: <a href="mailto:info@ncrr.nih.gov">info@ncrr.nih.gov</a>).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Audiovisual Activities</td>
<td>Allowable for the production of an audiovisual. “Audiovisual” means any product containing visual imagery, sound, or both, such as motion pictures, films, videotapes, live or recorded radio or television programs or public service announcements, slide shows, filmstrips, audio recordings, multimedia presentations, or exhibits where visual imagery, sound, or both are an integral part. “Production” refers to the steps and techniques used to create a finished audiovisual product including, but not limited to, design, layout, scriptwriting, filming or taping, fabrication, sound recording, and editing. A recipient with in-house production capability must determine whether it would be more efficient and economical to use that capability or to contract for the production of an audiovisual. If an audiovisual intended for members of the general public (i.e., people who are not researchers or health professions personnel or who are not directly involved in project activities as employees, trainees, or participants such as volunteers or patients) is produced under an NIH grant-supported project, the grantee must submit two prints or tapes of the finished product along with its annual or final progress report (see “Administrative Requirements—Monitoring—Reporting” and “Administrative Requirements—Closeout”). The costs of such prints or tapes are allowable project costs. Audiovisuals produced under an NIH grant-supported project must bear an acknowledgment and disclaimer, such as the following: The production of this [type of audiovisual (motion picture, television program, etc.)] was supported by Grant No.__________ from [name of NIH awarding office]. Its contents are solely the responsibility of [name of grantee organization] and do not necessarily represent the official views of [name of NIH awarding office].</td>
</tr>
<tr>
<td>Audit Costs</td>
<td>Allowable (see “Administrative Requirements—Monitoring—Audit” and section 230 of OMB Circular A-133). The charges may be treated as a direct cost when the audit’s scope is limited to a single NIH grant-supported project or program, as specified in 45 CFR 74.26(d), or when it includes more than one project but the costs can be specifically identified with, and allocated to, each project on a proportional basis, and this practice is followed consistently by the grantee. Otherwise, charges for audits should be treated as F&amp;A costs.</td>
</tr>
<tr>
<td>Bad Debts</td>
<td>Unallowable.</td>
</tr>
<tr>
<td>Bid and Proposal Costs</td>
<td>Allowable as an F&amp;A cost. See 45 CFR 74.27(b)(1) for policy for non-profit organizations covered by OMB Circular A-122.</td>
</tr>
<tr>
<td>Bonding</td>
<td>Allowable. See 45 CFR 74.21, 74.47(c) and 92.36 for policies and requirements concerning bonding.</td>
</tr>
<tr>
<td>Books and Journals</td>
<td>Allowable. If an organization has a library, books and journals generally should be provided as part of normal library services and treated as F&amp;A costs.</td>
</tr>
<tr>
<td><strong>Building Acquisition</strong></td>
<td>Unallowable unless building acquisition or construction is specifically authorized by program legislation and is provided for in the NGA. For real property acquired with NIH grant support, the cost of title insurance may be charged to the grant in proportion to the Federal share of the acquisition cost. Filing fees for recording the Federal interest in the real property in appropriate records of the applicable jurisdiction also may be charged to the grant. (Also see “Construction Grants—Allowable and Unallowable Costs and Activities” in Subpart B of this part)</td>
</tr>
<tr>
<td><strong>Child Care Costs</strong></td>
<td>Allowable if incurred to assist individuals to participate as subjects in research projects. Such costs also may be allowable as a fringe benefit for individuals working on a grant-supported project (see “Fringe Benefits” in this subsection).</td>
</tr>
<tr>
<td><strong>Communications</strong></td>
<td>Allowable. Such costs include local and long-distance telephone calls, telegrams, express mail, and postage, and usually are treated as F&amp;A costs.</td>
</tr>
<tr>
<td><strong>Conference Grant Costs</strong></td>
<td>See “Support of Scientific Meetings (Conference Grants)” in Subpart B of this part for allowability of costs for scientific meetings (conferences).</td>
</tr>
<tr>
<td><strong>Consortium Agreements/Contracts under Grants</strong></td>
<td>Allowable to carry out a portion of the programmatic effort or for the acquisition of routine goods or services under the grant. Such arrangements may require NIH approval as specified in “Administrative Requirements—Changes in Project and Budget.” (See “Administrative Requirements—Management Systems and Procedures—Procurement System Standards and Requirements” for policies that apply to the acquisition of routine goods and services and “Consortium Agreements” in Subpart B of this part for policies that apply to grantee collaboration with other organizations in carrying out the grant-supported research.)</td>
</tr>
<tr>
<td><strong>Construction</strong></td>
<td>Allowable only when program legislation specifically authorizes new construction, modernization, or major A&amp;R, and NIH specifically authorizes such costs in the NGA. When authorized, construction activities may include construction of a new facility or projects in an existing building that are considered to be construction, such as relocation of exterior walls, roofs, and floors; attachment of fire escapes; or completion of unfinished shell space to make it suitable for human occupancy (see “Construction Grants” in Subpart B of this part).</td>
</tr>
<tr>
<td><strong>Consultant Services</strong></td>
<td>Allowable. A consultant is an individual retained to provide professional advice or services for a fee but usually not as an employee of the requiring organization. The term “consultant” also includes a firm that provides paid professional advice or services. Grantees must have written policies governing their use of consultants that are consistently applied regardless of the source of support. Such policies should include the conditions for paying consulting fees. The general circumstances of allowability of these costs, which may include fees and travel and subsistence costs, are addressed in the applicable cost principles under “professional services costs.” In unusual situations, a person may be both a consultant and an employee of the same party, receiving compensation for some services as a consultant and for other work as a salaried employee as long as those separate services are not related to the same project and are not charged to the same project. For example, consulting fees that are paid by an educational institution to a salaried faculty member as extra compensation above that individual’s base salary are allowable, provided the consultation is across departmental lines or involves a separate or remote operation and the work performed by the consultant is in addition to his or her regular departmental workload.</td>
</tr>
</tbody>
</table>
Grantees, consortium participants, and contractors under grants that want to be able to charge employee consulting costs to grant-supported projects must establish written guidelines permitting such payments regardless of the source of funding and indicating the conditions under which the payment of consulting fees to employees is proper. Unless subject to OMB Circular A-21, the grantee, consortium participant, or contractor also must document that it would be inappropriate or infeasible to compensate the individual for those services through payment of additional salary. Under no circumstances can an individual be paid as a consultant and an employee under the same NIH grant.

Authorization for consulting fees paid to individuals serving as both employees and consultants of the same party must be provided in writing, on a case-by-case basis, by the head of the recipient organization, consortium participant, or contractor incurring the costs, or his/her designee. If the designee is personally involved in the project, the authorization may be given only by the head of the recipient organization, consortium participant, or contractor. This authorization must include a determination that the required conditions are present and that there is no apparent or actual conflict of interest.

Grantees, consortium participants, and contractors under grants are encouraged to obtain written reports from consultants unless such a report is not feasible given the nature of the consultation or would not be useful. Documentation maintained by the receiving organization should include the name of the consulting firm or individual consultant; the nature of the services rendered and their relevance to the grant-supported activities, if not otherwise apparent from the nature of the services; the period of service; the basis for calculating the fee paid (e.g., rate per day or hour worked or rate per unit of service rendered); and the amount paid. This information may be included in the consultant’s invoice, in the report, or in another document. See “Grants to Federal Institutions and Payments to (or on Behalf of) Federal Employees under Grants” in Subpart B of this part for allowable costs associated with consultant payments to Federal employees and the circumstances of allowability.

### Contingency Funds

Unallowable. Contributions set aside for events whose occurrence cannot be foretold with certainty as to time, intensity, or assurance of their happening are unallowable under nonconstruction grants. Contingency funds do not include pension funds, self-insurance funds, and normal accruals (also see “Reserve Funds” in this subsection). (See “Construction Grants—Allowable and Unallowable Costs and Activities” in Subpart B of this part concerning contingency funds under construction grants.)

### Customs and Import Duties

Allowable under grants to domestic organizations when performance will take place entirely within the United States, its possessions, or its territories, or when foreign involvement in the project is incidental to the overall grant-supported project. Charges may include consular fees, customs surtaxes, value-added taxes, and other related charges. (Also see “Grants to Foreign Institutions, International Organizations, and Domestic Grants with Foreign Components—Allowable and Unallowable Costs” in Subpart B of this part for the allowability of these costs.)

### Depreciation or Use Allowances

Allowable. Such costs usually are treated as F&A costs. Depreciation or use charges on equipment or buildings acquired under a federally supported project are not allowable.

### Donor Costs

Allowable for payment to volunteers or research subjects who contribute blood, urine samples, and other body fluids or tissues that are specifically project-related.

### Drugs

Allowable if within the scope of an approved research project. Project funds may not be used to purchase drugs classified by FDA as “ineffective” or “possibly effective” except in approved clinical research projects or in cases where there is no alternative other than therapy with “possibly effective” drugs.
<table>
<thead>
<tr>
<th>Category</th>
<th>Allowability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dues or Membership Fees</td>
<td>Allowable as an F&amp;A cost for organizational membership in business, professional, or technical organizations or societies. Payment of dues or membership fees for an individual’s membership in a professional or technical organization is allowable as a fringe benefit or an employee development cost, if paid according to an established organizational policy consistently applied regardless of the source of funds.</td>
</tr>
<tr>
<td>Entertainment Costs</td>
<td>Unallowable. This includes the cost of amusements, social activities, and related incidental costs.</td>
</tr>
<tr>
<td>Equipment</td>
<td>Allowable for purchase of new, used, or replacement equipment as a direct cost or as part of F&amp;A costs, depending on the intended use of the equipment. NIH prior approval may be required as specified in “Administrative Requirements—Changes in Project and Budget.” Funds provided under a conference grant may not be used to purchase equipment. For policies governing the classification, use, management, and disposition of equipment, see “Administrative Requirements—Management Systems and Procedures—Property Management System Standards.” For policies governing the allowability of costs for rental of equipment, see “Rental or Lease of Facilities and Equipment” in this subsection.</td>
</tr>
<tr>
<td>Federal (U.S. Government)</td>
<td>See “Grants to Federal Institutions and Payments to (or on Behalf of) Federal Employees under Grants—Allowable and Unallowable Costs” for the allowability of payments made to, or on behalf of, Federal employees under NIH grants, including grants to Federal institutions.</td>
</tr>
<tr>
<td>Fines and Penalties</td>
<td>Unallowable except when resulting from violations of, or failure of the organization to comply with, Federal, State, or local laws and regulations and incurred as a result of compliance with specific provisions of an award, or when such payments are authorized in advance in writing by the NIH awarding office.</td>
</tr>
<tr>
<td>Fringe Benefits</td>
<td>Allowable as part of overall compensation to employees in proportion to the amount of time or effort employees devote to the grant-supported project, provided such costs are incurred under formally established and consistently applied policies of the organization (see “Salaries and Wages” in this subsection). Tuition or tuition remission for regular employees is allowable as a fringe benefit. For organizations subject to OMB Circular A-21, tuition benefits for family members other than the employee are unallowable. For policies applicable to tuition remission for students working on grant-supported research projects, see “Salaries and Wages” in this subsection. See “Ruth L. Kirschstein National Research Service Awards—Individual Fellowships—Allowable and Unallowable Costs—Tuition and Fees” and “Ruth L. Kirschstein National Research Service Awards—Institutional Research Training Grants—Allowable and Unallowable Costs—Trainee Tuition, Fees, and Health Insurance” in Subpart B of this part for the allowability of tuition costs for fellows and trainees.</td>
</tr>
<tr>
<td>Fundraising Costs</td>
<td>Unallowable.</td>
</tr>
<tr>
<td>Honoraria</td>
<td>Unallowable when the primary intent is to confer distinction on, or to symbolize respect, esteem, or admiration for, the recipient of the honorarium. A payment for services rendered, such as a speaker’s fee under a conference grant, is allowable.</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>See “Research Patient Care” in this subsection.</td>
</tr>
<tr>
<td>Topic</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Indemnification</td>
<td>Allowable to the extent expressly provided in the award for indemnification against liabilities to third parties and any other loss or damage not compensated by insurance or otherwise.</td>
</tr>
<tr>
<td>Independent Research and Development Costs</td>
<td>Unallowable, including their proportionate share of F&amp;A costs.</td>
</tr>
<tr>
<td>Insurance</td>
<td>Allowable. Insurance usually is treated as an F&amp;A cost. In certain situations, however, where special insurance is required as a condition of the grant because of risks peculiar to the project, the premium may be charged as a direct cost if doing so is consistent with organizational policy. Medical liability (malpractice) insurance is an allowable cost of research programs at educational institutions only if the research involves human subjects. If so, the insurance should be treated as a direct cost and assigned to individual grants based on the manner in which the insurer allocates the risk to the population covered by the insurance. The cost of insuring equipment, whether purchased with project funds or furnished as federally owned property, normally should be included in F&amp;A costs but may be allowable as a direct cost if this manner of charging is the normal organizational policy. Health insurance for trainees and fellows is addressed in “Ruth L. Kirschstein National Research Service Awards” in Subpart B of this part.</td>
</tr>
<tr>
<td>Interest</td>
<td>Allowable as an F&amp;A cost for certain assets as specified in the applicable cost principles. Unallowable for hospitals.</td>
</tr>
<tr>
<td>Invention, Patent, or Licensing Costs</td>
<td>Unallowable as a direct cost unless specifically authorized on the grant award. May be allowable as F&amp;A costs, provided they are authorized under applicable cost principles and are included in the negotiation of F&amp;A cost rates. Such costs include licensing or option fees, attorney's fees for preparing or submitting patent applications, and fees paid to the U.S. Patent and Trademark Office for patent application, patent maintenance, or recordation of patent-related information. (Section Revised per 5/27/2004 NIH Guide)</td>
</tr>
<tr>
<td>Leave</td>
<td>Allowable for employees as a fringe benefit (see “Fringe Benefits” in this subsection). See “Ruth L. Kirschstein National Research Service Awards—Individual Fellowships—Other Terms and Conditions—Leave” and “Ruth L. Kirschstein National Research Service Awards—Institutional Research Training Grants—Other Terms and Conditions—Leave” in Subpart B of this part for NIH policy on leave for fellows and trainees.</td>
</tr>
<tr>
<td>Legal Services</td>
<td>Allowable. Generally treated as an F&amp;A cost but, subject to the limitations described in the applicable cost principles, may be treated as a direct cost for legal services provided by individuals who are not employees of the grantee organization. Before a grantee incurs legal costs that are extraordinary or unusual in nature, the grantee should make an advance agreement regarding the appropriateness and reasonableness of such costs with the GMO. Legal costs incurred in defending or prosecuting claims, whether equitable or monetary, including administrative grant appeals, are unallowable charges to NIH grant-supported projects, except as provided in the applicable cost principles.</td>
</tr>
<tr>
<td>Library Services</td>
<td>General library support is not allowable as a direct cost but may be included in the grantee’s F&amp;A pool. However, such services are allowable as a direct cost when specifically required for the conduct of the project and when identifiable as an integral part of the grant-supported activity (e.g., in those programs designed to develop and support such services).</td>
</tr>
<tr>
<td>Category</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lobbying</td>
<td>Generally unallowable, including costs of lobbying activities to influence the introduction, enactment, or modification of legislation by the U.S. Congress or a State legislature. Under certain circumstances, as provided in the applicable cost principles, costs associated with activities that might otherwise be considered &quot;lobbying&quot; that are directly related to the performance of a grant may be allowable. The grantee should obtain an advance understanding with the GMO if it intends to engage in these activities. (Also see “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—Lobbying” and “Administrative Requirements—Monitoring—Reporting” concerning lobbying restrictions, the required certification, and reporting.)</td>
</tr>
<tr>
<td>Meals</td>
<td>Allowable for subjects and patients under study, or where specifically approved as part of the project activity, provided that such charges are not duplicated in participants' per diem or subsistence allowances, if any.</td>
</tr>
<tr>
<td>Moving</td>
<td>See “Recruitment Costs,” “Relocation Costs,” and “Transportation of Property” in this subsection.</td>
</tr>
<tr>
<td>Nursery Items</td>
<td>Allowable for the purchase of items such as toys and games to allow patients to participate in research protocols.</td>
</tr>
<tr>
<td>Overtime</td>
<td>See “Salaries and Wages” in this subsection.</td>
</tr>
</tbody>
</table>
| Pension Plan Costs| Allowable. For institutions of higher education and non-profit organizations, such costs must be incurred according to the established policies of the organization consistently applied regardless of the source of funds, the organization’s policies must meet the test of reasonableness, the methods of cost allocation must be equitable for all activities, the amount assigned to each fiscal year must be determined in accordance with generally accepted accounting principles, and the cost assigned to a given fiscal year must be paid or funded for all plan participants within 6 months after the end of that fiscal year.  
State, local, or Indian tribal governments or hospitals may use the “pay-as-you-go” cost method (i.e., when pension benefits are paid by the grantee directly to, or on behalf of, retired employees or their beneficiaries) in lieu of the method described above. Under this method, the benefits may be charged in the grantee’s fiscal year in which the payments are made to, or on behalf of, retired employees or their beneficiaries, provided that the grantee follows a consistent policy of treating such payments as expenses in the year of payment. See the applicable cost principles for additional information on the allowability of costs associated with pension plans. |
| Pre-Award (Pre-Agreement) Costs | Allowable. A grantee may, at its own risk and without NIH prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new or competing continuation award if such costs:  
| | ◆ are necessary to conduct the project, and  
| | ◆ would be allowable under the grant, if awarded, without NIH prior approval.  
| | If specific expenditures would otherwise require prior approval, the grantee must obtain NIH approval before incurring the cost. NIH prior approval is required for any costs to be incurred more than 90 days before the beginning date of the initial budget period of a new or competing continuation award.  
| | Grantees may incur pre-award costs before the beginning date of a non-competing continuation award without regard to the time parameters stated above.  
| | The incurrence of pre-award costs in anticipation of a competing or non-competing award imposes no obligation on NIH either to make the award or to increase the amount of the approved budget if an award is made for less than the amount anticipated and is inadequate to cover the pre-award costs incurred.  
| | NIH expects the grantee to be fully aware that pre-award costs result in borrowing against future support and that such borrowing must not impair the grantee’s ability to accomplish the project objectives in the approved time frame or in any way adversely affect the conduct of the project. |
| Public Relations Costs | Allowable only for costs specifically required by the award or for costs of communicating with the public and the press about specific activities or accomplishments under the grant-supported project or other appropriate matters of public concern. Such costs may be treated as direct costs but should be treated as F&A costs if they benefit more than one sponsored agreement or if they benefit the grant and other work of the organization. |
| Publications | Allowable. Page charges for publication in professional journals are allowable if the published paper reports work supported by the grant and the charges are levied impartially on all papers published by the journal, whether or not by government-sponsored authors.  
| | The costs of reprints and publishing in other media, such as books, monographs, and pamphlets, also are allowable.  
| | Publications and journal articles produced under an NIH grant-supported project must bear an acknowledgment and disclaimer, as appropriate, as provided in “Administrative Requirements—Availability of Research Results: Publications, Intellectual Property Rights, and Sharing Research Resources.” |
| Recruitment Costs | Allowable subject to the conditions and restrictions contained in the applicable cost principles. These costs may include help-wanted advertising costs, costs of travel by applicants to and from preemployment interviews, and travel costs of employees while engaged in recruiting personnel. Project funds may not be used for a prospective trainee’s travel costs to or from the grantee organization for the purpose of recruitment. However, other costs incurred in connection with recruitment under training programs, such as advertising, may be allocated to a grant-supported project according to the provisions of the applicable cost principles (also see “Travel” and “Relocation Costs” in this subsection). |
| Registration Fees (for Symposiums and Seminars) | Allowable if necessary to accomplish project objectives. |
| **Relocation Costs** | Allowable—in other than change of grantee organization situations—when such costs are incurred incidental to a permanent change of duty assignment (for an indefinite period or for a stated period of no less than 12 months) for an existing employee working on a grant-supported project, or when a new employee is recruited for work on the project, provided that the move is for the grantee’s benefit rather than the individual’s and that payment is made according to established organizational policies consistently applied regardless of the source of funds. Relocation costs may include the cost of transporting the employee and his or her family, dependents, and household goods to the new location and certain expenses associated with the sale of the former home. If relocation costs have been incurred in connection with the recruitment of a new employee, whether as a direct cost or an F&A cost, and the employee resigns for reasons within his or her control within 12 months after hire, the grantee must credit the grant account for the full cost of the relocation charged to the grant.

When there is a change in the grantee organization, the personal relocation expenses of the PI and others moving from the original grantee to the new grantee are not allowable charges to NIH grants (see “Administrative Requirements—Changes in Project and Budget—Prior-Approval Requirements”). |
|---|---|
| **Rental or Lease of Facilities and Equipment** | Allowable subject to the limitations below. Rental costs are allowable to the extent that the rates are reasonable at the time of the decision to lease in light of such factors as rental costs of comparable property, if any; market conditions in the area; the type, life expectancy, condition, and value of the property leased; and available alternatives. Because of the complexity involved in determining the allowable amount under certain types of leases, grantees are encouraged to consult the GMO before entering into leases that will result in direct charges to the grant project.

In general, the rental costs for facilities and equipment applicable to each budget period should be charged to that period. However, see “Administrative Requirements—Management Systems and Procedures—Procurement System Standards and Requirements” for an exception to this general rule.

Rental costs under leases that create a material equity in the leased property, as defined in the applicable cost principles, are allowable only up to the amount that would be allowed had the grantee purchased the property on the date the lease agreement was executed. This would include depreciation or use allowances, maintenance, taxes, and insurance, but would exclude unallowable costs.

When a grantee transfers property to a third party through sale, lease, or otherwise and then leases the property back from that third party, the lease costs that may be charged to NIH projects generally may not exceed the amount that would be allowed if the grantee continued to own the property.

Rental costs under “less-than-arms-length” leases are allowable only up to the amount that would be allowed under the applicable cost principles had title to the property been vested in the grantee. A less-than-arms-length lease is one in which one party to the lease agreement is able to control or substantially influence the actions of the other. Such leases include, but are not limited to, those between divisions of an organization; between organizations under common control through common officers, directors, or members; and between an organization and its directors, trustees, officers, or key employees (or the families of these individuals), directly or through corporations, trusts, or similar arrangements in which they hold a controlling interest. |
| **Research Patient Care** | The costs of routine and ancillary services provided by hospitals to individuals, including patients and volunteers, participating in research programs are allowable. Incurrence of patient care costs if not previously approved by NIH and rebudgeting additional funds into, or rebudgeting approved amounts out of, the research patient care costs category may be considered a change in scope and require prior approval by the NIH awarding office.

“Routine services” include the regular room services, minor medical and surgical supplies, and the use of equipment and facilities for which a separate charge is not customarily made. “Ancillary services” are those special services for which charges customarily are made in addition to routine services, e.g., x-ray, operating room, laboratory, pharmacy, blood bank, and pathology. See “Research Patient Care Costs” in Subpart B of this part for NIH policy concerning reimbursement of these costs.

The following otherwise allowable costs are not classified as research patient care costs:

- Items of personal expense reimbursement, such as patient travel; consulting physician fees; and any other direct payments to individuals, including inpatients, outpatients, subjects, volunteers, and donors. Such costs should be included in the “Other Expenses” category of the grant budget.

| **Reserve Funds** | Contributions to a reserve fund for self-insurance are allowable as specified in the governing cost principles (also see “Contingency Funds” in this subsection).

| **Sabbatical Leave Costs** | Sabbatical leave costs may be included in a fringe benefit rate or in the organization’s F&A rate. Salary may be charged directly to a project for services rendered to the project by individuals while they are on sabbatical leave, provided the salary is proportional to the service rendered and is paid according to established organizational policies applicable to all employees regardless of the source of funds. Sabbatical leave paid by an individual’s employer, in combination with other compensation (e.g., partial salary from an NIH grant), may not exceed 100 percent of that individual’s regular salary from his or her organization.

| **Salaries and Wages** | Allowable. Compensation for personal services covers all amounts, including fringe benefits, paid currently or accrued by the organization for employee services rendered to the grant-supported project. Compensation costs are allowable to the extent that they are reasonable, conform to the established policy of the organization consistently applied regardless of the source of funds, and reflect no more than the percentage of time actually devoted to the NIH-funded project. As required in its annual appropriations act, NIH will not reimburse grantees for the direct salaries of individuals at a rate in excess of the level specified in the appropriations language. Direct salary is exclusive of fringe benefits and F&A costs. This salary limitation does not apply to consultant payments or to contracts for routine goods and services but it does apply to consortium participants (see “Consortium Agreements” in Subpart B of this part). |
Salary and wage amounts charged to grant-supported projects for personal services must be based on an adequate payroll distribution system that documents such distribution in accordance with generally accepted practices of like organizations. Standards for payroll distribution systems are contained in the applicable cost principles (other than those for for-profit organizations). Briefly summarized, acceptable systems are as follows:

**Hospitals**
- Monthly after-the-fact reports of the distribution of time or effort for professional staff members.
- Time and attendance and payroll distribution records for non-professional employees.

**Non-profit organizations**
- Monthly after-the-fact reports, including a signed certification, by the employee, or by a responsible supervisory official having first-hand knowledge of the work performed, that the distribution of activity represents a reasonable estimate of the actual work performed by the employee during the period covered by the report. Each report must account for the total activity required to fulfill the employee’s obligations to the organization as well as the total activity for which he or she is compensated.
- For non-professional employees, additional supporting reports, indicating the total number of hours worked each day, must be maintained in conformance with DoL regulations implementing the Fair Labor Standards Act (29 CFR Part 516).
- The distribution of salaries and wages must be supported by personnel activity reports as described above, except when a substitute system has been approved, in writing, by the Federal cognizant agency designated under OMB Circular A-122.

**State, local, and Indian tribal governments**
- Time and attendance or equivalent records for all employees.
- Time distribution records for employees whose compensation is chargeable to more than one grant or other cost objective.

**Educational institutions**
- A plan confirmation system for professorial and other professional staff members that is based on budgeted, planned, or assigned work activity and that is updated to reflect any significant changes in work distribution. This system must be incorporated into the organization’s official records and must identify activity applicable to each sponsored agreement and to each category needed to identify F&A costs and the functions to which they are allocable. At least annually, the employee, PI, or responsible officials will verify, by suitable means, that the work was performed and that the salaries and wages charged to sponsored agreements, whether as direct charges or in other categories of cost, are reasonable in relation to the work performed; or
A system, supported by after-the-fact activity reports, that reflects the distribution of covered employees’ activity allocable to each NIH grant and includes identification and recording of significant changes in work activity when initial charges were based on estimates. The system also must specify each category of activity needed to identify F&A costs and the functions to which they are allocable. For professorial and other professional staff members, the activity reports will be prepared each academic term, but at least every 6 months. For other employees, unless NIH agrees to alternate arrangements, the reports will be prepared at least monthly and will coincide with one or more pay periods; or

A multiple confirmation records system, for professorial and other professional staff members, that is supported by records certifying costs separately for direct costs and F&A costs, with reports prepared each academic term, but at least every 6 months, that confirm the activities as allocable to direct or F&A costs; or

By mutual agreement, any other method meeting the criteria specified in paragraph J.8.b.(2) of OMB Circular A-21.

For-profit organizations

NIH requires for-profit organizations to conform with industry standards to support salary and wage charges to NIH grants. Therefore, unless an alternate system is approved by the GMO, the grantee must maintain a time-and-effort reporting system for both professional and other-than-professional staff reflecting daily after-the-fact reporting of hours expended on individual projects or indirect activities. The system must record both hours worked and hours absent. This information must be certified by an AOO no less frequently than every pay period.

Overtime Premiums

Premiums for overtime generally are allowable; however, such payments are not allowable for faculty members at institutions of higher education. If overtime premiums are allowable, the categories or classifications of employees eligible to receive overtime premiums should be determined according to the formal policies of the organization consistently applied regardless of the source of funds.

Bonus Funds/Incentive Payments

Allowable as part of a total compensation package, provided such payments are reasonable and are made according to a formal policy of the grantee that is consistently applied regardless of the source of funds.

Payments for Dual Appointments

For investigators with university and clinical practice plan appointments, compensation from both sources may be considered the base salary if the following criteria are met:

- Clinical practice compensation must be guaranteed by the university
- Clinical practice effort must be shown on the university appointment form and must be paid through the university
- Clinical practice effort must be included and accounted for on the university’s effort report.

Support from Multiple Grants

See “Cost Considerations—Allocation of Costs and Closely Related Work.”
### Compensation of Students

Tuition remission and other forms of compensation paid as, or in lieu of, wages to students (including fellows and trainees) under research grants are allowable, provided the following conditions are met:

- The individual is performing activities necessary to the grant
- Tuition remission and other forms of compensation are consistently provided, in accordance with established institutional policy, to students performing similar activities conducted in nonsponsored as well as in sponsored activities
- During the academic period, the student is enrolled in an advanced degree program at a grantee or affiliated institution and the activities of the student in relation to the federally sponsored research project are related to the degree program.

Charges for tuition remission and other forms of compensation paid to students as, or in lieu of, salaries and wages are subject to the reporting requirements in section J.8. of OMB Circular A-21, or an equivalent method for documenting the individual’s effort on the research project. Tuition remission may be charged on an average rate basis. NIH will determine the allowability and reasonableness of such compensation under a grant on the basis of OMB Circular A-21 and its current operating guidelines. The maximum amount NIH will award for compensation of a graduate student receiving support from a research grant is tied to the zero-level Kirschstein-NRSA stipend in effect when NIH issues the grant award (see current levels posted at [http://grants.nih.gov/training/nrsa.htm](http://grants.nih.gov/training/nrsa.htm)).

Payments made for educational assistance (e.g., scholarships, fellowships, and student aid costs) may not be paid from NIH research grant funds even when they would appear to benefit the research project.

### Service Charges

Allowable. The costs to a user of organizational services and central facilities owned by the grantee organization, such as central laboratory and computer services, are allowable and must be based on organizational fee schedules consistently applied regardless of the source of funds.

### Severance Pay

Allowable only to the extent that such payments are required by law, are included in an employer-employee agreement, are part of an established policy effectively constituting an implied agreement on the part of the organization, or meet the circumstances of the particular employment. The amount of severance pay to be provided should be determined according to established organizational policy consistently applied regardless of the source of funds and should be reasonable, taking into consideration the practice of similar types of organizations and the extent of the organization’s dependence on Federal funds. The applicable cost principles should be consulted regarding the different treatment of severance pay in regular and mass termination situations.

### Stipends

Allowable as cost-of-living allowances for trainees and fellows only under Kirschstein-NRSA individual fellowships and institutional research training grants. These payments are made according to a preestablished schedule based on the individual’s experience and level of training. A stipend is not a fee-for-service payment and is not subject to the cost accounting requirements of the cost principles. Additional information, including NIH policy on stipend supplementation, is included in “Ruth L. Kirschstein National Research Service Awards—Individual Fellowships—Supplementation of Stipends, Compensation, and Other Income—Stipend Supplementation” and “Ruth L. Kirschstein National Research Service Awards—Institutional Research Training Grants—Stipend Supplementation, Compensation, and Other Income—Stipend Supplementation” in Subpart B of this part. Stipends are not allowable under research grants even when they appear to benefit the research project.

### Subject Costs

See “Research Patient Care” in this subsection.
<table>
<thead>
<tr>
<th>Supplies</th>
<th>Allowable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taxes</td>
<td>Allowable. Such costs include taxes that an organization is required to pay as they relate to employment, services, travel, rental, or purchasing for a project. Grantees must avail themselves of any tax exemptions for which activities supported by Federal funds may qualify. State sales and use taxes for materials and equipment are allowable only when the State does not grant a refund or exemption on such taxes.</td>
</tr>
<tr>
<td>Termination or Suspension Costs</td>
<td>Unallowable except as follows. If a grant is terminated or suspended, the grantee may not incur new obligations after the effective date of the termination or suspension and must cancel as many outstanding obligations as possible (see &quot;Administrative Requirements—Enforcement Actions—Suspension, Termination, and Withholding of Support&quot;). NIH will allow full credit to the grantee for the Federal share of otherwise allowable costs if the obligations were properly incurred by the grantee before suspension or termination—and not in anticipation of it—and, in the case of termination, are not cancelable. The GMO may authorize other costs in, or subsequent to, the notice of termination or suspension. See 45 CFR 74.62(c) and 92.43.</td>
</tr>
<tr>
<td>Trailers and Modular Units</td>
<td>Allowable only if considered equipment as provided below. A “trailer” is defined as a portable vehicle built on a chassis that is designed to be hauled from one site to another by a separate means of propulsion and that serves, wherever parked, as a dwelling or place of business. A “modular unit” is a prefabricated portable unit designed to be moved to a site and assembled on a foundation to serve as a dwelling or a place of business. The determination of whether costs to acquire trailers or modular units are allowable charges to NIH grant-supported projects depends on whether such units are classified as real property or equipment. The classification will depend on whether the grantee’s intended use of the property is permanent or temporary. A trailer or modular unit is considered real property when the unit and its installation are designed or planned to be installed permanently at a given location so as to seem fixed to the land as a permanent structure or appurtenance thereto. Units classified as real property may not be charged to an NIH grant-supported project unless authorizing legislation permits construction or acquisition of real property and the specific purchase is approved by the NIH awarding office.</td>
</tr>
<tr>
<td>A trailer or modular unit is considered equipment when the unit and its installation are designed or planned to be used at any given location for a limited time only. Units classified as equipment may be charged to NIH grant-supported projects only if the terms and conditions of the award do not prohibit the purchase of equipment and NIH prior approval is obtained, as appropriate. A trailer or modular unit properly classified as real property or as equipment at the time of acquisition retains that classification for the life of the item, thereby determining the appropriate accountability requirements under 45 CFR 74.32 or 74.34 or 92.31 or 92.32, as applicable.</td>
<td></td>
</tr>
<tr>
<td>Trainee Costs</td>
<td>Allowable only under predoctoral and postdoctoral training grants. (See “Ruth L. Kirschstein National Research Service Awards—Institutional Research Training Grants—Allowable and Unallowable Costs” in Subpart B of this part for detailed information.)</td>
</tr>
<tr>
<td>Transportation of Property</td>
<td>Allowable for freight, express, cartage, postage, and other transportation services relating to goods either purchased, in process, or delivered, including instances when equipment or other property is moved from one grantee to another. In a change-of-grantee situation, the cost of transportation may be charged to the grant at either the original or the new organization, depending on the circumstances and the availability of funds in the appropriate active grant account (see &quot;Administrative Requirements—Changes in Project and Budget—Prior-Approval Requirements&quot;).</td>
</tr>
<tr>
<td>Travel</td>
<td>Allowable as a direct cost where such travel will provide direct benefit to the project.</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Employees</strong></td>
<td>Consistent with the organization’s established travel policy, these costs for employees working on the grant-supported project may include associated per diem or subsistence allowances and other travel-related expenses, such as mileage allowances if travel is by personal automobile. Domestic travel is travel performed within the recipient’s own country. For U.S. and Canadian recipients, it includes travel within and between any of the 50 States of the United States and its possessions and territories and also travel between the United States and Canada and within Canada. Foreign travel is defined as any travel outside of Canada and the United States and its territories and possessions. However, for an organization located outside Canada and the United States and its territories and possessions, foreign travel means travel outside that country. In all cases, travel costs are limited to those allowed by formal organizational policy and, in the case of air travel, the lowest reasonable commercial airfares must be used. For-profit grantees’ allowable travel costs may not exceed those established by the FTR, issued by GSA, including the maximum per diem and subsistence rates prescribed in those regulations. This information is available at <a href="http://www.gsa.gov">http://www.gsa.gov</a>. If a recipient organization has no formal travel policy, those regulations will be used to determine the amount that may be charged for travel costs.</td>
</tr>
<tr>
<td><strong>Grantees</strong></td>
<td>Grantees are strongly encouraged to take advantage of discount fares for airline travel through advance purchase of tickets if travel schedules can be planned in advance (such as for national meetings and other scheduled events). Grantees must comply with the requirement that U.S. flag air carriers be used by domestic grantees to the maximum extent possible when commercial air transportation is the means of travel between the United States and a foreign country or between foreign countries. This requirement must not be influenced by factors of cost, convenience, or personal travel preference. The cost of travel under a ticket issued by a U.S. flag air carrier that leases space on a foreign air carrier under a code-sharing agreement is allowable if the purchase is in accordance with GSA regulations on U.S. flag air carriers and code shares (<a href="http://www.gsa.gov/gsa/cm_attachments/GSA_DOCUMENT/110304_FTR_R2QA53_025RDZ-i34K-pR.pdf">http://www.gsa.gov/gsa/cm_attachments/GSA_DOCUMENT/110304_FTR_R2QA53_025RDZ-i34K-pR.pdf</a>). (A code-sharing agreement is an arrangement between a U.S. flag carrier and a foreign air carrier in which the U.S. flag carrier provides passenger service on the foreign air carrier’s regularly scheduled commercial flights.) Applicants and grantees should consult application instructions to determine how to budget for travel costs under specific mechanisms and for certain types of travelers because they are not all required to be budgeted as travel.</td>
</tr>
<tr>
<td><strong>Research Patients</strong></td>
<td>If research patient care is an approved activity of the grant-supported project, the costs of transporting individuals participating in the research protocol to the site where services are being provided, including costs of public transportation, are allowable. The purchase of motor vehicles for this purpose also may be allowable. (See “Research Patient Care.”)</td>
</tr>
</tbody>
</table>
In general, NIH grantees are allowed a certain degree of latitude to rebudget within and between budget categories to meet unanticipated needs and to make other types of post-award changes. Some changes may be made at the grantee’s discretion as long as they are within the limits established by NIH. In other cases, NIH prior written approval may be required before a grantee makes certain budget modifications or undertakes particular activities. The grantee-initiated changes that may be made under the grantee’s authority and the changes that require NIH approval are outlined below and, with respect to particular types of awards, activities, or recipients, in Subpart B of this part. In addition, individual awards may restrict grantees’ authorities to make budget and project changes without NIH prior approval. If NIH approval is required, it must be requested of, and obtained from, the awarding office GMO in advance of the change or obligation of funds as specified below under “Requests for Prior Approval.”

Changes in project or budget resulting from NIH-initiated actions are discussed in other sections of this subpart.

Expanded Authorities

NIH has waived cost-related and other prior-approval requirements for many activities and expenditures, and provided authority for these activities and expenditures to the grantee. These operating authorities are termed “expanded authorities.” Exhibit 3 presents a summary of expanded authorities. Certain award instruments, mechanisms, and types of recipients are excluded from the expanded authority to automatically carry over unobligated balances. This includes centers (P50, P60, P30, and others); cooperative agreements (U); Kirschstein-NRSA institutional research training grants (T); non-Fast Track Phase 1 SBIR and STTR awards (R43 and R41); clinical trials; and awards to individuals.

Certain grants or grantees also may be excluded from expanded authorities, including those that require closer project monitoring or technical assistance, and certain large multi-project grants. If excluded from some or all expanded authorities, the NGA will indicate this change from the standard terms and conditions. In addition, one or more of these authorities may be overridden by a special term or condition of the award. Therefore, grantees must review the NGA to determine whether and to what extent they are permitted to use expanded authorities.

When using expanded authorities, grantees must ensure that they exercise proper stewardship over Federal funds and that costs charged to awards are allowable, allocable, reasonable, necessary, and consistently applied regardless of the source of funds. NIH may disallow the costs if it determines, through audit or otherwise, that the costs do not meet the tests of allowability, allocability, reasonableness, necessity, and consistency.

Several expanded authorities have specific deadlines for submission of reports or for timely notification to the NIH awarding office. Grantees should be aware that any consistent pattern of failure to adhere to those deadlines for reporting or notification will be grounds for excluding that grantee from expanded authorities.
Exhibit 3. Summary of Expanded Authorities

<table>
<thead>
<tr>
<th>May exercise as expanded authority</th>
<th>Except</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carryover of unobligated balances from one budget period to the next</td>
<td>Centers (P50, P60, P30, other), cooperative agreements (U), Kirschstein-NRSA institutional research training grants (T), non-Fast Track Phase I SBIR and STTR awards (R43 and R41), clinical trials, and awards to individuals, or if the NGA indicates otherwise.</td>
</tr>
<tr>
<td>Cost-related prior approvals, including research patient care costs and equipment</td>
<td>If the scope would change.</td>
</tr>
<tr>
<td>Extension of final budget period of a project period without additional NIH funds</td>
<td>If the grantee already has given itself one extension of up to 12 months.</td>
</tr>
<tr>
<td>Transfer of performance of substantive programmatic work to a third party (by consortium agreement)</td>
<td>If the transfer would be to a foreign component or it would result in a change in scope.</td>
</tr>
</tbody>
</table>

**Carryover of Unobligated Balances from One Budget Period to Another Within an Approved Project Period.** Awards routinely excluded from the automatic carryover of unobligated balances include centers (P50, P60, P30, other), cooperative agreements (U), Kirschstein-NRSA institutional research training grants (T), non-Fast Track Phase I SBIR and STTR awards (R43 and R41), clinical trials (regardless of mechanism), and awards to individuals. For these mechanisms, carryover of unobligated balances always requires NIH awarding office prior approval unless that requirement is waived by a term or condition of the NGA. Other awards may be excluded from use of this authority through a special term or condition in the NGA.

For awards using SNAP (see “Administrative Requirements—Monitoring—Reporting—Streamlined Non-Competing Award Process” for applicability), funds are automatically carried over to the subsequent budget period. However, the grantee will be required to indicate, as part of its grant progress report, whether its estimated unobligated balance (including prior-year carryover) is expected to be greater than 25 percent of the current year’s total approved budget. If so, the grantee must provide an explanation and indicate plans for expenditure of those funds.

For those awards subject to expanded authorities but excluded from SNAP, the FSR must specify the amount to be carried over. The notification must be provided under item 12, “Remarks,” on the FSR. When a grantee reports a balance of unobligated funds in excess of 25 percent of the total amount awarded, the GMO will review the circumstances resulting in the balance to ensure that these funds are necessary to complete the project, and may request additional information from the grantee, including a revised budget, as part of the review.

Whether or not under SNAP, if the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the grantee’s authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset NIH funding for a subsequent budget period, or use a combination of these actions. The GMO also may indicate whether the balance may be carried forward to a budget period other than the...
succeeding one. The GMO’s decision about the disposition of the reported unobligated balance will be reflected in the NGA.

**Cost-Related Prior Approvals.** NIH prior approval is not required to rebudget funds for any direct cost item that the applicable cost principles identify as requiring the Federal awarding agency’s prior approval, unless the incurrence of costs is associated with or is considered to be a change in scope. This also includes research patient care as described in the NIHGPS.

**Extension of Final Budget Period of a Previously Approved Project Period without Additional NIH Funds.** The grantee may extend the final budget period of the previously approved project period one time for a period of up to 12 months beyond the original expiration date shown in the NGA if

- no additional funds are required to be obligated by the NIH awarding office,
- the project’s originally approved scope will not change, and
- any one of the following applies:
  - Additional time beyond the established expiration date is required to ensure adequate completion of the originally approved project.
  - Continuity of NIH grant support is required while a competing continuation application is under review.
  - The extension is necessary to permit an orderly phase-out of a project that will not receive continued support.

The fact that funds remain at the expiration of the grant is not, in itself, sufficient justification for an extension without additional funds.

The grantee must notify the NIH awarding office, in writing, of the extension 10 days before the expiration date of the project period. Upon notification, the NIH awarding office will revise the project period ending date and provide an acknowledgment to the grantee. In extending the final budget period of the project period through this process, the grantee agrees to update all required certifications and assurances, including those pertaining to human subjects and animal welfare, in accordance with applicable regulations and policies. Grantees may not extend project periods previously extended by the NIH awarding office. Any additional project period extension beyond the one-time extension of up to 12 months requires NIH prior approval. (See “Prior-Approval Requirements” in this section for extensions requiring additional funds.) Grantees are reminded that all terms and conditions of the award apply during the extended period.

**Transfer of the Performance of Substantive Programmatic Work to a Third Party by Means of a Consortium Agreement.** Prior approval by the NIH awarding office is not required to transfer the performance of substantive programmatic work unless the activity constitutes a change in scope or results in the transfer of substantive programmatic work to a foreign component.
Prior-Approval Requirements

This subsection describes the activities and/or expenditures that require NIH prior approval. NIH prior-approval requirements are summarized in Exhibit 4, which is provided for guidance only. For the prior-approval requirements specified in the exhibit, approval is required whether or not the change has a budgetary impact and whether or not the grant also is subject to expanded authorities. The circumstances under which prior approval is required also are summarized in the exhibit.

Grantees also should consult Subpart B of this part for prior-approval requirements that apply to specific mechanisms, types of grants, and types of recipients.

Any question about the need for prior approval for an activity or cost under a specific NIH award should be directed to the GMO.

<table>
<thead>
<tr>
<th>Exhibit 4. Summary of Actions Requiring NIH Prior Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NIH prior approval is required for</strong></td>
</tr>
<tr>
<td>A&amp;R</td>
</tr>
<tr>
<td>Capital expenditures (construction, land, or building acquisition)</td>
</tr>
<tr>
<td>Change in scope</td>
</tr>
<tr>
<td>Changes in status of key personnel</td>
</tr>
<tr>
<td>Change of grantee organization</td>
</tr>
<tr>
<td>Carryover of unobligated balances</td>
</tr>
<tr>
<td>Deviation from award terms and conditions</td>
</tr>
<tr>
<td>Foreign component added to a grant to a domestic organization</td>
</tr>
<tr>
<td>Need for additional NIH funding</td>
</tr>
<tr>
<td>Pre-award costs</td>
</tr>
<tr>
<td>Retention of research grant funds when K award made</td>
</tr>
</tbody>
</table>
Exhibit 4. Summary of Actions Requiring NIH Prior Approval

<table>
<thead>
<tr>
<th>NIH prior approval is required for</th>
<th>Under the following circumstances</th>
</tr>
</thead>
<tbody>
<tr>
<td>Second no-cost extension or extension greater than 12 months</td>
<td>All instances.</td>
</tr>
<tr>
<td>Transfer of funds between construction and nonconstruction work</td>
<td>All instances.</td>
</tr>
<tr>
<td>Transferring amounts from trainee costs</td>
<td>All instances.</td>
</tr>
</tbody>
</table>

**Alterations and Renovations.** NIH prior approval is required if a grantee rebudgets more than 25 percent of the total approved budget for a budget period into A&R costs. NIH prior approval also is required for lesser rebudgeting into A&R costs if the rebudgeting would result in a change in scope. If rebudgeting results in an A&R project exceeding $300,000, NIH always will consider the rebudgeting to be a change in scope. (See “Construction Grants—Administrative Requirements—Prior-Approval Requirements—Alteration and Renovation Projects under Nonconstruction Grants” in Subpart B of this part for documentation requirements for A&R projects exceeding $300,000).

**Capital Expenditures.** Capital expenditures for land or buildings require NIH prior approval. In addition, real property acquired with NIH grant funds may not be conveyed, transferred, assigned, mortgaged, leased, or in any other manner encumbered by the grantee without the written prior approval of the NIH awarding office or its successor organization.

**Change in Scope.** In general, the PI may make changes in the methodology, approach, or other aspects of the project objectives. However, the grantee must obtain prior approval from the NIH awarding office for a change in the direction, type of research or training, or other areas that constitute a significant change from the aims, objectives, or purposes of the approved project (hereafter “change in scope”). The grantee must make the initial determination of the significance of a change and should consult with the GMO as necessary.

Actions likely to be considered a change in scope and, therefore, requiring NIH awarding office prior approval include, but are not limited to, the following:

- Change in the specific aims approved at the time of award.
- Substitution of one animal model for another.
- Any change from the approved use of animals or human subjects.
- Shift of the research emphasis from one disease area to another.
- A clinical hold by FDA under a study involving an IND or an IDE.
◆ Application of a new technology, e.g., changing assays from those approved to a different type of assay.

◆ Transfer of the performance of substantive programmatic work to a third party through a consortium agreement, by contract, or any other means. If the third party is a foreign component, this type of action always requires NIH prior approval.

◆ Change in key personnel (see “Change in Status, Including Absence, of Principal Investigator and Other Key Personnel” for requirements for NIH approval of alternate arrangements for or replacement of key personnel).

◆ Significant rebudgeting, whether or not the particular expenditure(s) require prior approval. Significant rebudgeting occurs when expenditures in a single direct cost budget category deviate (increase or decrease) from the categorical commitment level established for the budget period by more than 25 percent of the total costs awarded. For example, if the award budget for total costs is $200,000, any rebudgeting that would result in an increase or decrease of more than $50,000 in a budget category is considered “significant rebudgeting.” The base used for determining significant rebudgeting excludes the effects of prior-year carryover balances but includes competing and non-competing supplements.

◆ Incurrence of research patient care costs if costs in that category were not previously approved by NIH or if a grantee desires to rebudget additional funds beyond those approved into or rebudget funds out of the research patient care category.

◆ Purchase of a unit of equipment exceeding $25,000.

Change in Status, Including Absence, of Principal Investigator and Other Key Personnel.
The grantee is required to notify the GMO in writing if the PI or key personnel specifically named in the NGA will withdraw from the project entirely, be absent from the project during any continuous period of 3 months or more, or reduce time devoted to the project by 25 percent or more from the level that was approved at the time of award (for example, a proposed change from 40 percent effort to 30 percent or less effort). NIH must approve any alternate arrangement proposed by the grantee, including any replacement of the PI or key personnel named in the NGA.

The request for approval of a substitute PI/key person should include a justification for the change, the biographical sketch of the individual proposed, other sources of support, and any budget changes resulting from the proposed change. If the arrangements proposed by the grantee, including the qualifications of any proposed replacement, are not acceptable to the NIH awarding office, the grant may be suspended or terminated. If the grantee wishes to terminate the project because it cannot make suitable alternate arrangements, it must notify the GMO, in writing, of its wish to terminate, and NIH will forward closeout instructions.

The requirement to obtain NIH prior approval for a change in status pertains only to the PI and those key personnel NIH names in the NGA regardless of whether the applicant organization designates others as key personnel for its own purposes.
**Change of Grantee Organization.** NIH prior approval is required for the transfer of the legal and administrative responsibility for a grant-supported project or activity from one legal entity to another before the expiration of the approved project period (competitive segment). A change of grantee organization may be accomplished under most NIH grants, including construction grants, if any of the following conditions are met:

- The grant to be transferred has been terminated in accordance with 45 CFR 74.61 or 92.43.
- A non-competing continuation award that is within an approved project period has been withheld because of the grantees actions (see “Administrative Requirements—Enforcement Actions—Suspension, Termination, and Withholding of Support”).
- The original grantee has agreed to relinquish responsibility for an active project before the expiration of the approved project period. This includes any proposed change of grantee as a result of a PI on a research project transferring from one organization to another organization. The project under the same PI may be supported at a new organization for a period up to the remainder of the previously approved project period in an amount not to exceed that previously recommended for direct costs (plus applicable F&A costs) for the remaining period.

A change of grantee that involves the transfer of a grant to or between foreign institutions or international organizations also must be approved by the IC’s Advisory Council or Board.

A grant to an individual may not be transferred. However, an individual fellowship may be transferred to a new sponsoring organization. The transfer process will be the same as for a change of grantee organization. A change in an individual fellow’s department or sponsor within the same organization is not considered a change of grantee organization. A successor-in-interest or a name change is not considered a change of grantee (see “Change in Grantee Organizational Status” in this section).

A change of grantee organization may involve the transfer of equipment purchased with grant funds. The transfer may be accomplished as part of the original grantee’s relinquishment of the grant; otherwise, NIH reserves the right to transfer title to equipment to the new organization as indicated in “Administrative Requirements—Management Systems and Procedures—Property Management System Standards.”

A change of grantee organization request must be made before the anticipated start date at the new organization and preferably several months in advance. Failure to provide timely notification may result in disapproval of the request or a delay in processing.

A change of grantee request normally will be permitted only when all of the permanent benefits attributable to the original grant can be transferred, including equipment purchased in whole or in part with grant funds. In reviewing a request to transfer a grant, NIH will consider whether there is a continued need for the grant-supported project or activity and the impact of any proposed changes in the scope of the project. A change may be made without peer review, provided the PI plans no significant change in research objectives and the facilities and resources
at the new organization will allow for successful performance of the project. If these conditions or other programmatic or administrative requirements are not met, the NIH awarding office may require peer review or may disapprove the request and, if appropriate, terminate the award.

A request for a change of grantee organization must be submitted to the GMO and must include an Official Statement Relinquishing Interests and Rights in a Public Health Service Research Grant (PHS 3734) (relinquishing statement) and a Final Invention Statement and Certification from the original grantee as well as an application (PHS 398 or 416-1) from the proposed grantee or sponsoring organization. (A final FSR is due to NIH from the relinquishing organization no later than 90 days after the end of NIH support of the project.) If the original award was the result of a modular application, modular procedures apply to the request for change of grantee. For awards using the PHS 398, the application from the proposed grantee should include, at a minimum, the following:

- Face page
- Budget pages (current and future years) (Under awards resulting from modular applications, the application should include narrative budget information, including total direct and F&A costs for the current budget period and, if future budget periods remain, information about the number of modules and the basis for computing F&A costs for all future years)
- Updated biographical sketches for the PI and existing key personnel and biographical sketches for any proposed new key personnel
- Statement indicating whether the overall research plans/aims have changed from the original submission, and, if so, providing updated information
- Updated “other support” page(s), if necessary
- Resources page
- Checklist page
- Certification of IRB/IACUC approval, if applicable
- Detailed list of any equipment purchased with grant funds being transferred to the new organization (inclusion of this list in the transfer application from the new organization indicates its acceptance of title to that equipment).

NIH may request additional information necessary to accomplish its review of the request. Acceptance of a relinquishing statement by NIH does not guarantee approval of a transfer application for the continued funding of a project.

NIH will accomplish a change of grantee organization by issuing a revised NGA to the original grantee reflecting the revised budget/project period end dates, deletion of any future-year support, and deobligation of remaining funds, if applicable. (A deobligation of funds will be based on the estimated grant expenditures through the relinquishment date, as determined from
the relinquishing statement.) Concurrently, the new grantee will receive an NGA reflecting the balance reported on the relinquishing statement or, if the change of grantee organization occurs on the anniversary date of the project, the NGA to the new grantee will reflect the previously committed direct cost level plus applicable F&A costs). This amount is subject to change as a result of the closeout of the original grant and may be adjusted downward.

**Change in Grantee Organizational Status.** Grantees must give NIH advance notice of the following types of change in organizational status (that are not considered to be a change of grantee organization as described in this subsection):

- **Merger.** Legal action resulting in the unification of two or more legal entities. When such an action involves the transfer of NIH grants, the procedures for recognizing a successor-in-interest will apply. When the action does not involve the transfer of NIH grants, the procedures for recognizing a name change normally will apply.

- **Successor-in-Interest.** Process whereby the rights to and obligations under an NIH grant(s) are acquired incidental to the transfer of all of the assets of the grantee or the transfer of that part of the assets involved in the performance of the grant(s). An SII may result from legislative or other legal action, such as a merger or other corporate change.

- **Name Change.** Action whereby the name of an organization is changed without otherwise affecting the rights and obligations of that organization as a grantee.

Advance notification is required to ensure that the grantee still is able to meet its legal and administrative obligations to NIH and payments are not interrupted.

Grantees are encouraged to contact the GMO of the lead awarding office to explain the nature of the change in organizational status and receive guidance on whether it will be treated as a name change or SII. The lead awarding office ordinarily will be the IC with which the organization has the most NIH grants. If there is no advance consultation, NIH reserves the right to review the material provided, seek clarification or additional information, and make an independent determination.

A grantee’s formal request for a change in organizational status should be submitted to NIH as soon as possible so that NIH can determine whether the organization will continue to meet the grant program’s eligibility requirements and take the necessary action to reflect the change in advance of the change in status.

For an SII, a letter signed by the AOOs of the current grantee (transferor) and the successor-in-interest (transferee) must be sent to the lead NIH awarding office, following consultation with the GMO of that awarding office. The letter must do the following:

- Stipulate that the transfer will be properly effected in accordance with applicable law.

- Indicate that the transferor relinquishes all rights and interests in all of the affected grants.

- Request that the NIH awarding office(s) modify its (their) records to reflect the transferee as the grantee of record.
State the effective date of the transfer.

Provide the transferee’s Entity Identification Number.

Include verification of the transferee’s compliance with applicable requirements (e.g., research misconduct).

Include a list of all affected NIH grants (active and pending) with the following information for each:

- Complete grant number (e.g., 5 R01 GM 12345-04).
- Name of PI.
- Current budget period and project period.
- The total direct costs (as originally recommended) plus applicable F&A costs for each remaining budget period. If the SII will occur during a budget period rather than on the anniversary date, the transferor also must provide estimated levels of current-year direct and F&A costs remaining as of the SII effective date. The estimate may be reported on the PHS 3734 (Official Statement Relinquishing Interests and Rights in a Public Health Service Research Grant) or an equivalent relinquishing statement for each affected grant or may be itemized by grant number as an attachment to the letter.

Include a complete face page (PHS 398) for each affected grant showing the transferee as the applicant organization. Each face page must be signed by both the PI and the AOO at the transferee organization.

Include a copy of the current negotiated F&A rate agreement for the transferee.

In order to be recognized as the SII, the “new” (transferee) organization must meet each grant program’s eligibility requirements. Upon review and acceptance of this information, NIH will revise the NGA(s) to show the transferee as the grantee of record.

For name changes, the grantee’s written notification to the lead NIH awarding office must include the effective date of the change. Revised face pages are not required for name changes because name changes are processed with the next award action (e.g., non-competing continuation award) and the organization will submit a face page with the new information as part of that action.

**Deviation from Award Terms and Conditions, including Restrictions on the NGA.** NIH prior approval is required for any deviation from terms or conditions stated or referenced in the NGA, including those in the NIHGPS. This includes undertaking any activities disapproved or restricted as a condition of the award.

**Foreign Component Added to a Grant to a Domestic Organization.** Adding a foreign component under a grant to a domestic organization requires NIH prior approval.
Need for Additional NIH Funding without Extension of Budget and Project Period. A request for additional funding for a current budget period to meet increased costs that are within the scope of the approved application, but that were unforeseen when the new or competing continuation application or grant progress report for non-competing continuation support was submitted, is a non-competing supplemental application. Such requests are submitted, in writing, directly to the GMO and are not required to compete with other applications for funding. Other grantee-initiated requests for supplemental funding during a current budget period are considered to change the scope of the approved project and may be required to compete for funding with other applications.

Need for Additional NIH Funding with Extension of the Final Budget Period of a Project Period. A request for a non-competing extension of the final budget period of a project period with a minimal amount of additional funds should be submitted to the GMO, in writing, at least 30 days before the project period is scheduled to expire. Such requests usually are for a period of up to 12 months, based on a need to provide continuity of project activities while a competing continuation application is being reviewed or to permit orderly phaseout of project activities for which there will be no further NIH support. The request must specify the proposed revised ending date and must include justification for both the extension and the additional funds requested. Special justification will be required for an extension that would exceed 12 months. NIH will not approve such requests if the primary purpose of the proposed extension is to permit the use of unobligated balances of funds. All terms and conditions of the award apply during the extended period.

Pre-Award Costs. See “Cost Considerations—Selected Items of Cost—Pre-Award (Pre-Agreement) Costs.”

Retention of Research Grant Funds When a K Award is Made. Funds budgeted under an NIH grant for an individual’s salary and fringe benefits, but available as a result of receiving a K award for that individual, may not be used for any other purpose without NIH prior approval.

Transfer of Amounts from Trainee Costs. The transfer of amounts previously awarded for trainee costs (stipends, tuition, and fees) to other categories of expense requires NIH prior approval. This excludes trainee travel, which NIH does not consider to be a trainee cost, and training-related expenses (see “Ruth L. Kirschstein National Research Service Awards—Institutional Research Training Grants—Rebudgeting of Funds” in Subpart B of this part).

Transfer of Funds Between Construction and Nonconstruction Work. Under awards that provide for both construction and nonconstruction work, NIH prior approval is required to transfer funds between the two types of work.

Requests for Prior Approval

All requests for NIH awarding office prior approval must be made in writing (which includes submission by e-mail) to the GMO no later than 30 days before the proposed change. The request must be signed by both the PI and the AOO. Failure to obtain required prior approval, from the appropriate NIH awarding office may result in the disallowance of costs, termination of the award, or other enforcement action within NIH’s authority.
E-mail requests must be clearly identified as prior-approval requests, must reflect the complete
grant number in the subject line, and should be sent by the AOO to the GMO that signed the
NGA. (E-mail addresses for NIH staff can be obtained from the NIH Directory and E-Mail
Forwarding Services at http://directory.nih.gov.) E-mail requests must include the name of the
grantee, the name of the initiating PI, the PI’s telephone number, fax number, and e-mail address,
and comparable identifying information for the AOO. If the entire message of the request cannot
be included in the body of the e-mail, the request should be submitted to NIH in hard copy.

The GMO will review the request and provide a response to the AOO indicating the final
disposition of the request. The GMO will provide copies of the response to the PI and to the
cognizant NIH PO. Only responses provided by the GMO are to be considered valid. Grantees
that proceed on the basis of actions by unauthorized officials do so at their own risk, and NIH is
not bound by such responses.

Whenever grantees contemplate rebudgeting or other post-award changes and are uncertain
about the need for prior approval, they are strongly encouraged to consult, in advance, with the
GMO.

Under a consortium agreement or contract, the prior-approval authority usually is the grantee.
However, the grantee may not approve any action or cost that is inconsistent with the purpose or
terms and conditions of the NIH grant. If an action by a consortium participant will result in a
change in the overall grant project or budget requiring NIH approval, the grantee must obtain
that approval from NIH before giving its approval to the consortium participant.

**Availability of Research Results: Publications, Intellectual Property Rights, and Sharing Research Resources**

It is NIH policy that the results and accomplishments of the activities that it funds should be
made available to the public. PIs and grantee organizations are expected to make the results and
accomplishments of their activities available to the research community and to the public at
large. (See also “Public Policy Requirements and Objectives—Availability of Information—
Access to Research Data” for policies related to providing access to certain research data at
public request.) If the outcomes of the research result in inventions, the provisions of the Bayh-
Dole Act of 1980, as implemented in 37 CFR Part 401, apply.

As long as grantees abide by the provisions of the Bayh-Dole Act, as amended by the
Technology Transfer Commercialization Act of 2000 (P.L. 106-404), and 37 CFR Part 401, they
have the right to retain title to any invention conceived or first actually reduced to practice using
NIH grant funds. The principal objectives of these laws and the implementing regulation are to
promote commercialization of federally funded inventions, while ensuring that inventions are
used in a manner that promotes free competition and enterprise without unduly encumbering
future research and discovery.

The regulation requires the grantee to use patent and licensing processes to transfer grant-
supported technology to industry for development. Alternatively, unpatented research products
or resources—“research tools”—may be made available through licensing to vendors or other
investigators. Sharing of copyrightable outcomes of research may be in the form of journal articles or other publications.

The importance of each of these outcomes of funded research is reflected in the specific policies pertaining to rights in data, sharing of research data and unique research resources, and inventions and patents described in the following subsections.

Rights in Data (Publication and Copyrighting)

In general, grantees own the rights in data resulting from a grant-supported project. Special terms and conditions of the award may indicate alternative rights, e.g., under a cooperative agreement or based on specific programmatic considerations as stated in the applicable RFA. Except as otherwise provided in the terms and conditions of the award, any publications, data, or other copyrightable works developed under an NIH grant may be copyrighted without NIH approval. Rights in data also extend to students, fellows, or trainees under awards whose primary purpose is educational, with the authors free to copyright works without NIH approval. In all cases, NIH must be given a royalty-free, nonexclusive, and irrevocable license for the Federal government to reproduce, publish, or otherwise use the material and to authorize others to do so for Federal purposes. Data developed by a consortium participant also is subject to this policy.

As a means of sharing knowledge, NIH encourages grantees to arrange for publication of NIH-supported original research in primary scientific journals. Grantees also should assert copyright in scientific and technical articles based on data produced under the grant where necessary to effect journal publication or inclusion in proceedings associated with professional activities.

Journal or other copyright practices are acceptable unless the copyright policy prevents the grantees from making copies for its own use (as provided in 45 CFR 74.36 and 92.34). The disposition of royalties and other income earned from a copyrighted work is addressed in “Administrative Requirements—Management Systems and Procedures—Program Income.”

For each publication that results from NIH grant-supported research, grantees must include an acknowledgment of NIH grant support and a disclaimer stating the following:

“This publication was made possible by Grant Number ________ from ________” or “The project described was supported by Grant Number ________ from ________” and “Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the [name of awarding office or NIH].”

If the grantee plans to issue a press release concerning the outcome of NIH grant-supported research, it should notify the NIH awarding office in advance to allow for coordination.

________________________

12 For this purpose, “data” means recorded information, regardless of the form or media on which it may be recorded, and includes writings, films, sound recordings, pictorial reproductions, drawings, designs, or other graphic representations, procedural manuals, forms, diagrams, work flow charts, equipment descriptions, data files, data processing or computer programs (software), statistical records, and other research data.
One copy of each publication resulting from work performed under an NIH grant-supported project must accompany the annual or final progress report submitted to the NIH awarding office (see “Administrative Requirements—Monitoring—Reporting—Non-Competing Grant Progress Reports” and “Administrative Requirements—Closeout—Final Reports—Final Progress Report”).

Sharing of Research Data

NIH believes that data sharing is essential for expedited translation of research results into knowledge, products, and procedures to improve human health. NIH endorses the sharing of final research data to serve these and other important scientific goals and expects and supports the timely release and sharing of final research data from NIH-supported studies for use by other researchers. “Timely release and sharing” is defined as no later than the acceptance for publication of the main findings from the final data set. Effective with the October 1, 2003 receipt date, investigators submitting an NIH application seeking $500,000 or more in direct costs in any single budget period are expected to include a plan for data sharing or state why data sharing is not possible.

NIH recognizes that data sharing may be complicated or limited, in some cases, by organizational policies, local IRB rules, and local, State and Federal laws and regulations, including the “Privacy Rule” (See “Public Policy Requirements and Objectives—Requirements Affecting the Rights and Welfare of Individuals as Research Subjects, Patients, or Recipients of Services—Confidentiality—Standards for Privacy of Individually Identifiable Health Information”). The rights and privacy of individuals who participate in NIH-sponsored research must be protected at all times. Thus, data intended for broader use should be free of identifiers that would permit linkages to individual research participants and variables that could lead to deductive disclosure of the identity of individual subjects.

Sharing of Unique Research Resources

Investigators conducting biomedical research frequently develop unique research resources. Categories of these resources include synthetic compounds, organisms, cell lines, viruses, cell products, and cloned DNA, as well as DNA sequences, mapping information, crystallographic coordinates, and spectroscopic data. Specific examples include specialized or genetically defined cells, including normal and diseased human cells; monoclonal antibodies; hybridoma cell lines; microbial cells and products; viruses and viral products; recombinant nucleic acid molecules; DNA probes; nucleic acid and protein sequences; certain types of animals, such as transgenic mice; and intellectual property, such as computer programs.

NIH considers the sharing of such unique research resources (also called research tools) an important means to enhance the value of NIH-sponsored research. Restricting the availability of unique resources can impede the advancement of further research. Therefore, when these resources developed with NIH funds and the associated research findings have been published or after they have been provided to NIH, it is important that they be made readily available for research purposes to qualified individuals within the scientific community.
To provide further clarification of the NIH policy on disseminating unique research resources, NIH published *Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources* (64 FR 72090, December 23, 1999), which is available on the NIH website (http://www.ott.nih.gov/policy/rt_guide_final.html). This document will assist grantees in determining reasonable terms and conditions for disseminating and acquiring research tools.

The terms of those agreements also must reflect the objectives of the Bayh-Dole Act and the Technology Transfer Commercialization Act of 2000 to ensure that inventions made are used in a manner to promote free competition and enterprise without unduly encumbering future research and discovery.

In addition to sharing research resources with the research community, upon request of the NIH awarding office, the grantee also must provide a copy of documents or a sample of any material developed under an NIH grant award. The grantee may charge a nominal fee to cover shipping costs for providing this material. Income earned from these charges must be treated as program income (see “Administrative Requirements—Management Systems and Procedures—Program Income”).

To facilitate the availability of unique or novel biological materials and resources developed with NIH funds, investigators may distribute the materials through their own laboratory or organization or submit them, if appropriate, to entities such as the American Type Culture Collection or other repositories. Investigators are expected to submit unique biological information, such as DNA sequences or crystallographic coordinates, to the appropriate data banks so that they can be made available to the broad scientific community. When distributing unique resources, investigators are to include pertinent information on the nature, quality, or characterization of the materials.

Investigators must exercise great care to ensure that resources involving human cells or tissues do not identify original donors or subjects, directly or through identifiers such as codes linked to the donors or subjects.

Organizations that believe they will be unable to comply with these requirements should promptly contact the GMO to discuss the circumstances, obtain information that might enable compliance, and reach an understanding in advance of an award.

### Inventions and Patents

The Bayh-Dole Act of 1980 (Public Law 96-517; 35 U.S.C. 200-212) and the related EO 12591 (April 10, 1987) provide incentives for the practical application of research supported through Federal funding agreements. To be able to retain rights and title to inventions made with Federal funds, so-called “subject” inventions, the grantee must comply with a series of regulations that ensure the timely transfer of the technology to the private sector, while protecting limited rights of the Federal government.

The regulations apply to any subject invention—defined as any invention either conceived or first actually reduced to practice in the performance of work under the Federal award—and to all
types of recipients of Federal funding. This includes non-profit entities and small businesses or large businesses receiving funding through grants, cooperative agreements, or contracts as direct recipients of funds, or as consortium participants or subcontractors under those awards.

NIH grantees may retain intellectual property rights to subject inventions provided they do the following:

- Report all subject inventions to NIH.
- Make efforts to commercialize the subject invention through patent or licensing.
- Formally acknowledge the Federal government’s support in all patents that arise from the subject invention.
- Formally grant the Federal government a limited use license to the subject invention.

Exhibit 5 summarizes recipient responsibilities for invention reporting as specified in the regulations in 37 CFR Part 401. Grantees should refer to 37 CFR Part 401 (available on the Interagency Edison site: https://s-edison.info.nih.gov/iEdison/) for a complete discussion of the regulations.

<table>
<thead>
<tr>
<th>Exhibit 5. Extramural Invention Reporting Compliance Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Action required</strong></td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td><strong>Employee Agreement to Disclose All Inventions</strong></td>
</tr>
<tr>
<td>The PI (employee) must sign an agreement to abide by the terms of the Bayh-Dole Act and the NIHGPS as they relate to intellectual property rights.</td>
</tr>
<tr>
<td><strong>Invention Report and “Disclosure”</strong></td>
</tr>
<tr>
<td>The grantee organization must submit to NIH a report of any subject invention. This includes a written description (the so-called “invention disclosure”) of the invention.</td>
</tr>
</tbody>
</table>
### Exhibit 5. Extramural Invention Reporting Compliance Responsibilities

<table>
<thead>
<tr>
<th>Action required</th>
<th>When action must be taken</th>
<th>Discussion</th>
<th>37 CFR 401 reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rights to Consortium Participant Inventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consortium participants under NIH grants retain rights to any subject inventions they make.</td>
<td>Within 2 months of the inventor’s initial report of the invention to the consortium participant. (The consortium participant has the same invention reporting obligations as the grantee.)</td>
<td>The grantee cannot require ownership of a consortium participant’s subject inventions as a term of the consortium agreement.</td>
<td><code>401.14(g)(1) 401.14(g)(2)</code></td>
</tr>
<tr>
<td><strong>Election of Title to Invention</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The grantee must notify NIH of its decision to retain or waive title to invention and patent rights.</td>
<td>Within 2 years of the initial reporting of the invention to NIH.</td>
<td></td>
<td><code>401.14(b) 401.14(c)(2) 401.14(f)(1)</code></td>
</tr>
<tr>
<td><strong>Confirmatory License</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For each invention, the grantee must provide a use license to NIH for each invention.</td>
<td>When the initial non-provisional patent application is filed.</td>
<td></td>
<td><code>401.14(f)(1)</code></td>
</tr>
<tr>
<td><strong>Patent Application</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The grantee must inform NIH of the filing of any non-provisional patent application. The patent application must include a Federal government support clause.</td>
<td>Within 1 year after election of title, unless there is an extension.</td>
<td>Initial patent application is defined as a non-provisional U.S. application. The patent application number and filing date must be provided.</td>
<td><code>401.14(c)(3) 401.2(n)</code></td>
</tr>
<tr>
<td><strong>Assignment of Rights to Third Party</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If the grantee is a non-profit organization, it must ask NIH approval to assign invention or U.S. patent rights to any third party, including the inventor(s).</td>
<td>As needed. The NIH Office of Technology Transfer serves in an advisory capacity to OER for the processing of such assignment requests.</td>
<td>Grantees that are for-profit entities (including small businesses) do not need to ask approval.</td>
<td><code>401.14(k)</code></td>
</tr>
<tr>
<td><strong>Issued Patent</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The grantee must notify NIH that a patent has been issued.</td>
<td>When the patent is issued.</td>
<td>The patent issue date, number, and evidence of Federal government support clause must be provided.</td>
<td><code>401.5(f)(2)</code></td>
</tr>
</tbody>
</table>
## Exhibit 5. Extramural Invention Reporting Compliance Responsibilities

<table>
<thead>
<tr>
<th>Action required</th>
<th>When action must be taken</th>
<th>Discussion</th>
<th>37 CFR 401 reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Extension of Time to Elect Title or File Patent</strong></td>
<td>The grantee may request an extension of up to 2 years for election of title, or 1 year for filing a patent application.</td>
<td>As needed.</td>
<td>Request for extension of time must be made. Such requests are preapproved.</td>
</tr>
<tr>
<td><strong>Change in Patent Application Status</strong></td>
<td>The grantee must notify NIH of changes in patent status.</td>
<td>At least 30 days before any pending patent office deadline.</td>
<td>This notification allows NIH to consider continuing the patent action.</td>
</tr>
<tr>
<td><strong>Invention Utilization Report</strong></td>
<td>The grantee must submit information about the status of commercialization of any invention for which title has been elected.</td>
<td>Annually.</td>
<td>This report gives an indication of whether the objectives of the law are being met. Specific reporting requirements can be found in iEdison (<a href="https://s-edison.info.nih.gov/iEdison/">https://s-edison.info.nih.gov/iEdison/</a>).</td>
</tr>
<tr>
<td><strong>Annual Invention Statement</strong></td>
<td>The grantee must indicate any inventions made during the previous budget period on all grant awards.</td>
<td>Part of all competing applications and non-competing grant progress reports.</td>
<td>The information is requested as a checklist item on the PHS 398 application and on the non-competing grant progress report.</td>
</tr>
<tr>
<td><strong>Final Invention Statement and Certification</strong></td>
<td>The grantee must submit to the NIH awarding office GMO a summary of all inventions made during the entire term of each grant award.</td>
<td>Within 90 days after the project period (competitive segment) ends.</td>
<td>Required information is specified on the HHS 568 form. If no inventions occurred during the project period, a negative report must be submitted.</td>
</tr>
</tbody>
</table>

Failure of the grantee to comply with any of these or other regulations cited in 37 CFR Part 401 may result in the loss of patent rights or a withholding of additional grant funds.

The Bayh-Dole Act includes provisions for the grantee to assign invention rights to third parties. Grantees that are non-profit organizations must request NIH approval for the assignment. If the assignment is approved and the rights are assigned to a third party, invention and patent reporting requirements apply to the third party. The grantee should review existing agreements with third
parties and revise them, as appropriate, to ensure they are consistent with the terms and conditions of their NIH grant awards and that the objectives of the Bayh-Dole Act are adequately represented in the assignment.

Any invention made using funds awarded for educational purposes, e.g. fellowships, training grants or certain types of career development awards, is not considered a subject invention and therefore is not subject to invention reporting requirements (as provided in 45 CFR 74. and 37 CFR 401.1(b)). The grantee should seek the advice of NIH to verify whether any invention made under a career development award should be considered a subject invention.

Details regarding invention reporting and iEdison are discussed under “Administrative Requirements—Monitoring—Reporting—Invention Reporting.”

All issues or questions regarding extramural technology transfer policy and reporting of inventions and their utilization should be referred to the following address:

Extramural Inventions and Technology Resources Branch  
Division of Grants Policy  
Office of Policy for Extramural Research Administration  
Office of Extramural Research  
NIH  
6705 Rockledge Drive, MSC 7980  
Bethesda, MD 20892-7980  
301-435-1986 (voice)  
301-480-0272 (fax)

Management Systems and Procedures

Grantee organizations are expected to have systems, policies, and procedures in place by which they manage funds and activities. Grantees may use their existing systems to manage NIH grant funds and activities as long as they are consistently applied regardless of the source of funds and meet the standards and requirements set forth in 45 CFR Part 74 or 92 and the NIHGPS. NIH may review the adequacy of those systems and may take appropriate action, as necessary, to protect the Federal government’s interests, including, but not limited to, the use of special terms and conditions. NIH also will oversee the grantee’s systems as part of its routine post-award monitoring. The grantee’s systems also are subject to audit (see “Administrative Requirements—Monitoring—Audit”).

NIH seeks to foster within grantee organizations an organizational culture that is committed to compliance, leading to both exemplary research and exemplary supporting systems and use of resources to underpin that research. Actions to achieve this result should include a clear delineation of the roles and responsibilities of the organization’s staff, both programmatic and administrative; written policies and procedures; training; management controls and other internal controls; performance assessment; administrative simplifications; and information sharing.
Financial Management System Standards

Grantees are required to meet the standards and requirements for financial management systems set forth or referenced in 45 CFR 74.21 or 92.20, as applicable. The standards and requirements for a financial management system are essential to the grant relationship. NIH cannot support the research unless it has assurance that its funds will be used appropriately, adequate documentation of transactions will be maintained, and assets will be safeguarded.

Grantees must have in place accounting and internal control systems that provide for appropriate monitoring of grant accounts to ensure that obligations and expenditures are reasonable, allocable, and allowable. In addition, the systems must be able to identify large unobligated balances, accelerated expenditures, inappropriate cost transfers, and other inappropriate obligation and expenditure of funds. Grantees must notify NIH when problems are identified.

A grantee’s failure to establish adequate control systems constitutes a material violation of the terms of the award. Under these circumstances, NIH may include special conditions on awards or take any of the range of actions specified in “Administrative Requirements—Enforcement Actions,” as necessary and appropriate.

Program Income

Program income is gross income—earned by a grantee, a consortium participant, or a contractor under a grant—that was directly generated by the grant-supported activity or earned as a result of the award. Program income includes, but is not limited to, income from fees for services performed; charges for the use or rental of real property, equipment or supplies acquired under the grant; the sale of commodities or items fabricated under an award; charges for research resources; and license fees and royalties on patents and copyrights. (Note: Program income from license fees and royalties from copyrighted material, patents, and inventions is exempt from reporting requirements.) The requirements for accountability for these various types of income under NIH grants are specified in this subsection. Accountability refers to whether NIH will specify how the income is to be used and whether the income needs to be reported to NIH and for what length of time. Unless otherwise specified in the terms and conditions of the award, NIH grantees are not accountable for program income accrued after the period of grant support.

NIH applies the additive alternative to all grantees, including for-profit entities, unless there is a concern with the recipient or activity and NIH uses special terms and conditions, or the program requires a different program income alternative. NIH may require a different use of program income if a grantee has deficient systems; if the PI has a history of frequent, large annual unobligated balances on previous grants; or if the PI has requested multiple extensions of the final budget period of the project period. Regardless of the alternative applied, program income may be used only for allowable costs in accordance with the applicable cost principles and the terms and conditions of the award.

Consortium agreements and contracts under grants are subject to the terms of the agreement or contract with regard to the income generated by the activities, but the terms specified by the grantee must be consistent with the requirements of the grant award. Program income must be reported by the grantee as discussed in this subsection.
Program income earned during the period of grant support (other than income earned as a result of copyrights, patents, or inventions or as a result of the sale of real property, equipment, or supplies) shall be retained by the grantee and, as specified by NIH in the NGA, may be used in one or a combination of the ways indicated in Exhibit 6.

Exhibit 6. Use and Applicability of Program Income Alternatives

<table>
<thead>
<tr>
<th>Program income alternative</th>
<th>Use of program income</th>
<th>Applicability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additive Alternative</td>
<td>Added to funds committed to the project or program and used to further eligible project or program objectives.</td>
<td>Applies to all NIH awards unless there is a concern with the recipient or activity or the program requires a different alternative.</td>
</tr>
<tr>
<td>Deductive Alternative</td>
<td>Deducted from total allowable costs of the project or program to determine the net allowable costs on which the Federal share of costs will be based.</td>
<td>Available for use by NIH programs on an exception basis.</td>
</tr>
<tr>
<td>Combination Alternative</td>
<td>Uses all program income up to (and including) $25,000 as specified under the additive alternative and any amount of program income exceeding $25,000 under the deductive alternative.</td>
<td>Available for use by NIH programs on an exception basis.</td>
</tr>
<tr>
<td>Matching Alternative</td>
<td>Used to satisfy all or part of the non-Federal share of a project or program.</td>
<td>Available for use by NIH programs that require matching.</td>
</tr>
</tbody>
</table>

Sale of Real Property, Equipment, and Supplies

The requirements that apply to the sale of real property are addressed in “Construction Grants.” For equipment and supplies purchased under NIH grants for basic or applied research by non-profit institutions of higher education or non-profit organizations whose principal purpose is the conduct of scientific research, the grantee is exempt from any requirement to account to NIH for proceeds from the sale of the equipment or supplies; however, NIH has certain rights with respect to such property as specified in “Administrative Requirements—Management Systems and Procedures—Property Management System Standards.”

All other types of grants and grantees are subject to the requirements in 45 CFR 74.34 or 92.32, if title to the equipment vests in the grantee rather than in NIH. If the grant-supported project or program for which equipment was acquired is still receiving NIH funding at the time of sale, the grantee must credit the NIH share of the proceeds to the grant and use that amount under the deductive alternative for program income. If the grantee is no longer receiving NIH grant support, the amount due should be paid in accordance with instructions from NIH. These grants and grantees also are subject to the requirements in 45 CFR 74.35 or 92.33 with respect to the use or sale of unused supplies. If the grantee retains the supplies for use on other than federally sponsored activities, an amount is due NIH as if they were sold.
Reporting of Program Income

The amount of program income earned and the amount expended must be reported on the FSR (SF 269—Long Form). Any costs associated with the generation of the gross amount of program income that are not charged to the grant should be deducted from the gross program income earned, and the net program income should be the amount reported. Program income subject to the additive alternative must be reported on lines 10r and 10s, as appropriate, of the FSR; program income subject to the deductive alternative must be reported on lines 10c and 10q of the FSR; and program income subject to the matching alternative must be reported on lines 10g and 10q of the FSR. (See “Administrative Requirements—Monitoring—Reporting—Financial Reporting.”) For awards under SNAP, the amount of program income earned must be reported in the non-competing grant progress report.

Income resulting from royalties or licensing fees is exempt from reporting as program income.

Income earned from the sale of equipment must be reported on the FSR for the period in which the proceeds are received in accordance with the reporting requirements for the program income alternative specified. Amounts due NIH for unused supplies must be reflected as a credit to the grant on line 10c of the FSR.

When the terms of the NGA, including the NIHGPS, do not specify any accountability requirement for income earned, no reporting of income is required. Reporting requirements for accountable income accrued after grant support ends will be specified in the NGA.

Royalties and Licensing Fees from Copyrights, Inventions, and Patents

NIH grantees do not have to report program income resulting from royalties or licensing fees from sale of copyrighted material unless specific terms and conditions of the award provide otherwise. The NGA may include special terms and conditions if commercialization of an invention is an anticipated outcome of a research project.

However, the regulations implementing the Bayh-Dole Act (37 CFR 401.14(h)) require reporting of income resulting from NIH-funded inventions and patents. Specifically, as part of the annual invention utilization report, grantees must report income generated by all subject inventions to which title has been elected and by inventions (“research tools”) that have been licensed but not patented (see “Administrative Requirements—Availability of Research Results: Publications, Intellectual Property Rights, and Sharing Research Resources” and “Administrative Requirements—Monitoring—Reporting”).

Property Management System Standards

Generally, grantees may use their own property management policies and procedures for property purchased, constructed, or fabricated as a direct cost using NIH grant funds, provided
they observe the requirements in 45 CFR 74.31 through 74.37 or 92.31 through 92.34,\textsuperscript{13} as applicable, and the following.

The dollar threshold for determining the applicability of several of the requirements in those regulations is based on the unit acquisition cost of an item of equipment. As defined in 45 CFR 74.2, the cost of an item of equipment to the grantee includes necessary modifications and attachments that make it usable for the purpose for which it was acquired or fabricated. When such accessories or attachments are acquired separately and serve to replace, enhance, supplement, or otherwise modify the equipment’s capacity and they individually meet the definition of equipment (see “Glossary”), any required NIH prior approval for equipment must be observed for each item. However, the aggregate acquisition cost of an operating piece of equipment will be used to determine the applicable provisions of 45 CFR 74.34 or 92.32. If property is fabricated from individual component parts, each component must itself be classified as equipment if it meets the definition of equipment. In this case, the aggregate acquisition cost of the resulting piece of equipment will determine the appropriate accountability requirements in 45 CFR 74.34 or 92.32.

Grantees are required to be prudent in the acquisition of property under a grant-supported project. It is the grantee’s responsibility to conduct a prior review of each proposed property acquisition to ensure that the property is needed and that the need cannot be met with property already in the possession of the organization. If prior approval is required for the acquisition, the grantee must ensure that appropriate approval is obtained in advance of the acquisition. The grantee also must follow appropriate procurement procedures in acquiring property as specified in “Administrative Requirements—Management Systems and Procedures—Procurement System Standards and Requirements.”

Recipients of NIH grants other than Federal institutions cannot be authorized to use Federal supply sources.

\textit{Real Property}

See “Construction Grants—Administrative Requirements—Real Property Management Standards” for requirements that apply to the acquisition, use, and disposition of real property. Fixed equipment that is part of a construction grant is subject to those requirements.

\textit{Equipment and Supplies}

In general, title to equipment and supplies acquired by a grantee with NIH funds vests in the grantee upon acquisition, subject to the property management requirements of 45 CFR 74.31, 74.34, 74.35, and 74.37, or 92.32 and 92.33. Limited exceptions to these general rules are States, which may use, manage, and dispose of equipment acquired under a grant in accordance with State laws and procedures, and certain research grant recipients with exempt property. These requirements do not apply to equipment for which only depreciation or use allowances are

\textsuperscript{13} State governments will use, manage, and dispose of equipment acquired under a grant in accordance with state laws and procedures as specified in 45 CFR 92.32.
charged, donated equipment, or equipment acquired primarily for sale or rental rather than for use.

**Exempt Property**

Under the Federal Grant and Cooperative Agreement Act, 31 U.S.C. 6306, NIH may permit non-profit institutions of higher education and non-profit organizations whose primary purpose is the conduct of scientific research to obtain title to equipment and supplies acquired under grants for support of basic or applied scientific research without further obligation to the Federal government. However, there is one exception: NIH has the right to require transfer of title to equipment with an acquisition cost of $5,000 or more to the Federal government or to an eligible third party named by the NIH awarding office under the conditions specified in 45 CFR 74.34(h). NIH may exercise this right within 120 days of the completion or termination of an award or within 120 days of receipt of an inventory, as provided in 45 CFR 74.34(h)(2), whichever is later.

**Nonexempt Property**

All other equipment and supplies acquired under all other NIH grant-supported projects by any other type of grantee are subject to the full range of acquisition, use, management, and disposition requirements of 45 CFR 74.34 and 74.35, or 45 CFR 92.32 and 92.33. Property acquired or used under an NIH grant-supported project, including any federally owned property, also is subject to the requirements for internal control specified in 45 CFR 74.21 or 92.20. Pursuant to 45 CFR 74.37, equipment (and intangible property and debt instruments) acquired with, or improved with, NIH funds must not be encumbered without NIH approval.

The grantee’s management system for equipment must meet the requirements of 45 CFR 74.34(f) or 92.32, which include the following:

- Records that adequately identify (according to the criteria specified in the regulations) items of equipment owned or held by the grantee and state the current location of each item
- A physical inventory of the equipment, at least once every 2 years, to verify that the items in the records exist and either are usable and needed or are surplus (a statistical sampling basis is acceptable)
- Control procedures and safeguards to prevent loss, damage, and theft
- Adequate maintenance procedures to keep the equipment in good condition
- Proper sales procedures when the grantee is authorized to sell the equipment.

For items of equipment having a unit acquisition cost of $5,000 or more, NIH has the right to require transfer title to the equipment to the Federal government or to an eligible third party named by the NIH awarding office under the conditions specified in 45 CFR 74.34(h) and 92.32, respectively. This right applies to nonexempt property acquired by all types of grantees, including Federal institutions, under all types of grants under the stipulated conditions.
If there is a residual inventory of unused supplies exceeding $5,000 in aggregate fair market value upon termination or completion of the grant and if the supplies are not needed for other federally sponsored programs or projects, the grantee may either retain them for use on other than federally sponsored activities or sell them, but, in either case, the grantee must compensate the NIH awarding office for its share as a credit to the grant.

Recipients of NIH grants must not use equipment acquired with grant funds to provide services for a fee to compete unfairly with private companies that provide equivalent services, unless the terms and conditions of the award provide otherwise.

**Revocable License**

As permitted under Federal property management statutes and regulations and NIH property management policies, federally owned tangible personal property may be made available to grantees under a revocable license agreement. The revocable license agreement between NIH and the grantee provides for the transfer of the equipment for the period of grant support under the following conditions:

- Title to the property remains with the Federal government.
- NIH reserves the right to require the property to be returned to the Federal government should it be determined to be in the best interests of the Federal government to do so.
- The use to which the grantee puts the property does not permanently damage it for Federal government use.
- The property is controlled and maintained in accordance with the requirements of 48 CFR 45.5 (the FAR).

**Procurement System Standards and Requirements**

**General**

Grantees may acquire a variety of goods or services in connection with a grant-supported project, ranging from those that are routinely purchased goods or services to those that involve substantive programmatic work. States may follow the same policies and procedures they use for procurements from non-Federal funds. All other grantees must follow the requirements in 45 CFR 74.40 through 74.48 or 92.36, as applicable, for the purchase of goods or services through contracts under grants. The requirements for third-party activities involving programmatic work are addressed under “Consortium Agreements.”

A contract under a grant must be a written agreement between the grantee and the third party. The contract must, as appropriate, state the activities to be performed; the time schedule; the policies and requirements that apply to the contractor, including those required by 45 CFR 74.48 or 92.36(i) and other terms and conditions of the grant (these may be incorporated by reference where feasible); the maximum amount of money for which the grantee may become liable to the third party under the agreement; and the cost principles to be used in determining allowable costs in the case of cost-type contracts. The contract must not affect the grantee’s overall responsibility
for the direction of the project and accountability to the Federal government. Therefore, the agreement must reserve sufficient rights and control to the grantee to enable it to fulfill its responsibilities.

When a grantee enters into a service-type contract in which the term is not concurrent with the budget period of the award, the grantee may charge the costs of the contract to the budget period in which the contract is executed even though some of the services will be performed in a succeeding period if the following conditions are met:

◆ The NIH awarding office has been made aware of this situation either at the time of application or through post-award notification.

◆ The project has been recommended for a project period extending beyond the current year of support.

◆ The grantee has a legal commitment to continue the contract for its full term.

However, costs will be allowable only to the extent that they are for services provided during the period of NIH support. To limit liability if continued NIH funding is not forthcoming, it is recommended that grantees insert a clause in such contracts of $100,000 or less stipulating that payment beyond the end of the current budget period is contingent on continued Federal funding. The contract provisions prescribed by 45 CFR 74.48 and 92.36(i)(2) specify termination provisions for contracts in excess of $100,000.

Approval Requirements

The procurement standards in 45 CFR 74.44 and 92.36(g) allow NIH to require approval of specific procurement transactions under the following circumstances (and provide a mechanism for governmental grantees to be exempt from this type of review):

◆ A grantee’s procurement procedures or operations do not comply with the procurement standards required by those regulations.

◆ The procurement is expected to exceed the “simplified acquisition threshold” (currently $100,000) (formerly the “small purchase threshold”) established by the Federal Property and Administrative Services Act, as amended, and is to be awarded without competition or only one bid or proposal is received in response to a solicitation.

◆ A procurement that will exceed the simplified acquisition threshold specifies a “brand name” product.

◆ A proposed award over the simplified acquisition threshold is to be awarded to other than the apparent low bidder under a sealed-bid procurement.

◆ A proposed contract modification changes the scope of a contract or increases the contract amount by more than the amount considered to be a simplified acquisition.
When NIH prior approval is required, the grantee must make available sufficient information to enable review. This may include, at NIH discretion, presolicitation technical specifications or documents, such as requests for proposals or invitations for bids, or independent cost estimates. Approval may be deferred pending submission of additional information by the applicant or grantee or may be conditioned on the receipt of additional information. Any resulting NIH approval does not constitute a legal endorsement of the business arrangement by the Federal government nor does such approval establish NIH as a party to the contract or any of its provisions.

Contracting with Small Businesses, Minority-Owned Firms, and Women’s Business Enterprises

Grantees must make positive efforts to use small businesses, minority-owned firms, and women’s business enterprises as sources of goods and services whenever possible. Grantees are required to take the following steps to implement this policy:

◆ Place qualified small, minority, and women-owned business enterprises on solicitation lists.

◆ Ensure that small, minority, and women-owned business enterprises are solicited whenever they are potential sources.

◆ Consider contracting with consortia of small businesses, minority-owned businesses, or women’s business enterprises when an intended contract is too large for any one such firm to handle on its own or, if economically feasible, divide larger requirements into smaller transactions for which such organizations might compete.

◆ Make information on contracting opportunities available and establish delivery schedules that encourage participation by small, minority, and women-owned business enterprises.

◆ Use the services and assistance of the SBA and DoC’s Minority Business Development Agency, as appropriate.

◆ If subcontracts are to be let, require the prime contractor to take the affirmative steps listed above.

Monitoring

Grantees are responsible for managing the day-to-day operations of grant-supported activities using their established controls and policies, as long as they are consistent with NIH requirements. However, to fulfill their role in regard to the stewardship of Federal funds, NIH awarding offices monitor their grants to identify potential problems and areas where technical assistance might be necessary. This active monitoring is accomplished through review of reports and correspondence from the grantee, audit reports, site visits, and other information available to NIH. The names and telephone numbers of the individuals responsible for monitoring the programmatic and business management aspects of a project or activity will be provided to the grantee at the time of award.
Monitoring of a project or activity will continue for as long as NIH retains a financial interest in the project or activity as a result of property accountability, audit, and other requirements that may continue for a period of time after the grant is administratively closed out and NIH is no longer providing active grant support (see “Administrative Requirements—Closeout”).

Reporting

NIH requires that grantees periodically submit financial and progress reports. Other required reports may include annual invention utilization reports, lobbying disclosures, audit reports, reports to the appropriate payment points (in accordance with instructions received from the payment office), and specialized programmatic reports. Grantees also are expected to publish and provide information to the public on the objectives, methodology, and findings of their NIH-supported research activities, as specified in “Administrative Requirements—Availability of Research Results: Publications, Intellectual Property Rights, and Sharing Research Resources.”

The GMO is the receipt point for most required reports, including non-competing and final grant progress reports, final invention statements and certifications, and lobbying disclosure statements. Non-competing grant progress reports must be submitted in an original and two copies. Submission of these reports to individuals other than the GMO may result in delays in processing of the non-competing continuation award or the submission being considered delinquent. FSRs are to be submitted to OFM (see “Financial Reports” in this subsection) unless otherwise indicated in the award’s terms and conditions.

Grantees are allowed a specified period of time in which to submit required financial and final progress reports (see 45 CFR 74.51 and 74.52, 92.40 and 92.41, and the discussion in this subsection). Failure to submit complete, accurate, and timely reports may indicate the need for closer monitoring by NIH or may result in possible award delays or enforcement actions, including withholding, removal of expanded authorities, or conversion to a reimbursement payment method (also see “Administrative Requirements—Enforcement Actions”). The schedule for submission of the non-competing grant progress report is discussed in the next subsection.

Non-Competing Grant Progress Reports

Progress reports usually are required annually as part of the non-competing continuation award process. However, NIH may require these reports more frequently. The “Grant Progress Report” (PHS 2590) or equivalent documentation must be submitted to, and approved by, NIH to non-competitively fund each additional budget period within a previously approved project period (competitive segment). Except for awards subject to SNAP, the progress report includes an updated budget in addition to other required information.

The information to be included in the progress report is specified in the PHS 2590 instructions, which also include alternate instructions for awards under SNAP (as described in the next subsection). Forms for non-competing grant progress reports are available at http://grants.nih.gov/grants/funding/2590/2590.htm.
Non-competing grant progress reports must be submitted directly to the awarding office. Grantees should routinely query and review the list of pending grant progress reports and due dates available at the NIH website (http://era.nih.gov/commons/quick_queries/index.cfm). Late submission or receipt of an incomplete grant progress report will result in delaying the issuance and funding of the non-competing continuation award and may result in a reduced award amount.

The progress report for the final budget period of a competitive segment for which a competing continuation application is submitted will be part of that application; however, if an award is not made or the grantee does not submit an application for continued support, a final progress report is required (see “Administrative Requirements—Closeout—Final Reports—Final Progress Report”).

The NIH awarding office will specify the requirements for progress reporting under construction grants or grants supporting both construction activities, including acquisition or modernization, and nonconstruction activities.

**Streamlined Non-Competing Award Process**

The NGA will specify whether an award is subject to SNAP. Award mechanisms routinely included in SNAP are “R” awards, with the exception of R35 and K awards. Award mechanisms excluded from SNAP are those that do not have the expanded authority to automatically carry over unobligated balances (centers; cooperative agreements, Kirschstein-NRSA institutional research training grants, non-Fast Track Phase I SBIR and STTR awards), clinical trials (regardless of mechanism), P01, R35, and awards to individuals. In addition, individual awards under any mechanism may be excluded from SNAP if:

- they require close project monitoring or technical assistance, e.g., high-risk grantees, certain large individual or multi-project grants, or grants with significant unobligated balances, or
- the grantee has a consistent pattern of failure to adhere to appropriate reporting or notification deadlines.

Under SNAP, the GMO negotiates the direct costs for the entire competitive segment at the time of the competing award or, in the case of modular awards, determines the applicable number of modules for each budget period within the competitive segment. This eliminates the need for annual budget submissions and any negotiations, and reduces the information NIH requires to review and approve non-competing continuation awards and to monitor these awards. As a result, for awards under SNAP, grantees are required to submit only limited portions of the Grant Progress Report. If there is a change in performance site or anticipated program income, grantees also must submit the PHS 2590 checklist. If program income is anticipated, the progress report should reflect the estimated amount and source of the income.

As part of the progress report, grantees must answer the following questions:

- Has there been a change in the “other support” of key personnel since the last reporting period? If so, the changes, including termination of a previously active grant or activation of a previously pending grant, must be explained. If not, the grantee must so state.
In the next budget period, will there be a significant change in the level of effort for key personnel from what was approved for this project? A “significant change” is a 25 percent or greater reduction in time devoted to the project. If so, the grantee must explain. If not, the grantee must so state.

Does the grantee anticipate that it will have an estimated unobligated balance (including prior-year carryover) that will be greater than 25 percent of the current year’s total budget? If so, the grantee will be required to explain why there is a significant balance and how it will be spent if carried forward into the next budget period. If not, the grantee should so state.

The awarding office will rely on the grantee’s assessment of whether significant changes have occurred or will occur in these areas; however, the GMO may require additional information to evaluate the project for continued funding. Failure to provide this information will result in a delayed award.

For awards under SNAP (other than awards to foreign organizations or Federal institutions), an FSR is required only at the end of a competitive segment rather than annually. The FSR must be submitted within 90 days after the end of the competitive segment and must report on the cumulative support awarded for the entire segment. An FSR must be submitted at this time whether or not a competing continuation award is made. If no further award is made, this report will serve as the final FSR (see “Administrative Requirements—Closeout”). For awards under SNAP, grantees (other than foreign grantees and Federal institutions) also are required to submit a quarterly FCTR (SF 272) to PMS. Foreign organizations and Federal institutions must submit an annual FSR even if an award is under SNAP. (Also see “Administrative Requirements—Monitoring—Reporting—Financial Reports.”)

Financial Reports

Reports of expenditures are required as documentation of the financial status of grants according to the official accounting records of the grantee organization. Financial or expenditure reporting is accomplished using the FSR (SF 269 or SF 269 A); the grantee must use the long form (SF 269) to report program income earned and used.

Except for awards under SNAP and awards that require more frequent reporting, the FSR is required on an annual basis. An annual FSR is required for awards to foreign organizations and Federal institutions, whether or not they are under SNAP. When required on an annual basis, the report must be submitted for each budget period no later than 90 days after the close of the budget period. The report also must cover any authorized extension in time of the budget period. If more frequent reporting is required, the NGA will specify both the frequency and due date.

For domestic awards under SNAP, in lieu of the annual FSR, NIH will use the quarterly FCTR, submitted to PMS to monitor the financial aspects of grants. The GMO may review the report for patterns of cash expenditures, including accelerated or delayed drawdowns, and to assess whether performance or financial management problems exist. For these awards, an FSR is required only at the end of a competitive segment. It must be submitted within 90 days after the end of the competitive segment and must report on the cumulative support awarded for the entire period.
An FSR must be submitted at this time whether or not a competing continuation award is made. If no further award is made, this report will serve as the final FSR (see “Administrative Requirements—Closeout”).

FSRs may be transmitted electronically to OFM through NIH’s eRA Commons website at https://commons.era.nih.gov/commons. Before submitting FSRs to NIH, grantees must ensure that the information submitted is accurate, complete, and consistent with the grantee’s accounting system. The AOO’s signature on the FSR certifies that the information in the FSR is correct and complete and that all outlays and obligations are for the purposes set forth in grant documents, and represents a claim to the Federal government. Filing a false claim may result in the imposition of civil or criminal penalties.

Unobligated Balances and Actual Expenditures

Disposition of unobligated balances is determined in accordance with the terms and conditions of the award. (See “Administrative Requirements—Changes in Project and Budget” for NIH approval authorities for unobligated balances.) Using the principle of “first in-first out,” unobligated funds carried over are expected to be used before newly awarded funds.

Upon receipt of the annual FSR for awards other than those with authority for the automatic carryover of unobligated balances, the GMO will compare the total of any unobligated balance shown and the funds awarded for the current budget period with the NIH share of the approved budget for the current budget period. If the funds available exceed the NIH share of the approved budget for the current budget period, the GMO may select one of the following options:

- In response to a written request from the grantee, revise the current NGA to authorize the grantee to spend the excess funds for additional approved purposes
- Offset the current award or a subsequent award by an amount representing some or all of the excess.

In some cases the grantee may have to revise or amend a previously submitted FSR. When the revision results in a balance due to NIH, the grantee must submit a revised FSR whenever the overcharge is discovered, no matter how long the lapse of time since the original due date of the report. Revised expenditure reports representing additional expenditures by the grantee that were not reported to NIH within the 90-day time frame may be submitted to the GMO with an explanation for the revision. The explanation also should indicate why the revision is necessary and describe what action is being taken by the grantee to preclude similar situations in the future. This should be done as promptly as possible, but no later than 1 year from the due date of the original report, i.e., 15 months following the end of the budget period (or competitive segment for awards under SNAP). If an adjustment is to be made, the NIH awarding office will advise the grantee of actions it will take to reflect the adjustment. NIH will not accept any revised report received after that date and will return it to the grantee.
**Invention Reporting**

A complete list of the reporting requirements under the Bayh-Dole Act can be found at 37 CFR 401.14. The requirements also are specified in “Administrative Requirements—Availability of Research Results: Publications, Intellectual Property Rights, and Sharing Research Resources.”

In addition to complying with Bayh-Dole-related regulations, each NIH competing grant application and non-competing progress report must indicate whether or not any subject inventions were made during the preceding budget period. If inventions were made, the grantee must also indicate whether they were reported.

The grantee also must submit an annual invention utilization report for all subject inventions to which title has been elected and inventions that have been licensed but not patented (research tools). The utilization report provides a way to evaluate the extent of commercialization of subject inventions, consistent with the objectives of the Bayh-Dole Act.

A grantee’s failure to comply with invention reporting requirements may result in the loss of patent rights or a withholding of grant funds.

Bayh-Dole regulations allow grantees to report inventions electronically (37 CFR 401.16). NIH strongly supports electronic reporting through an Internet-based system, Interagency Edison (https://s-edison.info.nih.gov/iEdison/). To meet the objectives of the Federal Financial Assistance Management Improvement Act of 1999 (P.L. 106-107), grantees should make all reasonable efforts to submit invention reports using iEdison. The system supports confidential transmission of required information and provides a utility for generating reports and reminders of pending reporting deadlines. Further information about the system, including instructions for creating an account needed to submit reports electronically, are on the iEdison site. Grantees also may contact NIH at

Extramural Inventions and Technology Resources Branch  
Office of Policy for Extramural Research Administration  
Office of Extramural Research  
NIH  
6705 Rockledge Drive, MSC 7980  
Bethesda, MD 20892-7980  
edison@od.nih.gov  
1-866-504-9552 (toll-free)  
301-480-0272 (fax)

**Record Retention and Access**

Grantees generally must retain financial and programmatic records, supporting documents, statistical records, and all other records that are required by the terms of a grant, or may reasonably be considered pertinent to a grant, for a period of 3 years from the date the annual FSR is submitted. For awards under SNAP (other than those to foreign organizations and Federal institutions), the 3-year retention period will be calculated from the date the FSR for the entire
competitive segment is submitted. Those grantees must retain the records pertinent to the entire competitive segment for 3 years from the date the FSR is submitted to NIH. Foreign organizations and Federal institutions must retain records for 3 years from the date of submission of the annual FSR to NIH. See 45 CFR 74.53 and 92.42 for exceptions and qualifications to the 3-year retention requirement (e.g., if any litigation, claim, financial management review, or audit is started before the expiration of the 3-year period, the records must be retained until all litigation, claims, or audit findings involving the records have been resolved and final action taken). Those sections also specify the retention period for other types of grant-related records, including F&A cost proposals and property records. See 45 CFR 74.48 and 92.36 for record retention and access requirements for contracts under grants.

Audit

An audit is a systematic review or appraisal made to determine whether internal accounting and other control systems provide reasonable assurance of the following:

- Financial operations are properly conducted.
- Financial reports are timely, fair, and accurately.
- The entity has complied with applicable laws, regulations, and other grant terms.
- Resources are managed and used economically and efficiently.
- Desired results and objectives are being achieved effectively.

NIH grantees (other than Federal institutions) are subject to the audit requirements of OMB Circular A-133, as implemented by 45 CFR 74.26 and 92.26, or the audit requirements stated in 45 CFR 74.26(d) and in the NIHGPS (for types of organizations to which OMB Circular A-133 does not directly apply). In general, OMB Circular A-133 requires a State government, local government, or non-profit organization (including institutions of higher education) that expends $500,000 or more per year under Federal grants, cooperative agreements, and/or procurement contracts to have an annual audit by a public accountant or a Federal, State, or local governmental audit organization. The audit must meet the standards specified in generally accepted government auditing standards (GAGAS). The audit requirements for foreign grantees and for-profit grantees are addressed in the sections of this NIHGPS that provide specific requirements for those types of grantees.

When a grantee procures audit services, the procurement must comply with the procurement standards of 45 CFR Part 74 or 92, as applicable, including obtaining competition and making positive efforts to use small businesses, minority-owned firms, and women’s business enterprises. Grantees should ensure that comprehensive solicitations made available to interested firms include all audit requirements and specify the criteria to be used for selection of the firm. Grantees’ written agreements with auditors must specify the rights and responsibilities of each party.
OMB Circular A-133 explains in detail the scope, frequency, and other aspects of the audit. Some highlights of this Circular are as follows:

- Covered organizations expending $500,000 or more per year in Federal awards are required to have an audit made in accordance with the Circular. However, if the awards are under one program, the organization can have either a single organization-wide audit or a program-specific audit of the single program, subject to the provisions of section 235 of the Circular. NIH’s research awards may not be considered a single program for this purpose. Covered organizations expending less than $500,000 in any year are exempt from these audit requirements in that year but must have their records available for review as required by “Administrative Requirements—Monitoring—Record Retention and Access.”

- The reporting package must contain the following:
  - Financial statements and schedule of expenditures of Federal awards
  - Independent auditor’s report, including an opinion on the financial statements and the schedule of expenditures of Federal awards, a report on compliance and internal control over financial reporting, and a report on compliance with requirements applicable to each major program and on internal control over such compliance requirements
  - A schedule of findings and questioned costs
  - If applicable, a summary of prior audit findings and a corrective action plan.

- An audit under OMB Circular A-133 is in lieu of a financial audit of individual Federal awards. However, Federal agencies may request additional audits necessary to carry out their responsibilities under Federal law or regulation. Any additional audits will build upon work performed by the independent auditor.

- The data collection form and copies of the reporting package must be submitted to the FAC at the following address:

  Federal Audit Clearinghouse
  Bureau of the Census
  1201 E. 10th Street
  Jeffersonville, IN 47132
  (http://harvester.census.gov/sac/)

If the schedule of findings and questioned costs discloses an audit finding related to an HHS or NIH award or if the schedule of prior audit findings reports the status of any audit finding relating to an HHS or NIH award, the FAC will provide copies of the audit report to NEARC, OIG, HHS. NEARC will, in turn, distribute them within HHS for further action, as necessary. Audit reports should not be sent directly to the GMO.
Recipients must follow a systematic method for ensuring timely and appropriate resolution of audit findings and recommendations, whether discovered as a result of a Federal audit or a recipient-initiated audit. Grantees usually are allowed 30 days from the date of request to respond to the responsible audit resolution official (Action Official) concerning audit findings. Failure to submit timely responses may result in cost disallowance or other actions by NIH or HHS. At the completion of the audit resolution process, the grantee will be notified of the Action Official’s final decision. The grantee may appeal this decision if the adverse determination is of a type covered by the NIH or HHS grant appeals procedures (see “Administrative Requirements—Grant Appeals Procedures”). Refunds owed to the Federal government as a result of audit disallowances must be made in accordance with instructions issued by the Action Official or OFM.

It is imperative that grantees submit required OMB Circular A-133 audits within the time limits specified in the Circular. If grantees are delinquent in complying with the provisions of the Circular, HHS or NIH will impose sanctions that may result in the loss of Federal funds. No audit costs will be allowed either as F&A costs or direct costs to Federal awards if the required audits have not been completed or have not been conducted in accordance with the provisions of OMB Circular A-133.

See “Cost Considerations—Selected Items of Cost” for the allowability of audit costs.

**Enforcement Actions**

A grantee’s failure to comply with the terms and conditions of award, including confirmed instances of research misconduct, may cause NIH to take one or more enforcement actions, depending on the severity and duration of the non-compliance. NIH will undertake any such action in accordance with applicable statutes, regulations, and policies. NIH generally will afford the grantee an opportunity to correct the deficiencies before taking enforcement action unless public health or welfare concerns require immediate action. However, even if a grantee is taking corrective action, NIH may take proactive action to protect the Federal government’s interests, including placing special conditions on awards or precluding the grantee from obtaining future awards for a specified period, or may take action designed to prevent future non-compliance, such as closer monitoring. If NIH imposes sanctions on a grantee as a result of research misconduct or will more closely monitor an award(s) through the use of special conditions, NIH will share this information with other HHS components.

**Modification of the Terms of Award**

During grant performance, the GMO may include special conditions in the award to require correction of identified financial or administrative deficiencies. When the special conditions are imposed, the GMO will notify the grantee of the nature of the conditions, the reason why they are being imposed, the type of corrective action needed, the time allowed for completing corrective actions, and the method for requesting reconsideration of the conditions. See 42 CFR 52.9 and 45 CFR 74.14 or 92.12.

The awarding office also may withdraw approval of the PI or other key personnel if there is a reasonable basis to conclude that the PI and other key personnel are no longer qualified or
competent to perform. In that case, the awarding office may request that the grantee designate a new PI or other key personnel.

The decision to modify the terms of an award—by imposing special conditions, by withdrawing approval of the PI or other key personnel, or otherwise—is discretionary on the part of the NIH awarding office.

**Suspension, Termination, and Withholding of Support**

If a grantee has failed to materially comply with the terms and conditions of award, NIH may suspend the grant, pending corrective action, or may terminate the grant for cause. The regulatory procedures that pertain to suspension and termination are specified in 45 CFR 74.61 and 74.62, and in 92.43.

NIH generally will suspend (rather than immediately terminate) a grant and allow the grantee an opportunity to take appropriate corrective action before NIH makes a termination decision. NIH may decide to terminate the grant if the grantee does not take appropriate corrective action during the period of suspension. NIH may terminate—without first suspending—the grant if the deficiency is so serious as to warrant immediate termination or public health or welfare concerns require immediate action. Termination for cause may be appealed under the NIH and HHS grant appeals procedures (see “Administrative Requirements—Grant Appeals Procedures”). Pending the outcome of an appeal or other action by the grantee, NIH may award a replacement grant for a limited period of time (up to 18 months) without competition.

A grant also may be terminated, partially or totally, by the grantee or by NIH with the consent of the grantee. If the grantee decides to terminate a portion of a grant, NIH may determine that the remaining portion of the grant will not accomplish the purposes for which the grant was originally awarded. In any such case, NIH will advise the grantee of the possibility of termination of the entire grant and allow the grantee to withdraw its termination request. If the grantee does not withdraw its request for partial termination, NIH may initiate procedures to terminate the entire grant for cause.

See “Cost Considerations—Selected Items of Cost” for the allowability of termination costs. Allowability of these costs does not vary whether a grant is terminated for cause by NIH, terminated at the request of the grantee, or terminated by mutual agreement.

Withholding of support is a decision not to make a non-competing continuation award within the current competitive segment. Support may be withheld for one or more of the following reasons:

- Adequate Federal funds are not available to support the project.
- A grantee failed to show satisfactory progress in achieving the objectives of the project.
- A grantee failed to meet the terms and conditions of a previous award.
- For whatever reason, continued funding would not be in the best interests of the Federal government.
If a non-competing continuation award is denied (withheld) because the grantee failed to comply with the terms and conditions of a previous award, the grantee may appeal that determination.

Other Enforcement Actions

Depending on the nature of the deficiency, NIH may use other means of obtaining grantee compliance. Other options available to NIH include, but are not limited to, temporary withholding of payment or other actions specified at 45 CFR 74.62 or 92.43, conversion from an advance payment method to a reimbursement method, suspension or debarment under 45 CFR Part 76, and other available legal remedies, such as civil action. Suspension under 45 CFR Part 76 is a distinct action from “suspension” as a post-award remedy described under “Suspension, Termination, and Withholding of Support” in this subsection. The subject of debarment and suspension as an eligibility criterion is addressed in “Completing the Pre-Award Process—Eligibility” and “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—Debarment and Suspension.”

Recovery of Funds

NIH may administratively recover funds paid to a grantee in excess of the amount to which the grantee is finally determined to be entitled under the terms and conditions of the award, including misspent funds or unallowable costs incurred. If the grantee does not pay back the funds in accordance with the demand by the awarding office, which specifies the period of time for repayment, the awarding office may collect the debt by

- making an administrative offset against payments that would be due under other grant awards,
- withholding advance payments that would otherwise be due, or
- taking any other action permitted by statute.

Debt Collection

The Federal Debt Collection Act (Act) (31 U.S.C. 3711) and the Federal Claims Collection Standards (4 CFR Parts 101-105) require NIH to collect debts due to the Federal government and, except where prohibited by law, to charge interest on all delinquent debts owed to NIH by grantees (also see HHS claims collection regulations at 45 CFR Part 30). Debts may result from cost disallowances, recovery of funds, unobligated balances, or other circumstances.

Unless otherwise specified in law, regulation, or the terms and conditions of the award, debts are considered delinquent 30 days after notification to the grantee of the indebtedness. The interest on delinquent debts will be computed from the original notification date to the grantee of the indebtedness. The interest rate applied will be the current value of funds rate or the private consumer rate of interest fixed by Treasury, whichever is higher. A higher rate may be charged if necessary to protect the interests of the Federal government.
Penalties and administrative collection costs also will be charged in accordance with the Act and the implementing HHS regulations, as follows:

◆ A penalty charge of 6 percent a year will be assessed on debts that are more than 90 days overdue. Penalty charges will accrue from the date the debt became overdue until the indebtedness is paid.

◆ Delinquent debtors will be assessed charges to cover the Federal government’s administrative costs of collecting overdue debts. From time to time, HHS will publish a notice in the Federal Register setting forth the amounts to be assessed for administrative collection costs.

If a grantee appeals an adverse monetary determination under 42 CFR Part 50, Subpart D, or 45 CFR Part 16, collection will be suspended pending a final decision on the appeal. If the determination is sustained (either fully or partially), interest will be charged beginning with the date of the original notification to the grantee of the indebtedness.

Closeout

NIH will close out a grant as soon as possible after expiration if the grant will not be extended or after termination as provided in 45 CFR 74.71 through 74.73 and in 45 CFR 92.50. Closeout includes ensuring timely submission of all required reports and adjustments for amounts due the grantee or NIH. Closeout of a grant does not automatically cancel any requirements for property accountability, record retention, or financial accountability. Following closeout, the grantee remains obligated to return funds due as a result of later refunds, corrections, or other transactions, and the Federal government may recover amounts based on the results of an audit covering any part of the period of grant support.

Final Reports

Unless the GMO grants an extension, grantees must submit a final FSR, final progress report, and Final Invention Statement and Certification within 90 days of the end of grant support. Failure to submit timely and accurate final reports may affect future funding to the organization or awards with the same PI.

Final Financial Status Report

A final FSR is required for

◆ any grant that is terminated,

◆ any grant that is transferred to a new grantee, or

◆ any award, including awards under SNAP, which will not be extended through award of a new competitive segment.

The final FSR must cover the period of time since the previous FSR submission or, for awards under SNAP, the entire competitive segment or as much of the competitive segment as has been
funded before termination. Final FSRs must have no unliquidated obligations and must indicate
the exact balance of unobligated funds. Unobligated funds must be returned to NIH or must be
reflected by an appropriate accounting adjustment in accordance with instructions from the GMO
or from the payment office. For those organizations receiving their funds through PMS, final
reports, as specified by PMS, must be submitted to that office. It is the grantee’s responsibility to
reconcile reports submitted to PMS and to the NIH awarding office. Withdrawal of the
unobligated balance following expiration or termination of a grant is not considered an adverse
action and is not subject to appeal (see “Administrative Requirements—Enforcement Actions—
Recovery of Funds”).

When the submission of a revised final FSR results in additional claims by the grantee, NIH will
consider the approval of such claims subject to the following minimum criteria:

◆ The grantee must indicate why the revision is necessary and explain and implement
internal controls that will preclude similar occurrences in the future.

◆ The charge must represent otherwise allowable costs under the provisions of the grant.

◆ There must be an unobligated balance for the budget period sufficient to cover the claim.

◆ The funds must still be available for use.

◆ NIH must receive the revised FSR within 15 months of its original due date.

**Final Progress Report**

A final progress report is required for any grant that is terminated and any award that will not be
extended through award of a new competitive segment. The final progress report should include
a summary of progress toward the achievement of the originally stated aims, a list of significant
results (positive or negative), and a list of publications. The final progress report also should
address the following:

◆ Report on the inclusion of gender and minority study subjects (using the gender and
minority inclusion table as provided in the PHS 2590)

◆ Where appropriate, indicate whether children were involved in the study or how the study
was relevant for conditions affecting children (see “Public Policy Requirements and
Objectives—Requirements for Inclusiveness in Research Design—Inclusion of Children
as Subjects in Clinical Research” and the PHS 398)

◆ Describe any data, research materials (such as cell lines, DNA probes, animal models),
protocols, software, or other information resulting from the research that is available to
be shared with other investigators and how it may be accessed.

An original and one copy of this report should be submitted to the GMO.
**Final Invention Statement and Certification**

The grantee must submit a Final Invention Statement and Certification (HHS 568), whether or not the funded project results in any subject inventions. The HHS 568 must list all inventions that were conceived or first actually reduced to practice during the course of work under the project, and it must be signed by the PI and an AOO. The completed form should cover the period from the original effective date of support through the date of expiration or termination or the award, and it should be submitted to the NIH awarding office. If there were no inventions, the form should indicate “None.” Copies of the HHS 568 form are available on the iEdison website at [https://s-edison.info.nih.gov/iEdison/](https://s-edison.info.nih.gov/iEdison/).

**Grant Appeals Procedures**

HHS permits grantees to appeal to the DAB certain post-award adverse administrative decisions made by HHS officials (see 45 CFR Part 16). NIH has established a first-level grant appeal procedure that must be exhausted before an appeal may be filed with the DAB (see 42 CFR Part 50, Subpart D). NIH will assume jurisdiction for the following adverse determinations:

- **Termination,** in whole or in part, of a grant for failure of the grantee to carry out its approved project in accordance with the applicable law and the terms and conditions of award or for failure of the grantee otherwise to comply with any law, regulation, assurance, term, or condition applicable to the grant

- **Determination** that an expenditure not allowable under the grant has been charged to the grant or that the grantee has otherwise failed to discharge its obligation to account for grant funds

- **Denial (withholding)** of a non-competing continuation award for failure to comply with the terms of a previous award

- **Determination** that a grant is void (i.e., a decision that an award is invalid because it was not authorized by statute or regulation or because it was fraudulently obtained).

The formal notification of an adverse determination will contain a statement of the grantee’s appeal rights. As the first level in appealing an adverse determination, the grantee must submit a request for review to the NIH official specified in the notification, detailing the nature of the disagreement with the adverse determination and providing supporting documents in accordance with the procedures contained in the notification. The grantee’s request to NIH for review must be postmarked no later than 30 days after receipt of the written notification of the adverse determination; however, an extension may be granted if the grantee can show good cause why an extension is warranted (42 CFR 50.406).

If the NIH decision on the appeal is adverse to the grantee or if a grantee’s request for review is rejected on jurisdictional grounds, the grantee then has the option of submitting a request to the DAB for a further review of the case in accordance with the provisions of 45 CFR Part 16.

A grantee may not submit an appeal directly to the DAB because the DAB will review only those appeals that have been reviewed and acted on by NIH.
In addition to the adverse determinations indicated, the DAB is the single level of appeal for disputes related to the establishment of F&A cost rates, research patient care rates, and certain other cost allocations used in determining amounts to be reimbursed under NIH grants (e.g., cost allocation plans negotiated with State or local governments and computer, fringe benefit, and other special rates).\textsuperscript{14}

\textsuperscript{14} The determination leading to such disputes may be made by an HHS official other than the GMO and may affect NIH grants as well as other HHS grants.
Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities

This subpart includes terms and conditions that vary from, are in addition to, elaborate on, or highlight the standard requirements and terms and conditions in Subpart A of this part because of the type of grant, grantee, or grant-supported activity. Each section of this subpart specifies how the coverage relates to that in Subpart A and must be used in conjunction with Subpart A to determine all of the applicable terms and conditions of a covered type of activity, grantee, or award. Cross-references in this subpart to other sections within this subpart are specifically noted; otherwise the cross-reference is to the cited section in Subpart A.

This subpart contains the following sections:

- Construction grants, including major A&R activities under grants with specific statutory authority for construction or modernization activities (this section also includes requirements for specified A&R activities under nonconstruction grants)

- Individual fellowships and institutional research training grants (also termed “fellowships” and “training grants”) under the Kirschstein-NRSA program

- Modular applications and awards

- Conference grants

- Consortium agreements

- Grants to foreign institutions, international organizations, and domestic grants with a foreign component

- Grants to Federal institutions and payments to (or on behalf of) Federal employees under grants

- Grants to for-profit organizations

- Research patient care costs.
CONSTRUCTION GRANTS

General

The following requirements apply to NIH construction grants and major A&R activities under grants with statutory construction or modernization authority (hereafter, “construction grants”) and, as specified, to A&R projects under nonconstruction grants. Construction grants are awarded under the C06 activity code or support mechanism.

Except as indicated in this section, these requirements apply to construction grants in lieu of the requirements in Subpart A of this part. Applicants and grantees also should refer to the construction grant program regulations (42 CFR Part 52b), 45 CFR Part 74 or 92, and any applicable IC guidance. Any questions concerning the applicability of particular requirements or policies should be directed to the GMO or other official designated on the NGA.

This section uses the following definitions:

◆ **Construction.** Construction of new buildings or the modernization of, or completion of shell space in, existing buildings (including the installation of fixed equipment, but excluding the cost of land and off-site improvements).

◆ **Modernization.** Alteration, renovation, remodeling, improvement, expansion, and repair of existing buildings and the provision of equipment necessary to make a building suitable for use by a particular program.

Eligibility

In addition to any program-specific eligibility criteria, eligible applicants for construction grants must be public or private non-profit entities and must be located in the United States or in U.S. territories or possessions. For-profit organizations and foreign organizations are not eligible to receive construction grants.

Review and Approval

Construction grant applications are subject to peer review. Review criteria and NIH selection factors are as follows:

◆ Scientific merit of the research program activities that will be carried out in the proposed facility

◆ NIH programmatic relevance

◆ Research and financial need for the project

◆ Scientific or professional standing or reputation of the applicant and of its existing or proposed officers and research staff
Relationship to the applicant’s overall research programs and impact on relevant research programs and facilities in the geographic area and nationwide

Availability, by affiliation or other association, of other scientific or health personnel and facilities for carrying out the proposed research program, including, when warranted, the adequacy of a biohazard control and containment program

Project cost and design.

Public Policy Requirements and Objectives

In addition to the public policy requirements and objectives specified in Subpart A, construction grants are subject to the following public policy requirements. Questions about whether a particular requirement applies to A&R activities under nonconstruction grants should be directed to the GMO. Grantees receiving construction grants also must require contractors and subcontractors providing construction services to comply with certain Federal labor standards. These labor standards are discussed in “Equal Employment Opportunity, Labor Standards, and Other Contract Requirements” in this section.

The National Environmental Policy Act of 1969

NEPA, as amended (Public Law 91-190), establishes national policy goals and procedures to protect and enhance the environment, including protection against natural disasters. NEPA requires all Federal agencies to consider the probable environmental consequences of any major Federal activity, including grant-supported activities. To comply with NEPA for its grant-supported activities, NIH requires the environmental aspects of construction grants (and certain nonconstruction projects as specified by NIH) to be reviewed and evaluated by NIH technical staff before final action on the application. With respect to earthquakes, structures will be evaluated in accordance with the lateral forces provisions of the Uniform Building Code.

If NEPA applies, the application must be accompanied by the applicant’s own separately bound environmental analysis to facilitate review and evaluation for environmental concerns before approval or other action on the application. An environmental analysis means a written review that indicates the expected environmental effects resulting from the proposed action, defines the current and future implications of those effects, and lists any proposed actions or safeguards to avoid or reduce any negative environmental effects. If NIH has not indicated in the RFA that NEPA applies, no environmental analysis is necessary, unless, in an unusual situation, the applicant anticipates a significant environmental consequence or, following receipt of an application, an official of the NIH awarding office indicates the need for an environmental analysis. In those cases, an environmental analysis shall be provided with the application or as requested by NIH.

Public Disclosure

Section 102 of NEPA and EO 11514 (March 5, 1970) provide for public comment and participation in the environmental impact review process. Applicants are required to publicly disclose the project in a newspaper or other publicly available medium and to describe its environmental impact concurrent with notification to the SPOC (see “Intergovernmental Review
Notice is hereby given that the Uptown Medical School proposes to construct additional space, partially utilizing Federal funds. The proposed construction project is the addition of 2,700 square feet connected to the existing Allen Building, which is located at 5333 Main Street, Downtown, Ohio.

The Medical School has evaluated the environmental and community impact of the proposed construction. There will be construction noise and increased construction traffic during the construction period. No significant permanent environmental impacts are foreseen. All building permits and zoning approvals have been obtained. In accordance with Executive Order 11514 (March 5, 1970), which implements the National Environmental Policy Act of 1969, as amended, any individual or group may comment on, or request information concerning, the environmental implications of the proposed project. Communications should be addressed to the Office of Planning, Uptown Medical School, and must be received by (date). The Federal grant application may be reviewed at the Office of the Dean, School of Medicine, 5333 Main Street, during normal working hours.

Flood Insurance

The Flood Disaster Protection Act of 1973, as amended (Public Law 93-234), provides that no Federal financial assistance to acquire, modernize, or construct property may be provided in identified flood-prone communities in the United States, unless the community participates in the National Flood Insurance Program and flood insurance is purchased within 1 year of the identification. The flood insurance purchase requirement applies to both public and private applicants for NIH support. Lists of flood-prone areas that are eligible for flood insurance are published in the Federal Register by FEMA.

Historic Properties and Archeological Sites

Under the provisions of the National Historic Preservation Act, as amended, and the Archeological and Historical Preservation Act of 1960, as amended, the Secretary of the Interior has compiled a National Register of Historic Places—sites and buildings of significant importance to U.S. history. The statutes require that, before approval of a construction grant application (or other applications as specified by NIH), NIH take into account the effect on these sites of the proposed construction (or other) project. The applicant must determine whether activities using NIH financial assistance will affect a property listed in the National Register. If a designated historic property will be affected, the applicant must obtain clearance from the appropriate State Historic Preservation Office before submitting the application. Failure to obtain

15 This list may be obtained from the State Liaison Officers designated by their respective states to administer this program or from the Advisory Council on Historic Preservation, 1100 Pennsylvania Avenue NW, Washington, DC 20004 (telephone: 202-606-8503; website: http://www.achp.gov/). The National Trust for Historic Preservation is located at 1785 Massachusetts Avenue NW, Washington, DC 20036 (telephone: 202-588-6000; website: http://www.nationaltrust.org/).
Intergovernmental Review under Executive Order 12372

EO 12372, Intergovernmental Review of Federal Programs (July 14, 1982), as amended, requires consultation with State and local officials on certain proposed Federal assistance. NIH construction grants are subject to these requirements, as implemented by 45 CFR Part 100, Intergovernmental Review of Department of Health and Human Services Programs and Activities. Applicants (other than federally recognized Indian tribal governments) should contact their SPOC as early as possible to alert the SPOC to the forthcoming application and to obtain necessary instructions on the State process (see http://www.whitehouse.gov/omb/grants/s poc.html for a list of SPOCs). The SPOC is given 60 days to review the application. To accommodate this time frame and the NIH review process, an applicant must provide a copy of the application to the SPOC no later than the time the application is submitted to NIH. SPOC comments must be submitted to NIH with the application, or the application must indicate the date on which the application was provided to the SPOC for review. If SPOC comments are not submitted with the application, the applicant must provide them upon receipt and may include its reaction to the comments, or it must notify NIH that it did not receive any SPOC response.

Metric System

Consistent with EO 12770 (July 25, 1991), Metric Usage in Federal Government Programs, all construction projects supported by NIH grant funds shall be designed using the metric system.

Relocation Assistance and Real Property Acquisition

The Uniform Relocation Assistance and Real Property Acquisition Policies Act of 1970 (the Uniform Relocation Act), 42 U.S.C. 4601 et seq., applies to all programs or projects undertaken by Federal agencies or with Federal financial assistance that cause the displacement of any person.

The HHS requirements for complying with the Uniform Relocation Act are set forth in 49 CFR Part 24. Those regulations provide uniform policies and procedures for the acquisition of real property, including acquisition by grantees, and require that displaced people be treated fairly and equitably. They encourage acquiring entities to negotiate promptly and amicably with property owners so property owners’ interests are protected and litigation can be avoided.

Other Public Policy Requirements

Recipients of NIH construction grants must comply with, or require their contractors to comply with, the requirements set forth in the following:

- Clean Air Act, 42 U.S.C. 7401 et seq., and Federal Water Pollution Control Act (Clean Water Act), as amended, 33 U.S.C. 1251 et seq., for contracts exceeding $100,000
• Uneconomical, hazardous, or unnecessary use of flood plains for construction—
  EO 11988 (May 24, 1977)

• Provisions for potable water supply—Safe Drinking Water Act (Title XIV of the Public
  Health Service Act, as amended)

• Conservation of petroleum and natural gas—EO 12185 (December 17, 1979)

**Design Requirements for NIH-Assisted Construction**

Grantees may not advertise for bids or negotiate a contract for construction or A&R activities
exceeding $500,000 in direct costs until working drawings and specifications have been
approved by the designated NIH official. One purpose of the NIH review is to apply program-
specific design standards to the working drawings and specifications to ensure that program
needs are met and the facility will suitably accommodate the activities to be carried out there. In
addition, NIH will determine whether the final plans and specifications conform to the minimum
standards of construction and equipment specified in 42 CFR Part 52b, in the *NIH Design Policy
and Guidelines* issued by NIH’s DES, and in the documents cited in this subsection. (The NIH
Design Policy and Guidelines are available at [http://des.od.nih.gov/eWeb/planning/html/nihpol.htm](http://des.od.nih.gov/eWeb/planning/html/nihpol.htm).) These standards may be modified by
DES. The grantee will be subject to the standards in effect at the time of design or construction,
as appropriate. NIH will monitor compliance during the project’s design phase.

Where State or local codes are proposed as a basis for facility design in lieu of the NIH design
requirements, a prior determination must be made by NIH that the specific State or local code is
equivalent to, or exceeds, NIH requirements. If State and local codes or requirements exceed the
design requirements set forth in NIH regulations or incorporated in policy guidance, the more
stringent requirements will apply.

**Elimination of Architectural Barriers to the Physically Handicapped**

The Architectural Barriers Act of 1968, as amended, the Federal Property Management
Regulations 101-19.6 (41 CFR 101-19.6), and the Uniform Federal Accessibility Standards
issued by the General Services Administration (41 CFR 101-19.6, Appendix A) set forth
requirements to make facilities accessible to, and usable by, the physically handicapped and
include minimum design standards. All new facilities constructed with NIH grant support must
comply with these requirements. These minimum standards must be included in the
specifications for any NIH-funded new construction unless the grantee proposes to substitute
standards that meet or exceed these standards. Where NIH assistance is provided for alteration or
renovation (including modernization and expansion) of existing facilities, the altered facility (or
part of the facility) must comply, including use of the minimum standards in the specifications.
The grantee will be responsible for conducting inspections to ensure compliance with these
standards by any contractor performing construction services under the grant. Also see “Public

---

16 References are to the latest editions of cited publications. Grantees and their contractors are responsible for
determining what applies at the time of the affected activity.
Seismic Safety for Federally Assisted Construction

The Earthquake Hazards Reduction Act of 1977, as amended (Public Law 95-124), and EO 12699, Seismic Safety of Federal and Federally Assisted or Regulated New Building Construction (January 5, 1990) apply to NIH-assisted construction. The EO requires that new federally assisted or regulated buildings be designed and constructed using appropriate seismic standards. Where necessary, special structural and other features to protect life and minimize damage to facilities from tornadoes also may be required.

The model codes listed in Exhibit 7 provide a level of seismic safety considered appropriate for implementing EO 12699 and apply to all federally assisted construction in the applicable geographic location. Also acceptable are State, county, or local jurisdictional building ordinances that adopt and enforce these model codes in their entirety or without material revisions that would reduce the level of seismic safety.

Additional Design Requirements

Exhibit 7 lists additional NIH design requirements and their sources.

<table>
<thead>
<tr>
<th>Exhibit 7. Design Requirements for NIH-Assisted Construction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Requirement</strong></td>
</tr>
</tbody>
</table>
| Uniform Building Code | International Conference of Building Officials  
5360 Workman Mill Road  
Whittier, CA 90601-2298  
Telephone: 562-699-0541 or 800-284-4406  
Website: [http://www.iccsafe.org/e/category.html](http://www.iccsafe.org/e/category.html)  
(Online Product Store) |
4051 West Fossmoor Road  
Country Club Hills, IL 60478  
Telephone: 800-214-4321, ext. 371  
Website: [http://www.bocai.org/boca-es/](http://www.bocai.org/boca-es/) |
900 Montclair Road  
Birmingham, AL 35213-1206  
Telephone: 205-591-1853  
Website: [http://www.sbcci.org](http://www.sbcci.org)  
(Order and Price List) |
| Recommended Lateral Force Requirements/Commentary (1999), Structural Engineers Association of California | International Conference of Building Officials  
5360 Workman Mill Road  
Whittier, CA 90601-2298  
Telephone: 562-699-0541 or 800-284-4406  
Website: [http://www.iccsafe.org/e/category.html](http://www.iccsafe.org/e/category.html)  
(Product Store) |
<table>
<thead>
<tr>
<th>Requirement</th>
<th>Notes (if appropriate) and source</th>
</tr>
</thead>
</table>
Telephone: 202-626-7541 or 800-242-3837 (press 4)  
Website: [http://www.aia.org/publications/](http://www.aia.org/publications/) |
| **American Society of Heating, Refrigeration, and Air Conditioning Engineers Handbook—HVAC Applications (1999)** | ASHRAE  
Website: [http://www.ashrae.org](http://www.ashrae.org) |
| **Life Safety Code (NFPA Publication 101 and supplements)**                | NFPA  
1 Batterymarch Park  
Quincy, MA 02269-9101  
Telephone: 617-770-3000 or 800-344-3555  
Website: [http://www.nfpa.org/Codes/index.asp](http://www.nfpa.org/Codes/index.asp) |
| **Standard on Fire Protection for Laboratories Using Chemicals (NFPA Publication 45)** | NFPA  
1 Batterymarch Park  
Quincy, MA 02269-9101  
Telephone: 617-770-3000 or 800-344-3555  
Website: [http://www.nfpa.org/Codes/index.asp](http://www.nfpa.org/Codes/index.asp) |
ISBN 0-309-05229-7  
Website: [http://books.nap.edu/catalog/4911.html](http://books.nap.edu/catalog/4911.html) |
| **National Sanitation Foundation Standard 49 for Class II (Laminar Flow) Biohazard Cabinetry (2002)** | National Sanitation Foundation  
327 Jones Drive  
Ann Arbor, MI 48105  
Telephone: 800-699-9277  
Website: [http://www.techstreet.com/nsfgate.html](http://www.techstreet.com/nsfgate.html) |
900 Montclair Road  
Birmingham, AL 35213-1206  
Telephone: 205-591-1853  
Website: [http://www.sbcci.org](http://www.sbcci.org) (Order and Product List) |
| **Industrial Ventilation: A Manual of Recommended Practice (2001)**       | American Conference of Government Industrial Hygienists  
1330 Kemper Meadow Drive  
Cincinnati, OH 45240-1634  
Telephone: 513-742-2020  
Website: [http://www.acgih.org/Products/](http://www.acgih.org/Products/) |
| **Health Care Facilities Handbook (2002)**                               | NFPA  
1 Batterymarch Park  
Quincy, MA 02269-9101  
Telephone: 617-770-3000 or 800-344-3555  
Website: [http://www.nfpa.org/Codes/index.asp](http://www.nfpa.org/Codes/index.asp) |
| **Standard for Healthcare Facilities (NFPA Publication 99).**             | NFPA  
1 Batterymarch Park  
Quincy, MA 02269-9101  
Telephone: 617-770-3000 or 800-344-3555  
Website: [http://www.nfpa.org/Codes/index.asp](http://www.nfpa.org/Codes/index.asp) |
Exhibit 7. Design Requirements for NIH-Assisted Construction

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Notes (if appropriate) and source</th>
</tr>
</thead>
</table>
| National Electric Code (NFPA Publication 70) | NFPA  
1 Batterymarch Park  
Quincy, MA 02269-9101  
Telephone: 617-770-3000 or 800-344-3555  
Website: [http://www.nfpa.org/Codes/index.asp](http://www.nfpa.org/Codes/index.asp) |
| Laboratory Ventilation Codes            | American Industrial Hygiene Association  
2700 Prosperity Avenue, Suite 250  
Fairfax, VA 22031  
Telephone: 703-849-8888  
Fax: 703-207-3561  

**Funding**

Construction grants usually involve a single award, covering more than 1 year, made on the basis of an application for the entire construction project. The project period system of funding normally is not used for construction grants.

**Matching**

NIH construction grants generally require the grantee to share in the costs of the project. This requirement, if applicable, is stated as a matching percentage; the grantee’s match is usually at least 50 percent of the total allowable project costs. Any required non-Federal participation may be in the form of allowable costs incurred by the grantee or a contractor under the grant. Unless required by statute or regulation, NIH generally does not allow grantees to use the value of third-party in-kind contributions as a source of matching. Matching costs and in-kind contributions (if authorized) must meet the allowability and documentation requirements of 45 CFR 74.23 or 92.24, as applicable. Costs claimed as matching also are subject to the requirements of the NIHGPS which apply to the expenditure of NIH funds.

The source and amount of funds proposed by an applicant to meet a matching requirement must be identified in the application. The applicant will be required to demonstrate that the funds are committed or available before award. This may take the form of an assurance as specified by the NIH awarding office. The amount of NIH (Federal) funds awarded, combined with the non-Federal share, will constitute the total approved budget as shown in the NGA. The prior-approval and other dollar thresholds contained in this section are determined on the basis of the total approved budget unless otherwise specified.

**Allowable and Unallowable Costs and Activities**

Construction activity is allowable only when program legislation includes specific authority for construction, modernization, or major alteration and renovation of facilities and when NIH specifically authorizes such costs. The following lists indicate types of costs and activities
generally allowable and unallowable under NIH construction grants. The lists are not all-inclusive. Program guidelines and other terms and conditions of the award should be consulted for the specific costs allowable under a particular program or grant.

Allowable costs and activities include the following:

- **Acquisition and installation of fixed equipment.**

- **A&R.** Under programs that have statutory A&R, modernization, or construction grant authority, the costs of adapting any of the following interior building features to the needs of the grant-supported activity are allowable:
  - Physical characteristics of space, such as interior dimensions, surfaces, and finishes
  - Internal environment, such as heating, ventilation, humidity, and acoustics
  - Utility services, such as plumbing, electricity, gas, vacuum, or other laboratory piping
  - Completion of unfinished shell space to make it suitable for purposes other than human occupancy, such as the storage of pharmaceuticals
  - Fixed equipment, such as casework, fume hoods, large autoclaves, or biological safety cabinets.

  A&R costs of this type associated with a building under construction or an otherwise incomplete structure may be allowed if
  - the space is to be adapted to particular program needs,
  - it is cost-effective to perform the work while the building is being constructed or the structure is being completed, and
  - A&R costs are limited to the difference between the cost of completing the interior space for general use and the cost of adapting the space and utilities to meet specific program requirements.

  When the grantee’s own construction and maintenance staffs are used in carrying out the A&R (i.e., force account), the associated costs are allowable provided the grantee can document that force account is less expensive than if the project were competitively bid and can substantiate all costs with appropriate receipts for the purchase of materials and certified pay records for the labor involved. This requires prior approval by the NIH awarding office.

- **Architectural and engineering services.** Also see “Pre-Award Costs” in this subsection.

- **Bid advertising.**
Bid guarantees and performance and payment bonds. Bid guarantees and performance and payment bonds are allowable as provided in 45 CFR 74.48 or 92.36(h).

Contingency fund. Applicants for construction grants may include a project contingency fund in initial cost estimates to provide for unanticipated charges. These funds will be limited to 5 percent of construction and equipment costs before bids are received and must be reduced to 2 percent after a construction contract has been awarded.

Filing fees for recording the NFI. See “Real Property Management Standards—Notice of Federal Interest” in this section.

Inspection fees.

Insurance. Costs of title insurance, physical destruction insurance, and liability insurance are generally allowable. Physical destruction and liability insurance are usually treated as F&A costs but may be treated as direct costs in accordance with the established policy of the grantee, consistently applied regardless of the source of funds. Title insurance, if required, may be charged to the grant in proportion to the amount of NIH participation in the property (see “Real Property Management Standards—Insurance Requirements” in this section).

Legal fees. Legal fees related to obtaining a legal opinion regarding title to a site.

Pre-award costs. Costs incurred before an award for architect’s fees and consultant’s fees necessary to the planning and design of the project are allowable if the project is subsequently approved and funded.

Project management.

Relocation expenses.

Sidewalks necessary for use of facility.

Site survey and soil investigation.

Site clearance. Site clearance costs are allowable as long as they are reflected in the bid.

Unallowable costs and activities include the following:

Bonus payments to contractors. Bonus payments to contractors, including those to guaranteed maximum price contractors, are unallowable.

Construction of shell space designed for completion at a future date.

Consultant fees not related to actual construction.

Damage judgment suits.

Equipment purchased through a conditional sales contract.
Procurement Requirements for Construction Services
under NIH Construction Grants

General

Construction activity usually is carried out through one or more contracts under the grant. Therefore, the circumstances of the procurement are critical to the successful completion of the grant-supported project. All construction work must be procured by the methods described in 45 CFR 74.40 through 74.48 or in 92.36, as applicable. Normally, this means a prime construction contract is awarded following a competitive sealed bidding process (previously “formal advertising” in Federal contracting) resulting in a lump-sum, fixed-price contract. NIH may authorize other procurement methods and other types of contracts when sealed bidding or a fully competitive negotiated process is impractical. The specific requirements for contracting for construction management services and design-build services are described below.

In general, grantees must do the following:

◆ Ensure that all qualified contractors are given an opportunity to bid and have their bids fairly considered.

◆ Guarantee, insofar as possible, that the contract(s) will result in the completion of a facility (ready for occupancy) that conforms to the design and specifications approved by the NIH awarding office (or any appropriate modification thereof with NIH awarding office approval, as required) at a cost within the grantee’s ability to pay. (NIH expects that the applicant holds (or will hold) title to the property on which the grant-supported construction is performed.)

◆ Obtain NIH awarding office approval of plans and specifications both before soliciting bids or proposals and before awarding a prime construction contract. The procurement methods to be employed must be reviewed and approved by the NIH awarding office. The grantee is responsible for ensuring that the project is constructed to completion in accordance with the approved plans or specifications and for obtaining necessary approvals for changes as specified in this section.

◆ Take adequate steps to ensure that the total cost of construction—i.e., the total cost of all contracts awarded under a project—will be within the amount of funds available for the
project. This can be accomplished by accurate price estimating and/or the use of bid alternates. A precise description of the scope of work, specifications, materials, and construction techniques in the invitation for bids will facilitate accurate cost estimating by both the bidder and the grantee’s professional representatives. The description of work becomes especially important when multiple contracts will be let in support of the same project, because each contractor must know exactly what is involved in the portion(s) of the job on which it is bidding.

- In invitations for bids, stipulate a time for completion of the project, expressed either in calendar days or as a fixed date, for each prime contract to be awarded under the project.

Where more than one NIH or HHS program will support a construction project, or where the NIH-supported project is less than the entire facility or construction to be bid, the grantee must obtain bids that provide, to the maximum extent possible, the costs for that portion of the total job that will be financed by NIH funds and any required grantee matching. This may be done by

- showing the cost for each building or site in the project, if it consists of more than one building or construction site and can be divided for bidding and construction purposes, or

- identifying, to the extent possible, or prorating the applicable costs when the project is a single site or contains common space and cannot be divided for bidding and construction purposes.

Where practical, the grantee may request, in the invitation for bids, alternates to the base bid that are keyed to specified and explicitly stated changes in the project scope, materials, or construction techniques. Alternates may be used when it is anticipated that the amount of the low bid will exceed the amount of funds available to the grantee to award a contract, and the grantee must make adjustments to the project to reduce costs in order to award a contract within the funds available. “Add” alternates will make it possible to incorporate necessary features that otherwise would not have been included in the project. Alternates that are selected may be included in determining the low aggregate bid. The grantee must identify, in its bid schedule, whether the low bid will be determined inclusive or exclusive of alternates. If inclusive, then alternates must be awarded in order, up to the amount of funds available. For example, Alternate 1 will be awarded first, Alternate 2 second, Alternate 3 third, etc. No alternate may be awarded out of sequence. If all bids exceed the funds available even after the steps described above have been taken, the grantee may do the following:

- Decline to award a contract and instead issue a revised invitation for bids containing changes in specifications or other factors affecting price that have been approved by the NIH awarding office.

- Negotiate with the low bidder (this is an exception to sealed bidding) or, if that bidder should refuse, in writing, to negotiate, negotiate with the next lowest bidder. Any changes in design and specifications resulting from such negotiations must be approved by the NIH awarding office. If efforts to negotiate are unsuccessful, all bids must be canceled, and the project rebid.
Obtain approval from the NIH awarding office to authorize a construction management firm already employed by the grantee to perform the construction work. The price for the work involved must not exceed the line-item prices (GMP) stipulated in the construction management contract as approved by the NIH awarding office (see “Construction Management Services” in this section for requirements for a construction management agreement).

Enter into a design-build contract (see “Design-Build Services” in this section) for a functionally equivalent facility.

Construction Management Services

Construction management services are management services generally procured through negotiation rather than by sealed bidding. These services include technical consultation during the design stage of a project and, during the construction phase, organization and direction of construction activities. In the negotiated procurement process, the RFP must address both the technical qualifications of the offeror (possibly 75 percent of the evaluated score) and the business (cost) aspects of the proposal (possibly 25 percent of the evaluated score). The award must be based on a combination of both the technical and business evaluations. The basis of the award, i.e., whether cost or technical qualifications will weigh more heavily in the award decision, must be stated in the RFP. The services of construction managers may be procured by sealed bidding if State or local governments prohibit the procurement of construction management services through negotiation.

Contracting for construction work on a project covered by a construction management agreement is subject to all of the requirements otherwise applicable to the solicitation and award of contracts, except that bids may be obtained by prequalification and selective solicitation. When prequalification and selective solicitation are used, the construction manager must

- prequalify all firms that respond to the announcement and are determined to meet the prequalification standards;
- establish bidders lists for each of the invitations for bids, including, at least, all prequalified firms, and possibly including other known qualified firms;
- solicit, in writing, bids from all firms on the bidders list;
- consider bids from any contractor who requests permission to bid and who is determined by the grantee to meet the prequalification standards; and
- prepare a bid abstract.
The GMP method may not be used to acquire construction management services under NIH grants unless the grantee obtains NIH prior written approval. If this method is used, the grantee must comply with the following requirements:

- The construction management contract must place total financial responsibility on the construction manager to complete construction of the project at or below the GMP. If the contract exceeds $100,000, the construction manager will be required to comply with bid guarantee and bonding requirements as specified in 45 CFR 74.48(c) or 92.36(h).

- The GMP must be obtained from the construction manager before NIH will authorize the solicitation and award of the first construction contract. This requirement applies whether or not phased construction techniques are employed. Each portion of the work for which a separate contract is expected to be let shall be separately priced as an individual line item in the GMP contract.

The grantee must transmit all GMP bids to the GMO, with its recommendation for award to the lowest responsive, responsible bidder.

After the award of a GMP contract, the following applies:

- All GMP subcontracts must be bid on the open market, and there must be at least three bidders to allow for an award. If three bids cannot be obtained, the grantee must submit, in writing, to the GMO or other designated official, a detailed explanation of why the GMP contractor is unable to comply, along with supporting documentation for NIH consideration and approval or other action.

- All GMP bids must be completely itemized, by trade, to include a separation of labor and materials, all markups, and no contingency other than that which will cover change orders as approved by the grantee.

- All costs lower than the GMP line item bid as approved by the NIH awarding office shall be refunded or credited to the grantee by the contractor and by the grantee to NIH. All costs in excess of the GMP after all items have been bid are the responsibility of the GMP contractor.

- All subcontract prices must be approved by the NIH awarding office before making individual awards. The awards shall be made to the lowest-priced responsible, responsive bidders.

If a contract with a GMP clause was awarded to a construction management firm before the NIH grant award, the firm’s subcontractors must compete in an open competition for the subcontract work under the GMP contract. The GMP contractor must make available to the public all pertinent information that could influence bids and interpretation of the design intent.
Design-Build Services

In design-build contracting, construction firms respond to an RFP by submitting building designs to meet the grantee’s performance requirements within a GMP (see GMP requirements under “Construction Management Services” in this section) that covers all required architectural, engineering, and construction services. The design-build firm must be selected in a manner that allows maximum feasible competition. The selection process must include public announcement of the RFP, provided that at least one form of the announcement receives nationwide distribution; consideration of all proposals from firms that are determined to be qualified; and selection based on the firms’ qualifications, responsiveness to the criteria in the RFP, and cost.

Because of the nature of design-build contracting, the following departures from sealed bidding are authorized:

- Technical considerations and cost may be treated as competitive factors.
- The grantee may negotiate cost or design with one or more firms.

On all design-build projects, the grantee must ensure a firm total cost by including in the contract a provision that extra costs resulting from errors or omissions in the drawings or estimates will be the design-build firm’s responsibility.

Equal Employment Opportunity, Labor Standards, and Other Contract Requirements

Labor standards and equal employment opportunity requirements for federally assisted construction must be specified in the information provided to bidders on construction contracts under NIH grants and must be included in the resulting contract documents (see 45 CFR Part 74, Appendix A, and 45 CFR 92.36(i)). NIH construction grants are not subject to the requirements of the Davis-Bacon Act or the Copeland “Anti-Kickback” Act.

Equal Employment Opportunity

Construction contracts (and subcontracts) awarded under NIH grants are subject to the requirements of EO 11246 (September 24, 1965), as amended, as implemented in 41 CFR Part 60-1 by OFCCP, DoL. The grantee is required to include the “Equal Opportunity Clause” at 41 CFR 60-1.4(b) in any construction contract under the grant. The contractor must be directed to include this clause in any applicable subcontracts.

In addition, grantees and construction contractors under NIH grants are required to comply with the solicitation and contract requirements for affirmative action specified in 41 CFR Part 60-4 for contracts in specified geographical areas that will exceed $10,000. These requirements are specified in the “Notice of Requirement for Affirmative Action to Ensure Equal Employment Opportunity (EO 11246)” and the “Standard Federal Equal Employment Opportunity Construction Contract Specifications (EO 11246).”

The OFCCP regulations also require that the grantee notify the applicable OFCCP regional, area, or field office when it expects to award a construction contract that will exceed $10,000.
Preservation of Open Competition and Government Neutrality Toward Government Contractors’ Labor Relations on Federal and Federally Funded Construction Projects

EO 13202, Preservation of Open Competition and Government Neutrality Towards Government Contractors’ Labor Relations on Federal and Federally Funded Construction Projects (February 17, 2001), as amended by EO 13208 (April 6, 2001), requires executive agencies issuing grants, providing Federal assistance, or entering into cooperative agreements for construction projects (including major and minor A&R) to ensure that bid specifications, project agreements, or other controlling documents for construction contracts awarded by recipients of grants, cooperative agreements, or other financial assistance do not do the following:

♦ Require bidders, offerors, contractors, or subcontractors, or prohibit them, from entering into or adhering to agreements with one or more labor organizations, on the same or other related construction projects.

♦ Otherwise discriminate against bidders, offerors, contractors, or subcontractors for becoming, refusing to become, or remaining signatories, or otherwise adhering to agreements with one or more labor organizations, on the same or other related construction projects.

Nonsegregated Facilities

Pursuant to 41 CFR 60-1.8, for any contract that will exceed $10,000, the grantee must require each prospective construction contractor to submit a certification that the contractor

♦ does not, and will not, maintain any facilities it provides for its employees in a segregated manner;

♦ does not or will not permit its employees to perform their services at any location, under the contractor’s control, where segregated facilities are maintained; and

♦ will obtain a similar certification before awarding any covered subcontract.

Labor Standards

*Contract Work Hours and Safety Standards Act*

Construction contractors and subcontractors under NIH grants with contracts or subcontracts exceeding $100,000 are subject to the requirements of the Contract Work Hours and Safety Standards Act, 40 U.S.C. 327-333, concerning the payment of overtime and the maintenance of healthful and safe working conditions.

Wages paid any laborer or mechanic employed by the contractor or subcontractor must be computed on the basis of a standard workweek of 40 hours. For all work in excess of the
standard workweek, mechanics and laborers shall be compensated at a rate not less than one-and-a-half times the basic rate of pay. If this requirement is violated, the contractor or subcontractor is liable to the employee for the unpaid wages and may be liable to the Federal government for liquidated damages. NIH or the grantee may withhold otherwise payable funds to satisfy any such liability. The statute also specifies penalties for intentional violation of these requirements.

Further, pursuant to standards issued by the Secretary of Labor, no contractor or subcontractor under an NIH grant shall require any laborer or mechanic employed in the performance of the contract to work in surroundings or under working conditions that are unsanitary, hazardous, or dangerous to an individual’s health or safety. Violation of these requirements may be cause for debarment from future Federal contracts or financial assistance.

**Liquidated Damages**

Invitations for bids must stipulate a time for completion of the project, expressed either in calendar days or as a fixed date, for each prime contract to be awarded under the project.

At the option of the grantee, a liquidated damages provision may be included in the construction contract, allowing for assessment of damages when the contractor has not completed construction by the date specified in the contract. Liquidated damages must be real and justified and must be approved by NIH before solicitation. Where damages are assessed, any amounts paid belong to the grantee.

**Disposition of Unclaimed Wages**

During or after the period of performance of an NIH-assisted construction contract, if it is discovered that an employee is entitled to wages but cannot be located for the purposes of payment (or for some reason refuses to accept payment), the grantee may eventually have to repay the Federal government. Therefore, NIH suggests that the contractor be required to turn over any unclaimed wages to the grantee.

The grantee should notify the GMO that an escrow account has been established in the affected employee’s name and should maintain the account for 2 years, or longer if required by State or local law, following the completion of the contract. Upon the expiration of this period, any amounts still unclaimed will be disbursed by refunding to NIH either the entire amount, if the construction project was 100 percent funded by NIH, or an amount representing the percentage of NIH participation in the project. If the project was funded by more than one NIH or HHS program at differing rates, the refund should be based on an average percentage calculated by weighting each program’s rate of participation by the dollar amount of that program’s contribution.

If the contractor has made a reasonable effort to locate the employee by having mail forwarded and contacting the employee’s union, the grantee need not repeat such attempts. If there is reason to believe that the contractor’s efforts to locate employees that are due wages were not thorough, the grantee should attempt to locate the employees. Doing so will reduce the likelihood of future claims against the grantee.
If any wages held in escrow are paid to an employee or an employee’s legal representative while the account is maintained, a complete report must be made to the GMO when the account is closed.

**Administrative Requirements**

**Prior-Approval Requirements**

**Construction Grants**

Grantees must obtain written prior approval from the GMO for grantee-initiated project or budget changes under the following circumstances:

- A revision that would result in a change in scope of the project, including proposed modifications that would materially alter the costs of the project, space utilization, or financial layout, and associated changes in the previously approved solicitation or contract

- A revision that would increase the amount of Federal funds needed to complete the project

- Any other applicable change as specified in “Administrative Requirements—Changes in Project and Budget.”

The request for approval must include sufficient information to allow NIH review of the circumstances and need for the proposed change. After receipt of written prior approval from the GMO, the grantee may make or authorize the approved modifications of the construction contract. Other less substantive modifications to construction contracts may be made without the prior approval of the NIH awarding office. However, copies of all change orders to construction contracts must be retained as grant-related records (see “Administrative Requirements—Monitoring—Record Retention and Access”).

**Alteration and Renovation Projects under Nonconstruction Grants**

Two copies of each of the following documents must be submitted with each request for approval of minor A&R costs greater than $300,000, but not more than $500,000 (whether proposed in the application or as a post-award rebudgeting request):

- Single-line drawing of the existing space and proposed alterations.

- Narrative description of the proposed functional utilization of the space and equipment requirements prepared by the program and administrative managers who will use and be responsible for the working space and, when appropriate, with input from architectural and engineering advisors. Final drawings and specifications will be based on this description.
The description must include a detailed explanation of the need, character, and extent of the functions to be housed in the space proposed for A&R, using the following headings, as appropriate:

- General information
- Description of the functions to be performed in the space
- Space schedule (detailed description of floor space)
- List of fixed equipment proposed for the facility
- Cost estimate (see sample format in Exhibit 8)
- Special design problems
- Description of the existing and proposed utility systems for the modified space
- Description of plans to provide accessibility for the physically handicapped
- Provisions for meeting the requirements of the Life Safety Code
- Length of the property lease if the space is rented
- Other information required by program legislation or regulations.

When the proposed alteration is to occur in a building that is under construction or in an incomplete structure, two copies of the following documentation also must be provided:

◆ Detailed justification for the need to perform the work before the building is completed
◆ Cost comparison between doing the work before and after the building is completed
◆ Description of other specific benefits to be gained by doing the work before the building is completed.

Applicants/grantees undertaking A&R projects that will require NIH funding of more than $500,000 are subject to the review, approval, and documentation requirements included or referenced in this section for construction grants.
Exhibit 8. Sample Format for A&R Cost Estimate

<table>
<thead>
<tr>
<th>Cost category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>A&amp;R costs (to Federal government)</td>
<td>$</td>
</tr>
<tr>
<td>Demolition</td>
<td>$</td>
</tr>
<tr>
<td>General alteration and renovation (carpentry, masonry, painting)</td>
<td>$</td>
</tr>
<tr>
<td>Plumbing</td>
<td>$</td>
</tr>
<tr>
<td>Heating, ventilation, and air conditioning</td>
<td>$</td>
</tr>
<tr>
<td>Electrical</td>
<td>$</td>
</tr>
<tr>
<td>Architect's and engineer's fees</td>
<td>$</td>
</tr>
<tr>
<td>Other costs (specify)</td>
<td>$</td>
</tr>
<tr>
<td>Total A&amp;R costs</td>
<td>$</td>
</tr>
<tr>
<td>Fixed equipment costs</td>
<td>$</td>
</tr>
</tbody>
</table>

List sources and amounts of funds for total A&R project

<table>
<thead>
<tr>
<th>NIH sources and amounts</th>
<th>Sources and amounts other than NIH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other Information

<table>
<thead>
<tr>
<th>Total gross square meters/feet of floor area in A&amp;R proposal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Estimated cost per gross square meter/foot excluding fixed equipment</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Total net square meters/feet of floor area in A&amp;R proposal</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Estimated cost per net square meter/foot, excluding fixed equipment</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Real Property Management Standards

General

Real property constructed under an NIH grant-supported project is subject to the requirements of 42 CFR Part 52b and the provisions of 45 CFR 74.30 through 74.32 and 74.37 or 92.31, as applicable, regarding use, transfer of title, and disposition, unless alternate requirements are specified in the governing statute. Statutory provisions may specify alternate requirements for the length of the grantee’s accountability obligations, the Federal right of recovery, or waivers. For example, the governing statute for a construction grant program may contain usage and disposition requirements that are in addition to or different from the usage and disposition requirements of the governing regulations. To the extent statutory provisions differ from the requirements of 42 CFR Part 52b and/or 45 CFR Part 74 or 92, including those described in this subsection, the statutory provisions, as reflected in the terms and conditions of the award, apply.
Real property constructed or renovated with NIH grant support may not be conveyed, transferred, assigned, mortgaged, leased, or in any other manner encumbered by the grantee, except as expressly authorized in writing by NIH. If the grantee defaults in any way on a mortgage, the grantee shall immediately notify the GMO by telephone and in writing. If the mortgagor intends to foreclose, the grantee must notify the GMO in writing at least 30 days before the foreclosure action is initiated.

The mortgage agreement must specifically allow, in the case of default, that NIH or its designee may assume the role of mortgagor and continue to make payments. If NIH (or its designee) chooses not to assume the role of mortgagor in the case of default, the grantee shall pay NIH an amount equal to the share of the sales proceeds otherwise due the grantee multiplied by the NIH share of the property.

Any NIH assignment of the property and mortgage responsibilities to any party other than NIH shall be subject to prior approval of the mortgagor.

**Use and Disposition**

NIH construction awards generally require that a facility be used for biomedical or behavioral research as long as needed for that purpose. NIH defines this period as 20 years from the date of beneficial occupancy unless another period is prescribed by statute. During that time, the grantee shall comply with applicable disposition requirements. If, during the required usage period, the facility is no longer used for the original intended purpose and NIH did not provide prior approval for an alternate use, NIH may recover its share. NIH will monitor grantee compliance with these requirements for the duration of the required usage period. After the required usage period, the grantee has no further accountability to NIH concerning the use of the property or any sales proceeds.

For disposition of property acquired on an amortized acquisition basis, the formulas in 45 CFR 74.32 and 92.31 do not apply in determining the Federal share. In cases of amortized acquisition, the Federal share will be determined by multiplying the amount of mortgage principal already repaid at the time of disposition by the average Federal participation (taken from the FSR) plus the increase in value over the purchase price multiplied by the average Federal participation plus the Federal participation in the down payment. The computation of the Federal share of real property acquired with long-term debt financing must be computed for each year of grant support in which Federal funds are used to meet all or a portion of the down payment and/or principal on the mortgage.

**Real Estate Appraisals**

If a real estate transaction funded in whole or in part by NIH requires the use of a real estate appraisal (including, but not limited, to appraisals to determine the Federal share of real property and appraisals to determine required insurance levels), the appraisal must be performed by appraisers certified or licensed by the applicable State in accordance with the requirements established by Title XI of the Financial Institutions Reform, Recovery, and Enforcement Act of 1989, as amended (Public Law 101-73).
Notice of Federal Interest

To protect the Federal interest in real property that has been constructed or has undergone major renovation with NIH grant funds, grantees shall record a NFI in the appropriate official records of the jurisdiction in which the property is located. The time of recordation shall be when construction or renovation begins. Fees charged for recording the NFI may be charged to the grant (see “Allowable and Unallowable Costs and Activities” in this section).

Insurance Requirements

Immediately upon completion of construction, a nongovernmental grantee shall, at a minimum, provide the same type of insurance coverage as it maintains for other property it owns, consistent with the minimum coverage specified below. “Completion of construction” means either the point at which the builder turns the facility over to the grantee (e.g., the date of the final acceptance of the building) or the date of beneficial occupancy, whichever comes first.

If title to real property acquired with NIH grant funds vests in the grantee, the following minimum insurance coverage is required:

◆ Title insurance policy that insures the fee interest in the real property for an amount not less than the full appraised value of the property. When the Federal participation in the construction of real property covers only a portion of a building, title insurance should cover the total cost of the facility to prevent liens on the unsecured portion from having an adverse impact on the portion with a Federal interest. In those instances where the grantee already owns the land, such as a building being constructed in the middle of a campus setting, in lieu of a title insurance policy, the grantee may provide evidence satisfactory to the NIH awarding office, such as legal or title opinion, that it has good and merchantable title free of all mortgages or other foreclosable liens to all land, rights of way, and easements necessary for the project. In instances where a grantee is given land by the State, if the State recently acquired the land in a land swap transaction, the grantee should obtain title insurance. However, if the State has owned the land for a considerable period of time, title insurance would not be necessary; a copy of the State documents giving the land to the grantee would be sufficient. If the grantee must buy the land on which to build, a legal opinion would not be sufficient; title insurance must be obtained in order to protect the Federal interest in the building to be constructed.

◆ Physical destruction insurance policy that insures the full appraised value of the facility from risk of partial and total physical destruction. When the Federal participation in the construction or renovation of real property covers only a portion of a building, the insurance should cover the total cost of the facility, because any damage to the building could make the building unusable and could thus affect the Federal interest. The insurance policy is to be maintained for the duration of the Federal interest in the property (usually 20 years) (see “Real Property Management Standards—Use and Disposition” in this section). The cost of insurance coverage after the period of grant support must be borne by a source other than the grant that provided the funds for the construction or renovation. The grant account will not remain active for this purpose.
Governmental grantees may follow their own insurance requirements. Federally owned property provided to a grantee for use need not be insured by the grantee.

Within 5 days of completion or beneficial occupancy, the grantee shall submit, to the GMO, a written statement signed by the AOO assuring that the grantee has purchased the required insurance policies on the NIH-funded facility and will maintain the insurance coverage at the full appraised value of the facility throughout the period of Federal interest as specified in the NGA.

The NIH awarding office may waive one or both of the requirements above if the grantee shows that it is effectively self-insured against the risks involved. The term “effectively self-insured” means that the grantee has sufficient funds to pay for any damage to the facility, including total replacement if necessary, or to satisfy any liens placed against the facility. If the grantee claims self-insurance, the grantee must provide to NIH assurance that it has sufficient funds available to replace or repair the facility or to satisfy all liens. This certification should state the source of the funds, such as the organization’s endowment or other special funds set aside specifically for this purpose.

RUTH L. KIRSCHSTEIN NATIONAL RESEARCH SERVICE AWARDS

General

This section includes general information about and application requirements for Kirschstein-NRSA individual fellowships and institutional research training grants. For Kirschstein-NRSA individual fellowships, this section includes coverage of the public policy requirements concerning human subjects, including data safety and monitoring requirements; inclusion in research of women, minorities, and children; human embryonic stem cells; animal welfare; recombinant DNA molecules and human gene transfer; responsible conduct of research; and acknowledgment of funding. The detailed coverage of these public policy requirements is found in Subpart A. For institutional research training grants, other requirements of Subpart A also apply; this section of Subpart B mentions the applicable requirements with cross-references to Subpart A.

Background

Section 487 of the PHS Act (42 U.S.C. 288) provides authority for NIH to award Kirschstein-NRSA individual fellowships to support predoctoral and postdoctoral training of individuals to undertake biomedical, behavioral, or clinical research at domestic and foreign, public and private institutions (profit and non-profit). Section 487(a)(1)(B) authorizes Kirschstein-NRSA institutional research training grants and limits institutional Kirschstein-NRSA support to training and research at public and non-profit private entities. The legislation requires recipients to pay back to the Federal government their initial 12 months of Kirschstein-NRSA postdoctoral support by engaging in health-related biomedical, behavioral and/or clinical research, research

---

17 In 2002, the National Research Service Awards program was renamed the Ruth L. Kirschstein National Research Service Awards program as a tribute to Dr. Kirschstein’s years of exceptional service to the nation.
training, health-related teaching, or any combination of these activities. (See “Payback Reporting Requirements” in this section). The regulations at 42 CFR Part 66 apply to these awards.

Nondiscrimination

The Kirschstein-NRSA program is conducted in compliance with applicable laws that provide that no person shall, on the grounds of race, color, national origin, handicap, or age, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any program or activity (or, on the basis of sex, with respect to any education program or activity) receiving Federal assistance. Applicant organizations are required to have appropriate Assurance of Compliance forms filed with HHS’s OCR before a grant may be made to that institution. The NIH awarding office should be contacted if there are any questions concerning compliance. (See “Public Policy Requirements and Objectives—Civil Rights” for detailed requirements.)

Individual Fellowships

General

The Kirschstein-NRSA program helps ensure that a diverse pool of highly trained scientists is available in adequate numbers and in appropriate research areas to carry out the Nation’s biomedical and behavioral research agenda. Under this authority, NIH awards individual postdoctoral fellowships (F32) to promising applicants with the potential to become productive, independent investigators in fields related to the mission of the NIH ICs. Some specialized individual pre-doctoral fellowships (F31 and F30), Senior Fellowships (F33), and other unique fellowship programs also are provided under this authority. For individual predoctoral fellowships, NIH ICs have differing requirements. Thus specific PAs and RFAs should be consulted for guidance.

Kirschstein-NRSA fellowships are awarded as a result of national competition for research training in specified health-related areas. All NIH ICs except FIC and NLM award Kirschstein-NRSA fellowships. FIC and NLM have unique funding authorities for fellowships that are not under the Kirschstein-NRSA authority.

Eligibility

Research Areas

Kirschstein-NRSA fellowships may be made for research training in areas that fall within the missions of the NIH ICs. Applications that do not fit these areas will be returned. Research training of physicians has been increasingly emphasized. The HHS Secretary is required by law, in taking into account the overall national needs for biomedical research personnel, to give special consideration to physicians who agree to undertake a minimum of 2 consecutive years of biomedical, behavioral, or clinical research training. NIH recognizes the critical importance of training clinicians to become researchers and encourages them to apply. For those who have a health professional degree, the proposed training may be used to satisfy a portion of the degree requirements for a master’s degree, a doctoral degree, or any other advanced research degree program.
Research Training Program

The Kirschstein-NRSA fellowship must be used to support a program of research training. It may not support studies leading to M.D., D.O., D.D.S., D.V.M., or other similar health professional degrees or to support the clinical portion of residency training. Research trainees in clinical areas are expected to devote full time to the proposed research training and to confine clinical duties to those that are part of the research training.

Degree Requirements

Predoctoral training. Individuals must have received, as of the activation date of their Kirschstein-NRSA pre-doctoral fellowship award, a baccalaureate degree and must be enrolled in and training at the postbaccalaureate level in a program leading to the award of a Doctor of Philosophy of Science (Ph.D. or Sc.D.) or a combined clinical degree and Ph.D. degree such as M.D./Ph.D.

Postdoctoral training. Before a Kirschstein-NRSA postdoctoral fellowship award can be activated, individuals must have received a Ph.D., M.D., D.O., D.C., D.D.S., D.V.M., O.D., D.P.M., Sc.D., Eng.D., Dr. P.H., D.N.S., N.D., Pharm.D., D.S.W., Psy.D., or equivalent doctoral degree from an accredited domestic or foreign institution. Also acceptable is a statement by an AOO of the degree-granting institution that all degree requirements have been met.

Senior fellows. As of the beginning date of their award, senior fellows must have received a doctoral degree (as specified in “General—Degree Requirements—Postdoctoral Training”) and must have had at least 7 subsequent years of relevant research and professional experience. The senior fellowship is awarded to provide opportunities for experienced scientists to make major changes in the direction of their research careers or to broaden their scientific backgrounds by acquiring new research capabilities. In addition, these awards will enable individuals beyond the new investigator stage to take time from regular professional responsibilities to enhance their capabilities to engage in health-related research. Senior fellowships are made for full-time research training. Health professionals may use some of their time in clinical duties as part of their research training. More information on the senior fellowship program can be found in the NIH Kirschstein-NRSA Senior Fellows (F33) program announcement available on the NIH website at http://grants.nih.gov/training/nrsa.htm - fellowships.

Citizenship

The individual to be trained must be a citizen or a noncitizen national of the United States or have been lawfully admitted for permanent residence by the time of award. Noncitizen nationals are people, who, although not citizens of the United States, owe permanent allegiance to the United States. They generally are people born in outlying possessions of the United States (e.g., American Samoa and Swains Island). Individuals who have been lawfully admitted for permanent residence must have a currently valid Alien Registration Receipt Card (I-551) or other legal verification of such status. For example, if an individual has the proper validation on his/her passport, a notarized photocopy of the passport could suffice. Because there is a 6-month limitation on this validation, it is the responsibility of the sponsoring institution to follow up and ensure that the individual receives the I-551 before the 6-month expiration date.
An individual expecting to be admitted as a permanent resident by the earliest possible award date listed in the Kirschstein-NRSA individual fellowship program announcement may submit an application for a fellowship. The submission of documentation concerning permanent residency is not required as part of the initial application. Any applicant selected to receive an award must provide a notarized statement of admission for permanent residence prior to award.

Applicants who have been lawfully admitted for permanent residence, i.e., have an Alien Registration Receipt Card or other legal verification of such status, should check the Permanent Resident box in the citizenship section on the face page of the fellowship application. Applicants who have applied for and have not yet been granted admission as a permanent resident should check the same box, but should write in the word “pending.”

Individuals on temporary or student visas are not eligible to apply for Kirschstein-NRSA individual fellowships.

**Sponsorship**

**General.** Before submitting a Kirschstein-NRSA individual fellowship application, the applicant must identify a sponsoring institution and an individual who will serve as a sponsor (also called mentor or supervisor) and supervise the training and research experience. The sponsoring institution may be domestic or foreign, public or private (for-profit or non-profit), including the NIH intramural programs, other Federal laboratories, and units of State and local governments. The applicant’s sponsor should be an active investigator in the area of the proposed research who will directly supervise the candidate’s research. The sponsor must document in the application the training plan for the applicant as well as the availability of staff, research support, and facilities for high-quality research training. In most cases, postdoctoral fellowships support research training experiences in new settings in order to maximize acquisition of new skills and knowledge. Therefore, postdoctoral applicants proposing training at their doctoral institution or at the institution where they have been training for more than a year must document thoroughly the opportunity for new training experiences designed to broaden their scientific backgrounds.

**Foreign sponsorship.** An individual may request support for training abroad. In such cases, the applicant is required to provide detailed justification for the foreign training, including the reasons why the facilities, the mentor, or other aspects of the proposed experience are more appropriate than training in a domestic setting. The justification is evaluated in terms of the scientific advantages of the foreign training as compared to the training available domestically. Foreign training will be considered for funding only when the scientific advantages are clear.

**NIH Employees**

Both civil service employees and PHS commissioned officers at NIH are permitted to compete for predoctoral and postdoctoral fellowships. The proposed training should be primarily for career development rather than for the immediate research needs of NIH. The employee’s supervisor must disassociate himself/herself from the review and award process.
Successful NIH applicants for predoctoral or postdoctoral fellowship awards must either resign from NIH or take LWOP before activating the award. (There is no obligation or commitment by NIH or the fellow for future employment at NIH upon termination of the fellowship.)

**Individuals on Active Military Duty**

NIH does not restrict career military personnel from applying for Kirschstein-NRSA individual fellowship awards while on active military duty. At the time of application, the applicant’s branch of the military service should submit a letter endorsing his/her application and indicating willingness to continue normal active duty pay and allowances during the period of the requested fellowship. If an award is made, the institutional allowance and necessary tuition and fees permitted on a postdoctoral program will be paid by NIH. However, stipends, health insurance, and travel allowances are not allowable charges to a Kirschstein-NRSA individual fellowship for career military personnel. Payment of concurrent benefits by NIH to active duty career military awardees is not allowed.

**Application Requirements and Receipt Dates**

**Application**

Each applicant must submit an application using the PHS 416-1. At least three letters of reference on his or her behalf also must be submitted. The major emphasis of the application should be the research training experience and broadening of scientific competence. The application must include the sponsor’s Facilities and Commitment Statement. By signing the face page of the application, the applicant indicates that he or she has read the payback information and will meet any payback provisions required under the law as a condition for accepting the award.

Applicants and sponsoring institutions must comply with policies and procedures governing such requirements as civil rights; the protection of human subjects, including data safety and monitoring requirements; the humane care and use of live vertebrate animals; the inclusion of women, minorities and children in study populations; human embryonic stem cells; and recombinant DNA and human gene transfer research. (For a complete list of applicable requirements, see Exhibit 2, “Public Policy Requirements and Objectives” in Subpart A).

If an application is submitted in response to an IC-specific PA or RFA, the applicant should identify the number of the PA or RFA on the face page. This information will be used as a guide in the application assignment process.

**Concurrent applications.** An individual may not have two or more competing Kirschstein-NRSA individual fellowship applications pending review concurrently. In addition, CSR will not accept for review any application that is essentially the same as one already reviewed.

**Application availability.** Application forms and instructions are available from the NIH website at [http://grants.nih.gov/grants/forms.htm](http://grants.nih.gov/grants/forms.htm). Application form pages are available in pdf-fillable and rtf formats. Further assistance is available from GrantsInfo at 301-435-0714 or GrantsInfo@nih.gov.
Receipt Dates

Kirschstein-NRSA individual fellowship applications undergo a review process that takes 5 to 8 months. The appendix to this section shows the annual schedule for application receipt, review, and award.

Review

Each new and competing continuation application will be evaluated for scientific merit by an NIH SRG. Review criteria include the candidate’s previous academic and research performance and the potential to become an important contributor to biomedical, behavioral, or clinical science; the quality of the training environment and the qualifications of the sponsor; the merit of the scientific proposal and its relationship to the candidate’s career plans; and the value of the proposed fellowship experience. In determining scientific merit and the priority score, when applicable, the SRG also considers plans for the protection of human subjects from research risks; the inclusion of women, minorities, and children in research; and the care and use of vertebrate animals in the proposed research.

Kirschstein-NRSA individual fellowship applications receive a secondary level of review by IC staff. Criteria used in making award decisions include the SRG’s recommendation concerning the overall merit of the application, the relevance of the application to the IC’s research training priorities and program balance, and the availability of funds.

Notification of Action

Shortly after the initial review meeting, each candidate receives a mailer that includes the SRG recommendation/priority score and the name and telephone number of a PO in the assigned NIH IC. A copy of the summary statement is automatically forwarded to the applicant as soon as possible.

The PO will notify the applicant about the final review recommendation. The applicant should direct any questions about initial review recommendations and funding possibilities to the designated IC PO, not to the SRA of the SRG. An NRFA will be issued to applicants selected for funding.

Period of Support

No fellow may receive more than 5 years of aggregate Kirschstein-NRSA support at the predoctoral level and 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of Kirschstein-NRSA support from institutional research training grants and individual fellowships.

Any exception to the maximum period of support requires a waiver from the NIH awarding office based on review of a justification from the individual and sponsoring institution. The fellow must make the request in writing to the NIH awarding office. The fellow’s sponsor and an AOO must endorse the request. The request must specify the amount of additional support for which approval is sought. Individuals seeking additional support beyond the third year of
postdoctoral support are strongly advised to consult with their PO before submitting a waiver request.

Some generally recognized categories under which NIH may grant exceptions include the following:

◆ **Physicians/clinicians.** Individuals requiring additional time to complete training, either as participants in a combined M.D./Ph.D. program or as clinicians (e.g., physicians, dentists, veterinarians) who are completing postdoctoral research training, may anticipate favorable consideration of a request for waiver of the time limitation. This action is contingent upon an assurance of the recipient’s good academic standing and justified need for the exception.

◆ **Interruptions (break in service).** Requests for additional time also will be considered if an event unavoidably alters the planned course of the research training, if the interruption has significantly detracted from the nature or quality of the planned research training, and if a short extension would permit completion of the training as planned. Such events include sudden loss of the preceptor’s services or an accident, illness, or other personal situation, which prevent a fellow from effectively pursuing research training for a significant period of time. Requests for extension of support also will be considered if a short additional period would provide the fellow an opportunity to use an exceptional training resource directly related to the approved research training program.

Requests for additional time that do not arise from either of the above-described circumstances will be considered only if they are accompanied by an exceptionally strong justification.

**Full-Time and Part-Time Training**

All fellows are required to pursue their research training full time, normally defined as 40 hours per week or as specified by the sponsoring institution in accordance with its own policies. Under unusual or pressing personal circumstances, a fellow may submit a written request to the NIH awarding office to permit less than full-time training.

Written requests for part-time training will be considered case by case and must be approved by the NIH awarding office in advance of each budget period. The circumstances requiring part-time training might include medical conditions, disability, or pressing personal or family situations such as a child or elder care. Part-time training will not be approved to accommodate other sources of funding, job opportunities, clinical practice, clinical training, or for responsibilities associated with the fellow’s position at the sponsoring institution.

Each written request from the fellow must be countersigned by the sponsor and an AOO and must include documentation supporting the need for part-time training. The written request also must include an estimate of the expected duration of the period of part-time training and assurances that the fellow intends to return to full-time training when that becomes possible and intends to complete the proposed research training program. Individuals may not engage in Kirschstein-NRSA support for less than 50 percent effort. Individuals unable to devote 50
percent effort will be required to take a leave of absence from Kirschstein-NRSA fellowship support.

NIH will issue a revised NRFA and the stipend will be prorated during the period of any approved part-time training. Part-time training may affect the rate of accrual or repayment of the service obligation for postdoctoral fellows.

Initiation of Support

Process

The NIH IC will notify the individual of the intention to make an award and confirm the plans for the start of fellowship support. The NRFA allows the individual to begin the fellowship immediately on or after the issue date, but permits up to 6 months for the individual to make final arrangements, such as the completion of degree requirements, final coordination with the sponsor, and, if necessary, a move to the sponsoring institution. The fellow must start the period of training under the award by the latest activation date as shown on the NRFA, i.e., 6 months from the award issue date. The activation period may be extended in unusual circumstances. Written requests for extensions should be submitted by the fellow, and must be countersigned by the sponsor and the AOO.

The Activation Notice must be submitted to the NIH awarding office as of the day the fellow begins training. A Payback Agreement also must be completed and submitted but only by postdoctoral fellows in their first 12 months of Kirschstein-NRSA postdoctoral support. See “Reporting Requirements—Activation Notice” and “Reporting Requirements—Payback Agreement” in this section. A stipend may not be paid until the forms are submitted and the fellow begins training. If necessary for payroll purposes, the Activation Notice and Payback Agreement may be submitted up to 30 days before the start date. However, any change in the planned activation start date must be reported immediately to the sponsoring institution’s business office and to the NIH awarding office. If an award is conditioned upon completion of degree requirements, the fellow must submit, with the Activation Notice, proof of completion by the degree-granting institution.

Individual fellowship support generally is approved for consecutive years of training. The initial award usually is for 12 months. Subsequent periods of approved fellowship training are consecutive with the first year of support and are usually in 12-month increments (budget periods). Awards for less than 12 months will be prorated accordingly. If a fellow decides not to activate the award, or to terminate early, he or she should notify the institution’s business office, the sponsor, and the NIH awarding office immediately, in writing. NIH will make any necessary adjustments in the stipend and other costs, including the institutional allowance.

Payment

Domestic. Non-Federal sponsoring institutions receive an award for the stipend, institutional allowance, and tuition and fees (when applicable). The institution directly pays the fellow and disburses all other awarded costs.
**Federal laboratories.** Fellows training at Federal laboratories are paid stipends directly by the NIH awarding office through NIH’s OFM. Reimbursement to the fellow for appropriate expenditures from the institutional allowance also is coordinated by the NIH awarding office and paid through OFM.

**Foreign.** Fellows training at foreign sites receive stipends directly from NIH’s OFM. However, the institutional allowance is awarded to and disbursed by the sponsoring institution.

### Allowable and Unallowable Costs

#### Stipends

A stipend is provided as a subsistence allowance for Kirschstein-NRSA fellows to help defray living expenses during the research training experience. It is not provided as a condition of employment with either the Federal government or the sponsoring institution. Stipends must be paid in accordance with stipend levels established by NIH, which are based on a 12-month full-time training appointment. In the event of early termination, the stipend will be prorated according to the amount of time spent in training, and NIH will issue a revised NRFA. No departure from the standard stipend provided by NIH under the fellowship may be negotiated by the sponsoring institution with the fellow.

#### Stipend Levels

Stipend levels are updated nearly every year. When increases are approved, they are published in the *NIH Guide for Grants and Contracts*. Current levels are posted at [http://grants.nih.gov/training/nrsa.htm](http://grants.nih.gov/training/nrsa.htm). The NIH awarding office will adjust fellowship awards on their anniversary dates to include the currently applicable stipend amount.

General information related to stipends follows:

- **Predoctoral.** One stipend level is used for all pre-doctoral candidates, regardless of the level of experience.

- **Postdoctoral.** The stipend level for the entire first year of support is determined by the number of full years of relevant postdoctoral experience when the award is issued. Relevant experience may include research experience (including industrial), teaching assistantship, internship, residency, clinical duties, or other time spent in a health-related field beyond that of the qualifying doctoral degree. Once the appropriate stipend level has been determined, the fellow must be paid at that level for the entire grant year. The stipend for each additional year of Kirschstein-NRSA support is the next level in the stipend structure and does not change mid-year.

- **Senior fellows.** The amount of the Kirschstein-NRSA stipend to be paid must be commensurate with the base salary or remuneration that the individual receiving the award would have been paid by the institution with which he or she has permanent affiliation on the date of the fellowship award. In no case shall the stipend award exceed the current Kirschstein-NRSA stipend limit set by NIH. The level of Kirschstein-NRSA support will take into account concurrent salary support provided by the institution and
the policy of the sponsoring institution. NIH support does not provide fringe benefits for senior fellows.

**Institutional Allowance**

NIH awards an institutional allowance to help support the costs of training. The specific levels of allowance for predoctoral and postdoctoral support, including those for individuals training at Federal laboratories, for-profit organizations, or foreign institutions, are published in the *NIH Guide for Grants and Contracts*. They also are available on the NIH website at [http://grants.nih.gov/training/nrsa.htm#fellowships](http://grants.nih.gov/training/nrsa.htm#fellowships). For postdoctoral fellowships, costs for tuition and fees, where appropriate, will be awarded independent of the institutional allowance. (See “Allowable and Unallowable Costs—Tuition and Fees” in this subsection for details on tuition reimbursement.)

The institutional allowance is a fixed amount. Expenditures under institutional allowances are not subject to NIH prior-approval requirements, and the institution is not required to account for these expenditures on an actual cost basis.

Except for fellows at Federal training sites, consistent with NIH policy governing the type of expenditures appropriate for the institutional allowance, the sponsoring institution authorizes the expenditure of the institutional allowance on behalf of the fellow according to the institution’s policy. The institution is entitled to expend up to the full institutional allowance upon official activation of the award. However, if an individual fellow is not in a training status for more than 6 months of the award year, only one-half of that year’s institutional allowance may be charged to the grant. The NRFA will be revised and the balance must be refunded to NIH.

For fellows at Federal training sites, the NIH awarding office authorizes the expenditure of the allowance. Payment is made through NIH’s OFM.

The type of sponsoring institution dictates what costs may be charged to this category and how the funds are to be administered:

- **Non-Federal public and private non-profit institutions (domestic and foreign).** The allowance is intended to defray expenses for the individual fellow such as research supplies, equipment, travel to scientific meetings, and health insurance and to otherwise offset, insofar as possible, appropriate administrative costs of training. Funds are paid directly to and administered by the sponsoring institution.

- **Federal laboratories.** The allowance is intended to cover the costs of scientific meeting travel, health insurance, and books. Funds are administered by the NIH awarding office and disbursed by OFM.

- **For-profit institutions.** The allowance is intended to cover the costs of scientific meeting travel, health insurance, and books. Funds are paid directly to the sponsoring institution for disbursement to the fellow.
The following are guidelines for the use of the institutional allowance:

- **Travel.** Payment for travel to scientific meetings is appropriate when it is necessary for the individual’s training and when the costs are incurred within the period of grant-supported training.

  For fellows at Federal laboratories, reimbursement of travel costs must be in accordance with current Federal travel regulations.

  Funds may not be expended to cover the costs of travel between the fellow’s place of residence and the domestic training institution, except that the sponsoring institution may authorize the cost of a one-way travel allowance in an individual case of extreme hardship.

- **Health insurance.** A fellow’s health insurance is an allowable cost only if applied consistently to all people in a similar training status regardless of the source of support. Family health insurance is an allowable cost for fellows who have families and are eligible for family health insurance coverage at the sponsoring institution. Self-only health insurance is an allowable cost for fellows without families. Health insurance can include coverage for costs such as vision and/or dental care if consistent with organizational policy.

- **Extraordinary costs.** Additional funds may be requested by the institution when the training of a fellow involves extraordinary costs for travel to field sites remote from the sponsoring institution or accommodations for fellows who are disabled, as defined by the Americans with Disabilities Act. The funds requested for extraordinary costs must be reasonable in relationship to the total dollars awarded under a fellowship and must be directly related to the approved research training project. Such additional funds shall be provided only in exceptional circumstances that are fully justified and explained by the institution.

**Tuition and Fees**

Currently NIH offsets the combined cost of tuition and fees for Kirschstein-NRSA postdoctoral fellows at the following rate: 100 percent of all costs up to $3,000 and 60 percent of costs above $3,000. Any change in this formula is published in the *NIH Guide for Grants and Contracts*.

For postdoctoral fellows, costs associated with tuition and fees are allowable only if they are required for specific courses in support of the research training. Health insurance is not included in this budget item because it is part of the institutional allowance.

For predoctoral fellows, the award of tuition and fees (including health insurance) may vary depending on the policy of the NIH awarding office. Specific programmatic guidelines should be consulted for guidance.

When tuition, fees, and insurance are awarded as a separate budget item, these funds may not be rebudgeted into any other budget category without written prior approval from the NIH awarding office.
Travel to Foreign Training Sites

For fellows at foreign training sites, in addition to the institutional allowance, awards may include a single economy or coach round-trip travel fare. No allowance is provided for dependents. U.S. flag air carriers must be used to the maximum extent possible when commercial air transportation is the means of travel between the United States and a foreign country or between foreign countries. This requirement shall not be influenced by factors of cost, convenience, or personal travel preference.

Employee Benefits

Since Kirschstein-NRSA fellowships are not provided as a condition of employment with either the Federal government or the sponsoring institution, institutions may not seek funds, or charge individual fellowship awards, for costs that normally would be associated with employee benefits (for example, FICA, workman’s compensation, and unemployment insurance).

Supplementation of Stipends, Compensation, and Other Income

Stipend Supplementation

Kirschstein-NRSA fellows receive stipends to defray living expenses. Stipends may be supplemented by an institution from non-Federal funds provided this supplementation does not require any additional obligation from the fellow. An institution can determine the amount of stipend supplementation, if any, it will provide according to its own formally established policies governing stipend support. These policies must be consistently applied to all individuals in a similar status regardless of the source of funds. Federal funds may not be used for stipend supplementation unless specifically authorized under the terms of the program from which funds are derived. Under no circumstances may PHS funds be used for supplementation.

An individual may use Federal educational loan funds or VA benefits when permitted by those programs as described in this subsection.

Compensation

NIH recognizes that Kirschstein-NRSA fellows may seek part-time employment incidental to their training program to offset further their expenses. Funds characterized as compensation may be paid to fellows only when there is an employer-employee relationship, the payments are for services rendered, and the situation otherwise meets the conditions for compensation of students as detailed in “Cost Considerations—Selected Items of Cost—Salaries and Wages—Compensation of Students.” In addition, compensation must be in accordance with organizational policies applied consistently to both federally and non-federally supported activities and must be supported by acceptable accounting records that reflect the employer-employee relationship agreement. Under these conditions, the funds provided as compensation (salary, fringe benefits, and/or tuition remission) for services rendered, such as teaching or laboratory assistance, are not considered stipend supplementation; they are allowable charges to Federal grants, including PHS research grants. However, NIH expects that compensation from research grants will be for limited part-time employment apart from the normal training activities. Compensation may not be paid from a research grant that supports the same research
that is part of the fellow’s planned training experience as approved in the Kirschstein-NRSA individual fellowship application.

Under no circumstances may the conditions of stipend supplementation or the services provided for compensation interfere with, detract from, or prolong the fellow’s approved Kirschstein-NRSA training program. Fellowship sponsors must approve all instances of employment on research grants to verify that the circumstances will not detract from or prolong the approved training program.

**Concurrent Benefits**

A Kirschstein-NRSA individual fellowship may not be held concurrently with another federally sponsored fellowship or similar Federal award that provides a stipend or otherwise duplicates provisions of the Kirschstein-NRSA award.

**Educational Loans or GI Bill**

An individual may accept concurrent educational remuneration from the VA (GI Bill) and Federal educational loan funds. Such funds are not considered supplementation or compensation. Postdoctoral fellows also may be eligible to participate in the NIH Loan Repayment Program. Information on this program is available at [http://www.lrp.nih.gov/](http://www.lrp.nih.gov/).

**Taxability of Stipends**

Section 117 of the Internal Revenue Code applies to the tax treatment of scholarships and fellowships. Degree candidates may exclude from gross income (for tax purposes) any amount used for course tuition and related expenses such as fees, books, supplies, and equipment required for courses of instruction at a qualified educational organization. Nondegree candidates are required to report as gross income any monies paid on their behalf for stipends or any course tuition and fees required for attendance.

The taxability of stipends in no way alters the relationship between Kirschstein-NRSA fellows and sponsoring institutions. Kirschstein-NRSA stipends are not considered salaries. In addition, recipients of Kirschstein-NRSA individual fellowships are not considered to be in an employee-employer relationship with NIH or the sponsoring institution solely as a result of the Kirschstein-NRSA award. The interpretation and implementation of the tax laws are the domain of the IRS and the courts. NIH takes no position on what the status may be for a particular taxpayer, and it does not have the authority to dispense tax advice. Individuals should consult their local IRS office about the applicability of the law to their situation and for information on their tax obligations.

**Form 1099**

Although stipends are not considered salaries, this income is still subject to Federal and, sometimes, State income tax. Such income may be reported by the sponsoring institution on IRS Form 1099, Statement of Miscellaneous Income. Normally, the business office of the sponsoring institution will be responsible for annually preparing and issuing IRS Form 1099 for fellows paid through the institution (fellows at domestic non-Federal institutions). Sponsoring institutions are
not required to issue a Form 1099, but it is a useful form of documentation of income received and a reminder to the fellow that some tax liability may exist. Fellows are reminded that, even if the sponsoring institution does not issue a Form 1099, they still are required to report Kirschstein-NRSA stipends as income. NIH will issue a Form 1099 for each fellow training at a Federal or foreign laboratory and receiving a stipend check from the U.S. Treasury.

**Reporting Requirements**

The submission of the forms described in this subsection is critical to establishing and paying stipends and other costs and determining possible payback service. All of these forms are available in pdf-fillable and rtf formats at [http://grants.nih.gov/grants/forms.htm](http://grants.nih.gov/grants/forms.htm). The NIH awarding office may provide copies of applicable forms with the NRFA or reference this website in the NRFA.

**Activation Notice**

Immediately upon the initiation of training, the individual must complete and sign the Ruth L. Kirschstein Individual Fellowship Activation Notice (Form PHS 416-5), obtain the signature of the AOO, and forward the notice along with the Payback Agreement (required only for postdoctoral fellows in their first 12 months of Kirschstein-NRSA support) to the NIH awarding office.

For Kirschstein-NRSA fellows paid directly by NIH, the Activation Notice is required at the start of each award year. The form should not be submitted before the fellow actually begins training. Stipend checks are issued when both the Activation Notice and the Payback Agreement (required only for postdoctoral fellows in their first 12 months of Kirschstein-NRSA support) are received by the NIH awarding office.

For fellows whose stipend is paid through the institution, the Activation Notice is required for the initial year only. The Activation Notice may be submitted up to 30 days before the individual begins training if necessary for payroll purposes. However, the institution must not release any funds until the individual has started training. Furthermore, if the individual does not begin research training on the day indicated, the institution must notify the NIH awarding office immediately. Competing continuation awards must be activated on the day following the end of the last budget period of the previous award.

**Payback Agreement**

A Ruth L. Kirschstein National Research Service Award Payback Agreement (Form PHS 6031) that covers the initial 12 months of Kirschstein-NRSA postdoctoral support must be signed by each person who is to receive an individual postdoctoral fellowship. This form is not required if the individual has already received 12 months of postdoctoral Kirschstein-NRSA support under any Kirschstein-NRSA institutional research training grant or fellowship award. For details on Kirschstein-NRSA payback, see “Payback Reporting Requirements” in this section.

No Payback Agreement is required for predoctoral fellows.
Termination Notice

The Ruth L. Kirschstein National Research Service Award Termination Notice (Form PHS 416-7) (along with the Activation Notice and the NRFA) is the basis for validating the total period of Kirschstein-NRSA support and establishing the amount of payback obligation for each Kirschstein-NRSA fellow. For individual fellowships, a reminder of this reporting requirement may be sent to the fellow by the NIH awarding office before the scheduled termination date. For early terminations, the completed form will be required immediately upon receipt of notification from the fellow or an AOO. The lack of timely and accurate information on this form could adversely affect the payback process. For additional information on early termination, see “Changes in the Project” in this section.

Consecutive Support

If a fellow switches from one Kirschstein-NRSA grant mechanism to another (e.g., from an institutional research training grant to an individual fellowship or from one NIH IC to another), the requirement for payback service incurred is deferred until the total period of Kirschstein-NRSA support is completed. All fellowship applications are reviewed to determine if previous Kirschstein-NRSA support has been provided.

Progress Reports

Progress reports must be submitted for non-competing continuation support in accordance with the instructions accompanying the Progress Report for Continuation Support (Form PHS 416-9). Progress report forms and instructions are available from the NIH website at http://grants.nih.gov/grants/forms.htm. Report form pages are available in pdf-fillable and rtf formats. Inadequate or incomplete progress reports may be returned to the fellow for revision and may result in a delay of continued support. For Kirschstein-NRSA individual fellowship awards, the final progress report is required as part of the Termination Notice.

Financial Reporting

An annual or final FSR is not required on Kirschstein-NRSA individual fellowship awards.

Changes in the Project

Individual fellowship awards are made for training at a specific institution under the guidance of a particular sponsor. The approval of the NIH awarding office is required for a transfer of the award to another institution, a change in sponsor, or a project change. As part of the approval process, if a fellow sponsored by a domestic non-Federal institution requests a transfer to another domestic non-Federal institution before the end of the current award year, the initial institution may be requested to continue to pay the stipend until the end of the current year. Disposition of the institutional allowance is negotiable between the two sponsoring institutions. No Activation Notice is required from the new sponsoring institution.

Transfers involving Federal or foreign sponsoring institutions require unique administrative procedures and approvals. Because each transfer varies depending on individual circumstances, the sponsoring institution should contact the NIH awarding office for specific guidance.
Any proposed change in the individual’s specified area of research training must be reviewed and approved in writing by the NIH awarding office to ensure that the training continues to fall within the scientific area of the original peer-reviewed application.

When the sponsor is going to be absent for more than 3 months, an interim sponsor must be named by the institution and approved in writing by the NIH awarding office.

Other Terms and Conditions

Leave

Vacations and holidays. Kirschstein-NRSA fellows may receive the same vacations and holidays available to individuals in comparable training positions at the sponsoring institution. Fellows shall continue to receive stipends during vacations and holidays. At academic institutions, the time between semesters or academic quarters generally is considered an active part of the training period.

Sick leave and other leave. Kirschstein-NRSA fellows may continue to receive stipends for up to 15 calendar days of sick leave per year. Under exceptional circumstances, this period may be extended by the NIH awarding office in response to a written request from the sponsor, countersigned by an AOO. Sick leave may be used for medical conditions related to pregnancy and childbirth.

Parental leave. Kirschstein-NRSA fellows may receive stipends for up to 30 calendar days of parental leave per year for the adoption or the birth of a child when those in comparable training positions at the grantee or sponsoring institution have access to paid leave for this purpose. Either parent is eligible for parental leave. The use of parental leave requires approval by the sponsor.

Terminal leave. A period of terminal leave is not permitted, and payment may not be made from grant funds for leave not taken.

Unpaid leave. Individuals requiring extended periods of time away from their research training experience, that is, more than 15 calendar days of sick leave or more than 30 calendar days of parental leave, must seek approval for an unpaid leave of absence. Approval for a leave of absence must be requested in advance from the NIH awarding office. Fellows must provide a letter of support from the sponsor, countersigned by an AOO, and must advise the NIH awarding office of the dates of the leave of absence. Upon approval of the request, the NIH awarding office will issue a revised NRFA extending the ending date of the current budget period by the appropriate number of days or months of unpaid leave time. Recipients are precluded from spending award funds during the leave of absence.

During a leave of absence, documentation to suspend the award and/or the accrual of service for calculating the payback obligation must be completed by the sponsoring institution. When the fellowship is eventually terminated, the leave of absence must be clearly documented on the Termination Notice.
**Termination**

NIH may terminate a Kirschstein-NRSA individual fellowship before its normal expiration date if it determines that the recipient has materially failed to comply with the terms and conditions of the award or to carry out the purpose for which it was made. If an award is terminated for cause, NIH will notify the fellow in writing of the determination, the reasons for the determination, the effective date, and the right to appeal the decision.

NIH also may terminate an award at the request of the sponsoring institution or the recipient. The NIH awarding office must be notified immediately if a sponsoring institution wants to terminate an individual fellow or the fellow decides to terminate training before the scheduled expiration date.

If a Kirschstein-NRSA fellowship is terminated early, the stipend must be prorated according to the amount of time spent in training, and the NRFA will be revised. The balance of any institutional allowance (at least one-half) must be refunded if the training has been for 6 months or less.

**Publications and Sharing of Research Results**

NIH supports the practical application and sharing of outcomes of funded research. Therefore, recipients of Kirschstein-NRSA fellowships should make the results and accomplishments of their activities available to the research community and to the public at large. The sponsoring institution should assist the fellow in such activities, including the potential commercialization of inventions. No restrictions should be placed on the publication of results.

Kirschstein-NRSA fellows are encouraged to submit reports of their findings to the journals of their choice for publication. Responsibility for direction of the project should not be ascribed to NIH. However, NIH awarding office support must be acknowledged by a footnote in language similar to the following: “This research was supported by the National Institutes of Health under Ruth L. Kirschstein National Research Service Award (number) from the (name of NIH IC).” In addition, Federal funding must be acknowledged as provided in “Public Policy Requirements and Objectives—Availability of Information—Acknowledgment of Federal Funding.”

**Copyright**

Except as otherwise provided in the conditions of the award, when a publication or similar copyrightable material is developed from work supported by NIH, the author is free to arrange for copyright without approval of the NIH awarding office. Any such copyrighted materials shall be subject to a royalty-free, nonexclusive, and irrevocable license to the Federal government to reproduce them, translate them, publish them, and use and dispose of them, and to authorize others to do so for Federal government purposes.

**Inventions and Patents**

Fellowships funded primarily for educational purposes are not subject to invention reporting requirements nor does NIH have any rights to inventions under those awards (as specified in 37 CFR 401.1(b)). Kirschstein-NRSA fellows training at NIH represent an exception to this
policy. Those fellows are subject to the provisions of EO 10096 and NIH determines the disposition of rights to any invention conceived or actually reduced to practice during the period of the fellowship.

Disposion of Professional Fees

Fees resulting from clinical practice, professional consultation, or other comparable activities performed pursuant to the purpose of the award must be assigned to the sponsoring institution for disposition in accordance with established organizational policy. The term “professional fees” does not apply to honoraria, fees for scholarly writing, delivery of occasional outside lectures, or service in an advisory capacity to public or private non-profit organizations, which, if permitted by organizational policy, may be retained by the fellow.

Public Policy Requirements and Objectives

Human Subjects

Kirschstein-NRSA individual fellowship awards involving use of human subjects must comply with the requirements for their protection (see “Public Policy Requirements and Objectives—Requirements Affecting the Rights and Welfare of Individuals as Research Subjects, Patients, or Recipients of Services—Human Subjects”). For additional information on human subjects requirements, refer to the Kirschstein-NRSA individual fellowship application instructions (http://grants.nih.gov/grants/funding/416/phs416.htm) or contact OHRP (see contact information in Part III).

Monitoring Plan and Data and Safety Monitoring Board

Research involving clinical trials must include provisions to ensure the safety of participants and the validity and integrity of the data. A monitoring plan establishes the overall framework for data and safety monitoring. It should describe the entity that will be responsible for monitoring and how adverse events will be reported to IRBs, NIH, and FDA. The frequency of monitoring will depend on potential risks, complexity, and the nature of the trial.

NIH specifically requires the establishment of DSMBs for multi-site clinical trials involving interventions that entail potential risks to the subject and, generally, for Phase III clinical trials. Although Phase I and Phase II clinical trials also may use DSMBs, smaller clinical trials may not require this type of oversight, and alternative monitoring plans may be appropriate.


Inclusion of Women and Minorities in Clinical Research

Pursuant to the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43), NIH requires that women and members of minority groups and their subpopulations be included in all
NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research (see “Public Policy Requirements and Objectives—Requirements for Inclusiveness in Research Design”).


**Inclusion of Children as Participants in Research Involving Human Subjects**

NIH policy requires that children (individuals under the age of 21) be included in all human subjects research conducted or supported by NIH, unless there are scientific and ethical reasons not to include them (see “Public Policy Requirements and Objectives—Requirements for Inclusiveness in Research Design”). Individuals proposing research involving human subjects should read NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects, available on the NIH website at http://grants.nih.gov/grants/funding/children/children.htm.

**Human Embryonic Stem Cell Research**

Criteria for Federal funding of research on hESC can be found at http://stemcells.nih.gov/index.asp and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only research using hESC lines registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (see http://esrc.nih.gov). It is the individual’s responsibility to provide the official NIH identifiers for the hESC lines to be used in the proposed research (see “Public Policy Requirements and Objectives—Requirements Affecting the Rights and Welfare of Individuals as Research Subjects, Patients, or Recipients of Services”). Applications that do not provide this information will be returned without review.

**Responsible Conduct of Research**

Kirschstein-NRSA individual fellowship applicants must include, as part of their application, plans for obtaining instruction in the responsible conduct of research, including the rationale, subject matter, appropriateness, format, frequency, and duration of instruction. The amount and nature of faculty participation must be described.

While NIH does not establish specific curricula or formal requirements, applicants are encouraged to creatively tailor a plan to meet their own needs in relation to the proposed research training. It may include participating in formal activities, such as established courses (credit or noncredit) either as an instructor or a student, or informal activities, such as discussion groups. Possible coverage could include conflict of interest, responsible authorship, policies for handling misconduct, data management, data sharing, policies for the use of animals and/or human subjects, and organizational (rather than individual) responsibilities for scientific integrity.

No award will be made if an application lacks this component.
Vertebrate Animals

Kirschstein-NRSA individual fellowship awards involving use of vertebrate animals must comply with the requirements for their protection specified in “Public Policy Requirements and Objectives—Requirements Affecting the Right and Welfare of Individuals as Research Subjects, Patients, or Recipients of Services—Animal Welfare.” For additional information on vertebrate animals, refer to the Kirschstein-NRSA individual fellowship application instructions or contact OLAW (see contact information in Part III).

Recombinant DNA Molecules and Human Gene Transfer Research

Individuals receiving Kirschstein-NRSA fellowship awards involving use of recombinant DNA molecules must comply with the requirements of the NIH Guidelines for Research Involving DNA Molecules (see “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—NIH Guidelines for Research Involving Recombinant DNA Molecules and Human Gene Transfer Research”). The NIH Guidelines, available from NIH’s OBA (see Part III), should be consulted for complete requirements for the conduct of projects involving recombinant DNA techniques. A copy of the NIH Guidelines is available at http://oba.od.nih.gov/oba/raf/guidelines_02/NIH_Guidelines_Apr_02.htm.

Institutional Research Training Grants

General

NIH will award Kirschstein-NRSA institutional research training grants (T32, T34, and T35) to eligible institutions to develop or enhance research training opportunities for individuals, selected by the institution, who are training for careers in specified areas of biomedical, behavioral, and clinical research. The purpose of the Kirschstein-NRSA program is to help ensure that a diverse and highly trained workforce is available in adequate numbers and in the appropriate research areas and fields to carry out the nation’s biomedical and behavioral research agenda. The Kirschstein-NRSA program supports predoctoral, postdoctoral, and short-term research training as well as limited specialized support at the prebaccalaureate level. All NIH ICs except FIC and NLM award Kirschstein-NRSA institutional research training grants. FIC and NLM have unique funding authorities for training grants that are separate from the Kirschstein-NRSA authority.

Eligibility

Applicant Eligibility

A domestic, non-profit public or private organization may apply for a grant to support a research training program in a specified area(s) of research. Support for predoctoral, postdoctoral, or a combination of trainees may be requested. (Specific program announcements should be consulted for IC guidelines.) Support for short-term training positions for students in health-professional degree programs also may be requested as indicated in “Short-Term Research Training” in this subsection. Each applicant institution must submit an application using the PHS
398 and appropriate instructions (see “Application Requirements and Receipt Dates” in this subsection).

**Research Areas**

Kirschstein-NRSA institutional research training grants may be made for research training in areas that fall within the missions of the NIH ICs. Applications that do not fit these areas will be returned. An increased emphasis has been placed on the research training of physicians. The HHS Secretary is required by law, in taking into account the overall national needs for biomedical research personnel, to give special consideration to physicians who agree to undertake a minimum of 2 consecutive years of biomedical, behavioral, or clinical research training.

The applicant institution must have a strong research program in the areas proposed for research training and must have the staff and facilities required to carry out the proposed program.

Trainees appointed to the training program must have the opportunity to carry out supervised biomedical or behavioral research with the primary objective of developing or extending their research skills and knowledge in preparation for a research career.

**Training Program Director**

The training PD must be an individual with the skills, knowledge, and resources necessary to organize and implement a high-quality research training program at the recipient organization. The training PD at the recipient organization will be responsible for the selection and appointment of trainees to the Kirschstein-NRSA research training grant and for the overall direction, management, and administration of the program. In selecting trainees, the PD must make certain that individuals receiving support meet the eligibility requirements set forth in this subsection.

**Research Training Program**

A Kirschstein-NRSA institutional research training grant must be used to support a program of research training. It may not support studies leading to the M.D., D.D.S., D.V.M., or other clinical, health professional training except when those studies are a part of a formal combined research degree program, such as the M.D./Ph.D. Similarly, trainees may not accept Kirschstein-NRSA support for clinical training that is part of residency training leading to clinical certification in a medical or dental specialty or subspecialty. However, clinicians are permitted and encouraged to engage in Kirschstein-NRSA-supported full-time, postdoctoral research training even when that experience is creditable toward certification by a clinical specialty or subspecialty board.

Research trainees are expected to devote full time to the proposed research training, devoting at least 40 hours per week to the program. During the 40 hours per week required for research training, research trainees who also are training as clinicians must devote their time to the research training and must confine clinical duties to those that are an integral part of the research training experience.
Degree Requirements

Predoctoral Training

Predoctoral research training is for individuals who have a baccalaureate degree and are enrolled in a doctoral program leading to either a Ph.D., a comparable research doctoral degree, or a combined clinical degree and Ph.D, such as M.D./Ph.D. Students enrolled in health-professional programs that are not part of a formal, combined program (i.e., M.D./Ph.D.), and who wish to postpone their professional studies to gain research experience, also may be appointed to a Kirschstein-NRSA institutional research training grant. Predoctoral research training must emphasize fundamental training in areas of basic biomedical and behavioral sciences.

Postdoctoral Training

Postdoctoral research training is for individuals who have received a Ph.D., D.V.M., D.D.S., M.D., or comparable doctoral degree from an accredited domestic or foreign institution. Research training at the postdoctoral level must emphasize specialized training to meet national research priorities in the biomedical, behavioral, or clinical sciences.

Kirschstein-NRSA institutional research training grants are a desirable mechanism for the postdoctoral training of physicians and other health professionals who may have had extensive clinical training but limited research experience. For such individuals, the training may be a part of a research degree program. In all cases, health-professional postdoctoral trainees are to engage in at least 2 years of research, research training, or comparable experiences beginning at the time of appointment, since the duration of training has been shown to be strongly correlated with post-training research activity.

Short-Term Research Training

Short-term research training includes the following:

◆ **Students in health professional schools.** NIH offers two short-term training programs: those that are part of a traditional institutional research training grant (T32) and those that exclusively support short-term trainees (T35). Short-term research training experiences of 2 to 3 months are available to students in health-professional schools under both mechanisms. All short-term training must be full time. Unless otherwise stated, the requirements that apply to institutional research training grants also apply to short-term research training. Current stipend levels are published in NIH Guide for Grants and Contracts.

◆ **T32.** T32 (Kirschstein NRSA-Institutional Research Training Grant) applications may include a request for short-term positions reserved specifically to provide full-time health-related research training experiences during the summer or other “off-quarter” periods. Such positions are limited to medical students, dental students, students in other health-professional programs, and graduate students in the physical or quantitative sciences. Short-term appointments under institutional research training grants are intended to provide health-professional students with opportunities to participate in
biomedical or behavioral research in an effort to attract these individuals into research careers.

To be eligible for short-term predoctoral research training positions, students must be enrolled and in good standing and must have completed at least one quarter in a program leading to a clinical doctorate or a masters or clinical doctorate degree in a quantitative science, such as physics, mathematics, or engineering, before participating in the program. Individuals already matriculated in a formal research degree program in the health sciences, holding a research doctorate or master’s degree, or a combined professional and research doctorate normally are not eligible for short-term training positions. In schools of pharmacy, only candidates for the Pharm. D. degree are eligible for short-term positions.

Short-term positions should be requested in the application for approval at the time of award. Short-term research training positions should last at least 8, but no more than 12, weeks. Health-professional students and students in the quantitative sciences selected for appointment should be encouraged to obtain multiple periods of short-term, health-related research training during the years leading to their degrees. Such appointments may be consecutive or may be reserved for summers or other “off-quarter” periods.

Since some NIH ICs do not support short-term research training positions under the T32 or support them on a limited basis only, applicants are urged to contact the appropriate NIH IC before requesting short-term research training positions as part of a T32 application.

**T35.** Several NIH ICs provide short-term research using a separate training grant mechanism (T35). The program intent and student eligibility requirements are similar to those indicated for the T32. However, since this Kirschstein-NRSA funding mechanism is used by only a few NIH ICs, interested applicants are encouraged to contact specific ICs for details.

**Prebaccalaureate Training**

NIH offers two distinct programs for prebaccalaureate training under the auspices of the Kirschstein-NRSA undergraduate support mechanism (T34). Both programs are designed to support students from institutions with a substantial minority enrollment.

NIGMS administers the MARC U*STAR program. This program is designed to support selected junior/senior undergraduate honors students at baccalaureate colleges and universities.

NIGMS recognizes that there are differences in organizational environments and missions. Therefore, the emphasis of this program is on the specific objectives and measurable goals that the applicant institution sets.
Information about the program is available at http://www.nigms.nih.gov/funding/trngmech.html#ustar or through the following:

MARC Program Branch, NIGMS
Room 2AS.37D
45 Center Drive MSC-6200
Bethesda, MD 20892-6200

Telephone: 301-594-3900
Fax: 301-480-2753
E-mail: tolivera@nigms.nih.gov

NIMH administers the COR Program. The intent of this program is to provide focused undergraduate research and research training experiences in scientific disciplines related to mental health. An applicant institution (a 4-year college or university) must propose a 2-year COR Honors Undergraduate Program for which 6 to 10 highly talented third- and fourth-year undergraduate students will be selected. Students will be provided with mentored research training experiences designed to stimulate their entry into advanced research training programs leading to the doctoral-level or M.D. research career degrees. For more information on this program, contact:

COR Program
Office for Special Populations/NIMH
6001 Executive Blvd.
Suite 8125
MSC-9659
Bethesda, MD 20892-9659

Telephone: 301-443-2847
Fax: 301-443-8022
E-mail: rmays@mail.nih.gov

**Citizenship**

The individual to be trained must be a citizen or a noncitizen national of the United States or have been lawfully admitted for permanent residence at the time of appointment. Noncitizen nationals are people, who, although not citizens of the United States, owe permanent allegiance to the United States. They generally are people born in outlying possessions of the United States (e.g., American Samoa and Swains Island). Individuals who have been lawfully admitted for permanent residence must have a currently valid Alien Registration Receipt Card (I-551) or other legal verification of such status. For example, if an individual has the proper validation on his/her passport, a notarized photocopy of the passport could suffice. Because there is a 6-month limitation on this validation, it is the grantee’s responsibility to follow up and ensure that the individual received the I-551 prior to the 6-month expiration date.
A notarized statement verifying possession of permanent residency documentation must be submitted with the Statement of Appointment (PHS Form 2271). Individuals on temporary or student visas are not eligible for Kirschstein-NRSA support.

Application Requirements and Receipt Dates

Application

The application for Kirschstein-NRSA institutional research training grants is the PHS 398, which contains special instructions for those grants. Application forms, instructions, and related information may be obtained from http://grants.nih.gov/grants/forms.htm. For further assistance, contact GrantsInfo (telephone: 301-435-0714; e-mail: GrantsInfo@nih.gov).

Receipt Dates

Some NIH ICs receive training grant applications three times each year; however, most ICs have one receipt date only. Information on IC-specific receipt dates is available in the NIH Guide for Grants and Contracts in the NIH-wide T32 PA or in RFAs issued by the individual NIH ICs. For a list of the standard receipt dates and review cycle, see the appendix to this section. (Also see http://grants.nih.gov/training/nrsa.htm#inst).

Applicants are encouraged to contact the appropriate NIH staff before preparing and submitting an application. Applications (except those assigned to NIGMS, NICHD, NEI, NIDCR, or NINR) for funding requesting $500,000 or more in direct costs for any year must include a cover letter identifying the NIH staff member within one of the NIH ICs who has agreed to accept assignment of the application.

Special Program Considerations

The primary objective of the Kirschstein-NRSA program is to prepare qualified individuals for careers that have a significant impact on the Nation’s research agenda. Within the framework of the program’s longstanding commitment to excellence and projected need for investigators in certain areas of research, institutions must attempt to recruit individuals from racial or ethnic groups underrepresented in the biomedical and behavioral sciences. The following groups are ones that nationally are underrepresented in biomedical and behavioral research: African Americans, Hispanic Americans, Native Americans, Alaskan Natives, and Pacific Islanders. NIH’s requirements for minority recruitment and retention are described in “Review—Minority Recruitment Plan” in this subsection.

NIH also considers the duration of training and the transition of trainees to other support mechanisms. Studies have shown that the length of the research training grant appointment of postdoctoral trainees with health-professional degrees strongly correlates to subsequent application for and success in receiving independent NIH research support. Therefore, training PDs should appoint only those individuals who are committed to a career in research and plan to remain on the training grant or in a non-Kirschstein-NRSA research experience for a minimum of 2 years in the aggregate. It also has been shown that transition to independent support is related to career success. Therefore, training PDs also should encourage postdoctoral trainees to apply for Kirschstein-NRSA individual postdoctoral fellowships (F32) or mentored career...
development awards (K awards). When reviewing Kirschstein-NRSA institutional research training grant applications, peer reviewers will examine the training record to determine the average duration of training appointments for health-professional postdoctoral trainees and whether there is a history of transition to individual support mechanisms.

Studies also have shown that health professional trainees that train in combined programs with postdoctoral researchers with intensive research experience are more likely to apply for and receive research grant support. Programs in clinical departments that focus on research training for individuals with the M.D. or other health-professional degrees should consider developing ties to basic science departments or, if consistent with the goals of the program, modifying the program to include individuals with research doctorates. In these cases, applications should describe the basic science department’s contribution to the research training experience and indicate whether both health professional trainees and trainees with research doctorates will be included in the training program.

Training PDs also are encouraged to develop methods for ongoing evaluation of the quality of the training program. Although the T32 application process requires extensive career-tracking information, it often is useful to obtain more timely feedback. NIH encourages PDs to develop plans to obtain feedback from current and former trainees to help identify weaknesses in the training program and to provide suggestions for program improvement. Applicant institutions are encouraged to include a description of these plans in competing applications.

Review

Overall

Each initial and competing continuation application will be evaluated for scientific merit by an NIH peer review group. Kirschstein-NRSA institutional research training grant applications also must be reviewed by the National Advisory Council or Board of the IC whose activities relate to the proposed research training.

Applications for Kirschstein-NRSA institutional research training grants will be evaluated using criteria such as the following:

◆ Past research training record of both the program and the designated preceptors.

◆ Objectives, design, and direction of the research training program.

◆ Caliber of preceptors as researchers, including successful competition for research support.

◆ Quality of the organizational training environment for NRSA-supported trainees and relationship of the NRSA program to the broader training program, if appropriate. This includes the level of organizational commitment, quality of the facilities, availability of appropriate courses, and the availability of research support.

◆ Quality of the applicant pool and the selection of individuals for appointment to the training program, including an assessment of the racial and ethnic diversity of the trainee
pool. The assessment will take into account described recruitment and retention and the availability of individuals from underrepresented groups within the relevant pool of applicants.

- Record of the research training program in retaining health-professional postdoctoral trainees for at least 2 years.

In addition, when applicable, the concomitant training of health-professional postdoctorates (e.g., individuals with the M.D., D.O. or D.D.S. degree) with basic science postdoctorates (e.g., individuals with a Ph.D. or Sc.D. degree) or linkages with basic science departments will receive special consideration.

Applicants also are encouraged to consult the PHS 398 application instructions, the NIH T32 PA, and specific IC PAs for additional details.

**Short-Term Research Training Positions**

In addition to the overall programmatic criteria, applications that request short-term research training positions in conjunction with full-time positions will be assessed using specific criteria. The NIH T32 PA and/or specific IC PAs should be consulted for details.

**Minority Recruitment Plan**

The Kirschstein-NRSA institutional research training grant program must provide for the recruitment and retention of individuals from underrepresented minority groups including, but not limited to, African Americans, Hispanic Americans, Native Americans, Alaskan Natives, and Pacific Islanders. All competing applications for Kirschstein-NRSA institutional research training grants must include a specific plan to recruit minorities.

Competing continuation applications for Kirschstein-NRSA institutional research training grants also must include a detailed section on the outcomes of the minority recruitment plan proposed in the previous competing application. Information on successful and unsuccessful recruitment strategies must be included. The application also must include information on the racial/ethnic distribution of the following:

- Students or postdoctorates who applied for admission or positions within the department under the Kirschstein-NRSA institutional research training grant
- Students or postdoctorates who were offered admission to or a position within the department
- Students enrolled in the academic program related to the research training grant
- Students or postdoctorates appointed to the research training grant.

For trainees who were enrolled in the academic program, the application should include information about the duration of research training and whether those trainees have finished their training in good standing.
The success of efforts to recruit and retain minority trainees is a factor in the assessment of the quality of the trainee pool and thus will be included in the priority score. In addition, peer reviewers will evaluate the minority recruitment plan and accomplishments (for competing continuation applications) after the overall score has been determined. Reviewers will examine the strategies to be used in the recruitment of minorities and whether the experience in recruitment during the previous competitive segment has been incorporated into the formulation of the plan for the next competitive segment.

If an application is received without a minority recruitment plan, or without a report on the previous competitive segment, the application will be considered incomplete and may be returned to the applicant without review.

The findings of the review group will be included in an administrative note in the summary statement. If the minority recruitment plan of the application is judged to be unacceptable, funding will be withheld until a revised plan that addresses the deficiencies is received. Staff within the NIH IC, with guidance from its National Advisory Council or Board, will determine whether amended plans and reports submitted after the initial review are acceptable.

Information on the recruitment and retention of underrepresented minority trainees during the previous budget period also must be provided in the non-competing progress report submitted as a prerequisite to receiving non-competing continuation support.

Training in the Responsible Conduct of Research

All Kirschstein-NRSA institutional research training grant applications must include a description of the formal and informal activities related to instruction in the responsible conduct of research planned for the proposed research training program. In addition, NIH encourages institutions to provide instruction in the responsible conduct of research to all individuals in a training program or department, regardless of the source of support.

Every prebaccalaureate, predoctoral, and postdoctoral Kirschstein-NRSA trainee must receive instruction in the responsible conduct of research. Applications must describe a program to provide formal or informal instruction in research integrity and/or the responsible conduct of research, as follows:

- Although NIH does not establish specific curricula or formal requirements, all programs are strongly encouraged to consider instruction in the following areas: conflict of interest, responsible authorship, policies for handling misconduct, data management, data sharing, and policies regarding the use of human and animal subjects. Within the context of training in scientific integrity, it also is beneficial to discuss the mutual responsibilities of the institution and the trainees participating in the program.

- Plans must address the subject matter of the instruction, the format of the instruction, the degree of faculty participation, trainee attendance requirements, and the frequency of instruction. The rationale for the proposed plan of instruction must be provided.
Information on the type of instruction provided, topics covered, and other relevant information, such as attendance by trainees and faculty participation, must be included in future competing continuation applications.

Applications without plans for instruction in the responsible conduct of research will be considered incomplete and may be returned to the applicant without review.

NIH SRGs will assess the applicant’s plans on the basis of the appropriateness of topics, format, amount and nature of faculty participation, and frequency and duration of instruction. The plan will be discussed after the overall determination of merit, so that the quality of the plan will not be a factor in the determination of the priority score. Plans will be judged as acceptable or unacceptable. The acceptability of the plan will be described in an administrative note on the summary statement. Regardless of the priority score, applications with unacceptable plans will not be funded until the applicant provides a revised, acceptable plan. The acceptability of the revised plan will be judged by staff members in the NIH IC.

Following initial review, applications undergo a second-level review by the appropriate NIH IC’s National Advisory Council or Board. In addition to the assessment of the scientific and educational merit of the research training grant application, these advisory groups will consider the initial review group’s comments on the plan for instruction in the responsible conduct of research.

Information on the nature of the instruction in the responsible conduct of science and the extent of trainee and faculty participation also must be provided in the progress report submitted as a prerequisite to receiving non-competing continuation support.

**Notification of Action**

Shortly after the initial review meeting, the PD will be sent a mailer that includes the SRG recommendation/priority score and the name and telephone number of a PO in the assigned NIH IC. The NIH IC automatically forwards a copy of the summary statement to the PD as soon as possible after receiving it from the SRG. The PD will be notified by the PO of the final review recommendation. An NGA will be issued for applications selected for funding. Any questions about initial review recommendations and funding possibilities should be directed to the named PO, not to the SRA of the SRG.

**Period of Support**

*Training Grants*

Kirschstein-NRSA institutional research training grants may be made for competitive segments of up to 5 years and are renewable. Awards within an approved competitive segment normally are made in 12-month increments; support for additional non-competitive years depends on satisfactory progress and availability of funds.
Trainees

Trainees under Kirschstein-NRSA institutional research training grants generally are appointed for full-time 12-month continuous periods. An appointment or reappointment may not exceed 12 months without prior approval by the NIH awarding office. All trainees are required to pursue their research training full time, normally defined as 40 hours per week or as specified by the grantee in accordance with its own policies. Unless the NIH awarding office furnishes other instructions, the amount of the stipend, tuition, and fees for each full period of appointment must be obligated by the grantee from funds available when the individual begins training.

With the exception of specifically designated short-term research training positions, no trainee may be appointed under a regular Kirschstein-NRSA institutional research training grant for less than 9 months except with the prior written approval of the NIH awarding office and then usually only to complete a planned program of training. An initial appointment of less than 9 months may be allowed as long as an assurance is included that the individual will be immediately reappointed in the subsequent year so that the cumulative continuous training period is at least 9 months.

**Part-time training.** Under unusual and pressing personal circumstances, a PD may submit a written request to the NIH awarding office to change a trainee appointment to less than full time. Such requests will be considered case-by-case and must be approved by the awarding office before the applicable budget period. The circumstances requiring the part-time training might include medical conditions, disability, or pressing personal or family situations such as a child or elder care. Part-time training will not be approved to accommodate use of other sources of funding, job opportunities, clinical practice, or clinical training, or for other responsibilities associated with the trainee’s position at the organization. In each case, the written request must be countersigned by the trainee and an AOO and must include documentation supporting the need for part-time training. The written request also must include an estimate of the expected duration of the period of part-time training and assurances that the trainee intends to return to full-time training when that becomes possible and to complete the research training program.

The stipend may be prorated in the grant award during the period of any approved part-time training. Part-time training also may affect the rate of accrual or repayment of the service obligation for postdoctoral trainees. In no case will it be permissible for the trainee to be engaged in Kirschstein-NRSA-supported research for less than 50 percent effort. Individuals who must reduce their commitment to less than 50 percent effort must take a leave-of-absence from a Kirschstein-NRSA training grant.

**Kirschstein-NRSA Limitations**

No individual trainee may receive more than 5 years of aggregate Kirschstein-NRSA support at the predoctoral level and 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of support from Kirschstein-NRSA institutional research training grants and individual fellowships.

Any exception to the maximum period of support requires a waiver from the NIH awarding office based on review of a justification from the individual and the grantee organization. The
trainee must make the request in writing to the NIH awarding office. The trainee’s PD and an AOO must endorse the request certifying the need for additional support. The request must specify the amount of additional support for which approval is sought.

Some generally recognized categories under which NIH may grant exceptions include the following:

- **Physicians/clinicians.** Individuals requiring additional time to complete training, either as participants in a combined M.D./Ph.D. program or as clinicians (e.g., physicians, dentists, veterinarians) who are completing postdoctoral research training, may anticipate favorable consideration of a request for waiver of the time limitation. This action is contingent upon an assurance of the trainee’s good academic standing and justified need for the exception to this policy.

- **Interruptions (break in service).** Requests for additional time also will be considered if an event unavoidably has altered the planned course of the research training, if the interruption has significantly detracted from the nature or quality of the planned research training, and if a short extension would permit completion of the training as planned. Such events include sudden loss of the preceptor’s services or an accident, illness, or other personal situation that prevents a trainee from effectively pursuing research training for a significant period of time. Requests for extension of support also will be considered if a short additional period would provide the trainee an opportunity to use an exceptional training resource directly related to the approved research training program.

Requests that arise from circumstances other than those described above will be considered only if they are accompanied by an exceptionally strong justification.

**Initiation of Support**

An NGA is issued to the grantee organization, normally for a budget period of 12 months. A trainee may be appointed any time during the budget period for an appointment period of 9 to 12 months, without prior approval by the NIH awarding office.

At the time of the initial appointment and subsequent reappointment, the training PD must submit a Statement of Appointment to the NIH awarding office. In addition, a signed Payback Agreement must be submitted for each postdoctoral trainee who is in his/her first 12 months of Kirschstein-NRSA postdoctoral support. See “Reporting Requirements—Statement of Appointment (Form PHS 2271)” and “Reporting Requirements—Payback Agreement (Form PHS 6031)” in this subsection for specific information on required forms. The Statement of Appointment includes biographical data on the trainee and the stipend level for the period of appointment. The stipend is paid by the grantee organization directly to the trainee.

**Allowable and Unallowable Costs**

Policies included in the applicable cost principles and the NIHGPS govern the expenditure of all training grant funds, unless otherwise indicated in the NGA.
**Stipends**

Trainees generally are supported for 12-month full-time training appointments for which they receive a stipend as a subsistence allowance to help defray living expenses during the research training experience. The stipend is not provided as a condition of employment with either the Federal government or the grantee organization. Stipends must be paid in accordance with established stipend levels. No departure from the standard stipend provided by NIH under the grant may be negotiated by the grantee organization with the trainee. NIH stipend amounts may be adjusted only at the time of appointment or reappointment. For appointments of less than 12 months, the stipend will be prorated.

Stipend levels are updated almost every fiscal year. When increases are approved, they are published in *NIH Guide for Grants and Contracts*. Current levels also are posted at [http://grants.nih.gov/training/nrsa.htm](http://grants.nih.gov/training/nrsa.htm).

Stipend levels are as follows:

- **Prebaccalaureate.** Two separate levels are provided for trainees: freshman/sophomore or junior/senior.

- **Predoctoral.** One stipend level is used for all predoctoral trainees, regardless of the level of experience.

- **Postdoctoral.** The stipend level for the entire first year of support is determined by the number of full years of relevant postdoctoral experience at the time of appointment. Relevant experience may include research experience (including industrial), teaching assistantship, internship, residency, clinical duties, or other time spent in a health-related field beyond that of the qualifying doctoral degree. Once the appropriate stipend level has been determined, the trainee must be paid at that level for the entire period of appointment. The stipend for each additional year of Kirschstein-NRSA support is the next level in the stipend structure and does not change mid-year.

**Training-Related Expenses**

Funds are provided to defray costs such as staff salaries, consultant costs, equipment, research supplies, staff travel, and other expenses directly related to the training program. Funds are requested and awarded as a lump sum on the basis of the predetermined amount per predoctoral and postdoctoral trainee approved for support. Levels are published in the *NIH Guide for Grants and Contracts*. Interested applicants should consult the program announcement regarding the specific level for programs such as the short-term training program, the MARC U*STAR program, or the COR program.

Under exceptional circumstances, which can include accommodating the disabilities of a trainee, it is possible to request organizational costs above the standard level. Requests for additional costs must be explained in detail and justified in the application. Consultation with NIH program staff in advance of such requests is strongly advised.
Trainee Tuition, Fees, and Health Insurance

Tuition, fees, and health insurance (self-only or family) are allowable trainee costs only if such charges are applied consistently to all people in a similar training status at the organization, without regard to their source of support. Health insurance can include coverage for costs such as vision and/or dental care if consistent with organizational policy.

Tuition at the postdoctoral level is limited to that required for specific courses in support of the approved training program and requires NIH awarding office prior approval. For all Kirschstein-NRSA institutional research training grant awards, this budget category (tuition, fees, and health insurance) is calculated at the following rate: 100 percent of all costs up to $3,000 and 60 percent of costs above $3,000. Tuition, fees, and health insurance are awarded as a lump sum that can be allocated (without the prior approval of the NIH awarding office) based on recipient needs.

Trainee Travel Costs

If requested by the grantee, the NIH awarding office may provide grant funds to cover the costs of trainee travel, including attendance at scientific meetings, which the organization determines is necessary to the individual’s training. Funds may not be expended to cover the costs of travel between the trainee’s place of residence and the training institution, except that the grantee organization may authorize a one-way travel allowance in an individual case of extreme hardship.

In addition, support for travel to a research training experience away from the grantee organization may be permitted. Research training experiences away from the parent organization must be justified on the basis of the type of opportunities for training available, the opportunities offered that are different from those at the parent organization, and the relationship of the proposed experience to the trainee’s career stage and career goals. This type of research training requires prior approval of the NIH awarding office. Letters requesting such training may be submitted to the NIH awarding office at any time during the appointment period.

Short-Term Training Costs

The grantee may receive up to one-twelfth of the annual amount designated for training-related expenses each month to offset the costs of tuition, fees, travel, supplies, and other expenses for each short-term, health-professional research training position.

Employee Benefits

Because Kirschstein-NRSA awards are not provided as a condition of employment with either the Federal government or the grantee, it is inappropriate and unallowable for organizations to seek funds, or to charge Kirschstein-NRSA institutional research training grants, for costs that normally would be associated with employee benefits (for example, FICA, workers compensation, and unemployment insurance).
Facilities and Administrative Costs

Grantees, other than State, local, or Indian tribal governments, will receive F&A costs at 8 percent of modified total direct costs (exclusive of tuition and fees, health insurance, and expenditures for equipment) rather than on the basis of a negotiated rate agreement. State, local, and Indian tribal government agencies are eligible for full F&A cost reimbursement. For this policy, State universities or hospitals are not considered governmental agencies.

Rebudgeting of Funds

Funds may be rebudgeted only as follows:

◆ Trainee-related expenses. Rebudgeting of funds awarded in a lump sum for trainee-related expenses does not require NIH awarding office prior approval.

◆ Trainee costs. For rebudgeting purposes, trainee costs include funds awarded in the stipends or tuition/fees and health insurance budget categories. These costs may not be used for other purposes except under unusual circumstances and then only with the prior approval of the NIH awarding office. Unless otherwise restricted, rebudgeting into or within the stipends and tuition, fees, and health insurance categories is allowable without prior approval of the NIH awarding office.

◆ Trainee travel. For rebudgeting purposes, trainee travel is not considered a trainee cost and, therefore, may be rebudgeted into any other budget category without prior approval of the NIH awarding office.

Stipend Supplementation, Compensation, and Other Income

Stipend Supplementation

Grantees may supplement stipends from non-Federal funds provided the supplementation is without obligation to the trainee. An organization can determine what amount of stipend supplementation, if any, will be provided according to its own formally established policies governing stipend support. These policies must be consistently applied to all individuals in a similar training status regardless of the source of funds. Federal funds may not be used for stipend supplementation unless specifically authorized under the terms of the program from which funds are derived. An individual may use Federal educational loan funds or VA benefits when permitted by those programs as described in “Educational Loans or GI Bill” in this subsection. Under no circumstances may PHS funds be used for supplementation.

Student Compensation

NIH recognizes that trainees as students may seek part-time employment coincidental to their training program to further offset their expenses. Funds characterized as compensation may be paid to trainees only when there is an employer-employee relationship, the payments are for services rendered, and the situation otherwise meets the conditions of the compensation of students as detailed in “Cost Considerations—Allowability of Costs/Activities—Selected Items of Cost—Salaries and Wages—Compensation of Students.” In addition, compensation must be
in accordance with organizational policies consistently applied to both federally and non-
federally supported activities and must be supported by acceptable accounting records that reflect
the employer-employee relationship. Under these conditions, the funds provided as
compensation (salary, fringe benefits, and/or tuition remission) for services rendered, such as
teaching or laboratory assistance, are not considered stipend supplementation; they are allowable
charges to Federal grants, including PHS research grants. However, it is expected that
compensation from research grants will be for limited part-time employment apart from the
normal full-time training activities.

Compensation may not be paid from a research grant that supports the same research that is part
of the trainee’s planned training experience as approved in the Kirschstein-NRSA institutional
research training grant application. Under no circumstances may the conditions of stipend
supplementation or the services provided for compensation interfere with, detract from, or
prolong the trainee’s approved Kirschstein-NRSA training program. Training PDs must approve
all instances of employment on research grants to verify that the circumstances will not detract
from or prolong the approved training program.

Concurrent Benefits

An individual may not receive support under a Kirschstein-NRSA institutional research training
grant concurrently with another federally sponsored fellowship or similar Federal award that
provides a stipend or otherwise duplicates provisions of the Kirschstein-NRSA award.

Educational Loans or GI Bill

An individual may accept concurrent educational remuneration from the VA (GI Bill) and
Federal educational loan funds. Such funds are not considered supplementation or compensation.
In the case of the MARC-U*STAR program, funds from a PELL grant may be accepted as well.
Postdoctoral trainees also may be eligible to participate in the NIH Loan Repayment Program.
Information about this program is available at http://www.lrp.nih.gov/.

Taxability of Stipends

Section 117 of the Internal Revenue Code applies to the tax treatment of scholarships and
fellowships. Degree candidates may exclude from gross income (for tax purposes) any amount
used for course tuition and related expenses, such as fees, books, supplies, and equipment,
required for courses of instruction at a qualified educational organization. Nondegree candidates
are required to report as gross income any monies paid on their behalf for stipends or any course
tuition and fees required for attendance.

The taxability of stipends in no way alters the relationship between Kirschstein-NRSA trainees
and grantee organizations. Kirschstein-NRSA stipends are not considered salaries. In addition,
trainees supported under Kirschstein-NRSA institutional research training grants are not
considered to be in an employee-employer relationship with NIH or the grantee organization
solely as a result of the Kirschstein-NRSA support. Interpretation and implementation of the tax
laws are the domain of the IRS and the courts. NIH takes no position on what the status may be
for a particular taxpayer, and it does not have the authority to dispense tax advice. Individuals
should consult their local IRS office about the applicability of the law to their situation and for information on their tax obligations.

**Form 1099**

Although stipends are not considered salaries, the income still is subject to Federal and, sometimes, State taxes. The grantee organization may report such income on IRS Form 1099, Statement of Miscellaneous Income. Normally, the business office of the grantee organization will be responsible for annually preparing and issuing the IRS Form 1099 for trainees. Grantee organizations are not required to issue the Form 1099, but it is a useful form of documentation of income received and it serves as a reminder to the trainee that some tax liability may exist. Even if the grantee organization does not issue the Form 1099, trainees are required to report Kirschstein-NRSA stipends as income.

**Carryover Authority**

Kirschstein-NRSA institutional research training grants are included in expanded authorities (except for carryover of unobligated balances). In most cases, grantees must obtain awarding office prior approval to carry over funds; however, some NIH awarding offices have waived this requirement for training grants as well. The NGA for a Kirschstein-NRSA institutional research training grant will specify whether or not the grantee must obtain the prior approval of the awarding office to carry over funds.

**Program Income**

Applicants for NIH research grants, including Kirschstein-NRSA institutional research training grants, are required to include in their grant applications an estimate of the amount and source of program income expected to be generated as a result of the project for which support is being sought. See “Administrative Requirements—Management Systems and Procedures—Program Income” for policies that govern the disposition and reporting of program income.

**Reporting Requirements**

The submission of the forms described in this subsection is critical to establishing the payment of stipends and other costs and determining possible payback service. Failure to submit the required forms in a timely manner may result in an expenditure disallowance or a delay in any continuation funding. All of these forms are available in pdf-fillable and rtf formats at [http://grants.nih.gov/grants/forms.htm](http://grants.nih.gov/grants/forms.htm). The NIH awarding office also may provide copies of applicable forms along with the NGA or reference this website in the award.

**Statement of Appointment (Form PHS 2271)**

The grantee must submit a PHS 2271 to the NIH awarding office before or at the start of each trainee’s appointment or reappointment. If registered in the NIH eRA Commons, grantees may submit the PHS 2271 data electronically using the X-TRAIN application. More information on X-TRAIN is available at [https://commons.era.gov/commons/](https://commons.era.gov/commons/).
No stipend or other allowance may be paid until the appointment form has been submitted. If the support covers the individual’s initial 12 months of postdoctoral support, a signed Payback Agreement also must be submitted. The information on the Statement of Appointment (and the Termination Notice as discussed below) is the basis for determining the length or amount of an individual’s payback requirement. An accurate Social Security Number should be included on the Statement of Appointment and all other documents. The PD and the organizations’ financial officials should coordinate the information reported on the Statement of Appointment. It should be treated as a financial document for obligating funds (stipends), which later are reflected on the Termination Notice and as part of the total costs in the FSR.

**Interim revisions.** Any changes or corrections involving a trainee appointment under a Kirschstein-NRSA institutional research training grant, such as name, permanent mailing address, period of training, or stipend support, must be reported by the training PD to the NIH awarding office on an amended PHS 2271 at the time of the change.

**Consecutive support.** If a trainee switches from one Kirschstein-NRSA mechanism to another (e.g., from an individual fellowship to a training grant) or from one NIH awarding office to another, the requirement for payback service incurred is deferred until the total period of Kirschstein-NRSA support is completed. All Statement of Appointment forms are reviewed to determine if previous Kirschstein-NRSA support has been provided.

**Payback Agreement (Form PHS 6031)**

A Payback Agreement that covers the initial 12 months of Kirschstein-NRSA postdoctoral support must be signed by each postdoctoral trainee. If the individual has already received 12 months of postdoctoral support under any Kirschstein-NRSA training grant or fellowship award, this form is not required. For details on Kirschstein-NRSA payback, see “Payback Reporting Requirements” in this section.

No Payback Agreement is required for predoctoral or prebaccalaureate trainees.

**Termination Notice (Form PHS 416-7)**

The Termination Notice (along with the PHS 2271 Statement of Appointment form) is the basis for validating the total period of Kirschstein-NRSA support and establishing the amount of payback obligation, if any, for each Kirschstein-NRSA trainee. The PD is responsible for submitting a Termination Notice for each trainee within 30 days of the end of the total period of support. The lack of timely and accurate information on this form could adversely affect the payback process.

**Progress Reports**

Progress reports must be submitted for non-competing continuation support in accordance with the instructions accompanying the progress report forms (PHS 2590). Progress report forms and instructions are available from the NIH website at [http://grants.nih.gov/grants/forms.htm](http://grants.nih.gov/grants/forms.htm). Progress report form pages are available in pdf-fillable and rtf formats. Incomplete or inadequate progress reports may be returned for revision and may result in a delay of continued support.
Following completion or termination of a project period, the grantee must submit a final progress report to the NIH awarding office within 90 days after the end of grant support.

**Financial Status Report**

An annual FSR is required for all Kirschstein-NRSA institutional research training grant awards no later than 90 days after the close of each budget period. This report will document the financial status of the grant according to the official accounting records of the grantee organization. Trainee stipends and tuition are obligated for the full 12-month appointment from the budget period in which the appointment is initiated. Portions of stipends and tuition that extend beyond the budget period are carried over as unliquidated obligations. However, if the report covers the final budget period of the project period, it must have no unliquidated obligations and must indicate the exact balance of unobligated funds (see “Administrative Requirements—Monitoring—Reporting—Financial Reports” and “Administrative Requirements—Closeout—Final Reports”).

**Changes in the Project**

Changes in the program objectives as they relate to the area of research training for which the grant was approved require prior approval of the NIH awarding office.

If the PD is expected to be absent more than 3 months, plans for the conduct of the program during his or her absence must be approved in writing by the NIH awarding office. Any proposed change of PD must be requested by the grantee organization and be approved in writing by the NIH awarding office following review of the nominee’s qualifications and re-evaluation of the project in light of the proposed change.

Kirschstein-NRSA institutional research training grants may not be transferred from one domestic organization to another except under the most unusual circumstances. Such a change generally will be approved by the NIH awarding office only if all of the major benefits attributable to the original grant can be transferred and there is no negative impact on trainees active in the program.

**Other Terms and Conditions**

**Leave**

**Vacations and holidays.** Trainees may receive the same vacations and holidays available to individuals in comparable training positions at the grantee organization. Trainees will continue to receive stipends during vacations and holidays. At academic institutions, the time between semesters or academic quarters generally is considered an active part of the training period.

**Sick leave and other leave.** Trainees may continue to receive stipends for up to 15 calendar days of sick leave per year. Under exceptional circumstances, this period may be extended by the NIH awarding office in response to a written request from the training PD countersigned by an AOO. Sick leave may be used for the medical conditions related to pregnancy and childbirth.
Parental leave. Trainees may receive stipends for up to 30 calendar days of parental leave per year for the adoption or the birth of a child when those in comparable training positions at the grantee organization have access to paid leave for this purpose. Either parent is eligible for parental leave. The use of parental leave must be approved by the training PD.

Terminal leave. A period of terminal leave is not permitted, and payment may not be made from grant funds for leave not taken.

Unpaid leave. Individuals requiring extended periods of time away from their research training experience, that is, more than 15 calendar days of sick leave or more than 30 calendar days of parental leave, must seek approval from the NIH awarding office for an unpaid leave of absence. Approval for a leave of absence must be requested in advance by the training PD and be countersigned by an AOO.

During a leave of absence, documentation to suspend the period of appointment must be completed by submitting an amended Statement of Appointment and a Termination Notice. These forms should be submitted to the NIH awarding office at the beginning of the leave. Upon resumption of Kirschstein-NRSA support, the reappointment must be documented on another Statement of Appointment form.

Termination

NIH may terminate a Kirschstein-NRSA institutional research training grant before its normal expiration date if it determines that the grantee has materially failed to comply with the terms and conditions of the award or to carry out the purpose for which the award was made. If an award is terminated for cause, NIH will notify the grantee organization in writing of this determination, the reasons for the determination, the effective date, and the right to appeal the decision. NIH also may terminate an award at the request of the grantee.

An organization that wants to terminate a training grant before the scheduled termination date must notify the NIH awarding office immediately. In such cases, NIH will issue a revised NGA to specify the changed period of support and to show prorated trainee stipends, depending on the amount of time spent in training.

Publications and Sharing of Research Results

NIH supports the practical application and sharing of outcomes of funded research. Therefore, PDs and trainees should make the results and accomplishments of their Kirschstein-NRSA institutional training grant activities available to the research community and to the public at large. The grantee organization should assist trainees in these activities, including the potential commercialization of inventions. No restrictions should be placed on the publication of results.

Trainees are encouraged to submit reports of their findings for publication to the journals of their choice. Responsibility for direction of the project should not be ascribed to NIH. However, NIH IC support must be acknowledged by a footnote in language similar to the following: “This investigation was supported by the National Institutes of Health under Ruth L. Kirschstein National Research Service Award (number) from the (name of NIH IC).” In addition, Federal
funding must be acknowledged as provided in “Public Policy Requirements and Objectives—Availability of Information—Acknowledgment of Federal Funding.”

Copyright

Except as otherwise provided in the conditions of the award, when a publication or similar copyrightable material is developed from work supported by NIH, the author is free to arrange for copyright without the approval of the NIH awarding office. Any such copyrighted materials shall be subject to a royalty-free, nonexclusive, and irrevocable license to the Federal government to reproduce them, translate them, publish them, and use and dispose of them, and to authorize others to do so for Federal government purposes.

Inventions and Patents

All Kirschstein-NRSA institutional research training grants and other funding agreements awarded primarily for educational purposes are not subject to invention reporting requirements nor does NIH have any rights to inventions under those grants and agreements (as specified in 45 CFR 74.24(h) and in 37 CFR 401.1(b)).

Public Access to Research Data

As specified in 45 CFR 74.36(d), the public must be given access to research data (through FOIA) under specified circumstances. NIH guidance is available at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.

Disposition of Professional Fees

Fees resulting from clinical practice, professional consultation, or other comparable activities performed pursuant to the purpose of the award may not be retained by the trainee. Such fees must be assigned to the grantee organization for disposition in accordance with NIH policy on program income (see “Administrative Requirements—Management Systems and Procedures—Program Income”). The term “professional fees” does not apply to honoraria, fees for scholarly writing, delivery of occasional outside lectures, or service in an advisory capacity to public or private non-profit organizations. If permitted by organizational policy, these fees may be retained by the trainee.

Public Policy Requirements and Objectives

Human Subjects

Kirschstein-NRSA institutional research training grants involving human subjects must comply with the requirements for their protection (see “Public Policy Requirements and Objectives—Requirements Affecting the Rights and Welfare of Individuals as Research Subjects, Patients, or Recipients of Services—Human Subjects”). If the applicant organization has an approved FWA or other applicable assurance on file with OHRP but, at the time of application, plans for the involvement of human subjects are indefinite, the assurance number should be provided on the face page of the application. If an award is made, human subjects may not be involved until a certification of IRB approval or designation of exemption has been submitted.
In many instances, trainees supported by Kirschstein-NRSA institutional research training grants will be participating in research supported by research project grants for which the IRB review is already completed or an exemption is already designated. This review or exemption designation is sufficient, provided the research would not be substantially modified by the participation of a trainee. The appropriate grants must be identified along with their IRB review dates or exemption designation.

For additional information on human subjects requirements, refer to the PHS 398 or contact OHRP (see Part III for contact information).

Monitoring Plan and Data and Safety Monitoring Board

Research involving clinical trials must include provisions to ensure the safety of participants and the validity and integrity of the data. A monitoring plan establishes the overall framework for data and safety monitoring. It should describe the entity that will be responsible for monitoring and how adverse events will be reported to IRBs, NIH, and FDA. The frequency of monitoring will depend on potential risks, complexity, and the nature of the trial.

NIH specifically requires the establishment of DSMBs for multi-site clinical trials involving interventions that entail potential risks to the subject and, generally, for Phase III clinical trials. Although Phase I and Phase II clinical trials also may use DSMBs, smaller clinical trials may not require this type of oversight, and alternative monitoring plans may be appropriate.


Inclusion of Women and Minorities in Clinical Research

It is NIH policy that women and members of minority groups and their subpopulations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research (see “Public Policy Requirements and Objectives—Requirements for Inclusiveness in Research Design”). This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research, Amended, October 2001, is available on the NIH website at http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.

Inclusion of Children as Participants in Research Involving Human Subjects

NIH maintains a policy that children (individuals under the age of 21) must be included in all human subjects research conducted or supported by NIH, unless there are scientific and ethical reasons not to include them (see “Public Policy Requirements and Objectives—Inclusiveness in Research Design”). NIH Policy and Guidelines on the Inclusion of Children as Participants in
Research Involving Human Subjects is available on the NIH website at

Human Embryonic Stem Cell Research

Criteria for Federal funding of research on hESC can be found at
http://stemcells.nih.gov/index.asp and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (see http://escr.nih.gov). It is the responsibility of the trainee to provide the official NIH identifiers for the hESC lines to be used in the proposed research (see “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—NIH Guidelines for Research Using Human Embryonic Stem Cells”). Applications that do not provide this information will be returned without review.

Vertebrate Animals

Kirschstein-NRSA institutional research training grants involving use of vertebrate animals must comply with the requirements for their protection (see “Public Policy Requirements and Objectives—Animal Welfare”).

If the applicant organization has an approved Assurance of Compliance on file with OLAW but, at the time of application, its plans for the involvement of vertebrate animals are so indefinite that IACUC review and approval are not feasible, on the face page of the application, the organization should check “Yes,” include the animal welfare Assurance of Compliance number, and indicate “Indefinite.” If an award is made, vertebrate animals may not be involved until verification of the IACUC approval date has been submitted to the NIH awarding office.

In many instances, trainees supported by institutional research training grants will be participating in research supported by research project grants for which the IACUC review already is completed. This review is sufficient, provided the research would not be substantially modified by the participation of a trainee. The appropriate grants must be identified along with their IACUC review dates.

If the applicant organization does not have an approved Assurance of Compliance on file with OLAW or for additional information on vertebrate animals, refer to the PHS 398 or contact OLAW (see Part III).

Recombinant DNA Molecules and Human Gene Transfer Research

Institutions receiving Kirschstein-NRSA institutional research training grants involving use of recombinant DNA molecules must comply with the requirements of the NIH Guidelines for Research Involving Recombinant DNA Molecules (see “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—NIH Guidelines for Research Involving Recombinant DNA Molecules and Human Gene Transfer Research”). The NIH Guidelines, available from NIH’s OBA (see Part III), should be consulted.

**Payback Reporting Requirements**

**General**

The Kirschstein-NRSA legislation requires some recipients of support (fellows or trainees) to pay back the Federal government by engaging in health-related biomedical or behavioral research, including the direct administration or review of health-related research, health-related teaching, or any combination of these activities. See “Payback—Service Payback—Definitions” in this subsection for complete coverage of requirements.

The National Institutes of Health Revitalization Act of 1993, signed into law on June 10, 1993, included provisions in Section 1602 that substantially modified the service payback requirement for individuals supported by NRSA fellowships and research training grants.

An individual who was appointed to a research training grant or who had a fellowship award activated before June 10, 1993, is subject to the service payback provisions in effect at the time of the appointment or award.

**Implementation**

The incurrence of a payback obligation for an NRSA recipient is solely dependent upon when NRSA support was received.

**Before August 13, 1981**

Before August 13, 1981 (enactment of the Omnibus Reconciliation Act), a payback obligation existed for all prebaccalaureate, predoctoral, and postdoctoral support received.

**Effective August 13, 1981**

Effective August 13, 1981, a 12-month legislative allowance waiving payback obligation for the first 12 months of support was enacted for all predoctoral and postdoctoral trainees and fellows. This legislation provided that all trainees and fellows who were not in delinquent status on that date receive the allowance (this was retroactive to the beginning of the NRSA program). Individuals in delinquent status continued to have a payback obligation for all support received. This legislative change also eliminated the payback obligation for prebaccalaureate recipients.

Historically, short-term trainees supported by the T35 mechanism (NRSA short-term training) incurred no payback obligation. However, for short-term trainees supported within a T32 program, the periods of support accrued and ultimately counted toward the total NRSA support.
Effective June 10, 1993 (NIH Revitalization Act)

**Predoctoral recipients.** For predoctoral trainees beginning appointments and for predoctoral fellows activating awards on or after June 10, 1993, no payback obligation is incurred. Thus a Payback Agreement Form (PHS 6031) is not required.

**Postdoctoral recipients.** For individuals receiving postdoctoral support under individual fellowships or institutional research training grants, a payback obligation is incurred for the first 12 months of Kirschstein-NRSA support with the 13th and subsequent months of postdoctoral support serving to pay back this obligation month by month. A Payback Agreement (PHS 6031) is required but only for the initial 12-month postdoctoral support period.

The requirements established by the Revitalization Act also provide that the 13th and subsequent months of postdoctoral Kirschstein-NRSA-supported research training will be used to discharge any prior postdoctoral Kirschstein-NRSA service payback obligation. See “Payback—Service Payback—Initiation of Payback Service” in this subsection for other requirements of the Act.

**Short-Term Training**

Any individual receiving support for predoctoral short-term training does not incur a payback obligation. Postdoctoral short-term training incurs a payback obligation. Any support accrues along with any subsequent postdoctoral support until the first 12 months is established. At that point, the 13th and subsequent months of support serve to offset the obligation month by month. If subsequent postdoctoral support is not received, the individual has an obligation to pay back in the traditional manner.

**Payback**

Once a Termination Notice has been submitted and accepted, the NIH awarding office determines if a payback obligation exists. When a trainee or fellow must pay back, the Termination Notice and related documents are forwarded to the NIH Kirschstein-NRSA PSC. PSC personnel are NIH’s experts in Kirschstein-NRSA payback requirements. The PSC currently administers the payback activities of almost all of the NIH ICs and soon is expected to have this responsibility for all ICs. The authorities related to payback normally delegated to the IC are delegated to the Chief, Kirschstein-NRSA PSC. The PSC retains all records until an obligation is satisfied and transfers closed records to the Federal Records Center.

Most Kirschstein-NRSA recipients eventually fulfill their payback obligation by engaging in activities that are determined to be acceptable service. Some recipients fulfill their obligation via financial payback. On rare occasions, the payback obligation is waived.

As indicated in “Payback Reporting Requirements—Implementation” in this subsection, the amount of a payback obligation incurred is solely dependent on the total period of support and the laws in effect when the Kirschstein-NRSA support was received.
Service Payback

Definitions

For fulfilling the Kirschstein-NRSA service payback obligation, the following definitions apply:

◆ **Research.** Research is defined as an activity that involves designing experiments, developing protocols, and collecting and interpreting data. In addition, review of original research or administration of original research that includes providing scientific direction and guidance to research may be acceptable if a doctoral degree and relevant research experience is required for individuals filling such positions. Such research can be conducted in an academic, government, commercial, or other environment in either a foreign or domestic setting. In addition, when consistent with the cumulative amount, type, and frequency of research or research training experiences, functions that involve analytic or other technical activities conducted in direct support of research, as defined above, also will satisfy the service payback obligation.

◆ **Teaching.** Teaching is an instructional activity that takes place in an organized educational or other instructional environment. Activities classified as teaching are generally carried out in a formal didactic setting, but other activities will be considered if they are consistent with the certifying institution’s policy on the definition of teaching responsibilities. Such teaching can be conducted at universities, professional schools, research institutes, teaching hospitals, primary schools, secondary schools, or colleges. When calculating hours of teaching per week, it is permissible to include 3 hours of preparation time for each hour of direct instruction. Acceptable teaching activities must have a biomedical or health-related relevance.

◆ **Health-related activities.** This incorporates a broad range of activities related to the description, diagnosis, prevention, or treatment of disease from the most basic biomedical or behavioral research to the most applied or clinical research. Activities in fields other than those usually considered to be directly related to human disease, such as agriculture, environmental sciences, biotechnology, and bioengineering, also will be considered health-related.

Time Commitment

All acceptable activities must be undertaken for periods that average at least 20 hours per week. Total employment in such activities averaging less than 20 hours per week cannot be counted toward fulfilling the obligation except in cases of disability or other pressing personal or family circumstances, such as child care or elder care responsibilities. It is not permissible for individuals otherwise engaged in full-time employment to engage in service payback activities at effort levels below 20 hours per week.

If less than 20 hours commitment per week is permitted, the total period of service obligation will be prorated. For example, an individual who owes 12 months of service and can devote only 10 hours per week to service payback activities due to a disability will be required to engage in
such service for 24 months. These exceptions are rare and must receive prior approval from the PSC.

Initiation of Payback Service

Initiation of payback service depends on when awards were made:

- **Support received before NIH Revitalization Act.** For predoctoral NRSA recipients who incurred a payback obligation from support received prior to June 10, 1993, payback service must be performed, or financial repayment made, following completion of NRSA support. No amount or type of activity before or during the period of NRSA support will satisfy the NRSA service payback obligation. However, payback service may be initiated immediately after termination of NRSA support if the research or teaching activities meet the criteria cited in “Payback Reporting Requirements—Payback—Service Payback—Definitions.”

For postdoctoral NRSA recipients who incurred a payback obligation from support received prior to June 10, 1993, continued postdoctoral NRSA support can be used to satisfy any previous postdoctoral payback obligation. However, continued postdoctoral NRSA support cannot be used to payback any obligation remaining from predoctoral support received before June 10, 1993.

- **Support received after NIH Revitalization Act.** Beginning with awards made under the authority of the NIH Revitalization Act (appointments on or after June 10, 1993), service payback obligations for postdoctoral recipients may be discharged by

  - receiving an equal number of months of postdoctoral Kirschstein-NRSA support beginning in the 13th month of such postdoctoral Kirschstein-NRSA support, or

  - engaging in an equal number of months of health-related research, training, or teaching averaging more than 20 hours per week.

Trainees and fellows beginning appointments for the 13th and subsequent months of postdoctoral Kirschstein-NRSA support on or after June 10, 1993, will be engaging in service that also satisfies any postdoctoral NRSA service payback obligation incurred before June 10, 1993. Post-award service in non-Kirschstein-NRSA supported health-related research, training, or teaching is creditable toward any predoctoral or postdoctoral Kirschstein-NRSA service payback obligation.

Source of Funding

There is no restriction on the source of funds supporting an individual’s service payback activity except that predoctoral payback activities must not be supported by Kirschstein-NRSA funds. An individual could be supported by a PHS grant or any non-Kirschstein-NRSA Federal or non-Federal source. Unpaid service also is permitted.
Timing of Service Obligation

An individual must begin to undertake the payback service requirement within 2 years after the termination date of the individual’s Kirschstein-NRSA support unless an extension of time to begin payback has been approved by the PSC (see “Payback—Extensions of Payback—Extensions of the 2-Year Period to Initiate Payback”).

Financial Payback

Policy and Principal Calculation

If an individual does not perform payback service, the Federal government shall be entitled to recover certain costs. The amount the United States is entitled to recover depends on when support was received. Calculation formulas take into account the total amount paid the individual (see “Interest and Interest Rate Calculation” in this subsection), less any obligation already fulfilled through service or legislative allowance when applicable. The total paid an individual under an institutional research training grant or individual fellowship award at a domestic, non-Federal sponsoring institution is considered to be the stipend only. The total paid an individual under a fellowship award at a foreign sponsoring institution includes the payment for the round-trip travel costs. The total paid an individual under a fellowship award at a Federal sponsoring institution includes any money expended from the institutional allowance provided for such purposes as health insurance, travel, tuition, and fees.

Interest and Interest Rate Calculation

NIH computes interest on the principal amount beginning on the date the United States became entitled to recover stipends. The interest rate is the rate fixed by the Secretary of the Treasury after considering prevailing consumer rates of interest. Accordingly, interest may be accruing on any Kirschstein-NRSA obligation if the 2-year grace period has passed, if deferment has expired, or if service has terminated before completion of the payback obligation. The Department of the Treasury certifies Kirschstein-NRSA interest rates quarterly. Interest is computed on a 360 day-a-year basis and is applied through the date of receipt. Any outstanding amount will continue to bear interest at the initial rate set by the Secretary of the Treasury until financial payback is complete.

The date that sets the applicable rate of interest depends on the type of Kirschstein-NRSA account received for collection. If financial payback is voluntary, the signature date of the notification of voluntary payback is the date that determines the interest rate as well as the initiation of the 3-year repayment period. If financial payback is involuntary, the date that sets the interest rate and the 3-year repayment period is the date of expiration of the 2-year period following the termination of Kirschstein-NRSA support. For example, if during June 1998, OFM received an account reflecting January 31, 1996, as the termination date of NRSA support, the Federal government, lacking any documentation to the contrary, becomes entitled to financial payback effective February 1, 1998. The rate of interest applicable is determined based on the February 1, 1998, date, and the total NRSA obligation is required to be fulfilled by January 31, 2001.
The amount to be recovered financially, as determined from the Termination Notice plus applicable interest, shall be paid to the United States within the 3-year period following such date.

_Exensions of Payback_

The authorizing legislation and the implementing regulations (42 CFR Part 66) permit exceptions to certain requirements under the Act.

**Extensions of the 2-Year Period to Initiate Payback**

Frequently, an Annual Payback Activities Certification is returned requesting an extension of the 2-year period to initiate payback. Indication of valid plans to initiate payback soon after the 2-year grace period may be good reason to grant an extension.

**Basis for Extensions or Break in Service**

The Payback Service Center may extend the period for undertaking payback service or permit breaks in continuous service. These determinations are based on the following criteria:

- An extension or break in service is necessary so the individual may complete his or her research or clinical training.
- An extension or break in service is necessary so the individual may participate in the NIH Loan Repayment Program.
- The individual is unable to complete the requirements within the specified period because of a temporary disability.
- Completion by the individual of the requirement within the specified period would involve substantial hardship to the individual, and failure to extend the period would be against equity and good conscience.

Reasons for an extension or break in service include such things as completing residency training, where clinical teaching or research are not an integral part of their training, or seeking employment that would fulfill the payback requirements.

Requests must be made in writing (separate letter or APAC) to the PSC, specifying the need for additional time and the length of the required extension.

**Waiver**

**Policy**

The authorizing legislation and the implementing regulation (42 CFR Part 66) permit exceptions to certain requirements under the Act. NIH may waive, in whole or in part, the payback obligation, upon determination that compliance by the individual is impossible or would involve
substantial hardship, and enforcement of the individual’s obligation would be against equity and good conscience.

**Waiver Criteria**

Requests for waivers should be made in writing to the PSC and should explain the need for the waiver according to the following criteria:

- Compliance by an individual will be deemed impossible if the individual is permanently and totally disabled.

- In determining whether compliance would involve substantial hardship to the individual and would be inequitable, the PSC will consider the individual’s
  - financial resources and obligations at the time of request for a waiver and
  - estimated future financial resources and obligations.

In rare cases, the following also might be considered:

- Reasons for the individual’s failure to complete the requirements within the prescribed period, such as personal problems

- Extent to which the individual has engaged in payback activities

- Sufficiency of training to qualify the individual to perform such activities

- Lack of employment opportunities appropriate to the individual’s education and training

- Any other extenuating circumstances.

Any obligation of any individual toward payback will be canceled upon death of the individual.

**Certification of Payback Activities**

*Annual Payback Activities Certification (Form PHS 6031-1)*

**Annual Certification**

Payback service is certified through the use of the Kirschstein-NRSA APAC (PHS 6031-1). Individuals with an outstanding payback obligation must complete an APAC annually until their payback obligation is fulfilled.

If an individual has a payback obligation, an APAC is sent by NIH approximately one year after the completion of Kirschstein-NRSA support. Payback service may be initiated within the first 12 months of termination even though trainees and fellows have up to 24 months to initiate payback. There is no penalty to those individuals who do not initiate payback within the first 12
months; however, it is critical that they complete an APAC form to ensure contact is maintained and addresses are current.

The individual will report on the APAC the activity in which he or she was engaged for the preceding 12 months, within the specified reporting period. These forms are to be returned within 30 days of the reporting period end date to the address specified on the mailing label included with the form.

The PSC reviews the forms, determines acceptability of reported activities, and then informs the former trainee or fellow of his or her status. This process will continue annually until the individual’s total payback obligation is satisfied.

**Change of Address**

Any change in the mailing address of a Kirschstein-NRSA recipient must be reported promptly to the PSC until the service obligation is fully discharged. Notification of changes can be made by letter, telephone, fax, or e-mail.

**Breaks in Kirschstein-NRSA Support**

Sometimes a trainee/fellow will have a period of non-Kirschstein-NRSA support between two Kirschstein-NRSA awards. An appropriate activity performed during this period of time may count for payback purposes toward the first Kirschstein-NRSA award. If the nonsupport period is 6 months or longer, the individual receives an APAC form through the regular mechanism. However, if the break is less than 6 months, an APAC will not be mailed automatically. If acceptable payback service was performed during the break, the individual may complete an APAC, which can be obtained from the NIH website at [http://grants.nih.gov/grants/forms.htm](http://grants.nih.gov/grants/forms.htm).

**National Health Service Corps**

Occasionally, a Kirschstein-NRSA recipient may have been a NHSC scholar. Before October 26, 2002, legislation provided authority for holders of both awards to pay back the obligation of the two sources of support concurrently. Therefore, activities that qualified as Kirschstein-NRSA payback also served as payback for the NHSC obligation. However, no Kirschstein-NRSA legislative allowance is credited toward NHSC service. The PSC monitors both obligations until they are both satisfactorily completed.

Effective October 26, 2002, the legislation was changed to eliminate concurrent payback. As a result, Kirschstein-NRSA recipients that also are NHSC scholars now are required to fulfill their NHSC service commitment through direct clinical service to the underserved in accordance with NHSC policy. Any Kirschstein-NRSA payback must be fulfilled separately through acceptable payback service.
## Appendix
### Receipt, Review, and Award Schedule

**Ruth L. Kirschstein National Research Service Award Institutional Research Training Grants**

<table>
<thead>
<tr>
<th>Application receipt dates</th>
<th>Scientific merit review</th>
<th>Advisory Council review</th>
<th>Earliest award</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 10</td>
<td>June/July</td>
<td>September/October</td>
<td>December</td>
</tr>
<tr>
<td>May 10</td>
<td>October/November</td>
<td>January/February</td>
<td>April</td>
</tr>
<tr>
<td>September 10</td>
<td>February/March</td>
<td>May/June</td>
<td>July</td>
</tr>
</tbody>
</table>

**Ruth L. Kirschstein National Research Service Award Individual Fellowships**

<table>
<thead>
<tr>
<th>Application receipt dates</th>
<th>Initial review dates</th>
<th>Range of likely start dates</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fellowships other than minority and disability programs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>April 5</td>
<td>June/July</td>
<td>September/December</td>
</tr>
<tr>
<td>August 5</td>
<td>October/November</td>
<td>January/March</td>
</tr>
<tr>
<td>December 5</td>
<td>February/March</td>
<td>May/July</td>
</tr>
<tr>
<td><strong>Minority and disability programs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 1</td>
<td>June/July</td>
<td>September</td>
</tr>
<tr>
<td>November 15</td>
<td>January/February</td>
<td>May</td>
</tr>
</tbody>
</table>

*Several NIH ICs use only one or two of the receipt dates for Kirschstein-NRSA institutional research training grant applications. Applicants are encouraged to confirm the application receipt dates by calling the appropriate IC or checking the NIH-wide program announcement for institutional research training grants at [http://grants.nih.gov/training/nrsa.htm](http://grants.nih.gov/training/nrsa.htm).*
MODULAR APPLICATIONS AND AWARDS

General

Modular applications and awards employ a simplified process for developing and reviewing application budgets, documenting approved budgets, and making post-award budgetary changes.

Applicability

Modular procedures are required to be used for new, competing continuation, and revised (amended) applications as well as for competing supplements for individual research project grants (R01), small grants (R03), exploratory/development grants (R21), and Academic Research Enhancement Awards (R15) that request up to a total of $250,000 of direct costs per year, regardless of whether the application is an investigator-initiated application or is one submitted in response to a PA/RFA. Modular procedures also apply to SBIR and STTR Phase I grants (R43 and R41) that request up to a total of $100,000 (direct and F&A costs and fee).

Instructions for specific grant mechanisms other than the R01 and guidelines for IC programs may indicate a particular number or range of modules allowed. In addition, an IC may, at its discretion, specify in an RFA that the modular application requirements apply to applications for amounts in excess of the modular ceiling.

Modular applications and awards also are subject to other simplified procedures, specifically just-in-time requirements and SNAP.

Application Requirements

Modular applications are submitted on the PHS 398, with the following modifications.

Budget

Modular applications request direct cost funding in modules of $25,000, up to the ceiling amount (i.e., $250,000 for each year of support under covered mechanisms other than SBIR/STTR Phase I grants and $100,000 for SBIR/STTR Phase I grants) plus applicable F&A costs. The modules should be a reasonable estimate of allowable, allocable, and reasonable costs for the proposed project, since only limited budget information is required for submission of a modular application, the standard application budget forms are not used. Applicants must submit budget information in accordance with the Modular Budget Format Page included in the PHS 398 application instructions. Sample modular application budget pages are available at http://grants.nih.gov/grants/funding/modular/modular.htm.

The modular budget is accompanied by a narrative for all personnel by position, role, and percent level of effort. This includes consultants and any “to be appointed” positions. No individual salary information should be provided. Applicants must use the current salary cap when determining the number of modules (see “Cost Considerations—Allowability of Costs/Activities—Selected Items of Cost—Salaries and Wages”). Given the ability to re-budget and to carry forward unobligated balances, funds generally should be available to cover any modest increase in the statutorily imposed salary cap.
As appropriate, the narrative also must address consortium/contractual costs (including applicable F&A costs) rounded to the nearest $1,000. The narrative should list the individuals and organizations with whom consortium or contractual arrangements have been (or will be) made, the percent of effort of key personnel and their role on the project, and indicate whether the collaborating organization is foreign or domestic.

A typical modular application will request the same number of modules for each year; however, well-justified modular increments (up to the specified modular ceiling) or decrements in the total direct costs for any year of the project that reflect substantial changes in expected future activities may be requested at the outset. For example, a major equipment purchase in the first year may justify a higher overall budget in that year, but not necessarily in succeeding years. There is no provision for escalation in future years. NIH requires additional narrative budget justification if there is a variation in the number of modules requested from year to year.

Checklist

The application checklist must be completed and submitted with the application. The checklist should include F&A costs calculated at the current negotiated rate, less exclusions, for the initial budget period and all future budget periods covered by the application.

Non-Compliant Applications

The modular application instructions require only limited budgetary information. Therefore, applications not complying with those instructions will not be accepted for review and will be returned to the applicant by CSR as non-compliant applications.

An application will be considered non-compliant if one or more of the following occurs:

◆ The direct cost budget is not in modules of $25,000 for each year of support requested.

◆ A detailed itemized categorical budget is provided.

◆ The budget narrative justification includes an itemized justification for one or more of the following: equipment, travel, supplies, other expenses, etc., but the number of modules requested for each year is the same, or the information is not intended to explain the request for a different number of modules for one or more years.

A returned application, if revised and resubmitted to NIH in a timely manner, may remain in the review cycle for which it was originally submitted.

Application Review and Award

SRGs evaluate the budget on the basis of a general, expert estimate of the total effort and resources required to carry out the proposed research. If the SRG recommends an adjustment in the project budget, the recommended adjustment will be in terms of an entire module.

Following peer review, for applications being considered for award, the IC will request from the applicant information about “Other Support” and, as applicable, human subjects, animal subjects,
and education in the protection of human research participants. Additional budget information will be requested before award only under special circumstances.

NIH will attempt to make awards at or close to the level of total direct costs recommended by the SRG, taking other support into account. In unusual situations, an IC may have to reduce the funding amount to accommodate the IC’s cost management plan.

The award budget will be a noncategorical budget specifying approved total direct costs and F&A costs, if applicable.

**Post-Award Administration**

In accordance with the applicable cost principles and other cost policies included in Subpart A of this part, grantees are required to allocate and account for costs related to their awards by category within their organizational accounting system.

Modular awards are subject to expanded authorities and SNAP.

Grantees may request administrative supplements as under nonmodular awards.

**SUPPORT OF SCIENTIFIC MEETINGS (CONFERENCE GRANTS)**

**General**

NIH supports scientific meetings, conferences, and workshops (hereafter “conferences”) that are relevant to its scientific mission and to public health under the R13 and U13 activity codes. NIH’s support of conferences is contingent on the interests and priorities of the individual ICs. Most ICs provide conference support although their budget guidelines may vary. Prior approval is required before submission of an application for conference support. Therefore, potential applicants must contact the funding IC for specific information as well as to ensure compliance with submission requirements. Applications for conference support must be submitted based on the published receipt dates. NIH will not make an award unless it can be issued before the conference’s start date.

**Applicability**

This section applies to grants that support domestic and international conferences. If a policy is not addressed in this section, the Subpart A coverage applies.

Questions concerning the allowability of conference activity under research grants should be directed to the GMO.

**Definitions**

**Scientific Meeting (Conference).** A gathering, symposium, seminar, workshop, or any other organized, formal event where people assemble to coordinate, exchange, and disseminate information or to explore or clarify a defined subject, problem, or area of knowledge.
International Conference. A scientific meeting so designated by its sponsor or one to which open invitations are issued on an equal basis to potential participants in two or more countries other than the United States or Canada. The meeting may be held in any country, including the United States.

Domestic Conference. A scientific meeting held in the United States or Canada primarily for U.S. or U.S.-Canadian participation (even if foreign speakers are invited).

Eligibility

Domestic institutions or organizations, including established scientific or professional societies, are eligible to apply for conference support. Both domestic and international conferences may be supported; however, an international conference can be supported only through the U.S. representative organization of an established international scientific or professional society. An individual is not eligible to receive a grant in support of a conference.

Application Requirements

The PHS 398 is to be completed by an organization seeking NIH conference support. Supplemental application instructions for conference grants are available at the Kiosk for Conference Grants at http://grants.nih.gov/grants/funding/r13/index.htm.

Public Policy Requirements and Objectives

In addition to any applicable public policy requirements and objectives specified in Subpart A, conference grant applicants must comply with the Guidelines on the Inclusion of Women, Minorities, and Persons with Disabilities in NIH Supported Conference Grants (available through the NIH website at http://grants.nih.gov/grants/policy/policy.htm. Appropriate representation of women, individuals who are members of racial/ethnic minority groups, people with disabilities, and other individuals who have been traditionally underrepresented in science must be included in all aspects of planning, organization, and implementation of NIH-sponsored or -supported meetings. “Appropriate representation” is based on the availability of scientists from these groups known to be working in a particular field of biomedical or behavioral research. If appropriate representation is not apparent, NIH will not make an award until the applicant has submitted acceptable documentation of its compliance.

Application Review

Applications for conference grants will be reviewed for programmatic relevance and for merit as described in the conference grant PA (http://www.niehs.nih.gov/dert/programs/conferen.htm).

Depending on IC policy, applications for conference grants also may be reviewed by the IC’s National Advisory Council or Board.
Funding

Grants or cooperative agreements may be used to provide conference support. A cooperative agreement may be awarded if the NIH awarding office determines that it needs to have substantial involvement in the planning and conduct of a conference.

Grant funds may not be used to provide general support for international conferences held in the United States or Canada. Grant funds may be awarded to support only specific aspects of such conferences. An example would be a selected symposium, panel, or workshop, including the costs of planning and travel of U.S. participants.

Awards in support of a single conference will be made for a project period commensurate with the time involved in planning and conducting the conference and post-conference follow-up, usually 1 year. A conference grant made to a permanently sponsoring organization for conferences held annually or biennially on a recurring topic may be awarded for up to a total of 5 years and will be funded annually, based on the availability of funds. Continued funding beyond the first year will be contingent on a report of satisfactory progress submitted in accordance with SNAP instructions. A change in conference focus requires NIH awarding office prior approval.

Allowable and Unallowable Costs

The following highlights allowable and unallowable costs under conference grants. No costs other than those specified in this subsection as allowable, including any qualifications on their allowability, are permitted under conference grants.

Allowable Costs

Conference Services. Grant funds may be used for necessary recording of proceedings, simultaneous translation, and subsequent transcriptions.

Consultant Services. Grant funds may be used to pay consultant fees, including travel and supporting costs (per diem or, where applicable, subsistence).

Equipment Rental. Grant funds may be used for the rental of necessary equipment.

Federal Employees. See “Grants to Federal Institutions and Payments to (or on Behalf of) Federal Employees under Grants.”

Meals. When certain meals are an integral and necessary part of a conference (i.e., a working meal where business is transacted), grant funds may be used for such meals, as qualified under “Travel” in this subsection.

Publication Costs. When grant funds are awarded to pay for either the entire or partial cost of publication of proceedings or a book or pamphlet, allowable costs include special plates, charts, diagrams, printing, distribution, mailing, postage, and general handling, unless otherwise specified at the time the grant is awarded.
**Registration Fees.** Grant funds may be used for registration fees paid by the grantee to other organizations on behalf of attendees, provided such fees cover only those allowable costs properly chargeable to the grant.

**Salaries.** In accordance with the policy of the grantee organization, grant funds may be used for all or part of the salaries of professional personnel, clerical assistants, editorial assistants, and other non-professional staff in proportion to the time or effort directly related to the conference.

**Speakers Fees.** Speakers’ fees for services rendered are allowable.

**Supplies.** Grant funds may be used for the purchase of supplies for the conference if the supplies are received and used during the budget period.

**Travel.** Funds may be used for the travel of staff, speakers, participants, and attendees, if identified in the application and approved at the time of award. Travel expenses for employees of the grantee organization are governed by the grantee’s travel policies, consistently applied regardless of the source of funds.

Any U.S. foreign travel restrictions that are in effect at the time of the award will be followed, such as

- limitations or restrictions on countries to which travel will be supported or
- budgetary or other limitations on availability of funds for foreign travel.

Proposed per diem or subsistence allowances must be reasonable and limited to the days of attendance at the conference plus the actual travel time to reach the conference location by the most direct route. Local mileage costs only may be paid for local participants. Where meals and/or lodgings are furnished without charge or at a nominal cost (e.g., as part of the registration fee), the proposed per diem or subsistence allowance must take this into consideration.

Transportation costs for attendees and participants at the conference may not exceed coach class fares. In all cases, U.S. flag carriers will be used where possible (see “Cost Considerations—Allowability of Costs/Activities—Selected Items of Cost—Travel”).

**Unallowable Costs**

**A& R.** Not allowable.

**Entertainment and Personal Expenses.** Costs of amusement, diversion, social activities, ceremonials, and related incidental costs, such as bar charges, tips, personal telephone calls, and laundry charges of participants or guests, are unallowable. However, meals may be allowable as provided under “Allowable Costs—Meals” in this subsection.

**Equipment Purchase.** Grant funds may not be used for the purchase of equipment.

**F&A Costs.** Not allowable.
**Honoraria.** Honoraria or other payments given for the purpose of conferring distinction or to symbolize respect, esteem, or admiration may not be paid from grant funds.

**Local Participants’ Expenses.** With the exception of local mileage as indicated under “Allowable Costs—Travel” in this subsection, grant funds may not be used to pay per diem or expenses for local participants in the conference.

**Membership Dues.** Not allowable.

**Research Patient Care.** Not allowable.

### Administrative Requirements


If the grantee publishes material developed in whole or in part with NIH funds, the material may be distributed free of charge. If the grantee organization charges for the material, the sales proceeds are considered program income, and must be accounted for as specified in the NGA and reported on the FSR (see “Reporting and Record Retention” in this subsection).

Unless otherwise provided in the terms and conditions of the award, the grantee is free to arrange for copyright of any publication resulting from an NIH-supported conference. However, any such copyrighted publication shall be subject to a nonexclusive, irrevocable, royalty-free license to the Federal government to reproduce, translate, publish, and dispose of the material and to authorize others to use the work for government purposes. Copyright does not extend to any materials prepared by Federal employees as part of their official duties.

The grantee is cautioned to remind conference participants that any presentation or discussion constitutes public disclosure of information. Any such public disclosure would create a bar and seriously impact the degree to which any intellectual property rights could be protected.

### Reporting and Record Retention

Grantees are responsible for submitting the following reports to the NIH awarding office upon completion or termination of a grant in support of a conference.

**Progress/Final Report**

For single conferences, a final report of the conference must be submitted to the NIH awarding office within 90 days after the end of the project period. The report must include the following:

- Grant number
- Title, date, and place of the conference
- Name of the person shown on the application as the conference director, PI, or PD
- Name of the organization that conducted the conference
A list of the individuals, and their organizational affiliations, who participated as speakers or discussants in the formally planned sessions of the meeting

A summary of topics discussed/conclusions.

Under multiple-year awards, i.e., ones that support more than one conference, NIH requires an annual progress report that contains a description of specific plans for the next budget period, in similar detail and format as for a single conference. The annual progress report must be submitted at least 6 months before the next scheduled conference. The final progress report should be submitted within 90 days after the end of the project period.

With the approval of the NIH awarding office, copies of proceedings or publications resulting from the conference(s) may be substituted for the final report, provided that they contain the information specified for inclusion in the final report.

**Financial Status Report**

An FSR is required from the grantee within 90 days after the end of the project period. Records of expenditures and any program income generated must be maintained in accordance with the provisions of 45 CFR 74.53 or 92.42 (see “Administrative Requirements—Monitoring—Record Retention and Access”).

**CONSORTIUM AGREEMENTS**

**General**

This section includes the requirements for an applicant/grantee under consortium agreements in which the grantee collaborates with one or more other organizations in carrying out the grant-supported research. The grantee, as the direct and primary recipient of NIH grant funds, is accountable to NIH for the performance of the project, the appropriate expenditure of grant funds by all parties, and all other obligations of the grantee, as specified in the NIHGPS. In general, the requirements that apply to the grantee, including the intellectual property requirements in Subpart A and the program income requirements of the award, also apply to consortium participant(s). Exceptions are noted in this section. The grantee is responsible for including the applicable requirements of the NIHGPS in its agreements with collaborating organizations (see “Written Agreement” in this section).

Under grants that include consortium agreements:

- The award will be made to a single grantee with a single PI, even though one or more organizations other than the grantee will carry out portions of the planned programmatic activity.

- The grantee must perform a substantive role in the conduct of the planned research and not merely serve as a conduit of funds to another party or parties.

Applicants are expected to detail their proposed collaborations as part of the grant application. If the application is approved as submitted, no further approval is required unless, during
performance, the grantee plans to undertake additional or alternative collaborations that would constitute a change in the scope of the approved project (see “Administrative Requirements—Changes in Project and Budget”). Applicants for STTR grants should follow the specific requirements for research collaboration established for that program (see “Grants to For-Profit Organizations”).

The following information must be provided to NIH as part of a competing application that proposes consortium arrangements:

- A list of all proposed performance sites, including those of the applicant organization and the consortium participant(s); and
- Complete application budget pages (for the first year and each future year of support requested) for each consortium participant, unless the application is for a modular award (see “Modular Applications and Awards”).

The signature of the AOO on the application signifies that the applicant organization and all proposed consortium participants understand and agree with the following statement:

“The appropriate programmatic and administrative personnel of each organization involved in this grant application are aware of the NIH consortium agreement policy and are prepared to establish the necessary inter-organizational agreement(s) consistent with that policy.”

NIH may request additional information before award and may place a special condition(s) on the award.

**Administrative and Other Requirements**

The following highlights several areas within the consortium relationship that the grantee needs to address with the consortium participant to ensure compliance with NIH requirements. The requirement for a written agreement addressing these and other areas is specified in this section.

**Public Policy Requirements and Objectives**

The grantee is responsible for determining whether a consortium participant, including foreign consortium participants under domestic or foreign grants, has filed assurances with NIH that would cover its activities within the consortium and, if not, for ensuring that any required assurances or certifications are submitted to NIH. See “Public Policy Requirements and Objectives” for the full statement of these requirements and their applicability to consortium participants.

The grantee is responsible for ensuring that all sites engaged in human subjects research have an appropriate OHRP-approved assurance and IRB approval of the research consistent with 45 CFR Part 46, and for complying with NIH prior-approval requirements related to the addition of sites not included in the approved application (see “Administrative Requirements—Changes in Project and Budget”). The list of organizations with approved assurances is available at the OHRP website: [http://www.hhs.gov/ohrp/](http://www.hhs.gov/ohrp/).
The grantee also must ensure that all sites engaged in research involving the use of live, vertebrate animals have an appropriate animal welfare assurance. If collaborating institutions have full PHS Assurances, they may exercise discretion in determining which IACUC reviews research protocols and under which institutional animal welfare program the research will be performed. If an IACUC defers protocol review to another IACUC, then documentation of the review should be maintained by both committees. Similarly, an IACUC should be advised about any significant questions or issues raised during a semiannual program inspection of a facility housing a research activity for which that IACUC bears some responsibility or exposure.

**Allowable and Unallowable Costs**

The grantee must include in consortium agreements the applicable government-wide cost principles and NIH cost policies described in “Cost Considerations” and, as appropriate, requirements related to allowable and unallowable costs in other sections of Subpart B. For example, a university grantee must flow down the cost principles of OMB Circular A-122 to a consortium participant that is a non-profit research organization. This includes the application of F&A rates in determining consortium budgets and the reimbursement of costs.

**Approval Authorities**

The grantee is responsible for obtaining NIH awarding office approval for any actions to be undertaken by consortium participants that require prior approval. Grantees may establish requirements for review of consortium participants’ activities consistent with those requirements and with any authorities provided to the grantee; however, a grantee may not provide any authority to a consortium participant that the grantee has not been provided under its NIH award.

Regardless of whether there is a change in scope, in all cases, if a grantee (or consortium participant) proposes the transfer of work to a foreign site, awarding office prior approval is required.

**Tangible Personal Property**

**Exempt Property**

If the grantee provides exempt property to a consortium participant or authorizes a consortium participant to purchase property that would be considered exempt if acquired by the grantee, the grantee may vest title in the consortium participant upon transfer or purchase or may reserve the right to do so at a later time. The grantee also may establish its own use, disposition, and accountability requirements, provided they are consistent with the NIH right to transfer title (see “Administrative Requirements—Management Systems and Procedures—Property Management System Standards—Equipment and Supplies”).

**Nonexempt Property**

If the grantee provides nonexempt property to a consortium participant or authorizes a consortium participant to purchase property that would be considered nonexempt if purchased by the grantee, title to such property must remain with the grantee or be vested in the grantee upon acquisition of the property. The grantee may establish use, accountability, and disposition.
requirements for the property, provided they are consistent with, and do not impair, the grantee’s ability to comply with the requirements of 45 CFR Part 74 or 45 CFR Part 92, as appropriate.

Audit

The grantee must require consortium participants to comply with the requirements of OMB Circular A-133 or 45 CFR 74.26(d), as applicable, for audit of NIH grant funds expended by consortium participants. A consortium participant also may be a direct NIH grantee or contractor or may be receiving funds only under the consortium agreement. Regardless, if a non-profit consortium participant meets the OMB Circular A-133 threshold criterion of aggregate annual expenditures of $500,000 or more under applicable Federal awards, the grantee must receive a copy of that organization’s A-133 audit and take appropriate action based on any findings that relate to the consortium agreement. If a consortium participant will not reach that expenditure threshold, the grantee is responsible for monitoring the organization’s activities to ensure compliance with NIH requirements. The grantee may not require a consortium participant to have an audit and charge the audit costs to NIH grant funds unless required or authorized by OMB Circular A-133 or 45 CFR 74.26(d).

Written Agreement

The grantee must enter into a formal written agreement with each consortium participant that addresses the negotiated arrangements for meeting the scientific, administrative, financial, and reporting requirements of the grant, including those necessary to ensure compliance with all applicable Federal regulations and policies and facilitate a smoothly functioning collaborative venture. At a minimum, this agreement must include the following:

- Identification of the PI and individuals responsible for the research activity at each consortium participant along with their roles and responsibilities
- Procedures for directing and monitoring the research effort
- Procedures to be followed in reimbursing each consortium participant for its effort, including dollar ceiling, method and schedule of reimbursement, type of supporting documentation required, and procedures for review and approval of expenditures of grant funds at each organization
- If different from those of the grantee, a determination of policies to be followed in such areas as travel reimbursement and salaries and fringe benefits (the policies of the consortium participant may be used as long as they meet NIH requirements)
- Incorporation of applicable public policy requirements and provisions indicating the intent of each consortium participant to comply, including submission of applicable assurances and certifications (see “Public Policy Requirements and Objectives”)
- Whether the financial conflict of interest requirements of the collaborating organization or those of the grantee apply
- A provision addressing ownership and disposition of data produced under the consortium agreement

- A provision making the NIH data sharing and inventions and patent policy, including a requirement to report inventions to the grantee (see “Administrative Requirements—Availability of Research Results: Publications, Intellectual Property Rights, and Sharing Research Resources”), applicable to each consortium participant and its employees in order to ensure that the rights of the parties to the consortium agreement are protected and that the grantee can fulfill its responsibilities to NIH

- Provisions regarding property (other than intellectual property), program income, publications, reporting, and audit necessary for the grantee to fulfill its obligations to NIH.

GRANTS TO FOREIGN INSTITUTIONS, INTERNATIONAL ORGANIZATIONS, AND DOMESTIC GRANTS WITH FOREIGN COMPONENTS

General

Most of the policies contained in Subpart A of this part apply to NIH grants made to foreign institutions and international organizations (hereafter “foreign grants”), including the requirements of 45 CFR Part 74 or 45 CFR Part 92 and the cost principles incorporated by reference in those regulations. If an applicant/grantee would be unable to comply with these requirements, the AOO should contact the GMO. Specific exceptions and modifications of Subpart A requirements for foreign grants, and highlights of other policies, are set forth in this section. This section also includes policies that apply to domestic grants with a foreign component.

Eligibility

In general, foreign institutions and international organizations, including public or private non-profit or for-profit organizations, are eligible to apply for research project grants. Foreign institutions and international organizations are not eligible to apply for Kirschstein-NRSA institutional research training grants, program project grants, center grants, resource grants, SBIR/STTR grants, or construction grants. However, some mechanisms, such as program project grants (P01), may support projects awarded to a domestic institution with a foreign component. For purposes of this policy, a “foreign component” is defined as performance of any significant element or segment of the project outside the United States either by the grantee or by a researcher employed by a foreign institution, whether or not grant funds are expended. Activities that would meet this definition include the following:

- The involvement of human subjects or animals

- Extensive foreign travel by grantee project staff for the purpose of data collection, surveying, sampling, and similar activities
Any activity of the grantee that may involve the population, environment, resources, or affairs of a foreign country.

Foreign travel exclusively for consultation is not considered a “foreign component.”

See “Support of Scientific Meetings (Conference Grants)” in this subpart for NIH policy on support of international conferences.

Grants may not be made to individuals in a foreign location (i.e., outside of the United States and its territorial possessions). Occasionally, a Kirschstein-NRSA individual fellowship award is made to an American citizen or a non-citizen national to study in a foreign institution. (A “non-citizen national” is a person who although not a citizen of the United States owes permanent allegiance to the United States, such as a resident of American Samoa.)

Application Review

Applications from foreign institutions or international organizations will be evaluated and scored during the initial review process using the standard review criteria. In addition, the following will be assessed as part of the review process and award decision:

- Whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions in other countries that are not readily available in the United States or that augment existing U.S. resources.
- Whether the proposed project has specific relevance to the mission and objectives of the IC and has the potential for significantly advancing the health sciences in the United States.

Research grant applications from foreign or international organizations may not be funded unless approved by the IC National Advisory Council or Board.

Public Policy Requirements and Objectives

A complete listing of public policy requirements and objectives and their applicability to foreign grants is included in “Public Policy Requirements and Objectives” in Subpart A of this part. Several of the public policy requirements and objectives are highlighted below:

- Research misconduct. The research misconduct requirements included in “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—Research Misconduct” apply to foreign grants.
- Animal welfare. The animal welfare requirements contained in “Public Policy Requirements and Objectives—Animal Welfare” apply to foreign grants.
- Human subjects. The human subjects requirements contained in “Public Policy Requirements and Objectives—Requirements Affecting the Rights and Welfare of Individuals as Research Subjects, Patients, or Recipients of Services—Human Subjects,”
including the requirement for an assurance pursuant to 45 CFR Part 46, apply to foreign grants and foreign consortium participants under domestic or foreign grants.

◆ **Inclusiveness in research design.** Foreign grants are subject to the requirements for inclusion of women, members of minority groups, and children in research design as specified in “Public Policy Requirements and Objectives—Requirements for Inclusiveness in Research Design.”

◆ **Civil rights.** None of the civil rights requirements specified in “Public Policy Requirements and Objectives—Civil Rights” apply to foreign grants.

◆ **Lobbying.** The requirements of “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—Lobbying,” including disclosure reporting, apply to foreign grants.

◆ **Debt.** Foreign applicants are required to provide a certification of nondelinquency on debts owed to the United States as specified in “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—Nondelinquency on Federal Debt.”

◆ **Debarment and suspension.** Applicants/grantees that are foreign governments or governmental entities, public international organizations, or foreign-government-owned or -controlled (in whole or in part) entities are not subject to the debarment or suspension certification requirement or to debarment or suspension under 45 CFR Part 76. All other foreign institutions and international organizations are subject to these requirements.

◆ **Drug-free workplace.** Foreign applicants and grantees may be exempted from the drug-free workplace requirements of 45 CFR Part 76 based on a documented finding by the NIH awarding office that application of those requirements is inconsistent with U.S. international obligations or the laws and regulations of a foreign government.

### Funding and Payment

The application budget, requests for funds, and financial reports (see “Reporting and Record Retention” in this section) must be stated in U.S. dollars. Once an award is made, NIH will not compensate foreign grantees for currency exchange fluctuations through the issuance of supplemental awards.

Awards to foreign institutions and international organizations are not paid through PMS. These grants normally will be paid by U.S. Treasury check by OFM, NIH on a predetermined quarterly advance basis, usually in four equal installments. If the amount advanced to an organization based on the predetermined quarterly advance is insufficient to meet the grant’s cash requirements, the grantee must make a written request to the GMO for any additional funds needed. All payments will be in U.S. dollars. Foreign grantees are strongly encouraged to use U.S. banks to ensure that payments arrive on time. The funding and payment information outlined in this subsection applies when the foreign institution is the grantee organization. When a foreign component participates in a consortium arrangement, the funding and payment information should be reflected in the formal written agreement.
Any questions regarding payments to foreign grantees may be addressed to OFM (see Part III for address and telephone and fax numbers).

### Allowable and Unallowable Costs

The costs that are generally allowable under grants to domestic organizations also are allowable under foreign grants, with the following exceptions:

- **A&R.** Unallowable under foreign grants and domestic grants with foreign components.
- **Customs and import duties.** Unallowable under foreign grants and domestic grants with foreign components. This includes consular fees, customs surtax, value-added taxes, and other related charges.
- **F&A costs.** With the exception of American University of Beirut and the World Health Organization, full F&A costs will not be allowed. However, NIH provides limited F&A costs (8 percent of total direct costs less equipment) to foreign institutions and international organizations to support the costs of compliance with NIH requirements including, but not limited to, protection of human subjects, animal welfare, and research misconduct. NIH will not support the acquisition of, or provide for depreciation on, any capital expenditures, or support the normal, general operations of foreign and international organizations.

### Administrative Requirements

#### Changes in Project and Budget

Foreign grants are included in expanded authorities. Inclusion in SNAP is at the discretion of the NIH awarding office and will be specified on the NGA.

**Change in Scope**

A change in the performance site within a foreign country or performance in a country other than that specified in the approved application requires NIH awarding office prior approval. The transfer of work by a domestic grantee to a foreign component also requires awarding office prior approval.

**Change of Grantee Organization**

A change of grantee organization that involves the transfer of a grant to or between foreign institutions or international organizations requires approval of the NIH awarding office and it’s National Advisory Council or Board. NIH awarding office approval also is required for the transfer of a grant from a foreign organization to a domestic organization.
Audit

Foreign grantees are subject to the same audit requirements as for-profit organizations (specified in 45 CFR 74.26(d) and in “Grants to For-Profit Organizations” in this subpart).

Reporting and Record Retention

Foreign grantees must submit annual FSRs in U.S. dollars, whether or not they are under SNAP. This is due to the fact that foreign grantees are not paid through PMS and, therefore, do not submit the SF 272 (which NIH uses in lieu of the annual FSR for domestic awards under SNAP). The currency rate in effect at the time the FSR is prepared should be used in preparing the report.

Record retention requirements are the same as those for domestic grantees.

GRANTS TO FEDERAL INSTITUTIONS AND PAYMENTS TO (OR ON BEHALF OF) FEDERAL EMPLOYEES UNDER GRANTS

General

NIH may award grants to Federal entities. Although the activity under these grants will take place in a research environment, certain terms and conditions vary from those included in Subpart A due to the recipient’s status as a Federal institution. This section specifies those differences as well as differences in treatment among different Federal institutions. In addition, this section addresses the policies that apply to payments to (or on behalf of) Federal employees under grants, including grants awarded to organizations other than Federal institutions.

Eligibility

In general, Federal institutions are eligible to apply for NIH grants, including research project grants and training grants. Federal institutions also must meet the eligibility requirements of the grant program from which support is sought. PHS organizational segments, other than IHS hospitals, may receive NIH grant support under exceptional circumstances only. Such circumstances may include situations where a project cannot be supported within the mission of the applicant PHS agency or organizational segment, the activity cannot be performed elsewhere, or its nonpursuit would have an adverse impact or potentially important effect on the NIH mission, and NIH determines a grant is the appropriate means of carrying out the activity. However, NIH may not award a grant to an NIH component.

Although the performance site may be at a level lower than the agency or department level of the Federal institution, when an award is made to an eligible Federal institution, the Federal agency or department will be the grantee of record and must assume responsibility for the project. A Federal institution also must ensure that its own authorizing legislation will allow it to receive NIH grants and to be able to comply with the award terms and conditions.

A document that assures both the assumption of responsibility and authority to receive a grant must accompany each new and competing continuation application. The assurance must be signed by the head of the responsible Federal department or independent agency or a designee
who reports directly to the department or agency head. (In the case of the DoD, the Departments of the Army, Navy, and Air Force are considered the Federal department, and their Secretaries the responsible Department head.) This assurance is in addition to those made by the AOO’s signature on the face page of the application. The assurance requirement does not apply to VAMCs, Bureau of Prisons’ (Department of Justice) hospitals, IHS hospitals, or other PHS organizational segments.

**VA-University Affiliations**

Investigators with joint appointments at a VAMC (VA hospital) and an affiliated university must have an MOU that specifies the title of the investigator’s appointment, the responsibilities (at both the university and the VAMC) of the proposed investigator, and the percentage of effort available for research. The MOU must be signed by the appropriate officials of the grantee and the VAMC, and must be updated with each significant change of the investigator’s responsibilities or distribution of effort and, without a significant change, not less than annually. The joint VA/university appointment of the investigator constitutes 100 percent of his or her total professional responsibilities. However, NIH will recognize such a joint appointment only when a university and an affiliated VA hospital are the parties involved.

A grant application from a university may request the university’s share of an investigator’s salary in proportion to the effort devoted to the research project. The institutional base salary as contained in the individual’s university appointment determines the base for computing that request.

The signature of the AOO of the submitting university on an application to NIH that includes such an arrangement certifies that

- the individual whose salary is included in the application serves under a joint appointment documented in a formal MOU between the university and the VA, and
- there is no possibility of dual compensation for the same work or of an actual or apparent conflict of interest.

Under the above-described arrangement, there is no involvement of a VA-affiliated non-profit research corporation, which is eligible to apply for and receive NIH grants in its own right as a non-profit organization. The limitations on the payment of Federal salaries apply (see “Allowable and Unallowable Costs” in this section).

**Payment**

NIH grants to DoD normally will be paid by U.S. Treasury check after submission of the appropriate interagency form to OFM, NIH. Payments to all other Federal departments and agencies generally will be accomplished by transfers of funds between appropriations.

**Allowable and Unallowable Costs**

Allowable and unallowable costs under grants to Federal institutions will be determined by the established policies of the institution, consistently applied to both its own activities and to grant-
supported activities, and the requirements of this subsection. In the absence of a governing organizational policy, the cost principles for State, local, and Indian tribal governments (OMB Circular A-87) will apply.

**Salaries.** See “Federal (U.S. Government) Employees” in this subsection.

**Institutional allowances under Kirschstein-NRSA individual fellowships.** Institutional allowances may be requested by Federal institutions sponsoring a predoctoral or postdoctoral fellow.

**F&A costs.** F&A costs will not be provided to Federal institutions.

**Federal (U.S. Government) employees.** Whether or not costs will be charged to the grant, when a Federal employee will be involved in an NIH grant-supported activity in any capacity other than as an employee working on a grant to a Federal institution, an outpatient, or a study subject, special conditions apply as provided in this subsection. The limitations in this subsection do not apply to individuals that are classified as special government employees because of service on advisory groups or as a result of a formal consulting arrangement with a Federal agency. (See the HHS Standards of Conduct at 45 CFR 73, Subpart J for additional guidance.)

Only four types of costs—consultant fees, outpatient or subject costs, salary or fringe benefits, and travel costs—can be charged to NIH grants on behalf of Federal employees, whether by a grantee or a consortium participant, and under the conditions specified only. Applicants/grantees should advise any Federal employees with whom these types of arrangements may be made to consult with their employing agency concerning their ability to meet the required conditions. The applicant organization must submit, as part of the grant application, any letters or documentation specified below, and that documentation must be deemed acceptable by the GMO before the Federal employee’s involvement in the project.

**Consultant fees.** Consultant fees are allowable only for medical personnel of the Uniformed Services of the United States (excluding PHS Commissioned Officers) and when all of the following conditions are present:

- The employees are providing the kind and extent of medical services approved in the grant award.
- Adequate numbers of qualified civilian personnel are not available to provide these services, and eligible Federal medical personnel are hired only in addition to those qualified civilian medical personnel, if any, who are available.
- The applicant organization provides prior written authorization from the proposed consultant’s commanding officer that he or she is authorized to work on the grant-supported activity during non-duty hours or while on authorized leave, and can be paid for his or her efforts.

**Outpatient or subject costs.** These costs are allowable when the employee is an outpatient or subject under study in connection with grant-supported activities.
Salary or fringe benefits. Under grants to VANPCs, in accordance with the established policies and salary structure of the VANPC, if the PI is a part-time VA employee, NIH grant funds may be used to pay the differential between the individual’s VA part-time salary and the salary level for a full-time VANPC commitment in proportion to the level of effort devoted to the project. Therefore, if the PI has a part-time appointment with the VANPC, an appropriate portion of the individual’s salary that would otherwise be supported by the non-profit VANPC may be charged to the NIH grant. An NIH grant may not be the source of funding for an increase in an investigator’s salary regardless of the type of entity with which the investigator holds an appointment (e.g., university, VA, or VANPC).

Salary payments may be made from NIH grant funds to career, career-conditional, or other Federal employees (civilian or uniformed services) with permanent appointments provided under existing position ceilings of a Federal component only if prior approval is obtained from an authorized official of the employee’s agency and the employee is one of the following:

◆ A PHS Commissioned Officer or a civil service employee carrying out duties for which specific statutory authorization exists permitting direct Federal assistance in lieu of cash under the grant, or where the government is reimbursed for services rendered subject to restrictions applicable to such personnel, including the applicable Federal standards of conduct (for HHS, 45 CFR Part 73).

◆ A PHS Commissioned Officer on LWOP if the

➢ grantee has obtained written prior approval from the NIH awarding office;

➢ total amount of salary paid from NIH grant funds is proportional to the time devoted to the project and does not exceed the total annual amount of pay and allowances the individual would have received if not in LWOP status; and

➢ parties concerned have made a prior determination that there is no possibility of dual compensation and there is no actual or apparent conflict of interest or other violation of the applicable standards of conduct.

◆ A civil service employee participating in a grant to a non-Federal organization and all of the following conditions are met:

➢ The individual is participating as part of an approved IPA assignment in a role other than as PI. IPA assignments generally do not exceed 2 years and may not exceed 4 years of continuous duration (5 U.S.C. 3372). Based on this statutory time restriction, the involvement of the civil service employee should be limited in scope. Therefore, the proposed PI for an NIH grant may not be participating through an IPA. On a case-by-case basis, the NIH awarding office may determine that certain other key personnel on the project are sufficiently critical to its long-term success that participation through an IPA is not appropriate.

➢ Before making any payment from NIH grant funds to such an employee, the grantee must certify that the employee is on an IPA assignment and must provide adequate
documentation, as determined by NIH, of the IPA assignment and information about its nature and duration.

- The level of effort required for the research project must be allowed by the employing agency as part of the individual’s official duties. Salary payments from NIH grant funds must be proportional to the time an individual devotes to the grant-supported project. The total salary support may not exceed the normal level of compensation from Federal salary if the individual were not participating in the grant.

- The parties concerned have made a prior determination that there is no possibility of dual compensation and there is no actual or apparent conflict of interest or other violation of the applicable standards of conduct.

Unless the payments meet one the above-described exceptions, no salary or fringe benefit payments may be made from NIH grant funds to support career, career-conditional, or other Federal employees (civilian or uniformed services) with permanent appointments provided for under existing position ceilings of a given Federal component. While the level of effort required for the research project must be allowed by the employing agency as part of the individuals’ official duties, salary costs associated with an individual participating in an official capacity as a Federal employee are not allowable costs under an NIH grant.

Payments to temporary employees specifically hired to assist in the performance of an NIH grant are allowable.

**Travel costs.** Travel costs are allowable if the employee is

- working under a grant to a Federal institution;
- performing allowable reimbursable services as specified under “Salary or Fringe Benefits” immediately above; or
- attending an NIH grant-supported conference
  - during non-duty hours,
  - while in a preexisting LWOP status or one that continues beyond the conference, or
  - while on detail to a State or local government, educational institution, or other non-profit organization.

Such payments must be made in accordance with established organizational policy, consistently applied regardless of the source of funds, and the parties concerned must take reasonable steps to ensure that there is no actual or apparent conflict of interest.
Administrative Requirements

Equipment Accountability

NIH will consider all nonexpendable personal property acquired under a grant awarded to a Federal institution as exempt (see 45 CFR 74.33) for purposes of determining the accountability requirements of 45 CFR 74.34. However, NIH has the right to require transfer of equipment, including title, to NIH or an eligible third party named by the NIH awarding office under the conditions specified in 45 CFR 74.34.

Procurement Requirements

Procurement under grants to Federal institutions is governed by the FAR and the recipient agency’s FAR supplement.

Intellectual Property

Inventions resulting from grants supporting the activities of Federal employees under grants to Federal institutions must be reported simultaneously to NIH and to the employing agency under the terms of EO 10096, as amended, and are subject to the licensing requirements of 37 CFR Part 401. (See https://s-edison.info.nih.gov/iEdison/ for reporting requirements.) In cases where the VA is involved with the invention but is not the grant recipient, and the recipient institution chooses not to elect title or pursue practical application of an invention, the recipient must note VA’s involvement on its notice to NIH and provide a courtesy copy of the NIH notification to the appropriate VA office. NIH will notify the recipient and the VA whether NIH has an interest in taking title and/or continuing the pursuit of practical application of the invention.

Reporting Requirements

Federal institutions must submit annual FSRs regardless of whether the award is subject to SNAP. This is due to the fact that these grants are paid by OFM, NIH rather than through PMS.

GRANTS TO FOR-PROFIT ORGANIZATIONS

General

Some of the terms and conditions for grants to for-profit (commercial) organizations vary from the standard terms and conditions included in Subpart A of this part. In addition, the terms and conditions of the SBIR and STTR programs vary from those otherwise applicable to for-profit organizations. This section addresses separately the policies applicable to for-profit organizations generally, and those that apply to SBIR and STTR awards specifically. It also highlights several policies in Subpart A that apply equally to for-profit and non-profit recipients. If an exception is not stated below or in the NGA, the terms and conditions specified in Subpart A apply, including requirements for the protection of human subjects and animal welfare.
Eligibility

For-profit organizations are eligible to apply under all NIH programs and support mechanisms unless specifically excluded by statute.

Allowable and Unallowable Costs

Cost Principles

There are no cost principles specifically applicable to grants to for-profit organizations. Therefore, the cost principles for commercial organizations set forth in the FAR (48 CFR Part 31.2) generally are used to determine allowable costs under NIH grants to for-profit organizations. As provided in those costs principles, allowable travel costs may not exceed those established by the FTR (available on-line at http://www.gsa.gov). The cost principles in 45 CFR Part 74, Appendix E, are used to determine allowable costs under NIH grants to proprietary hospitals.

Independent Research and Development Costs

As provided in 45 CFR 74.27(a), NIH does not allow for-profit organizations to be reimbursed for IR&D (self-sponsored) costs.

Facilities and Administrative Costs (Indirect Costs)

F&A costs are allowable under awards to for-profit organizations.

Profit or Fee

Except for grants awarded under the SBIR/STTR programs, under an NIH grant, no profit or fee will be provided to a for-profit organization, whether as a grantee or as a consortium participant. A profit or fee under a grant is not a cost, but is an amount in excess of actual allowable direct and F&A costs. In accordance with normal commercial practice, a profit/fee may be paid to a contractor under an NIH grant providing routine goods or services to the grantee.

Administrative Requirements

For-profit organizations generally are subject to the same administrative requirements as non-profit organizations, including those relating to personal property title and management. Exceptions to or elaboration of those requirements for for-profit organizations are indicated below.

Intellectual Property

Intellectual property requirements set forth in 37 CFR Part 401 apply to for-profit organizations, whether small businesses or large businesses. However, invention reporting requirements for for-profit organizations differ somewhat from those for non-profit organizations. When the grantee is a for-profit organization, assignment of invention rights to a third party does not require NIH approval. (See “Administrative Requirements—Availability of Research Results: Publications,
Intellectual Property Rights, and Sharing Research Resources.”). Additional information about the requirements of 37 CFR 401 may be obtained from the Extramural Inventions and Technology Resources Branch, OPERA, NIH (see Part III for address and telephone number).

To the extent authorized by 35 U.S.C. 205 (the Patent Act, as amended), the Federal government will not make public any information disclosing a Federal government-supported invention.

Program Income

Consistent with expanded authorities, for-profit grantees, including those under the SBIR/STTR programs, are subject to the additive alternative for the use of program income described in “Administrative Requirements—Management Systems and Procedures—Program Income.”

Operating Authorities

Awards to for-profit organizations generally are subject to expanded authorities; however, some mechanisms do not allow automatic carryover of unobligated balances of funds. Under those mechanisms, the NIH awarding office will specify the disposition of the reported unobligated balance in the NGA. (See “Administrative Requirements—Changes in Project and Budget”).

Audit

The requirements for non-Federal audits of for-profit organizations are specified in 45 CFR 74.26(d). A for-profit organization is required to have a non-Federal audit if, during its fiscal year, it expended a total of $500,000 or more under one or more HHS awards (as a direct grantee and/or under a consortium participant) and at least one of those awards is an HHS grant. 45 CFR 74.26(d) incorporates the thresholds and deadlines of OMB Circular A-133 but provides for-profit organizations two options regarding the type of audit that will satisfy the audit requirements. The grantee either may have (1) a financial-related audit (as defined in, and in accordance with, the Government Auditing Standards (commonly known as the “Yellow Book”), GPO stock 020-000-00-265-4, of all the HHS awards, or (2) an audit that meets the requirements of OMB Circular A-133.

OMB Circular A-133 is available electronically at http://www.whitehouse.gov/omb/circulars/a133/a133.html.

The Government Auditing Standards are available electronically at http://www.gao.gov/govaud/ybk01.htm. Audits must be completed and submitted to the following office within 30 days after receipt of the auditor’s report(s), or 9 months after the end of the audit period, i.e., the end of the organization’s fiscal year, whichever is earlier. The address is:

National External Audit Review Center
HHS Office of Audit Services
323 West 8th Street
Lucas Place
Room 514
Kansas City, MO 64105

239
For-profit organizations expending less than $500,000 a year are not required to have an annual audit for that year but must make their grant-related records available to NIH or other designated officials for review or audit.

**Small Business Innovation Research and Small Business Technology Transfer Programs**

NIH is required by statute to reserve a portion of its annual extramural budget for projects under the SBIR and STTR programs. These programs primarily are intended to encourage private-sector commercialization of technology and to increase small business participation in federally funded R&D.

Both the SBIR and STTR programs consist of the following three phases; however, individual projects may not be eligible for all three phases:

- **Phase I.** The objective of this phase is to establish the technical merit and feasibility of proposed research or R&D efforts and to determine the quality of performance of the applicant (small business concern or SBC) before providing further Federal support in Phase II.

- **Phase II.** The objective of this phase is to continue the research or R&D efforts initiated in Phase I. Funding will be based on the results of Phase I and the scientific and technical merit and commercial potential of the Phase II application. Only Phase I grantees are eligible to receive Phase II funding. Unless submitted as a Fast-Track application (see below), Phase II applications may be submitted only after the Phase I award is made. NIH expects non Fast-Track Phase II applications to be submitted within the first six receipt dates following expiration of the Phase I budget period, i.e., normally 2 years beyond the expiration date of the Phase I award.

- **Phase III.** The objective of this phase, where appropriate, is for the SBC to pursue, with non-Federal funds, the commercialization of the results of the research or R&D funded in Phases I and II.

There are two major differences between the SBIR and STTR programs:

- The STTR program requires that the SBC formally partner with a single, non-profit research institution in the collaborative conduct of a project that has potential for commercialization. To be eligible for an STTR award, at least 40 percent of the research must be performed by the SBC and at least 30 percent of the research must be performed by a domestic non-profit research institution through a formal, cooperative arrangement. Such organizations include universities, non-profit hospitals, and other non-profit research organizations as well as Federally Funded Research and Development Centers. (The same requirement applies to Phase I and to Phase II.) STTR grants are awarded to the SBC, which will receive all of the funding for the project and disperse the appropriate funding to the research institution. The SBIR program does not have this requirement; therefore, the SBC may conduct the entire SBIR project without outside collaboration.
The SBIR program requires that the primary employment of the PI (greater than 50 percent of the individual’s time) be with the SBC at the time of award and during the conduct of the project. The STTR program does not have this requirement, i.e., the PI may have his or her primary employment with an organization other than the SBC, including the collaborating research institution. However, there must be an official relationship between the PI and the SBC. As an eligibility criterion, NIH also requires the PI to devote at least 10 percent of his or her time to the STTR project.

The NIH Fast-Track application process expedites award decisions and funding of SBIR and STTR Phase II applications for scientifically meritorious projects that have a high potential for commercialization. The Fast-Track process allows Phase I and Phase II grant applications to be submitted and reviewed together. Typically, Fast-Track applications will receive a single rating. NIH determines whether to allow SBCs to use the Fast-Track review option. Therefore, before submitting applications for Fast-Track review, applicants are strongly encouraged to consult with cognizant NIH program staff. SBIR/STTR Phase I and Phase II applications submitted concurrently without prior consultation with NIH may be redirected for review under NIH’s normal review procedures. For additional information on the submission of Fast-Track applications, see the SBIR/STTR program solicitations and instructions at http://grants.nih.gov/grants/funding/sbir.htm.

Eligibility

Qualification as a Small Business Concern

Each organization receiving a grant under the SBIR/STTR programs must qualify as a U.S.-owned SBC—an entity that, at the time of the Phase I and Phase II awards, meets all of the following criteria:

◆ The entity is organized for profit, with a place of business located in the United States, which operates primarily within the United States, or which makes a significant contribution to the U.S. economy through payment of taxes or use of American products, materials or labor.

◆ It is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust, or cooperative. If the entity is a joint venture, there can be no more than 49 percent participation by foreign business entities.

◆ As provided by the express terms of 13 CFR 121.702(a), it is at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States. In the case of a joint venture, each party to the venture must be 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States. Under these regulations, corporations or artificial entities cannot quality as individuals who are U.S. citizens. Further, indirect ownership of the entity by a U.S. citizen does not satisfy the requirements of 13 CFR 121.702(a).
Example 1. An entity applying for an SBIR/STTR grant is 100 percent owned by Company A. Company A is 100 percent owned by U.S. citizens. The entity is not eligible for support under the SBIR/STTR program because it is not 51 percent directly owned and controlled by citizens of, or permanent resident aliens in, the United States.

Example 2. An entity applying for an SBIR/STTR grant is 51 percent owned by U.S. citizens of and permanent resident aliens in the United States and 49 percent owned by a corporation. The entity is eligible for support under the SBIR/STTR program, assuming it meets the other eligibility criteria (e.g., size), because 51 percent of the ownership rests directly with U.S. citizens and permanent resident aliens of the United States.

The entity, including its affiliates, cannot have more than 500 employees. In accordance with 13 CFR Part 121.103, affiliation exists when, either directly or indirectly, (1) one concern controls or has the power to control the other, or (2) a third party or parties controls or has the power to control both. One of the circumstances that would lead to a finding that an organization is controlling or has the power to control another organization involves sharing common office space, employees, and/or other facilities (e.g., laboratory space). The research and analytical work performed by the grantee organization under an SBIR/STTR award is to be conducted in research space occupied by, available to, and under the control of, the grantee. However, when required by the project activity, access to special facilities or equipment in another organization is permitted, as in cases where the SBIR grantee has entered into a consortium arrangement with another organization for a specific, limited portion of the research project. See 13 CFR 121.3-2(a) and 13 CFR 121.3-2(t) for additional information concerning this criterion.

All appropriate factors will be considered in determining whether an entity qualifies as an SBC, including common ownership, common management, and contractual relationships.

Place of Performance

For both Phase I and Phase II SBIR/STTR awards, the research or R&D project activity must be performed in its entirety in the United States. (The United States is defined as the 50 States, the territories and possessions of the United States, the Commonwealth of Puerto Rico, the Federated States of Micronesia, the Republic of Palau, the Republic of the Marshall Islands, and the District of Columbia.)

In those rare instances where the study design requires use of a foreign site (e.g., to conduct testing of specific patient populations), the investigator must thoroughly justify in the application the need for use of a foreign site. Similarly, in those rare instances where it may be necessary to purchase materials from other countries, investigators must thoroughly justify the request. NIH will consider these instances on a case-by-case basis, and they should be discussed with cognizant NIH staff before submitting an application. Whether the request is approved or disapproved, it will be explicitly addressed in the NGA if an award is made. Whenever possible,
work outside the United States, which is necessary to the completion of the project, should be supported by funding other than SBIR/STTR grants.

Minimum Level of Effort

Generally, under SBIR Phase I awards, a minimum of two-thirds or 67 percent of the research or analytical effort must be carried out by the SBC. In addition, payments, in the aggregate, to consultants, consortium participants and contractors for portions of the scientific/technical effort generally may not exceed 33 percent of the total requested amount.

Generally under SBIR Phase II awards a minimum of one-half or 50 percent of the research or analytical effort must be carried out by the SBC. In addition, payments, in the aggregate, to consultants, consortium participants, and contractors for portions of the scientific/technical effort generally may not exceed 50 percent of the total requested amount.

For STTR awards (both Phase I and Phase II), at least 40 percent of the work is to be performed by the SBC and at least 30 percent of the work is to be performed by the single, non-profit research institution. The basis for determining the percentage of work to be performed by each of the cooperating parties is the total of direct and F&A costs attributable to each party, unless otherwise described and justified in the “Contractual Arrangements” portion of the “Research Plan” section of the grant application.

Public Policy Requirements and Objectives

The requirements concerning disclosure of financial conflicts of interest (see “Public Policy Requirements and Objectives—Ethical and Safe Conduct in Science and Organizational Operations—Financial Conflict of Interest”) do not apply to applications or awards under Phase I of the SBIR/STTR programs.

Allowable Costs and Fee

Profit or Fee

A reasonable profit or fee may be paid to a SBC receiving an award under Phase I or Phase II of the SBIR and STTR programs. The profit or fee is not considered a “cost” for purposes of determining allowable use, program income accountability, or audit thresholds. The profit or fee may be used by the SBC for any purpose, including additional effort under the SBIR/STTR award. It is intended to provide a reasonable profit consistent with normal profit margins for for-profit organizations for R&D work; however, the amount of the profit or fee normally will not exceed seven (7) percent of total costs (direct and F&A) for each phase of the project. The profit or fee should be drawn from PMS in increments proportional to the drawdown of funds for direct and F&A costs. The profit or fee applies solely to the SBC receiving the SBIR/STTR award and not to any other participant; however, in accordance with normal commercial practice, the SBC may pay a profit or fee to a contractor providing routine goods or services to the SBC under the grant.
Facilities and Administrative Costs (Indirect Costs)

Phase I

If the applicant SBC has a currently effective indirect cost rate(s)\(^{18}\) with a Federal agency, such rate(s) should be used when calculating proposed F&A costs for an NIH application. (However, the rates(s) must be adjusted for IR&D expenses, which are not allowable under HHS awards.) If the applicant SBC does not have a currently effective negotiated indirect cost rate with a Federal agency, the applicant should propose estimated F&A costs at a rate not to exceed 40 percent of the total direct costs. However, SBCs are reminded that only actual F&A costs are to be charged to projects. (If awarded at a rate of 40 percent or less, the rate used to charge actual F&A costs to projects cannot exceed the awarded rate unless the SBC negotiates an indirect cost rate(s) with a Federal agency.) NIH will not negotiate indirect cost rates for Phase I awards.

Phase II

If the applicant SBC has a currently effective negotiated indirect cost rate(s) with a Federal agency, such rate(s) should be used when calculating proposed F&A costs for an NIH application. (However, the rates(s) must be adjusted for IR&D expenses, which are not allowable under HHS awards.) If the applicant SBC does not have a currently effective negotiated indirect cost rate with a Federal agency, the applicant should propose an estimated F&A rate in the application. If the requested F&A cost rate is 25 percent of total direct costs or less, no further justification is required at the time of award, and F&A costs will be awarded at the requested rate. However, SBCs are reminded that only actual F&A costs may be charged to projects. If awarded at a rate of 25 percent or less of total direct costs, the rate used to charge actual F&A costs to projects cannot exceed the awarded rate unless the SBC negotiates an indirect cost rate(s) with DFAS. DFAS—the office authorized to negotiate indirect cost rates with SBC’s receiving NIH SBIR/STTR awards—will negotiate indirect cost rates for SBCs receiving Phase II awards that requested a rate greater than 25 percent of total direct costs.

Upon request, the applicant SBC should provide DFAS with an indirect cost proposal and supporting financial data for its most recently completed fiscal year. If financial data is not available for the most recently completed fiscal year, the applicant should submit a proposal showing estimated rates with supporting documentation. Further information about DFAS is available at its website or by telephone (see Part III of the NIHGPS).

Administrative Requirements

Market Research

NIH will not support market research, including studies of the literature that lead to a new or expanded statement of work, under the grant. For purposes of the SBIR/STTR programs, “market research” is the systematic gathering, editing, recording, computing, and analyzing of data about problems relating to the sale and distribution of the subject of the proposed research.

\(^{18}\) NIH ICs use the term F&A costs for all types of applicants and recipients; however, for-profit organizations will find that DFAS and organizations external to NIH refer to these costs as “indirect costs.”

244
It includes various types of research, such as the size of potential markets and potential sales volume, the identification of consumers most apt to purchase the products, and the advertising media most likely to stimulate their purchases. However, “market research” does not include activities under a research plan or protocol that include a survey of the public as part of the objectives of the project to determine the impact of the subject of the research on the behavior of individuals.

**Intellectual Property**

Rights to data, including software developed under the terms of any funding agreement resulting from an NIH award, shall remain with the grantee except that any such copyrighted material shall be subject to a royalty-free, nonexclusive and irrevocable license to the Federal government to reproduce, publish or otherwise use the material, and to authorize others to do so for Federal purposes. In addition, under the SBIR/STTR programs, in contrast to awards to for-profit organizations under other support mechanisms, such data shall not be released outside the Federal government without the grantee’s permission for a period of 4 years from completion of the project under which the data were generated.

The STTR program requires that the small business grantee and the single, non-profit research institution execute an agreement allocating between the parties intellectual property rights and rights, if any, to carry out follow-on research, development, or commercialization of the subject research. (A model agreement, entitled “Allocation of Rights in Intellectual Property and Rights to Carry Out Follow-On Research, Development, or Commercialization,” is available at the NIH website at [http://grants.nih.gov/grants/funding/sbir.htm](http://grants.nih.gov/grants/funding/sbir.htm).) By signing the face page of the grant application, the SBC’s AOO certifies that the agreement with the research institution will be effective at the time the grant award is made. A copy of the agreement must be furnished upon request to the NIH awarding office.

SBIR/STTR grantees are covered by 37 CFR 401 with respect to inventions and patents (see “Grants to For-Profit Organizations—Administrative Requirements—Intellectual Property” in this section).

**Data Sharing**

Applicants for SBIR Phase II funding of $500,000 or more of direct costs in any single year must comply with the NIH policy on data sharing as modified by the Small Business Act. If the final data would not be amenable to sharing, e.g., proprietary data, the SBC should explain that in the application. In addition, as indicated under “Intellectual Property” in this subsection, whether or not the award meets the threshold for data sharing, NIH will not release data outside the Federal government without the grantee’s permission for a period of 4 years from completion of the project under which the data were generated. The entire policy may be found at [http://grants.nih.gov/grants/policy/data_sharing](http://grants.nih.gov/grants/policy/data_sharing).
RESEARCH PATIENT CARE COSTS

General

This section provides NIH policy on the determination and reimbursement of research patient care costs under grants. This general policy is intended to be applied in conjunction with the requirements of 45 CFR Part 74, Appendix E, Principles for Determining Costs Applicable to Research and Development under Grants and Contracts with Hospitals. In addition, specific NIH programs may have additional or alternative requirements with which an applicant/grantee must comply. This includes the GCRC guidelines as specified in this section.

Definitions

**Research Patient Care Costs.** The costs of routine and ancillary services provided by hospitals to individuals participating in research programs. The costs of these services normally are assigned to specific research projects through the development and application of research patient care rates or amounts (hereafter “rates”). Research patient care costs do not include: (1) the otherwise allowable items of personal expense reimbursement, such as patient travel or subsistence, consulting physician fees, or any other direct payments related to all classes of individuals, including inpatients, outpatients, subjects, volunteers, and donors, (2) costs of ancillary tests performed in facilities outside the hospital on a fee-for-service basis (e.g., in an independent, privately owned laboratory) or in an affiliated medical school/university based on an organizational fee schedule, or (3) the data management or statistical analysis of clinical research results.

**Hospital.** Includes all types of medical, psychiatric, and dental facilities, such as clinics, infirmaries, and sanatoria.

**Research Patients.** Inpatient and outpatient subjects, volunteers, or donors participating in a research protocol.

**Routine Services.** Regular room services, minor medical and surgical supplies, and the use of equipment and facilities, for which a separate charge is not customarily made.

**Ancillary Services.** Those special services for which charges are customarily made in addition to routine services, e.g., x-ray, operating room, laboratory, pharmacy, blood bank, and pathology.

**Outpatient Services.** Services rendered to subjects/volunteers who are not hospitalized.

**Usual Patient Care.** Items and services (routine and ancillary) ordinarily furnished in the treatment of patients by providers of patient care under the supervision of the physician or other responsible health professional. Such items or services may be diagnostic, therapeutic, rehabilitative, medical, psychiatric, or any other related professional health services. These expenses are for care that would have been incurred even if the research study did not exist. The patient and/or third-party insurance generally will provide for reimbursement of charges for “usual patient care” as opposed to not reimbursing those charges generated solely because of participation in a research protocol.
**Discrete Centers.** Groups of beds that have been set aside for occupancy by research patients and are physically separated from other hospital beds in an environment that normally permits an ascertainable allocation of costs associated with the space they occupy and the service needs they generate.

**Scatter Beds.** Beds assigned to research patients based on availability. These beds are not physically separate from nonresearch beds. Scatter beds are geographically dispersed among all the beds available for use in the hospital and are not usually distinguishable in terms of services or costs from other general service beds within the hospital.

**Cost-Finding Process.** The technique of apportioning or allocating the costs of the non-revenue-producing cost centers to each other and to the revenue-producing centers on the basis of the statistical data that measure the amount of service rendered by each center to other centers.

**Policy**

NIH provides funds for research patient care costs under grants. Research patients may receive routine services as inpatients or ancillary services as either inpatient or outpatient subjects/volunteers. In order to receive reimbursement for research patient care costs, any hospital that, as a direct recipient of NIH funds, expects to incur more than $100,000 in patient care costs in any single budget period on a single NIH grant must either have in place or take steps to negotiate a research patient care rate agreement with the cognizant DCA office. These rates must be shown in all requests and/or claims for reimbursement of research patient care costs. Hospital grantees that expect to incur $100,000 or less in research patient care costs per budget period on a single NIH grant and consortium participants/contractors under grants are subject to the requirements specified in the subsection on “Special Procedures for Certain Hospitals” below. Failure to negotiate a research patient care rate with DCA when required may result in the disallowance of all research patient care costs charged to a grant.

**Allowable Costs**

The type of patient and services received are the determining factors for allowing research patient care costs as charges to NIH grants. If the patient is receiving service or care that neither differs from usual patient care nor results in expenses greater than those that would have been incurred if the study had not existed, then the patient is considered to be hospitalized for usual care purposes and the grant will not support the costs. When the research extends the period of hospitalization beyond that ordinarily required for usual care, or imposes procedures, tests or services beyond usual care, whether in an inpatient or outpatient setting, the grant may pay the additional costs. The grantee must decide whether, in fact, the hospitalization period, the tests, or the services have been extended beyond or added to what would ordinarily have been expected, and to what extent. Patient care costs for individuals who are receiving accepted treatment according to standard regimens would not ordinarily be acceptable charges to an NIH grant. Similarly, in certain kinds of clinical trials where accepted treatments are compared against new therapies, research patient care costs generally may be charged to a grant only insofar as they are measurements or services above and beyond those that constitute usual patient care and are specified by the study protocol.
NIH funds may be used to pay all costs (whether usual care costs or research care costs) for the entire period of hospitalization or research tests or services for individuals who would not have been hospitalized or received such tests or services except for their participation in the research study. Any such exceptions should be documented in the grantee’s records. These individuals may include the following:

◆ People to whom no health advantages may be expected to accrue as a result of the hospitalization. Examples would be normal controls for metabolic or other studies; people with genetic or certain abnormalities of interest to the investigator; and sick people brought to the hospital solely for studies when they otherwise would not require hospitalization.

◆ Sick people of research importance to the investigator but without funds of their own or without funds available to them through a responsible third party to pay hospitalization expenses. This includes patients for whom some third-party payer, such as a city, county, or State government, might pay hospitalization expenses in some other hospital but has no responsibility to pay in the hospital in which the approved clinical research is being conducted.

◆ Sick people with limited personal funds or health insurance but who are not willing to spend their own money or use their hospital plan coverage at that particular time. (Fear of more urgent need in the future for both personal funds and health insurance might be one reason for the patient’s reluctance to participate in the study.) The investigator has a special responsibility in making the decision to include patients in this group with full charges to the grant. Ordinarily, NIH expects the patient and/or third party to pay the total costs of the usual care portions of the hospitalization. However, in exceptional circumstances, the investigator may decide to pay the total expenses for hospitalization, research services, or tests from the grant if this is required to secure timely cooperation of a valuable study patient not otherwise available.

Computing Research Patient Care Costs

Research patient care costs, whether expressed as a rate or an amount, shall be computed in an amount consistent with the principles and procedures used by the Medicare program for determining the portion of Medicare reimbursement based on reasonable costs. Separate cost centers must be established for each discrete bed unit for purposes of allocating or distributing allowable routine costs to the discrete unit.

When provisional rates are used as the basis for award of research patient care costs, the amount awarded shall constitute the maximum amount that the NIH awarding office is obligated to reimburse the grantee for such costs. Provisional rates must be adjusted if a lower final rate is negotiated.

Facilities and Administrative Costs

F&A costs should not be paid on any cost component representing the cost of research patient care activities. Research patient care rates (routine and ancillary) include F&A costs related to
“hospital-type” employees (nurses, medical technicians, and similar personnel) supported as a direct cost under a grant. Therefore, to preclude over-recoveries of costs similar to these F&A costs, salaries and wages of all “hospital-type” employees working on the grant must be excluded from the S&W base used to claim F&A costs. Related fringe benefits also should be excluded if such costs are part of the S&W base. If a “total-direct-costs” base is used to compute and claim F&A costs, the above-mentioned “hospital-type” salaries also must be excluded from the base as well as any other base costs chargeable to the grant through the application of a research patient care rate.

If the grant or a consortium agreement/contract under a grant provides funding exclusively for research patient care activities, no F&A costs normally will be allowed as a separate cost element since all allocable F&A costs will be accounted for in the routine or ancillary activity costs contained in research patient care rates.

Special Procedures for Certain Hospitals

Grantees

If a grantee does not meet the threshold for negotiation of a research patient care rate agreement with DCA in a given budget period, as specified under “Policy” in this section, but has a currently negotiated research patient care rate, that rate will be used in awarding and reimbursing research patient care costs, regardless of the amount that the grantee expects to incur. In all other cases, the grantee will be reimbursed at a rate not to exceed the lesser of actual research patient care costs or the rate included in its Medicare cost report.

Consortium Participants/Contractors under Grants

If a hospital incurring research patient care costs is not the grantee, the grantee will be responsible for establishing the rate or amount that will be reimbursed for such costs unless the hospital also is a direct recipient of other HHS awards and in that capacity has established a research patient care rate with DCA.

If a participating hospital expects to incur more than $100,000 in research patient care costs as specified under “Policy” in this section, the grantee must negotiate a rate for that hospital unless the relationship between the grantee and the hospital is considered “less-than-arms-length.” In this case, the grantee should contact the GMO to determine whether DCA should negotiate the rate.

If a participating hospital expects to incur $100,000 or less in research patient care costs (as provided under “Policy” in this section), the grantee will use the lesser of actual costs or the rate in the hospital’s Medicare cost report as the basis for determining reimbursement. For purposes of this paragraph, the grantee will apply the thresholds to each hospital individually.

Financial Responsibilities

If the costs of patient care are funded by the grant, and whether those costs are classified as usual patient care or research patient care, the amount recovered from third parties must be credited to the grant. However, patient charges must be adjusted for both routine services and ancillaries...
prior to applying the third-party recoveries. The grantee is obligated to pursue recovery to the fullest extent possible and should be able to document those efforts. An example of such an adjustment follows:

If the standard fee schedule charge for a CT scan is $500, the negotiated research patient care agreement rate is 75 percent, and third-party insurance pays $300, the maximum amount that may be charged to the NIH grant is $75, based on the following calculation.

\[
\text{Standard Fee Schedule} \times \text{Negotiated Rate} - \text{Insurance} = \text{Maximum Charge to NIH Grant}
\]

\[\$500 \times .75 = \$375 - \$300 = \$75\]

In those instances when the grantee determines that the balance of the patient’s bill may be charged to the grant (see “Allowable Costs” in this section), the total bill must be adjusted to cost before applying any third-party recoveries. The remaining balance of allowable costs may then be charged to the grant.

In certain circumstances, funds may be awarded that support tests specifically developed for research purposes that are subsequently billed to third parties. In such cases, funds recovered from third parties must be credited to the grant account.

**Program Requirements**

An individual NIH IC/program may adopt special implementing procedures consistent with this section to meet its own specific needs. As an example, the majority of NIH-supported discrete centers are funded by NCRR’s GCRC program, which has developed detailed guidelines for the operation of these centers (see Part III for NCRR contact information).
Part III: Points of Contact

Various offices and officials are mentioned throughout the preceding parts of the NIHGPS as sources of information or as responsible for certain activities in the NIH grants process. Contact information for these and other offices and officials is provided in this part. These addresses should not be used for express mail or other types of hand-deliveries. The IC should be contacted to obtain the address to use for express mail.

For each IC that awards grants, a listing is provided for the CGMO as well as an extramural program official that may be contacted for general information. The web address for the IC’s home page also is included. Requests related to particular applications submitted or grants awarded should be directed to the individual(s) specified in formal communications from NIH, e.g., in the NGA.
## Institutes and Centers

<table>
<thead>
<tr>
<th>John E. Fogarty International Center (FIC)</th>
<th><a href="http://www.fic.nih.gov/">http://www.fic.nih.gov/</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>Building 31C, Room B2C29, MSC-2220</td>
<td>Building 31C, Room B2C29, MSC-2220</td>
</tr>
<tr>
<td>Bethesda, MD 20892-2220</td>
<td>Bethesda, MD 20892-2220</td>
</tr>
<tr>
<td>301/496-1670</td>
<td>301/496-1415</td>
</tr>
<tr>
<td>301/594-1211 (fax)</td>
<td>301/402-2173 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Cancer Institute (NCI)</th>
<th><a href="http://www.nci.nih.gov">http://www.nci.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6120 Executive Boulevard</td>
<td>6116 Executive Boulevard</td>
</tr>
<tr>
<td>Executive Plaza South, Room 234, MSC-7150</td>
<td>Executive Plaza North, Suite 8001, MSC-7405</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7150</td>
<td>Bethesda, MD 20892-7405</td>
</tr>
<tr>
<td>301/496-7753</td>
<td>301/496-5147</td>
</tr>
<tr>
<td>301/402-3409 (fax)</td>
<td>301/402-0956 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Center for Complementary and Alternative Medicine (NCCAM)</th>
<th><a href="http://nccam.nih.gov">http://nccam.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6707 Democracy Boulevard, MSC-5475</td>
<td>6707 Democracy Boulevard, MSC-5475</td>
</tr>
<tr>
<td>II Democracy Plaza, Suite 401</td>
<td>II Democracy Plaza, Suite 401</td>
</tr>
<tr>
<td>Bethesda, MD 20892-5475</td>
<td>Bethesda, MD 20892-5475</td>
</tr>
<tr>
<td>301/451-6330</td>
<td>301/496-4792</td>
</tr>
<tr>
<td>301/480-1552 (fax)</td>
<td>301/480-3621 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Center for Research Resources (NCRR)</th>
<th><a href="http://www.ncrr.nih.gov">http://www.ncrr.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6701 Democracy Boulevard</td>
<td>Building 31, Room 3B11, MSC-2128</td>
</tr>
<tr>
<td>One Democracy Plaza, Suite 1038, MSC-4874</td>
<td>Bethesda, MD 20892-2128</td>
</tr>
<tr>
<td>Bethesda, MD 20892-4874</td>
<td>301/496-6023</td>
</tr>
<tr>
<td>301/435-0844</td>
<td>301/480-3658 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Center on Minority Health and Health Disparities (NCMHD)</th>
<th><a href="http://www.ncmhd.nih.gov">http://www.ncmhd.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6707 Democracy Boulevard, Suite 800, MSC 5465</td>
<td>6707 Democracy Boulevard, Suite 800, MSC 5465</td>
</tr>
<tr>
<td>Bethesda, MD</td>
<td>Bethesda, MD</td>
</tr>
<tr>
<td>301/402-1366</td>
<td>301/402-1366</td>
</tr>
<tr>
<td>301/402-4049</td>
<td>301/402-4049</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6120 Executive Boulevard</td>
<td>6120 Executive Boulevard</td>
</tr>
<tr>
<td>Executive Plaza South, Room 350, MSC-7164</td>
<td>Executive Plaza South, Room 350, MSC-7164</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7164</td>
<td>Bethesda, MD 20892-7164</td>
</tr>
<tr>
<td>301/451-2020</td>
<td>301/496-5301</td>
</tr>
<tr>
<td>301/496-9997 (fax)</td>
<td>301/402-0528 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Heart, Lung and Blood Institute (NHLBI)</th>
<th><a href="http://www.nhlbi.nih.gov">http://www.nhlbi.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6701 Rockledge Drive</td>
<td>6701 Rockledge Drive</td>
</tr>
<tr>
<td>Rockledge II, Room 7160, MSC-7926</td>
<td>Rockledge II, Room 7100, MSC-7922</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7926</td>
<td>Bethesda, MD 20892-7922</td>
</tr>
<tr>
<td>301/435-0144</td>
<td>301/435-0260</td>
</tr>
<tr>
<td>301/480-3310 (fax)</td>
<td>301/480-3460 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Human Genome Research Institute (NHGRI)</th>
<th><a href="http://www.genome.gov">http://www.genome.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>5635 Fishers Lane, Suite 4076, MSC 9306</td>
<td>5635 Fishers Lane Suite 4076, MSC 9305</td>
</tr>
<tr>
<td>Bethesda, MD 20892-9306</td>
<td>Bethesda, MD 20892-9305</td>
</tr>
<tr>
<td>301/402-0733</td>
<td>301/496-7531</td>
</tr>
<tr>
<td>301/402-1951 (fax)</td>
<td>301/480-2770 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute on Aging (NIA)</th>
<th><a href="http://www.nia.nih.gov">http://www.nia.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>7201 Wisconsin Avenue</td>
<td>7201 Wisconsin Avenue</td>
</tr>
<tr>
<td>Gateway Bldg., Room 2N212, MSC-9205</td>
<td>Gateway Bldg., Room 2C218F, MSC-9205</td>
</tr>
<tr>
<td>Bethesda, MD 20892-9205</td>
<td>Bethesda, MD 20892-9205</td>
</tr>
<tr>
<td>301/496-1472</td>
<td>301/496-9322</td>
</tr>
<tr>
<td>301/402-3672 (fax)</td>
<td>301/402-2945 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</th>
<th><a href="http://www.niaaa.nih.gov">http://www.niaaa.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>5635 Fishers Lane, Room 3023, MSC 9304</td>
<td>5635 Fishers Lane, Room 3039, MSC 9304</td>
</tr>
<tr>
<td>Bethesda, MD 20892-9304</td>
<td>Bethesda, MD 20892-9304</td>
</tr>
<tr>
<td>301/443-4704</td>
<td>301/443-2531</td>
</tr>
<tr>
<td>301/443-3891 (fax)</td>
<td>301/443-6077 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute of Allergy and Infectious Diseases (NIAID)</th>
<th><a href="http://www.niaid.nih.gov">http://www.niaid.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6700-B Rockledge Drive, Room 2116, MSC-7614</td>
<td>6700-B Rockledge Drive, Room 2141, MSC-7610</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7614</td>
<td>Bethesda, MD 20892-7610</td>
</tr>
<tr>
<td>301/496-7075</td>
<td>301/496-7291</td>
</tr>
<tr>
<td>301/480-3780 (fax)</td>
<td>301/402-0369 (fax)</td>
</tr>
</tbody>
</table>

253
<table>
<thead>
<tr>
<th>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</th>
<th><a href="http://www.niams.nih.gov">http://www.niams.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chief Grants Management Officer</strong></td>
<td><strong>Extramural Program Official</strong></td>
</tr>
<tr>
<td>6701 Democracy Boulevard</td>
<td>6701 Democracy Boulevard</td>
</tr>
<tr>
<td>One Democracy Plaza, Suite 800, MSC-4872</td>
<td>One Democracy Plaza, Suite 800, MSC-4872</td>
</tr>
<tr>
<td>Bethesda, MD 20892-4872</td>
<td>Bethesda, MD 20892-4872</td>
</tr>
<tr>
<td>301/594-3535</td>
<td>301/594-2463</td>
</tr>
<tr>
<td>310/480-5450 (fax)</td>
<td>301/480-4543 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute of Biomedical Imaging and Bioengineering (NIBIB)</th>
<th><a href="http://www.nibib.nih.gov">http://www.nibib.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chief Grants Management Officer</strong></td>
<td><strong>Extramural Program Official</strong></td>
</tr>
<tr>
<td>6701 Democracy Boulevard</td>
<td>6701 Democracy Boulevard</td>
</tr>
<tr>
<td>One Democracy Plaza, Suite 900, MSC-5489</td>
<td>One Democracy Plaza, Suite 200, MSC-5489</td>
</tr>
<tr>
<td>Bethesda, MD 20892-5489</td>
<td>Bethesda, MD 20892-5489</td>
</tr>
<tr>
<td>301/451-4782</td>
<td>301/451-4772</td>
</tr>
<tr>
<td>301/408-4974</td>
<td>301/451-4973</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute of Child Health and Human Development (NICHD)</th>
<th><a href="http://www.nichd.nih.gov">http://www.nichd.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chief Grants Management Office</strong></td>
<td><strong>Extramural Program Official</strong></td>
</tr>
<tr>
<td>6100 Executive Boulevard, Room 8A01A</td>
<td>6100 Executive Boulevard, Room 2C01, MSC-7510</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7510</td>
<td>Bethesda, MD 20892-7510</td>
</tr>
<tr>
<td>301/496-5001</td>
<td>301/435-6856</td>
</tr>
<tr>
<td>301/480-4782 (fax)</td>
<td>301/402-2083 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute on Deafness and Other Communication Disorders (NIDCD)</th>
<th><a href="http://www.nidcd.nih.gov">http://www.nidcd.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chief Grants Management Officer</strong></td>
<td><strong>Extramural Program Official</strong></td>
</tr>
<tr>
<td>6120 Executive Boulevard</td>
<td>6120 Executive Boulevard</td>
</tr>
<tr>
<td>Executive Plaza South, Suite 400C, MSC-7180</td>
<td>Executive Plaza South, Suite 400C, MSC-7180</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7180</td>
<td>Bethesda, MD 20892-7180</td>
</tr>
<tr>
<td>301/402-0909</td>
<td>301/496-8693</td>
</tr>
<tr>
<td>301/402-1758 (fax)</td>
<td>301/402-6250 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute of Dental and Craniofacial Research (NIDCR)</th>
<th><a href="http://www.nidcr.nih.gov">http://www.nidcr.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chief Grants Management Officer</strong></td>
<td><strong>Extramural Program Official</strong></td>
</tr>
<tr>
<td>45 Center Drive</td>
<td>45 Center Drive</td>
</tr>
<tr>
<td>Natcher Bldg., Room 4AN.44B, MSC-6402</td>
<td>Natcher Bldg., Room 4AN.44F, MSC-6402</td>
</tr>
<tr>
<td>Bethesda, MD 20892-6402</td>
<td>Bethesda, MD 20892-6402</td>
</tr>
<tr>
<td>301/594-4808</td>
<td>301/594-2904</td>
</tr>
<tr>
<td>301/480-3562 (fax)</td>
<td>301/480-8303 (fax)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6707 Democracy Boulevard</td>
<td>6707 Democracy Boulevard</td>
</tr>
<tr>
<td>2 Democracy Plaza, Room 731, MSC-5456</td>
<td>2 Democracy Plaza, Room 631, MSC-5456</td>
</tr>
<tr>
<td>Bethesda, MD 20892-5456</td>
<td>Bethesda, MD 20892-5456</td>
</tr>
<tr>
<td>301/594-8854</td>
<td>301/594-8834</td>
</tr>
<tr>
<td>301/480-3504 (fax)</td>
<td>301/480-3504 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6101 Executive Boulevard</td>
<td>6101 Executive Boulevard</td>
</tr>
<tr>
<td>Neuroscience Center, Suite 242, MSC-8403</td>
<td>Neuroscience Center, Suite 200, MSC-8401</td>
</tr>
<tr>
<td>Bethesda, MD 20892-8403</td>
<td>Bethesda, MD 20892-9547</td>
</tr>
<tr>
<td>301/443-6710</td>
<td>301/443-8401</td>
</tr>
<tr>
<td>301/594-6849 (fax)</td>
<td>301/443-0538 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute of Environmental Health Sciences (NIEHS)</th>
<th><a href="http://www.niehs.nih.gov">http://www.niehs.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>P.O. Box 12233</td>
<td>P.O. Box 12233</td>
</tr>
<tr>
<td>Research Triangle Park, NC 27709</td>
<td>Research Triangle Park, NC 27709</td>
</tr>
<tr>
<td>919/541-7628</td>
<td>919/541-7723</td>
</tr>
<tr>
<td>919/541-2860 (fax)</td>
<td>919/541-2843 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute of General Medical Sciences (NIGMS)</th>
<th><a href="http://www.nigms.nih.gov">http://www.nigms.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>45 Center Drive</td>
<td>45 Center Drive</td>
</tr>
<tr>
<td>Natcher Bldg., Room 2AN.32C, MSC-6200</td>
<td>Natcher Bldg., Room 2AN.24H, MSC-6200</td>
</tr>
<tr>
<td>Bethesda, MD 20892-6200</td>
<td>Bethesda, MD 20892-6200</td>
</tr>
<tr>
<td>301/594-5135</td>
<td>301/594-4999</td>
</tr>
<tr>
<td>301/480-2554 (fax)</td>
<td>301/480-1852 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute of Mental Health (NIMH)</th>
<th><a href="http://www.nimh.nih.gov">http://www.nimh.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6001 Executive Boulevard</td>
<td>6001 Executive Boulevard</td>
</tr>
<tr>
<td>Neuroscience Center, Room 6115, MSC 9605</td>
<td>Neuroscience Center, Room 6120</td>
</tr>
<tr>
<td>Bethesda, MD 20892-9605</td>
<td>Bethesda, MD 20892-9605</td>
</tr>
<tr>
<td>301/443-3066</td>
<td>301/443-5047</td>
</tr>
<tr>
<td>301/443-6885 (fax)</td>
<td>301/443-9474 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Institute of Neurological Disorders and Stroke (NINDS)</th>
<th><a href="http://www.ninds.nih.gov">http://www.ninds.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Grants Management Officer</td>
<td>Extramural Program Official</td>
</tr>
<tr>
<td>6001 Executive Boulevard</td>
<td>6001 Executive Boulevard</td>
</tr>
<tr>
<td>Neuroscience Center, Room 3254, MSC-9537</td>
<td>Neuroscience Center, Room 3307, MSC-9537</td>
</tr>
<tr>
<td>Bethesda, MD 20892-9537</td>
<td>Bethesda, MD 20892-9537</td>
</tr>
<tr>
<td>301/496-9231</td>
<td>301/496-9248</td>
</tr>
<tr>
<td>301/402-0219 (fax)</td>
<td>301/402-4370 (fax)</td>
</tr>
<tr>
<td>National Institute of Nursing Research (NINR)</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td><strong>Chief Grants Management Officer</strong></td>
<td><strong>Extramural Program Official</strong></td>
</tr>
<tr>
<td>6701 Democracy Boulevard</td>
<td>6701 Democracy Boulevard</td>
</tr>
<tr>
<td>One Democracy Plaza, Suite 710, MSC-4870</td>
<td>One Democracy Plaza, Suite 710, MSC-4870</td>
</tr>
<tr>
<td>Bethesda, MD 20892-4870</td>
<td>Bethesda, MD 20892-4870</td>
</tr>
<tr>
<td>301/594-6869</td>
<td>301/594-6423</td>
</tr>
<tr>
<td>301/402-4502 (fax)</td>
<td>301/480-8260 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Library of Medicine (NLM)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chief Grants Management Officer</strong></td>
<td><strong>Extramural Program Official</strong></td>
</tr>
<tr>
<td>6705 Rockledge Drive</td>
<td>Building 38A, Room 5N503, MSC-6075</td>
</tr>
<tr>
<td>Rockledge I, Suite 301, MSC-7968</td>
<td>Bethesda, MD 20892-6075</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7968</td>
<td>301/496-4621</td>
</tr>
<tr>
<td>301/496-4222</td>
<td>301/402-0421 (fax)</td>
</tr>
<tr>
<td>301/402-0421 (fax)</td>
<td></td>
</tr>
</tbody>
</table>
### Other NIH Offices

#### Office of Extramural Research
**Office of Policy for Extramural Research Administration (OPERA)**  

<table>
<thead>
<tr>
<th>Division of Extramural Outreach and Information Resources (DEOIR)</th>
<th>Division of Extramural Inventions and Technology Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td>e-mail: <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></td>
<td>6705 Rockledge Drive</td>
</tr>
<tr>
<td>301/435-0714</td>
<td>Rockledge I, MSC-7980</td>
</tr>
<tr>
<td>301/480-0525 (fax)</td>
<td>Bethesda, MD 20892-7980</td>
</tr>
<tr>
<td></td>
<td>301/435-1986 or 1-866-504-9552</td>
</tr>
<tr>
<td></td>
<td>301/480-0272 (fax)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Division of Grants Policy</th>
<th>Division of Grants Compliance and Oversight</th>
</tr>
</thead>
<tbody>
<tr>
<td>6705 Rockledge Drive</td>
<td>6705 Rockledge Drive</td>
</tr>
<tr>
<td>Rockledge I, MSC-7974</td>
<td>Rockledge I, MSC-7974</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7974</td>
<td>Bethesda, MD 20892-7974</td>
</tr>
<tr>
<td>301/435-0949</td>
<td>301/435-0938</td>
</tr>
<tr>
<td>301/435-3059 (fax)</td>
<td>301/435-3059</td>
</tr>
</tbody>
</table>

#### Office of Laboratory Animal Welfare (OLAW)

<table>
<thead>
<tr>
<th>6705 Rockledge Drive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rockledge I, Suite 360, MSC-7982</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7982</td>
</tr>
<tr>
<td>301/496-7163</td>
</tr>
</tbody>
</table>

#### Center for Scientific Review (CSR)

<table>
<thead>
<tr>
<th>Division of Receipt and Referral</th>
</tr>
</thead>
<tbody>
<tr>
<td>6701 Rockledge Drive</td>
</tr>
<tr>
<td>Rockledge II, MSC-7768</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7768</td>
</tr>
<tr>
<td>Referral Office 301/435-0715</td>
</tr>
</tbody>
</table>

#### Office of Biotechnology Activities (OBA)
[http://www4.od.nih.gov/oba](http://www4.od.nih.gov/oba)

<table>
<thead>
<tr>
<th>6705 Rockledge Drive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suite 750, MSC-7985</td>
</tr>
<tr>
<td>Bethesda, MD 20892-7985</td>
</tr>
<tr>
<td>301/496-9838</td>
</tr>
</tbody>
</table>

#### Office of Intramural Research (OIR)
[http://www1.od.nih.gov/oir/sourcebook/oir/oir-staff.htm#OIR](http://www1.od.nih.gov/oir/sourcebook/oir/oir-staff.htm#OIR)

<table>
<thead>
<tr>
<th>6011 Executive Boulevard, Suite 325</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rockville, MD 20852</td>
</tr>
<tr>
<td>301/496-7057</td>
</tr>
<tr>
<td>301/402-3257 (fax)</td>
</tr>
<tr>
<td><strong>Office of Financial Management (OFM)</strong></td>
</tr>
<tr>
<td>----------------------------------------</td>
</tr>
<tr>
<td>To register for electronic submission of Financial Status Reports:</td>
</tr>
<tr>
<td>Government Accounting Branch</td>
</tr>
<tr>
<td>301/402-9123</td>
</tr>
<tr>
<td>or access website:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Office of Acquisition Management and Policy (OAMP)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Division of Financial Advisory Services (DFAS)</strong></td>
</tr>
<tr>
<td>6011 Executive Blvd, Room 549C</td>
</tr>
<tr>
<td>MSC-7663</td>
</tr>
<tr>
<td>Rockville, MD 20852</td>
</tr>
<tr>
<td>301/496-4401</td>
</tr>
<tr>
<td>301/402-0177</td>
</tr>
</tbody>
</table>
## Other HHS Offices

### Office of the Inspector General (OIG)
**http://www.oig.hhs.gov**

<table>
<thead>
<tr>
<th>Department of Health and Human Services</th>
<th>Questions concerning A-133 audit requirements:</th>
</tr>
</thead>
<tbody>
<tr>
<td>OIG Hotline</td>
<td>National External Audit Resources</td>
</tr>
<tr>
<td>Attn: HOTLINE</td>
<td>Office of Audit Services</td>
</tr>
<tr>
<td>330 Independence Avenue, SW</td>
<td>323 West 8th Street</td>
</tr>
<tr>
<td>Washington, DC 20201</td>
<td>Lucas Place, Room 514</td>
</tr>
<tr>
<td>800-HHS-TIPS (1-800-447-8477)</td>
<td>Kansas City, Missouri 64105</td>
</tr>
<tr>
<td>e-mail: <a href="mailto:HHSTips@org.hhs.gov">HHSTips@org.hhs.gov</a></td>
<td>800/732-0679 (voice)</td>
</tr>
<tr>
<td></td>
<td>816/374-6714 (voice)</td>
</tr>
<tr>
<td></td>
<td>816/374-6727 (fax)</td>
</tr>
<tr>
<td></td>
<td><a href="http://harvester.census.gov/sac">http://harvester.census.gov/sac</a></td>
</tr>
</tbody>
</table>

### Office for Human Research Protections (OHRP)
**http://www.hhs.gov/ohrp/**

<table>
<thead>
<tr>
<th>The Tower Building</th>
<th>Toll-Free Telephone within the U.S. (866) 447-4777</th>
</tr>
</thead>
<tbody>
<tr>
<td>1101 Wootton Parkway, Suite 200</td>
<td>Telephone: (240) 453-6900</td>
</tr>
<tr>
<td>Rockville, MD 20852</td>
<td>Fax: (240) 453-6909</td>
</tr>
<tr>
<td>301/496-7005</td>
<td>e-mail: <a href="mailto:ohrp@osophs.dhhs.gov">ohrp@osophs.dhhs.gov</a></td>
</tr>
</tbody>
</table>

### Office of Research Integrity (ORI)
**http://ori.dhhs.gov**

<table>
<thead>
<tr>
<th>The Tower Building</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1101 Wootton Parkway, Suite 750</td>
<td></td>
</tr>
<tr>
<td>Rockville, MD 20852</td>
<td></td>
</tr>
<tr>
<td>240/453-8200</td>
<td></td>
</tr>
<tr>
<td>e-mail: <a href="mailto:askori@osophs.dhhs.gov">askori@osophs.dhhs.gov</a></td>
<td></td>
</tr>
</tbody>
</table>

### Departmental Appeals Board (DAB)
**http://www.hhs.gov/dab/**

<table>
<thead>
<tr>
<th>200 Independence Avenue, SW</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hubert H. Humphrey Building, Room 637-D</td>
<td></td>
</tr>
<tr>
<td>Washington, DC 20201</td>
<td></td>
</tr>
<tr>
<td>202/690-5501</td>
<td></td>
</tr>
<tr>
<td>e-mail: <a href="mailto:DAB@hhs.gov">DAB@hhs.gov</a></td>
<td></td>
</tr>
</tbody>
</table>

### Office for Civil Rights (OCR)
**http://www.hhs.gov/ocr**

<table>
<thead>
<tr>
<th>Office of Program Operations</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>200 Independence Avenue, SW</td>
<td></td>
</tr>
<tr>
<td>Room 509 F</td>
<td></td>
</tr>
<tr>
<td>Washington, DC 20201</td>
<td></td>
</tr>
<tr>
<td>800/368-1019</td>
<td></td>
</tr>
</tbody>
</table>
## Program Support Center
Financial Management Service
Division of Payment Management (DPM)

http://www.dpm.psc.gov

P.O. Box 6021
Rockville, MD 20852
301/443-9193
301/443-3586 (fax)
e-mail: info@psc.dhhs.gov
Find Account Representative:
http://www.dpm.psc.gov/Contact.aspx

## Division of Cost Allocation (DCA)

http://rates.psc.gov/

| Mid-Atlantic Field Office | 330 Independence Avenue, S.W.
| (Services Alabama, Delaware, District of Columbia, Florida, Georgia, Kentucky, Maryland, Mississippi, North Carolina, Pennsylvania, South Carolina, Tennessee, Virginia and West Virginia) | Cohen Building, Room 10-67
| | Washington, DC 20201
| | 202/401-2808 |
| Northeastern Field Office | 26 Federal Plaza
| (Services Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, Vermont, Puerto Rico, the Virgin Islands, Canada and Europe) | Room 41-122
| | New York, NY 10278
| | 212/264-2069 |
| Central States Field Office | 1301 Young Street
| (Services Arkansas, Illinois, Indiana, Iowa, Kansas, Louisiana, Michigan, Minnesota, Missouri, Nebraska, New Mexico, Ohio, Oklahoma, Texas and Wisconsin) | Room 702
| | Dallas, TX 75202
| | 214/767-3261 |
| Western Field Office | 50 United Nations Plaza
| (Services Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, North Dakota, Oregon, South Dakota, Utah, Washington, Wyoming, Australia, and Asia) | Room 347
| | San Francisco, CA 94102
| | 415/437-7820 |
Index

Page references containing an n refer to footnotes.

A
Abbreviations list .......................................................... 1–5
Abortion funding restriction .......................................................... 43, 54
Accelerated expenditures .......................................................... 84
Accessibility standards, facilities .................................................. 40, 148
Activation Notice (Form PHS 416-5) ............................................. 173, 179
Administrative requirements
changes in project and budget .................................................. 102–113
closeout and final reports .................................................. 139–141
conference grants .......................................................... 223–224
construction grants .......................................................... 161–166
enforcement actions .......................................................... 136–139
exempt property .......................................................... 124–125
financial management system .................................................. 120
grant appeals procedures .................................................. 141–142
grants to Federal institutions .................................................. 237
grants to for-profit organizations .................................................. 238–240
management systems and procedures .................................................. 120–128
monitoring .......................................................... 128–136
property management .................................................. 123–126
procurement system .......................................................... 126–28
research results availability .................................................. 113–120
SBIR and STTR programs .................................................. 244–245
Advances of grant funds, interest earned on .................................. 78
Advertising, costs .......................................................... 87
Advisory Council on Historic Preservation .................................. 146n
Affiliated organization services, cost considerations .................................. 85
Age Discrimination Act of 1975 .................................................. 39, 68
Alcoholic beverages, costs .......................................................... 87
Allocability test, allowability of costs and .................................. 80
Allowability of costs .......................................................... 80

Also see Cost considerations and principles; specific funding mechanisms
Alteration and renovation (A&R). Also see Construction grants
costs .......................................................... 87
definition .......................................................... 6
prior-approval requirements .................................................. 105, 106, 161–163
public policy requirements and objectives .................................. 69
Animal welfare .......................................................... 39, 65–66, 185, 207, 229
Animals, costs .......................................................... 88
Annual Payback Activities Certification (Form PHS 6031-1) .................................................. 214–215
Appeals procedures
adverse determinations and .................................................. 141–142
initial scientific review appeals .................................................. 28–29
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicable credits</td>
<td>85</td>
</tr>
<tr>
<td>Application definition</td>
<td>6</td>
</tr>
<tr>
<td>false, fictitious, or fraudulent information in</td>
<td>24–25</td>
</tr>
<tr>
<td>types of applications</td>
<td>19</td>
</tr>
<tr>
<td>Application process</td>
<td>22–23</td>
</tr>
<tr>
<td>application forms</td>
<td>23–24</td>
</tr>
<tr>
<td>application receipt points and deadlines</td>
<td>22–25</td>
</tr>
<tr>
<td>application submission</td>
<td>22–25</td>
</tr>
<tr>
<td>confidentiality of information (proprietary information)</td>
<td>25</td>
</tr>
<tr>
<td>eligibility</td>
<td>19, 33–35</td>
</tr>
<tr>
<td>individual fellowships</td>
<td>170–171, 216</td>
</tr>
<tr>
<td>institutional research training grants</td>
<td>190, 216</td>
</tr>
<tr>
<td>Approved budget, definition</td>
<td>6</td>
</tr>
<tr>
<td>Archeological and Historical Preservation Act of 1960</td>
<td>146</td>
</tr>
<tr>
<td>Architectural Barriers Act of 1968, elimination of barriers to the handicapped and</td>
<td>40, 148</td>
</tr>
<tr>
<td>Assurance requirements</td>
<td></td>
</tr>
<tr>
<td>animals</td>
<td>65–66, 207</td>
</tr>
<tr>
<td>human subjects</td>
<td>59, 205</td>
</tr>
<tr>
<td>Audiovisual activities, costs</td>
<td>88</td>
</tr>
<tr>
<td>Audit costs</td>
<td>88</td>
</tr>
<tr>
<td>Audit requirements</td>
<td>134–136</td>
</tr>
<tr>
<td>consortium agreements</td>
<td>227</td>
</tr>
<tr>
<td>grants to for-profit organizations</td>
<td>239–240</td>
</tr>
<tr>
<td>grants to foreign institutions, international organizations, and domestic grants with</td>
<td>232</td>
</tr>
<tr>
<td>foreign components</td>
<td></td>
</tr>
<tr>
<td>Authorized organizational official (AOO)</td>
<td></td>
</tr>
<tr>
<td>definition</td>
<td>6</td>
</tr>
<tr>
<td>role and responsibilities</td>
<td>18</td>
</tr>
<tr>
<td>Award, definition</td>
<td>6</td>
</tr>
<tr>
<td>Award instruments, types of</td>
<td>19</td>
</tr>
<tr>
<td>Awardee, usage</td>
<td>iii</td>
</tr>
<tr>
<td>Awarding office, definition</td>
<td>6</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bad debts, costs</td>
<td>88</td>
</tr>
<tr>
<td>Ban on human embryo research and cloning</td>
<td>39, 54–55</td>
</tr>
<tr>
<td>Also see Inventions and patents</td>
<td></td>
</tr>
<tr>
<td>Bid and proposal costs</td>
<td>88</td>
</tr>
<tr>
<td>Bonding, costs</td>
<td>88</td>
</tr>
<tr>
<td>Bonus funds/incentive payments, costs</td>
<td>98</td>
</tr>
<tr>
<td>Books and journals, costs</td>
<td>88</td>
</tr>
<tr>
<td>Budget</td>
<td></td>
</tr>
<tr>
<td>changes in</td>
<td>102–113, 199, 231</td>
</tr>
<tr>
<td>approved budget, definition</td>
<td>6</td>
</tr>
<tr>
<td>budget period, definition</td>
<td>6</td>
</tr>
<tr>
<td>NGA and</td>
<td>76</td>
</tr>
<tr>
<td>significant rebudgeting, definition</td>
<td>14</td>
</tr>
<tr>
<td>Building acquisition, costs</td>
<td>89</td>
</tr>
</tbody>
</table>
C

Capital expenditures
  definition .......................................................................................................................... 7
  prior-approval requirements ....................................................................................... 105, 106

Career awards. See K awards
  Carryover of unobligated balances ........................................................................ 103–104, 105, 132
  Cash requests .............................................................................................................. 76, 77–78
  CASHLINE/ACH ........................................................................................................... 76, 77

Center. See Institutes and Centers
  Center for Scientific Review (CSR)
  responsibilities ............................................................................................................ 17, 23, 26–27
  Certificates of confidentiality ...................................................................................... 39, 57
  Change of grantee organization .............................................................................. 105, 108–110, 231
  Changes in project and budget
  about .............................................................................................................................. 102
  expanded authorities .................................................................................................. 102–104
  grants to foreign institutions, international organizations, and domestic grants with
    foreign components ................................................................................................. 231–232
  individual fellowships ............................................................................................... 180–181
  institutional research training grants ....................................................................... 203
  prior-approval requirements ..................................................................................... 105–112
  requests for prior approval ........................................................................................ 112–113
  Child care costs .......................................................................................................... 89

Children
  inclusion as subjects in clinical research ................................................................. 41, 67, 184, 206–207, 230
  Pro-Children Act of 1994 .......................................................................................... 42, 64–65

Citizenship requirements
  general ............................................................................................................................ 34
  individual fellowships ............................................................................................... 168–169
  institutional research training grants ....................................................................... 189–190

Civil False Claims Act .................................................................................................. 25

Civil rights, public policy requirements and objectives .................................................. 68–69, 230

Civil Rights Act of 1964 ................................................................................................ 39, 68

Clean Air Act .................................................................................................................. 147–148

Clean Water Act ............................................................................................................ 147–148

Clinical research
  definition ....................................................................................................................... 7
  inclusion of children as subjects in .......................................................................... 41, 66–67, 184, 206–207
  inclusion of women and minorities as subjects in .................................................... 41, 66–67, 183–184, 206, 230

Clinical trials
  data and safety monitoring ....................................................................................... 39, 62–63, 183, 206
  definitions ................................................................................................................... 7, 13

Cloning. See Human embryo research, cloning, and transplantation

Closeout ......................................................................................................................... 139–141

Co-investigator, definition .......................................................................................... 8

Communications, costs .............................................................................................. 89

Compensation
  Federal employees ..................................................................................................... 235–236
  general ......................................................................................................................... 96–99
  students and trainees ............................................................................................... 99, 177–178, 199–200
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confidentiality</td>
<td>40, 44–46, 61</td>
</tr>
<tr>
<td>Conflict of interest, financial</td>
<td>80</td>
</tr>
<tr>
<td>Consistency test, allowability of costs and</td>
<td>80</td>
</tr>
<tr>
<td>Conference grants</td>
<td>219–220</td>
</tr>
<tr>
<td>about</td>
<td>223–224</td>
</tr>
<tr>
<td>administrative requirements</td>
<td>221–222</td>
</tr>
<tr>
<td>allowable costs</td>
<td>220</td>
</tr>
<tr>
<td>application requirements</td>
<td>220</td>
</tr>
<tr>
<td>application review</td>
<td>220</td>
</tr>
<tr>
<td>copyrighting material</td>
<td>223</td>
</tr>
<tr>
<td>definitions</td>
<td>219–220</td>
</tr>
<tr>
<td>eligibility</td>
<td>220</td>
</tr>
<tr>
<td>facilities and administrative costs</td>
<td>83, 231</td>
</tr>
<tr>
<td>funding</td>
<td>221</td>
</tr>
<tr>
<td>public policy requirements and objectives</td>
<td>220</td>
</tr>
<tr>
<td>unallowable costs</td>
<td>222–223</td>
</tr>
<tr>
<td>Confidentiality</td>
<td>57</td>
</tr>
<tr>
<td>certificates of</td>
<td>40, 70–71</td>
</tr>
<tr>
<td>Freedom of Information Act and</td>
<td>57–58</td>
</tr>
<tr>
<td>individuals' rights and welfare requirements</td>
<td>25</td>
</tr>
<tr>
<td>of information (proprietary information)</td>
<td>39, 57</td>
</tr>
<tr>
<td>of patient records</td>
<td>42, 72</td>
</tr>
<tr>
<td>Privacy Act of 1974 and</td>
<td>40, 44–46, 61</td>
</tr>
<tr>
<td>Conformance test, allowability of costs and</td>
<td>80</td>
</tr>
<tr>
<td>Consistency test, allowability of costs and</td>
<td>80</td>
</tr>
<tr>
<td>Consortium agreements</td>
<td>224–225</td>
</tr>
<tr>
<td>about</td>
<td>225–227</td>
</tr>
<tr>
<td>administrative and other requirements</td>
<td>226</td>
</tr>
<tr>
<td>allowable/unallowable costs</td>
<td>226</td>
</tr>
<tr>
<td>approval authorities</td>
<td>227</td>
</tr>
<tr>
<td>audit</td>
<td>89</td>
</tr>
<tr>
<td>costs</td>
<td>8</td>
</tr>
<tr>
<td>definition</td>
<td>118, 228</td>
</tr>
<tr>
<td>intellectual property</td>
<td>225–226</td>
</tr>
<tr>
<td>public policy requirements and objectives</td>
<td>226–227</td>
</tr>
<tr>
<td>personal property</td>
<td>103, 104, 107</td>
</tr>
<tr>
<td>transfer of performance to third party by</td>
<td>227–228</td>
</tr>
<tr>
<td>written agreement</td>
<td>264</td>
</tr>
<tr>
<td>Construction grants</td>
<td>144</td>
</tr>
<tr>
<td>about</td>
<td>161–166</td>
</tr>
<tr>
<td>administrative requirements</td>
<td>151–154</td>
</tr>
<tr>
<td>allowable and unallowable costs and activities</td>
<td>148–151</td>
</tr>
<tr>
<td>design requirements</td>
<td>144</td>
</tr>
<tr>
<td>eligibility</td>
<td>41, 158–161</td>
</tr>
<tr>
<td>equal employment opportunity, labor standards, and other requirements</td>
<td>151</td>
</tr>
</tbody>
</table>
matching costs ........................................................................................................................................ 151
modernization, definition .......................................................................................................................... 144
prior-approval requirements ..................................................................................................................... 161
procurement requirements for services under ..................................................................................... 154–158
public policy requirements and objectives ............................................................................................. 40, 69, 145–148
review and approval ................................................................................................................................. 144–145
Construction management services, procurement requirements for .................................................. 156–157
Construction. Also see Construction grants
costs ............................................................................................................................................ 89
definition ........................................................................................................................................ 144
facilities and administrative costs and ................................................................................................. 83
Consultant, definition ................................................................................................................................. 8
Consultant services, costs .......................................................................................................................... 89–90
Contingency funds, costs ........................................................................................................................... 90
Contract under a grant
costs ............................................................................................................................................ 89
definition ........................................................................................................................................ 8
Contract Work Hours and Safety Standards Act .................................................................................... 159–160
Controlled substances
individuals' rights and welfare requirements ............................................................................................ 39, 58
use of funds for promotion/legalization ................................................................................................. 41, 49
Cooperative agreements
definition ........................................................................................................................................ 8
usage ................................................................................................................................................... iii
Copyrights. Also see Publishing and copyrighting data
general ........................................................................................................................................ 114
conference grants and ............................................................................................................................. 223
individual fellowships .............................................................................................................................. 182
institutional research training grants and .................................................................................................. 205
royalties and licensing fees from ............................................................................................................ 123
SBIR/STTR grants and ............................................................................................................................. 245
COR program ........................................................................................................................................ 189, 197
Cost analysis, in pre-award process ......................................................................................................... 35
Cost considerations and principles
accelerated expenditures .......................................................................................................................... 84
affiliated organization services .................................................................................................................. 85
allocation of costs and closely related work .............................................................................................. 84
applicable credits .................................................................................................................................. 85
conference grants ................................................................................................................................... 221–223
consortium agreements .......................................................................................................................... 226
construction grants ................................................................................................................................. 151–154
cost principles ........................................................................................................................................ 79–80
cost transfers ........................................................................................................................................... 83–84
delayed expenditures ............................................................................................................................... 84
determining allowability of costs ............................................................................................................. 80
direct costs ............................................................................................................................................ 81
facilities and administrative costs ........................................................................................................... 81–83
grants to Federal institutions ................................................................................................................... 233–236
grants to for-profit organizations ............................................................................................................ 238
grants to foreign institutions, international organizations, and domestic grants with
foreign components ................................................................................................................................. 231
individual fellowships ........................................................................................................................................ 174–177
institutional research training grants ........................................................................................................ 196–199
pre-award costs ........................................................................................................................................... 94
research patient care ................................................................................................................................... 247–250
SBIR and STTR programs ........................................................................................................................ 243–244
selected items of cost (table) ..................................................................................................................... 87–101
Cost overruns
  definition ......................................................................................................................................................... 8
Cost transfers .................................................................................................................................................. 83–84
Cost Principles for Commercial Organizations (48 CFR Subpart 31.2) ......................................................... 79
Cost Principles for Educational Institutions (OMB Circular A-21) .................................................................. 79
Cost Principles for Non-Profit Institutions (OMB Circular A-122) ............................................................... 79
Cost Principles for State and Local Governments and Indian Tribal Governments (OMB Circular A-87) .................... 79
Cost-related prior approvals ........................................................................................................................ 103, 104
Cost sharing. See Matching or cost sharing
Criminal False Claims Act .......................................................................................................................... 25
Customs and import duties, costs ................................................................................................................ 90

D
Data. See Publishing and copyrighting data; Research data and results
Data and safety monitoring requirements .................................................................................................. 39, 62–63, 183, 206
Deadlines. See Application process
Debarment and suspension .......................................................................................................................... 39, 46–47, 138, 230
Also see Suspension
Debt collection
  enforcement actions ...................................................................................................................................... 138–139
  nondelinquency on Federal debt .............................................................................................................. 42, 52–53, 230
Degree requirements
  individual fellowships ............................................................................................................................. 168
  institutional research training grants ...................................................................................................... 187
Delayed expenditures .................................................................................................................................... 84
Depreciation or use allowances .................................................................................................................... 90
Design-build services, procurement requirements for .................................................................................. 158
Design requirements for NIH-assisted construction .................................................................................... 148–151
Direct costs, definition .................................................................................................................................. 8, 81
Domestic conference, definition .................................................................................................................. 220
Domestic organization
  definition ......................................................................................................................................................... 8
  prior-approval requirements for foreign component added to grant ...................................................... 105, 111
Donor costs ................................................................................................................................................... 90
Drug-free workplace ...................................................................................................................................... 40, 47, 230
Drugs, costs .................................................................................................................................................... 90
Dues or membership fees .............................................................................................................................. 91

E
Earthquake Hazards Reduction Act of 1977 ............................................................................................... 149
Education Amendments of 1972, Title IX .................................................................................................. 40, 68
Education in the protection of human research participants ........................................................................ 61
Eligibility ........................................................................................................................................ 19, 33–35
Educational institutions, cost principles for .................................................................................. 79

Educational loans or GI bill
  individual fellowships .............................................................................................................. 178
  institutional research training grants .......................................................................................... 200

Eligibility ........................................................................................................................................ 19, 33–35
  conference grants ......................................................................................................................... 220
  construction grants .......................................................................................................................... 144
  grants to Federal institutions ........................................................................................................... 232–233
  grants to for-profit organizations .................................................................................................. 238
  grants to foreign institutions, international organizations, and domestic grants with foreign
  components ................................................................................................................................ 228–229
  individual fellowships .................................................................................................................... 167–168
  institutional research training grants ........................................................................................... 185–186
  SBIR and STTR ........................................................................................................................... 241–243

Enforcement actions
  about ............................................................................................................................................. 136
  debt collection .............................................................................................................................. 138–139
  modification of award terms ......................................................................................................... 136
  recovery of funds ........................................................................................................................... 138
  suspension and termination, withholding of support ..................................................................... 137, 138

Environmental impact requirements .................................................................................................. 69
  construction grants and .................................................................................................................. 42, 145–146

Equal employment opportunity requirements, construction grants .................................................. 158–159

Equipment. Also see Supplies
  accountability in grants to Federal institutions .............................................................................. 237
  allowable costs ............................................................................................................................... 91
  definition .......................................................................................................................................... 9
  management standards and procedures ....................................................................................... 124–126
  sale of ....................................................................................................................................... 122

Exempt property, administrative requirements .................................................................................. 124–125

Expanded authorities
  about .............................................................................................................................................. 102–103
  carryover of unobligated balances ................................................................................................. 103–104
  cost-related prior approvals .......................................................................................................... 103, 104
  definition ........................................................................................................................................ 9
  extension of final budget period .................................................................................................... 103, 104
  transfer of performance to third party by consortium agreement ............................................... 103, 104

Expenditures
  accelerated and delayed ................................................................................................................. 84
  financial reports ........................................................................................................................... 131–132, 139–140
  unobligated balances and actual expenditures reporting .................................................................. 132

Extensions
  expanded authority, of final budget period without additional NIH funding .................................. 103, 104
  of payback .................................................................................................................................. 213
  prior-approval, additional NIH funding with extension ................................................................. 105, 106, 112
  prior-approval, additional NIH funding without extension ............................................................ 105, 112
F
Facilities acquisition, alteration and renovation, and construction. See Alteration and renovation; Building acquisition; Construction; Construction grants
Facilities and administrative costs. Also see Indirect costs
  construction
definition ........................................................................................................................................... 9, 81
conference grants ........................................................................................................................................ 83, 222
construction grants .................................................................................................................................. 83, 154
Federal institutions ..................................................................................................................................... 83, 234
foreign and international organizations ..................................................................................................... 83, 231
for-profit organizations ............................................................................................................................... 238
individual fellowships .................................................................................................................................. 83
individuals, grants to .................................................................................................................................. 83
institutional research training grants ........................................................................................................... 83, 199
career awards ............................................................................................................................................ 83
reimbursement .......................................................................................................................................... 82–83
research patient care ................................................................................................................................ 248–249
SBIR and STTR programs ............................................................................................................................ 244
Federal Demonstration Partnership, definition .......................................................................................... 9
Federal employees
  payments to/on behalf of ........................................................................................................................... 91, 232–237

Federal funding. See Funding
Federal institution, definition .......................................................................................................................... 9
Fee
  definition .................................................................................................................................................... 9
  general86
general grants to for-profit organizations ................................................................................................ 238
  SBIR and STTR ......................................................................................................................................... 243–244
Fellowships. See Individual fellowships; Ruth L. Kirschstein National Research Service Awards
Final Invention Statement and Certification .................................................................................................. 141
Financial assistance, definition .................................................................................................................... 9
Financial conflict of interest .......................................................................................................................... 40, 44–46, 61
Financial management system standards .................................................................................................. 121
Financial reporting ..................................................................................................................................... 131–132, 139–140
  conference grants .................................................................................................................................... 224
  foreign institutions .................................................................................................................................. 232
  individual fellowships ............................................................................................................................... 180
  institutional research training grants ......................................................................................................... 203
Fines and penalties ....................................................................................................................................... 91
Flood Disaster Protection Act of 1973, flood insurance and ......................................................................... 40, 146
For-profit organization, definition ............................................................................................................... 10
  Also see Grants to for-profit organizations
Foreign component, definition .................................................................................................................... 9, 228
Foreign institution, definition ........................................................................................................................ 10
  Also see Grants to foreign institutions, international organizations, and domestic grants with foreign components
Foreign sponsorship/training abroad, individual fellowships ...................................................................... 169
Freedom of Information Act (FOIA) ........................................................................................................... 40, 70–71
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fringe benefits, costs</td>
<td>91</td>
</tr>
<tr>
<td>Full-time and part-time training, individual fellowships</td>
<td>172–173</td>
</tr>
<tr>
<td>Full-time appointment, definition</td>
<td>10</td>
</tr>
<tr>
<td>Funding</td>
<td></td>
</tr>
<tr>
<td>availability of information about</td>
<td>69</td>
</tr>
<tr>
<td>conference grants</td>
<td>221</td>
</tr>
<tr>
<td>construction grants</td>
<td>151</td>
</tr>
<tr>
<td>grants to foreign institutions, international organizations, and domestic grants with foreign components</td>
<td>230–231</td>
</tr>
<tr>
<td>NGA and</td>
<td>74–75</td>
</tr>
<tr>
<td>prior-approval requirements</td>
<td>105, 106, 112</td>
</tr>
<tr>
<td>Funding opportunities, types of</td>
<td>20–22</td>
</tr>
<tr>
<td>Funding principles</td>
<td>33</td>
</tr>
<tr>
<td>Fundraising costs</td>
<td></td>
</tr>
<tr>
<td>GI Bill. See Educational loans or GI bill</td>
<td></td>
</tr>
<tr>
<td>Glossary</td>
<td></td>
</tr>
<tr>
<td>abbreviations</td>
<td>1–5</td>
</tr>
<tr>
<td>definitions</td>
<td>6–15</td>
</tr>
<tr>
<td>Goods and services procurement</td>
<td></td>
</tr>
<tr>
<td>requirements under construction grants</td>
<td>154–158</td>
</tr>
<tr>
<td>system standards and requirements</td>
<td>126–128</td>
</tr>
<tr>
<td>Governments. See State, local, and Indian tribal governments</td>
<td></td>
</tr>
<tr>
<td>Grant appeals procedures</td>
<td>141–142</td>
</tr>
<tr>
<td>Grant-supported project or activity, definition</td>
<td>10</td>
</tr>
<tr>
<td>Grantee</td>
<td></td>
</tr>
<tr>
<td>definition</td>
<td>10</td>
</tr>
<tr>
<td>staff responsibilities</td>
<td>18–19</td>
</tr>
<tr>
<td>usage</td>
<td>iii</td>
</tr>
<tr>
<td>Grant</td>
<td></td>
</tr>
<tr>
<td>definition</td>
<td>10</td>
</tr>
<tr>
<td>usage</td>
<td>iii</td>
</tr>
<tr>
<td>Grants Management Officer (GMO)</td>
<td></td>
</tr>
<tr>
<td>definition</td>
<td>10</td>
</tr>
<tr>
<td>role and responsibilities</td>
<td>17</td>
</tr>
<tr>
<td>Grants Management Specialist (GMS)</td>
<td></td>
</tr>
<tr>
<td>definition</td>
<td>10</td>
</tr>
<tr>
<td>role and responsibilities</td>
<td>17</td>
</tr>
<tr>
<td>Grants to Federal institutions</td>
<td></td>
</tr>
<tr>
<td>administrative requirements</td>
<td>237</td>
</tr>
<tr>
<td>allowable/unallowable costs</td>
<td>233–236</td>
</tr>
<tr>
<td>eligibility</td>
<td>232–233</td>
</tr>
<tr>
<td>equipment accountability</td>
<td>237</td>
</tr>
<tr>
<td>facilities and administrative costs</td>
<td>83</td>
</tr>
<tr>
<td>intellectual property</td>
<td>237</td>
</tr>
<tr>
<td>payment</td>
<td>233</td>
</tr>
<tr>
<td>procurement requirements</td>
<td>237</td>
</tr>
<tr>
<td>reporting requirements</td>
<td>237</td>
</tr>
<tr>
<td>VA-university affiliations</td>
<td>233</td>
</tr>
<tr>
<td>Grants to for-profit organizations</td>
<td></td>
</tr>
</tbody>
</table>
H

Handicapped individuals
  facility accessibility standards ................................................................. 40, 148
  nondiscrimination ..................................................................................... 68
Hazardous waste disposal, costs ................................................................. 91
Health and Human Services, Department of (HHS)
  points of contact .......................................................................................... 258–259
  roles and responsibilities .......................................................................... 16, 17–18
Health and safety regulations and guidelines ............................................. 40, 48–49
Health insurance
  institutional allowance for ........................................................................ 176
  trainee 198
Health Insurance Portability and Accountability Act (HIPAA) .................. 40, 57–58
Historic properties and archeological sites, construction grants and ......... 40, 146
Honors, costs .................................................................................................. 91
Hospital, definition ....................................................................................... 11
Hospital cost principles ............................................................................... 79
  Also see Research patient care costs
Human embryo research, cloning, and transplantation requirements ......... 54–56
Human embryonic stem cell research .......................................................... 40, 53–54, 184, 207
Human fetal tissue, research on ................................................................. 43, 55–56
Human gene transfer research ................................................................... 51–52, 185, 207
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>health insurance</td>
<td>198</td>
</tr>
<tr>
<td>initiation of support</td>
<td>196</td>
</tr>
<tr>
<td>inventions and patents</td>
<td>205</td>
</tr>
<tr>
<td>leave</td>
<td>203–204</td>
</tr>
<tr>
<td>minority recruitment plan</td>
<td>192–193</td>
</tr>
<tr>
<td>notification of action</td>
<td>194</td>
</tr>
<tr>
<td>Payback Agreement</td>
<td>202</td>
</tr>
<tr>
<td>period of support</td>
<td>194–196</td>
</tr>
<tr>
<td>prebaccalaureate training</td>
<td>188–189</td>
</tr>
<tr>
<td>program income</td>
<td>201</td>
</tr>
<tr>
<td>progress reports</td>
<td>202–203</td>
</tr>
<tr>
<td>public access to research data</td>
<td>205</td>
</tr>
<tr>
<td>publication and sharing of research results</td>
<td>204–205</td>
</tr>
<tr>
<td>rebudgeting of funds</td>
<td>199</td>
</tr>
<tr>
<td>reporting requirements</td>
<td>201–203</td>
</tr>
<tr>
<td>short-term research training</td>
<td>187–188, 192</td>
</tr>
<tr>
<td>short-term training costs</td>
<td>198</td>
</tr>
<tr>
<td>Statement of Appointment</td>
<td>201–202</td>
</tr>
<tr>
<td>stipend supplementation</td>
<td>199</td>
</tr>
<tr>
<td>stipends and stipend levels</td>
<td>197</td>
</tr>
<tr>
<td>student compensation</td>
<td>99, 199–200</td>
</tr>
<tr>
<td>taxability of stipends</td>
<td>200–201</td>
</tr>
<tr>
<td>termination</td>
<td>204</td>
</tr>
<tr>
<td>Termination Notice (Form PHS 416-7)</td>
<td>202</td>
</tr>
<tr>
<td>travel costs</td>
<td>198</td>
</tr>
<tr>
<td>tuition and fees</td>
<td>198</td>
</tr>
<tr>
<td>training in responsible conduct of research</td>
<td>193–194</td>
</tr>
<tr>
<td>training Program Director</td>
<td>186</td>
</tr>
<tr>
<td>training-related expenses</td>
<td>197</td>
</tr>
<tr>
<td>Institutional Review Boards (IRBs)</td>
<td></td>
</tr>
<tr>
<td>financial conflict of interest and human subjects protection and</td>
<td>145–146</td>
</tr>
<tr>
<td>financial conflict of interest and human subjects protection and</td>
<td>60–61, 205–206</td>
</tr>
<tr>
<td>insurance. Also see specific types of insurance</td>
<td></td>
</tr>
<tr>
<td>costs</td>
<td>92</td>
</tr>
<tr>
<td>real property</td>
<td>165–166</td>
</tr>
<tr>
<td>Intellectual property</td>
<td>113–114, 116–120</td>
</tr>
<tr>
<td>conference materials</td>
<td>223</td>
</tr>
<tr>
<td>for-profit organizations</td>
<td>238–239</td>
</tr>
<tr>
<td>individual fellowships</td>
<td>182–183</td>
</tr>
<tr>
<td>institutional research training grants</td>
<td>205</td>
</tr>
<tr>
<td>Federal institutions</td>
<td>237</td>
</tr>
<tr>
<td>SBIR and STTR programs</td>
<td>245</td>
</tr>
<tr>
<td>Interest</td>
<td></td>
</tr>
<tr>
<td>costs</td>
<td>92</td>
</tr>
<tr>
<td>earned on advances of grant funds</td>
<td>78</td>
</tr>
<tr>
<td>Intergovernmental Review of Federal Programs (EO 12372)</td>
<td>41, 147</td>
</tr>
<tr>
<td>International conference, definition</td>
<td>220</td>
</tr>
<tr>
<td>International organization</td>
<td></td>
</tr>
<tr>
<td>definition</td>
<td>11</td>
</tr>
<tr>
<td>facilities and administrative costs</td>
<td>83</td>
</tr>
<tr>
<td>Inventions and patents. Also see Bayh-Dole Act of 1980</td>
<td></td>
</tr>
</tbody>
</table>

273
<table>
<thead>
<tr>
<th>Section</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>costs</td>
<td>92</td>
</tr>
<tr>
<td>extramural invention reporting compliance responsibilities (exhibit)</td>
<td>117–119</td>
</tr>
<tr>
<td>Final Invention Statement and Certification</td>
<td>141</td>
</tr>
<tr>
<td>individual fellowships</td>
<td>182–183</td>
</tr>
<tr>
<td>institutional research training grants</td>
<td>205</td>
</tr>
<tr>
<td>invention reporting</td>
<td>132–133</td>
</tr>
<tr>
<td>royalties and licensing fees from</td>
<td>123</td>
</tr>
<tr>
<td>Investigational new drug (INDs) applications/investigational device</td>
<td>41, 63–64</td>
</tr>
<tr>
<td>exceptions (IDEs)</td>
<td></td>
</tr>
<tr>
<td>Just-in-time procedures, in pre-award process</td>
<td>32–33</td>
</tr>
<tr>
<td>K awards</td>
<td></td>
</tr>
<tr>
<td>facilities and administrative costs and</td>
<td>83</td>
</tr>
<tr>
<td>prior-approval requirements for retention of funds</td>
<td>105, 112</td>
</tr>
<tr>
<td>Key personnel, definition</td>
<td>11</td>
</tr>
<tr>
<td>L</td>
<td></td>
</tr>
<tr>
<td>Labor standards, construction grants</td>
<td>41, 159–161</td>
</tr>
<tr>
<td>Laboratory Animal Welfare, Office of (OLAW)</td>
<td>65–66, 207</td>
</tr>
<tr>
<td>Leave</td>
<td></td>
</tr>
<tr>
<td>costs</td>
<td>92</td>
</tr>
<tr>
<td>individual fellowships</td>
<td>181</td>
</tr>
<tr>
<td>institutional research training grants</td>
<td>203–204</td>
</tr>
<tr>
<td>Legal services, costs</td>
<td>92</td>
</tr>
<tr>
<td>Library services, costs</td>
<td>92</td>
</tr>
<tr>
<td>Licensing</td>
<td></td>
</tr>
<tr>
<td>costs</td>
<td>92</td>
</tr>
<tr>
<td>fees from copyrights, inventions, and patents</td>
<td>123</td>
</tr>
<tr>
<td>Limited English proficiency, nondiscrimination</td>
<td>41, 69</td>
</tr>
<tr>
<td>Liquidated damages provisions, construction grants</td>
<td>159–160</td>
</tr>
<tr>
<td>Lobbying</td>
<td>41, 49–50, 230</td>
</tr>
<tr>
<td>costs</td>
<td>93</td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Management systems and procedures</td>
<td></td>
</tr>
<tr>
<td>about</td>
<td>120</td>
</tr>
<tr>
<td>assessment in pre-award process</td>
<td>35</td>
</tr>
<tr>
<td>financial management system</td>
<td>120–121</td>
</tr>
<tr>
<td>program income</td>
<td></td>
</tr>
<tr>
<td>procurement system</td>
<td>121–123</td>
</tr>
<tr>
<td>property management system</td>
<td>126–128</td>
</tr>
<tr>
<td>MARC U*STAR program</td>
<td>188–189, 200</td>
</tr>
<tr>
<td>Matching or cost sharing</td>
<td></td>
</tr>
<tr>
<td>affiliated organization services, costs</td>
<td>85</td>
</tr>
<tr>
<td>construction grants</td>
<td>151</td>
</tr>
<tr>
<td>definition</td>
<td>12</td>
</tr>
<tr>
<td>Meals, costs</td>
<td>93</td>
</tr>
</tbody>
</table>
Metric system use requirements .............................................................. 41, 72, 147
Military recruiting, access to institutions of higher learning ...................... 41, 72–73
Minorities
  contracting with minority-owned firms for goods and services ................ 128
  inclusion as subjects in clinical research ............................................. 41, 66–67, 183–184, 206, 230
  recruitment plan, institutional research training grants ......................... 192–193
Misconduct. See Research misconduct
Modernization, definition ..................................................................... 144
Modular applications and awards
  about ................................................................................................. 217
  application requirements ................................................................. 217–218
  application review and award .......................................................... 218–219
  modular application, definition ........................................................ 12
  post-award administration ................................................................ 219
Monitoring. Also see Reporting
  about ................................................................................................... 128
  audits ............................................................................................... 134–136
  data and safety monitoring requirements ........................................... 39, 62–63, 183, 206
  definition .......................................................................................... 12
  record retention and access .............................................................. 133–134
  reporting ......................................................................................... 129–133
Moving, costs. See Recruitment costs; Relocation costs; Transportation of property
Multiple Project Assurances (MPAs) ..................................................... 59n

N
National Advisory Council or Board (Council) review ................................. 29
National Environmental Policy Act of 1969 (NEPA) .................................. 42, 145
National External Audit Review Center ................................................... 239
National Health Service Corps (NHSC) scholars, payback reporting requirements .................................................. 215
National Historic Preservation Act .......................................................... 146
National Register of Historic Places ...................................................... 146
New application (Type 1) ...................................................................... 20
New investigator, definition ................................................................... 12
NIH Electronic Research Administration Commons (NIH eRA Commons) ................................................................. 30
NIH Guide for Grants and Contracts ....................................................... 30, iv
NIH Guidelines for Research Involving Recombinant
  DNA Molecules .................................................................................. 48, 51–52, 185, 207–208
NIH Loan Repayment Program ................................................................ 200, 213
NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human
  Subjects ............................................................................................ 184, 207
NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects
  in Clinical Research ......................................................................... 66–67, 184, 206
Non-Competing Grant Progress Report (PHS 2590) (Type 5) .................... 20, 129–130
Non-discrimination ............................................................................... 39, 68–69, 230
Non-profit institutions, cost principles for .............................................. 79
Nondelinquency on Federal debt ......................................................... 42, 52–53, 230
Nondiscrimination ............................................................................... 68–69, 167, 230
Nonexempt property, administrative requirements ................................... 125–126
Nonsegregated facilities requirement, construction grants ..................... 159
Notice of Grant Award (NGA)
about .......................................................................................................................... 74
budget 76
definition .................................................................................................................. 12
funding ........................................................................................................................... 74–75
terms and conditions ................................................................................................. 35–36, 74, 76
Notification of action
  individual fellowships ............................................................................................... 171
  institutional research training grants ....................................................................... 194
Nursery items, costs ..................................................................................................... 93

O
Occupational Health and Safety Administration (OSHA), standards regulations ................. 49
Organization, definition .............................................................................................. 12
Other support, definition ............................................................................................ 12
Overtime. See Salaries and wages

P
Parental leave
  individual fellowships ............................................................................................... 181
  institutional research training grants ....................................................................... 194
Patents. See Inventions and patents
Patient records, confidentiality of .................................................................................. 39, 57
Payback Agreement (Form PHS 6031)
  individual fellowships ............................................................................................... 173, 179
  institutional research training grants ....................................................................... 202
Payback reporting requirements
  about ........................................................................................................................... 208, 209
  Annual Payback Activities Certification ................................................................... 214–215
  breaks in support and ................................................................................................... 215
  certification of payback activities ............................................................................. 214–215
  change of address ........................................................................................................ 215
  definitions ................................................................................................................... 209–210
  extension of payback .................................................................................................. 213
  financial payback ....................................................................................................... 212–213
  implementation .......................................................................................................... 208–209
  initiation of payback service ...................................................................................... 211
  interest and interest rate calculation ....................................................................... 212–213
  National Health Service Corps scholars .................................................................. 215
  policy and principal calculation ............................................................................... 212
  service payback ......................................................................................................... 210–212
  short-term training ..................................................................................................... 209
  time commitment ....................................................................................................... 210–211
  timing of service obligation ...................................................................................... 212
  waiver .......................................................................................................................... 213–214
Payment
  about ........................................................................................................................... 76–77
  cash requests .............................................................................................................. 77–78
  CASHLINE/ACH ....................................................................................................... 77
  foreign institutions ...................................................................................................... 230–231
  individual fellowships ............................................................................................... 173–174
carryover of unobligated balances ................................................................. 105
change in grantee organizational status ..................................................... 110–111
change in scope ........................................................................................... 105, 106–107
change of grantee organization ................................................................... 105, 108–110
changes in status of PI and key personnel ................................................ 105, 107
construction grants ...................................................................................... 161
development from award terms and conditions and NGA restrictions .... 105, 111
foreign component added to domestic organization grant ....................... 105, 111
pre-award costs ........................................................................................... 105

Also see Cost considerations and principles

prior approval, definition ............................................................................. 13
real property management standards .......................................................... 163–166
retention of funds when K award is made ................................................... 105, 112
transfer of amounts from trainee costs ......................................................... 106, 112
transfer of funds between construction and nonconstruction work .......... 106, 112
Priority score, definition ............................................................................ 13
Privacy Act of 1974 ...................................................................................... 42, 69, 72
Pro-Children Act of 1994 requirements ....................................................... 42, 64–65
Procurement requirements
construction grants ....................................................................................... 154–156
in grants to Federal institutions ................................................................ 237
system standards ......................................................................................... 126–128
Professional fees, disposition of
individual fellowships ................................................................................ 183
institutional research training grants ......................................................... 205
Profit. See Fee
Program, definition .................................................................................... 13
Program Director, definition ....................................................................... 13

Also see Principal Investigator; Project Director
Program Fraud and Civil Remedies Act of 1986 ........................................... 25, 42
Program income .......................................................................................... 121-123
alternatives for use of ................................................................................ 122
definition .................................................................................................... 13
grants to for-profit organizations ............................................................... 239
institutional research training grants ......................................................... 201
reporting .................................................................................................... 123
Program Official (PO)
definition ................................................................................................ 13
role and responsibilities ............................................................................ 17
Progress Report for Continuation Support (Form PHS 416-9) ....................... 180
Progress reports
conference grants ........................................................................................ 223–224
definition .................................................................................................. 13
final progress report ................................................................................... 140
individual fellowships .............................................................................. 180
institutional research training grants ......................................................... 202–203
requirements ............................................................................................ 129–131
Project Director, definition ....................................................................... 13

Also see Principal Investigator; Program Director
Project period, definition ........................................................................... 14
Property management system standards and procedures ......................... 123–124
Proprietary information ................................................................................................................................. 25
Prudent Practices for Safety in Laboratories .................................................................................................. 49
Public disclosure
  conference materials ................................................................................................................................. 223
  environmental impact requirements in construction grants ................................................................. 42, 145–146
Public Health Security and Bioterrorism Preparedness and Response Act of 2002 .................................. 42, 48
Public policy requirements and objectives ............................................................................................... 36–43
  animal welfare ....................................................................................................................................... 39, 65–66, 185, 207, 229
  civil rights .................................................................................................................................................. 68–69, 230
  conference grants ....................................................................................................................................... 220
  consortium agreements ............................................................................................................................... 225–226
  construction grants ................................................................................................................................. 145–148
  determining applicability/inclusion (exhibit) ......................................................................................... 39–43
  facilities acquisition, alteration and renovation, and construction requirements ............................ 69
  grants for foreign institutions, international organizations, and domestic grants with foreign
  components .................................................................................................................................................. 229–230
  inclusiveness in research design requirements ...................................................................................... 66–67, 230
  individual fellowships .............................................................................................................................. 183–185
  information availability requirements ...................................................................................................... 69–72
  institutional research training grants ...................................................................................................... 205–206
  metric system use requirements .............................................................................................................. 41, 72, 147
  military recruiting and ROTC program access to institutions of higher
  learning ......................................................................................................................................................... 41, 72–73
  SBIR and STTR programs .......................................................................................................................... 243
Public relations costs ..................................................................................................................................... 94
Publications
  costs ........................................................................................................................................................... 94
  information resources ............................................................................................................................... 30–31
Publishing and copyrighting data
  conference materials ............................................................................................................................... 223
  individual fellowship research results ...................................................................................................... 182
  institutional research training grants research results ........................................................................... 204–205
  rights ........................................................................................................................................................ 114–115

R
Real estate appraisals ...................................................................................................................................... 164
Real property
  acquisition of ............................................................................................................................................. 42, 147
  definition .................................................................................................................................................... 14
  sale of ........................................................................................................................................................ 122
Real property management standards and procedures
  general standards ........................................................................................................................................ 163–164
  insurance requirements ........................................................................................................................... 165–166
  notice of Federal interest in real property .............................................................................................. 165
  real estate appraisals ............................................................................................................................... 164
  use and disposition .................................................................................................................................. 164
Reasonableness test, allowability of costs and ............................................................................................. 80
Recipient. Also see Grantee
  definition ....................................................................................................................................................... 14
  usage, iii
<table>
<thead>
<tr>
<th>Research</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant DNA molecules research</td>
<td>42, 48, 51–52, 185, 207</td>
</tr>
<tr>
<td>Record retention and access</td>
<td>133–134</td>
</tr>
<tr>
<td>Recovery of funds, enforcement actions</td>
<td>138</td>
</tr>
<tr>
<td>Recruitment costs</td>
<td>94</td>
</tr>
<tr>
<td>Registration fees (symposia/seminars)</td>
<td>94</td>
</tr>
<tr>
<td>Rehabilitation Act of 1973</td>
<td>42, 68</td>
</tr>
<tr>
<td>Reimbursement method of payment</td>
<td>138</td>
</tr>
<tr>
<td>Relocation assistance</td>
<td>42, 147</td>
</tr>
<tr>
<td>Relocation costs</td>
<td>95</td>
</tr>
<tr>
<td>Rental or lease of facilities and equipment, costs</td>
<td>95</td>
</tr>
<tr>
<td>Reporting</td>
<td>223</td>
</tr>
<tr>
<td>expenditures</td>
<td>131–132</td>
</tr>
<tr>
<td>invention reporting</td>
<td>117–119, 132, 141</td>
</tr>
<tr>
<td>final reports</td>
<td>139–141</td>
</tr>
<tr>
<td>financial reports</td>
<td>129–133, 223–224</td>
</tr>
<tr>
<td>Federal institutions</td>
<td>237</td>
</tr>
<tr>
<td>foreign institutions, international organizations, and domestic grants with foreign components</td>
<td>232</td>
</tr>
<tr>
<td>human gene transfer research</td>
<td>52</td>
</tr>
<tr>
<td>individual fellowships</td>
<td>179–180</td>
</tr>
<tr>
<td>institutional research training grants</td>
<td>201–203</td>
</tr>
<tr>
<td>inventions</td>
<td>132</td>
</tr>
<tr>
<td>program income</td>
<td>122–123,</td>
</tr>
<tr>
<td>progress reports</td>
<td>129–131, 223–224</td>
</tr>
<tr>
<td>unobligated balances and actual expenditures reporting</td>
<td>132</td>
</tr>
<tr>
<td>Research, definition</td>
<td>14, 59, 210</td>
</tr>
<tr>
<td>Research data and results</td>
<td>113–114</td>
</tr>
<tr>
<td>availability</td>
<td>71</td>
</tr>
<tr>
<td>definition of and access to</td>
<td>205</td>
</tr>
<tr>
<td>public access under institutional research training grants</td>
<td></td>
</tr>
<tr>
<td>rights. See Publishing and copyrighting data sharing115–116, 245</td>
<td></td>
</tr>
<tr>
<td>Research design requirements, inclusiveness in</td>
<td>66–67, 183–184, 206–207, 230</td>
</tr>
<tr>
<td>Research misconduct</td>
<td>43, 50–51, 229</td>
</tr>
<tr>
<td>definition</td>
<td>14</td>
</tr>
<tr>
<td>Research patient care costs</td>
<td>246</td>
</tr>
<tr>
<td>allowable costs</td>
<td>96, 101, 247–249</td>
</tr>
<tr>
<td>computing costs</td>
<td>248</td>
</tr>
<tr>
<td>consortium participants/contractors under grant</td>
<td>249</td>
</tr>
<tr>
<td>definitions</td>
<td>246–247</td>
</tr>
<tr>
<td>facilities and administrative costs</td>
<td>249</td>
</tr>
<tr>
<td>financial responsibilities</td>
<td>250</td>
</tr>
<tr>
<td>policy</td>
<td>247</td>
</tr>
<tr>
<td>special procedures</td>
<td>249</td>
</tr>
<tr>
<td>travel costs</td>
<td>101</td>
</tr>
<tr>
<td>Reserve funds, cost principles</td>
<td>96</td>
</tr>
<tr>
<td>Reserve Officer Training Corps (ROTC) program, access to institutions of higher learning</td>
<td>41, 72–73</td>
</tr>
</tbody>
</table>
"Responsibility of Applicants for Promoting Objectivity in Research for which PHS Funding is Sought"
(42 CFR Part 50, Subpart F) ................................................................................................................ 44-45
responsible conduct of research ........................................................................................................... 184, 193–194
Revised (Amended) Application ........................................................................................................ 20
Revocable license agreement ................................................................................................................. 126–128
Royalties and licensing fees from copyrights, inventions, and patents ................................................ 123
Ruth L. Kirschstein National Research Service Awards. Also see Institutional research training grants;
Individual fellowships
about .................................................................................................................................................. 166
background ........................................................................................................................................ 166–167
nondiscrimination ................................................................................................................................. 167
payback reporting requirements ........................................................................................................ 208–215
S
Sabbatical leave, costs ............................................................................................................................... 96
Safety issues
biosafety .................................................................................................................................................. 49, 52
data and safety monitoring requirements ........................................................................................... 39, 62–63, 183, 206
health and safety regulations and guidelines ....................................................................................... 40, 48–49
safety and annual reporting, human gene transfer research ................................................................. 52
Salaries and wages
cost considerations for allocation of costs and closely related work ................................................ 84
costs ....................................................................................................................................................... 96–99
dual appointment payments .................................................................................................................... 98
disposition of unclaimed wages, construction grants ......................................................................... 160–161
institutional base salary, definition ....................................................................................................... 11
Sale of real property, equipment, and supplies .................................................................................... 122
Scientific meetings. See Conference grants
Scientific Review Administrator (SRA), role and responsibilities .......................................................... 17–18
Seat belt use .......................................................................................................................................... 43, 54
Seismic Safety of Federal and Federally Assisted or Regulated New Building
Construction (EO 12699) ....................................................................................................................... 149
Senior fellows, individual fellowship degree requirements ................................................................ 168
Service charges, costs ............................................................................................................................ 99
Severance pay, costs .............................................................................................................................. 99
Sharing research results and resources
research data ............................................................................................................................................... 115
unique research resources ................................................................................................................... 115–116
Short-term research training .................................................................................................................. 187–188, 192, 198, 209
Sick and other leave
individual fellowships ........................................................................................................................... 181
institutional research training grants ................................................................................................... 203
Significant rebudgeting, definition ......................................................................................................... 14
Single Project Assurances (SPAs) ......................................................................................................... 59n
Small business innovation research and technology transfer programs (SBIR and STTR)
administrative requirements .................................................................................................................. 244–245
allowable costs and profit/fee ................................................................................................................. 243–244
data sharing requirements ..................................................................................................................... 245
differences between SBIR and STTR ................................................................................................... 240–241
eligibility .............................................................................................................................................. 241–243

281
facilities and administrative costs (indirect costs) ................................................................. 244
intellectual property requirements ......................................................................................... 245
market research requirements ............................................................................................... 244–245
minimum level of effort ....................................................................................................... 243
phases of .............................................................................................................................. 240
place of performance .......................................................................................................... 242–243
public policy requirements and objectives ........................................................................ 243
Small businesses
contracting for goods and services .................................................................................. 128
small business concern, definition and qualification .......................................................... 14, 241–242
SMARTLINK II/ACH ........................................................................................................... 76, 77
Smoke-free workplace ....................................................................................................... 43, 54
Pro-Children Act of 1994 and ......................................................................................... 42, 64–65
Standards of conduct, ....................................................................................................... 43, 44
responsible conduct of research ...................................................................................... 184, 193–194
Standards of Privacy of Individuals Identifiable Health Information (Privacy Rule) ...... 57–58
State, local, and Indian tribal governments
cost principles .................................................................................................................. 79
State government, definition .............................................................................................. 15
Uniform Administrative Requirements for Grants and Cooperative Agreements to ......................................................... 16, 228
Statement of Appointment (Form PHS 2271) ................................................................... 201–202
Statement of Miscellaneous Income (IRS Form 1099)
individual fellowships ......................................................................................................... 178
institutional research training grants .................................................................................. 201
Sterile needle/syringe distribution restriction ...................................................................... 43, 54
Stipends
costs .................................................................................................................................... 99
definition ............................................................................................................................ 15
levels for individual fellowships ....................................................................................... 174–175
levels for institutional research training grants ............................................................. 197
supplementation ................................................................................................................ 177, 199
taxability ............................................................................................................................ 178, 200–201
Streamlined non-competing award process (SNAP) .......................................................... 130–131
Students
compensation of ............................................................................................................... 99, 177–178, 199–200
Subject costs. See Research patient care costs
Submission of applications
application forms ................................................................................................................. 22–23
confidentiality of information (proprietary information) .................................................. 25
legal implications of application ...................................................................................... 24–25
receipt points and deadlines ............................................................................................ 23–24, 216
Supplies .............................................................................................................................. 100, 222
Also see Equipment
Support mechanisms ........................................................................................................ 19
Suspension. Also see Debarment and suspension
costs ................................................................................................................................ 100
definition .......................................................................................................................... 15
enforcement actions .......................................................................................................... 137
### Tuition and fees

<table>
<thead>
<tr>
<th>Costs</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>transfer of property, costs</td>
<td>100</td>
</tr>
<tr>
<td>transplantation, human fetal tissue</td>
<td>43, 55–56</td>
</tr>
<tr>
<td>transfers, individual fellowships</td>
<td>180</td>
</tr>
<tr>
<td>transfer of performance to third party by consortium agreement</td>
<td>103, 104</td>
</tr>
</tbody>
</table>

### Travel

<table>
<thead>
<tr>
<th>Costs</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>trailers and modular units, costs</td>
<td>100</td>
</tr>
<tr>
<td>trainee costs</td>
<td>100, 198</td>
</tr>
<tr>
<td>prior-approval requirements for transfer of amounts</td>
<td>106, 112</td>
</tr>
<tr>
<td>rebudgeting of funds</td>
<td>199</td>
</tr>
<tr>
<td>training program director, institutional research training grants</td>
<td>186</td>
</tr>
<tr>
<td>training-related expenses, institutional research training grants</td>
<td>197</td>
</tr>
<tr>
<td>transfer of funds between construction and nonconstruction work,</td>
<td></td>
</tr>
<tr>
<td>prior-approval requirements</td>
<td>106, 112</td>
</tr>
<tr>
<td>transfer of performance to third party by consortium agreement</td>
<td>103, 104</td>
</tr>
<tr>
<td>transfers, individual fellowships</td>
<td>180</td>
</tr>
<tr>
<td>transportation of property, costs</td>
<td>100</td>
</tr>
<tr>
<td>travel</td>
<td></td>
</tr>
<tr>
<td>to foreign training sites</td>
<td>101</td>
</tr>
<tr>
<td>institutional allowance for</td>
<td>176</td>
</tr>
<tr>
<td>trainees in institutional research training grants</td>
<td>198</td>
</tr>
</tbody>
</table>

### Tuition and fees

<table>
<thead>
<tr>
<th>Costs</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>individual fellowships</td>
<td>181</td>
</tr>
<tr>
<td>institutional research training grants</td>
<td>204</td>
</tr>
<tr>
<td>termination costs</td>
<td>100</td>
</tr>
<tr>
<td>definition</td>
<td>15</td>
</tr>
<tr>
<td>enforcement actions</td>
<td>137</td>
</tr>
<tr>
<td>individual fellowships</td>
<td>182</td>
</tr>
<tr>
<td>institutional research training grants</td>
<td>204</td>
</tr>
<tr>
<td>termination notice (form PHS 416-7)</td>
<td></td>
</tr>
<tr>
<td>individual fellowships</td>
<td>180</td>
</tr>
<tr>
<td>institutional research training grants</td>
<td>202</td>
</tr>
</tbody>
</table>

### Terms and conditions of award

Also see Administrative requirements; Cost considerations and principles;
Notice of Grant Award; Payment; Pre-award process; Public policy requirements and objectives

<table>
<thead>
<tr>
<th>Costs</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>definition</td>
<td>15</td>
</tr>
<tr>
<td>modification of award terms, enforcement actions</td>
<td>136</td>
</tr>
<tr>
<td>overview</td>
<td>35–36</td>
</tr>
<tr>
<td>prior-approval requirements for deviation from</td>
<td>105, 111</td>
</tr>
<tr>
<td>title insurance</td>
<td>165</td>
</tr>
<tr>
<td>total project costs, definition</td>
<td>15</td>
</tr>
<tr>
<td>trailers and modular units, costs</td>
<td>100</td>
</tr>
<tr>
<td>trainee costs</td>
<td>100, 198</td>
</tr>
<tr>
<td>prior-approval requirements for transfer of amounts</td>
<td>106, 112</td>
</tr>
<tr>
<td>rebudgeting of funds</td>
<td>199</td>
</tr>
<tr>
<td>training program director, institutional research training grants</td>
<td>186</td>
</tr>
<tr>
<td>training-related expenses, institutional research training grants</td>
<td>197</td>
</tr>
<tr>
<td>transfer of funds between construction and nonconstruction work,</td>
<td></td>
</tr>
<tr>
<td>prior-approval requirements</td>
<td>106, 112</td>
</tr>
<tr>
<td>transfer of performance to third party by consortium agreement</td>
<td>103, 104</td>
</tr>
<tr>
<td>transfers, individual fellowships</td>
<td>180</td>
</tr>
<tr>
<td>transportation of property, costs</td>
<td>100</td>
</tr>
<tr>
<td>travel</td>
<td></td>
</tr>
<tr>
<td>to foreign training sites</td>
<td>101</td>
</tr>
<tr>
<td>institutional allowance for</td>
<td>176</td>
</tr>
<tr>
<td>trainees in institutional research training grants</td>
<td>198</td>
</tr>
</tbody>
</table>

### Uniform Relocation Assistance and Real Property Acquisition

Pricing Act of 1970... 147

United States, definition... 15

283
Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act (USA PATRIOT Act)........................................................................................ 43, 48
Unobligated balances
  authorities for carryover of ................................................................. 103, 105, 132, 201, 239
  reporting.................................................................................................. 132
Unpaid leave
  individual fellowships ........................................................................... 181
  institutional research training grants ..................................................... 204
Use allowances............................................................................................ 90

V
VA-university affiliations.................................................................................. 233
Vacation and holiday leave
  individual fellowships ........................................................................... 181
  institutional research training grants ..................................................... 203
Vertebrate animals. See Animal welfare

W
Withholding of support
  definition ................................................................................................ 15
  enforcement actions.............................................................................. 137, 138
Women
  contracting with women's business enterprises for goods and services ............................................. 128
  inclusion as subjects in clinical research.............................................. 41, 66–67, 183–184, 206, 230